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The	  last	  three	  decades	  have	  seen	  a	  fundamental	  change	  in	  the	  profile	  of	  
oropharyngeal	  squamous	  cell	  carcinoma	  (OPSCC)	  within	  the	  developed	  world.	  The	  
incidence	  of	  OPSCC	  attributable	  to	  tobacco	  and	  alcohol	  exposure	  has	  been	  
gradually	  declining	  whilst	  Human	  papillomavirus	  (HPV)-­‐related	  OPSCC	  has	  seen	  a	  
rapid	  increase.	  Detection	  of	  High	  Risk	  HPV	  has	  profound	  prognostic	  significance	  as	  it	  
correlates	  with	  both	  a	  disease-­‐specific	  and	  an	  overall	  survival	  advantage.	  The	  
stringency	  of	  testing,	  both	  in	  terms	  of	  diagnostic	  and	  prognostic	  capacity	  is	  
therefore	  of	  increasing	  importance.	  This	  study	  sought	  to	  define	  the	  relative	  abilities	  
of	  the	  diagnostic	  tests	  presently	  available	  in	  clinical	  practice	  and	  to	  explore	  the	  
potential	  of	  a	  novel	  test	  in	  reaching	  the	  improved	  stringency	  called	  for	  by	  the	  
clinical	  community.	  
	  
Diagnostic	  biomarkers	  with	  prognostic	  capacity,	  such	  as	  those	  utilised	  in	  defining	  
HPV	  status	  in	  this	  research	  have	  been	  well	  described,	  however,	  despite	  HPV	  positive	  
OPSCC	  being	  biologically	  distinct	  from	  HPV	  negative	  malignancy,	  predictive	  
biomarkers	  defining	  the	  transition	  from	  persistent	  to	  transforming	  infection	  are	  yet	  
to	  be	  forthcoming.	  A	  lack	  of	  an	  apparent	  premalignant	  state,	  akin	  to	  that	  seen	  in	  
	  	  
v	  
HPV-­‐mediated	  cervical	  malignancy	  has	  restricted	  biomarker	  recognition.	  This	  
research	  aimed	  to	  better	  define	  the	  epigenetic	  state	  and	  clarify	  the	  impact	  of	  viral	  
integration	  for	  the	  virus	  and	  host	  in	  HPV	  positive	  OPSCC.	  Although	  detectable	  
epigenetic	  alterations,	  within	  the	  genome	  of	  the	  virus	  and	  that	  of	  the	  host,	  were	  
capable	  of	  providing	  an	  improved	  description	  of	  this	  burgeoning	  disease	  state,	  they	  
fell	  short	  of	  providing	  clinically	  relevant	  biomarkers.	  It	  was	  however	  demonstrated	  
that	  the	  previously	  held	  concept	  of	  preferential	  E2	  cleavage	  during	  viral	  integration	  
as	  a	  means	  to	  disrupt	  gene	  expression,	  is	  overstated	  and	  the	  model	  persists	  to	  the	  
exclusion	  of	  other	  viral	  and	  host	  genome	  disruptions.	  A	  paradigm	  shift	  may	  be	  
necessary	  in	  HPV	  positive	  OPSCC	  to	  an	  understanding	  of	  obligatory	  viral	  integration,	  
the	  significance	  of	  which	  however,	  is	  yet	  to	  be	  fully	  elucidated.	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1 THESIS	  AIMS	  
Oropharyngeal	  Squamous	  Cell	  Carcinoma	  (OPSCC)	  incidence	  has	  shown	  a	  dramatic	  
increase	  over	  the	  last	  two	  decades	  in	  both	  United	  Kingdom	  clinical	  practice1,2	  and	  
beyond3.	  Evidence	  for	  the	  role	  of	  Human	  papillomavirus-­‐16	  (HPV16)	  in	  the	  rapidly	  
evolving	  increase	  varies	  between	  geographical	  regions	  yet	  it	  is	  clear	  that	  those	  
tumours	  demonstrated	  to	  be	  HPV	  positive	  are	  biologically	  distinct	  from	  HPV	  
negative	  malignancies4.	  	  
Detection	  of	  HPV,	  and	  the	  tests	  with	  which	  detection	  is	  made,	  in	  OPSCC	  serves	  to	  
provide	  capacity	  for	  disease	  stratification	  and	  also	  effective	  prognostication,	  
however	  the	  optimal	  test	  has	  not	  been	  defined.	  
Although	  these	  tests	  provide	  utility	  once	  malignant	  transformation	  has	  occurred,	  
predictive	  biomarkers	  have	  not	  been	  forthcoming	  for	  application	  in	  the	  variable	  
latent	  period	  between	  viral	  infection	  and	  the	  development	  of	  cancer.	  Following	  
establishment	  of	  cellular	  viral	  infection	  and	  a	  variable	  latent	  period,	  both	  epigenetic	  
alterations	  and	  detectable	  changes	  in	  the	  viral	  state	  (integration)	  have	  been	  
demonstrated	  during	  the	  progression	  to	  invasive	  disease5-­‐7.	  	  
	  	  
It	  is	  hypothesised	  that	  in	  United	  Kingdom	  Head	  &	  Neck	  Cancer	  clinical	  practice,	  
HPV16	  plays	  an	  aetiological	  role	  in	  a	  significant	  proportion	  of	  Oropharyngeal	  
Squamous	  Cell	  Carcinomas	  and	  that	  the	  currently	  available	  clinical	  tests	  
demonstrate	  wide	  variation	  in	  both	  diagnostic	  and	  prognostic	  capacity	  when	  
detecting	  HPV	  positive	  malignancy.	  
	  	  
2	  
Further,	  it	  is	  proposed	  that	  developments	  in	  diagnostic	  tests	  are	  capable	  of	  levels	  of	  
diagnostic	  stringency	  on	  clinical	  samples	  comparable	  to	  current	  research-­‐based	  gold	  
standard	  testing.	  	  	  	  
	  
In	  addition	  to	  prognostic	  discrimination	  and	  tumour	  stratification	  on	  the	  basis	  of	  
HPV	  status,	  this	  thesis	  aims	  to	  test	  the	  hypothesis	  that	  both	  the	  distinct	  epigenetic	  
profile	  of	  HPV+	  OPSCC	  and	  the	  occurrence	  of	  viral	  DNA	  integration	  play	  a	  critical	  
role	  in	  oncogenesis	  through	  their	  influence	  on	  viral	  oncogene	  expression.	  Further,	  it	  
is	  hypothesised	  that	  epigenetic	  changes	  offer	  clinically	  relevant	  predictive	  
biomarkers	  in	  HPV	  mediated	  oncogenesis.	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2 INTRODUCTION:	  HUMAN	  PAPILLOMAVIRUS	  RELATED	  
MALIGNANCY	  
2.1 HUMAN	  PAPILLOMAVIRUS	  
Classification	  
Papillomaviruses	  are	  a	  heterogeneous	  group	  of	  viruses	  traditionally	  classified	  as	  
part	  of	  the	  Papoviviridae	  family,	  however	  under	  recently	  adopted	  general	  criteria	  
established	  by	  the	  International	  Committee	  on	  the	  Taxonomy	  of	  Viruses	  in	  2004,	  
they	  are	  now	  exclusively	  recognised	  as	  part	  of	  the	  Papillomaviridae	  family	  8.	  
Papillomaviruses	  are	  classified	  by	  genus	  and	  type,	  of	  which	  in	  excess	  of	  120	  have	  
been	  fully	  sequenced9.	  The	  human	  papillomaviruses	  (HPV)	  are	  ubiquitous	  infectious	  
agents	  characterised	  by	  strict	  species	  specificity.	  They	  are	  obligate	  epitheliotropic	  
human	  pathogens	  capable	  of	  causing	  both	  benign	  and	  malignant	  disease	  in	  mucosal	  
or	  cutaneous	  tissues10.	  Figure	  1	  (reproduced	  from	  de	  Villiers	  et	  al)	  demonstrates	  a	  
phylogenetic	  tree	  of	  the	  papillomaviruses	  based	  on	  the	  nucleotide	  sequence	  of	  the	  
major	  capsid	  protein,	  L1,	  which	  classifies	  viruses	  into	  genera.	  By	  definition,	  each	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type	  shares	  less	  than	  90%	  DNA	  sequence	  homology	  within	  the	  L1	  gene11.	  
	  
Figure	  1:	  Phylogenic	  Tree	  of	  the	  Papillomaviridae	  family	  	  
The	  numbers	  adjacent	  to	  each	  branch	  denote	  the	  HPV	  type	  whilst	  the	  outermost	  numbers	  refer	  to	  
HPV	  species,	  each	  of	  which	  contains	  more	  than	  HPV	  type.	  All	  other	  abbreviations	  refer	  to	  animal	  
papillomavirus	  types	  (modified	  from	  de	  Villiers	  et	  al	  20058).	  
	  
The	  genus	  with	  greatest	  clinical	  relevance	  is	  referred	  to	  as	  the	  alpha-­‐
papillomaviruses12.	  It	  contains	  all	  HPV	  types	  associated	  with	  mucosal	  and	  genital	  
lesions,	  however	  for	  reasons	  of	  clinical	  utility	  the	  more	  common	  subtypes	  are	  
subdivided	  into	  high	  and	  low	  risk	  groups	  to	  reflect	  their	  relative	  risk	  of	  inducing	  
malignancy	  within	  the	  infected	  tissues.	  There	  are	  12	  low-­‐risk	  types	  (6,	  11,	  40,	  42,	  
43,	  44,	  54,	  61,	  70,	  72,	  81	  and	  CP6108)	  and	  15	  known	  high-­‐risk	  types	  (16,	  18,	  31,	  33,	  
35,	  39,	  45,	  51,	  52,	  56,	  58,	  59,	  68,	  73	  and	  82)11,	  the	  latter	  being	  those	  types	  which	  
are	  found	  preferentially	  in	  precancerous	  and	  cancerous	  lesions9.	  
The	  beta	  genus	  comprises	  viruses	  that	  preferentially	  infect	  cutaneous	  sites,	  many	  of	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which	  have	  been	  implicated	  in	  non-­‐melanoma	  skin	  cancers13.	  HPV	  types	  within	  the	  
remaining	  genera	  are	  typically	  associated	  with	  cutaneous	  papillomata.	  
	  
Structure	  &	  Function	  
Viral	  Structure	  
HPV	  is	  a	  small	  (50-­‐55	  nm	  in	  diameter),	  double	  stranded,	  circular	  DNA	  virus	  with	  an	  
icosahedral	  capsid	  coat	  derived	  from	  major	  and	  minor	  elements,	  L1	  and	  L2	  
respectively.	  The	  genome	  contains	  approximately	  7900	  base	  pairs	  with	  8	  or	  9	  open	  
reading	  frames	  (ORFs)	  within	  the	  individual	  DNA	  strand14.	  The	  viral	  genome	  can	  be	  
considered	  as	  having	  three	  distinct	  regions	  according	  to	  the	  location	  of	  coding	  
regions	  for	  early	  genes,	  late	  genes	  and	  a	  further	  non-­‐coding	  region	  located	  between	  






Figure	  2	  Component	  parts	  of	  the	  circular	  HPV	  genome	  and	  gene	  functions	  
The	  three	  distinct	  regions	  are	  comprised	  of	  the	  early	  genes	  (E1,	  E2	  &	  E4-­‐7),	  the	  late	  genes	  (L1	  &	  L2)	  
and	  the	  long	  control	  region	  (LCR).	  The	  internal	  numbering	  reflects	  the	  nucleotide	  numbers.	  The	  early	  
and	  late	  promoters	  are	  also	  identified;	  p97	  &	  p670	  respectively.	  (Modified	  from	  Ghittoni	  et	  al	  
201014).	  
	  
The	  LCR	  is	  approximately	  800	  bp	  in	  length	  and	  contains	  both	  the	  origin	  of	  
replication	  (ori)	  for	  the	  virus	  and	  several	  transcriptional	  binding	  sites	  thus	  extending	  
control	  over	  the	  expression	  of	  viral	  genes15.	  Transcriptional	  modulation	  of	  early	  
gene	  expression	  is	  a	  central	  regulatory	  event	  initially	  activated	  by	  host	  cell	  
transcription	  factors.	  Subsequently,	  self-­‐regulation	  ensues	  through	  the	  effects	  of	  
the	  viral	  E2	  gene15	  on	  four	  conserved	  binding	  sites	  specific	  to	  the	  E2	  viral	  gene	  
product	  (E2-­‐BS)	  each	  within	  the	  LCR	  of	  high-­‐risk	  HPV	  genomes.	  Each	  site	  confers	  
replication	  and	  transcriptional	  effects	  during	  the	  viral	  life	  cycle15,16,	  the	  variability	  of	  
which	  has	  been	  suggested	  to	  be	  influenced	  by	  both	  binding	  site	  methylation	  and	  
order	  of	  E2-­‐BS	  occupancy15,16.	  The	  E2BSs	  are	  located	  immediately	  upstream	  to	  the	  
early	  promoter	  (P97)	  that	  regulates	  early	  viral	  gene	  expression,	  including	  that	  of	  the	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viral	  oncogenes	  E6	  and	  E715.	  In	  addition	  to	  the	  early	  promoter	  located	  in	  the	  LCR,	  
HPV	  contains	  a	  late	  promoter	  (P670)	  that	  is	  located	  within	  the	  E7	  ORF.	  Transcripts	  
originating	  at	  the	  P97	  promoter	  are	  polycistronic,	  with	  the	  potential	  to	  encode	  both	  
E6	  and	  E7	  proteins	  as	  well	  as	  the	  replication	  and	  transcription	  control	  proteins	  E1	  
and	  E2	  respectively9.	  	  
Six	  genes	  are	  expressed	  in	  the	  early	  stages	  of	  infection	  (E1,	  E2,	  E4,	  E5,	  E6	  &	  E7).	  
Variation	  in	  the	  presence	  of	  particular	  early	  genes	  and	  in	  the	  length	  of	  the	  LCR	  has	  
been	  described,	  according	  to	  different	  viral	  subtypes14.	  Whilst	  E6	  and	  E7	  genes	  are	  
highly	  conserved	  for	  almost	  all	  subtypes	  studied	  thus	  far,	  E5	  presence	  shows	  
greater	  variability	  and	  is	  generally	  not	  found	  in	  the	  majority	  of	  beta	  types.	  	  
The	  E1	  and	  E2	  genes	  encode	  for	  regulatory	  proteins	  that	  have	  fundamental	  roles	  in	  
both	  viral	  replication	  and	  in	  transcription	  of	  the	  remaining	  genes.	  E6	  and	  E7,	  and	  to	  
a	  lesser	  extent	  E5,	  are	  involved	  in	  host	  cell	  transformation,	  and	  are	  termed	  major	  
oncoproteins	  to	  reflect	  their	  role	  in	  tumourgenesis4,17.	  	  All	  viral	  gene	  products	  are	  
detailed	  in	  Table	  1	  including	  their	  relative	  quantities	  and	  intracellular	  locations,	  a	  
more	  detailed	  discussion	  of	  the	  functions	  of	  the	  key	  early	  genes	  involved	  in	  viral	  
oncogenesis	  (E6	  and	  E7)	  is	  made	  below	  (Molecular	  Pathogenesis).	  
Viral	  E2	  gene	  plays	  a	  pivotal	  role	  in	  the	  balance	  between	  optimal	  or	  controlled	  early	  
gene	  transcription	  necessary	  for	  regulation	  of	  the	  viral	  life	  and	  infection	  cycles	  and	  
uncontrolled	  permissive	  replication	  of	  oncogenes	  associated	  with	  malignant	  
progression15.	  	  As	  already	  mentioned,	  E2	  is	  a	  natural	  transcriptional	  repressor	  of	  
other	  early	  genes,	  E6	  &	  E7	  through	  its	  effects	  on	  the	  LCR.	  
Viral	  capsid	  formation	  requires	  the	  protein	  products	  of	  the	  late	  genes,	  L1	  and	  L2.	  
The	  L1	  major	  capsid	  protein	  self-­‐assembles	  to	  complete	  the	  72	  pentamers	  of	  the	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Early	   	   	   	   	  
E1	   68-­‐75	  kDa	  	   Nuclear	   	  +	   Initiator	  of	  viral	  replication.	  Activation	  of	  
helicase	  and	  maintainer	  of	  episomal	  
viral	  DNA	  	  
E2	   50	  kDa	  	   Nuclear	   	  +	   Viral	  transcription	  (inc	  E6	  &	  E7	  
repression)	  and	  DNA	  replication.	  
Segregation	  of	  viral	  genomes.	  
E4	   17	  kDa	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Mostly	  fusion	  
protein	  with	  E1	  
Cytoplasm	   	  +++	   Facilitator	  of	  viral	  genome	  packing	  and	  
maturation	  of	  the	  viral	  particles.	  
Destruction	  of	  cytokeratin	  filaments.	  
Interaction	  with	  RNA	  helicase	  
E5	   8-­‐10	  kDa	  	   Cytoplasm	   	  +	   Interaction	  with	  EGF-­‐receptor,	  activates	  
PDGF-­‐receptor.	  Oncoprotein,	  allows	  
continuous	  cellular	  proliferation,	  delays	  
differentiation	  
E6	   16-­‐18	  kDa	  	   Nuclear	   	  +	   Major	  Oncoprotein.	  Deregulation	  of	  cell	  
division/cell	  cycle	  control.	  Degrades	  p53	  
in	  presence	  of	  E6-­‐AP.	  Multiple	  host	  
protein	  interactions	  
E7	   11	  kDa	   Nuclear	   	  ++	   Major	  Oncoprotein.	  Deregulation	  of	  cell	  
division/cell	  cycle	  control.	  Degrades	  
pRb.	  Multiple	  host	  protein	  interactions	  
Late	   	   	   	   	  
L1	   55-­‐60	  kDa	   Nuclear	   	  ++++	   Major	  Capsid	  Protein	  
L2	   70	  kDa	   Nuclear	   	  ++	   Minor	  Capsid	  Protein.	  Aids	  in	  viral	  
internalisation	  and	  localisation	  to	  
nucleus.	  
	  
Table	  1:	  Viral	  Protein	  Structure	  &	  Function	  
(Modified	  from	  Ruatava	  et	  al9).	  	  
	  
Viral	  Cellular	  Internalisation	  
For	  non-­‐enveloped	  viruses,	  such	  as	  HPVs,	  the	  capsid	  coat	  provides	  essential	  
protection	  for	  the	  viral	  nucleic	  acid	  whilst	  also	  being	  instrumental	  in	  the	  initial	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phase	  of	  cell	  infection.	  Viral	  binding	  and	  internalization	  into	  a	  target	  keratinocyte	  is	  
reliant	  upon	  both	  L1	  and	  L2	  components	  of	  the	  viral	  capsid19.	  However,	  before	  
attachment	  is	  possible	  there	  is	  a	  pre-­‐requisite	  for	  basement	  membrane	  exposure	  
beneath	  either	  cutaneous	  or	  mucosal	  keratinocytes,	  either	  by	  chemical	  or	  
mechanical	  microtrauma20.	  Subsequently,	  it	  is	  believed	  that,	  the	  viral	  particles	  bind	  
to	  exposed	  heparin	  sulphate	  proteoglycans	  (HSPG)	  on	  the	  basement	  membrane	  
inducing	  a	  conformational	  change	  in	  the	  capsid.	  This	  alteration	  allows	  exposure	  and	  
cleavage	  of	  the	  L2	  protein	  from	  the	  viral	  particle	  permitting	  a	  previously	  unexposed	  
region	  of	  the	  L1	  capsid	  protein	  to	  bind	  to	  receptors	  on	  adjacent	  keratinocytes19.	  
Laterally	  migrating	  epithelial	  cells,	  such	  as	  those	  involved	  in	  mucosal	  wound	  repair,	  
seem	  to	  be	  particularly	  susceptible	  to	  HPV	  binding	  as	  a	  result	  of	  high	  levels	  of	  
expression	  of	  the	  putative	  HPV	  receptor	  α6β4-­‐integrin21,22.	  
The	  understanding	  of	  the	  mechanisms	  of	  viral	  cell	  entry	  remains	  incomplete	  and	  
continues	  to	  be	  a	  source	  of	  scientific	  interest	  and	  debate,	  however	  that	  which	  is	  
presently	  understood	  was	  reviewed	  with	  clarity	  by	  Hovarth	  et	  al23.	  Following	  an	  
extended,	  and	  as	  yet	  undefined	  time	  period	  following	  viral-­‐receptor	  interaction,	  
internalisation	  of	  the	  virus	  occurs	  most	  probably	  via	  an	  endocytotic	  mechanism23,24.	  
Subsequently	  L2	  facilitates	  egress	  from	  the	  endosome	  and	  allowing	  viral	  DNA	  to	  
remain	  within	  the	  cytoplasm	  for	  a	  protracted	  period	  before	  a	  small	  proportion	  of	  





Following	  infection,	  the	  dsDNA	  viral	  genome	  remains	  in	  its	  circular	  form	  within	  the	  
infected	  keratinocytes	  cytoplasm	  and	  only	  limited	  viral	  replication	  occurs,	  
independent	  of	  normal	  cell	  cycle,	  to	  produce	  a	  low	  viral	  copy	  number	  of	  
approximately	  50-­‐100	  copies/cell25.	  HPV	  encodes	  only	  a	  single	  DNA	  replication	  
enzyme	  (E1),	  a	  DNA	  helicase11	  and	  as	  such	  must	  harness	  the	  cellular	  transcriptional	  
and	  translational	  machinery	  of	  the	  host	  cell	  to	  permit	  increased	  DNA	  amplification	  
and	  ultimately	  production	  of	  encapsidated	  progeny	  virions	  for	  subsequent	  
release26.	  	  
To	  this	  end,	  HPV	  exploits	  the	  natural	  differentiation	  of	  keratinocytes,	  from	  basal	  
stem	  cells	  through	  to	  the	  terminally	  differentiated	  keratinocytes,	  present	  in	  the	  
most-­‐superficial	  layers	  of	  the	  stratified	  squamous	  epithelium,	  to	  achieve	  genome	  
amplification	  and	  expression	  of	  capsid	  proteins27.	  HPV	  DNA	  replicates	  during	  the	  S	  
phase	  of	  the	  cell	  cycle,	  in	  concert	  with	  host	  cell	  chromosomal	  replication.	  And	  the	  
initiation	  of	  replication	  is	  the	  same	  as	  that	  for	  all	  eukaryotic	  chromosomes.	  E2	  is	  the	  
initiating	  factor	  at	  the	  HPV	  origin	  of	  replication	  (ori)	  within	  the	  LCR	  and	  facilitates	  E1	  
recruitment,	  which	  in	  turn	  utilises	  cellular	  molecular	  of	  the	  replication	  machinery	  
(polymerases	  and	  replication	  proteins)28.	  
Ultimately,	  the	  infected	  keratinocyte	  will	  have	  a	  viral	  copy	  number	  exceeding	  1000	  
viral	  copies/cell	  with	  associated	  abundant	  expression	  of	  the	  viral	  oncogenes	  E6	  and	  
E7	  and	  the	  late	  genes	  L1	  and	  L2.	  It	  is	  the	  viral	  oncogenes	  that	  play	  the	  most	  
significant	  role	  at	  this	  stage,	  as	  the	  cell	  will	  no	  longer	  be	  naturally	  mitotically	  active	  
and	  hence	  it	  is	  reactivation	  of	  the	  cell	  cycle	  by	  E6	  and	  E7	  that	  creates	  an	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environment	  permissive	  of	  viral	  DNA	  replication.	  It	  is	  this	  feature	  too	  that,	  albeit	  
rarely,	  allows	  disregulation	  of	  growth	  control	  and	  creates	  the	  potential	  for	  
malignant	  transformation26,	  although	  in	  this	  situation	  it	  is	  both	  spatial	  and	  
quantitative	  deregulation	  of	  tight	  oncogene	  transcriptional	  control	  that	  occurs,	  
leading	  to	  production	  of	  E6	  and	  E7	  throughout	  the	  epithelium	  including	  the	  basal	  
layer6.	  The	  latter,	  “transforming”	  infection	  is	  discussed	  in	  greater	  detail	  later	  (2.4).	  
The	  duration	  of	  the	  process,	  from	  infection	  to	  viral	  sheading,	  follows	  the	  normal	  
squamous	  epithelial	  turnover	  of	  approximately	  3	  weeks,	  however	  this	  is	  dependent	  
up	  on	  the	  specific	  site	  and	  as	  such	  may	  take	  considerably	  longer.	  	  
	  
Host	  Immune	  Response,	  Natural	  History	  of	  Infection	  &	  Clearance	  
HPV	  infection	  can	  be	  characterised	  as	  acute,	  chronic	  or	  latent,	  however	  it	  is	  the	  
persistent	  infection,	  whether	  chronic	  or	  latent,	  that	  exposes	  the	  cell	  to	  an	  
environment	  suitable	  for	  cellular	  transformation.	  	  
In	  establishing	  a	  persistent	  infection,	  evasion	  of	  the	  host	  immune	  surveillance	  
mechanisms	  is	  essential29.	  The	  essential	  role	  of	  the	  immune	  system	  in	  controlling	  
HPV	  infections	  has	  been	  deduced	  from	  studies	  of	  immunocompromised	  women30.	  
In	  an	  intact	  immune	  system	  it	  is	  the	  three	  oncoproteins,	  E5,	  E6	  and	  E7,	  that	  
orchestrate	  immune	  escape	  both	  individually	  and	  in	  concert	  with	  one	  and	  other29.	  
In	  HPV	  positive	  tumour	  cells,	  immunogenic	  peptides	  from	  both	  E6	  ad	  E7	  proteins	  
are	  not	  processed	  or	  transported	  to	  the	  cell	  surface	  effectively,	  nor	  presented	  
successfully.	  HPV	  E6	  and	  E7	  target	  type	  I	  interferon	  (IFN)	  that	  is	  produced	  by	  cells	  in	  
response	  to	  viral	  infection.	  E7	  inhibits	  induction	  of	  IFN-­‐	  α	  whilst	  E6	  binds	  to	  the	  IFN-­‐
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associated	  transcription	  complex,	  ISG	  factor-­‐3,	  preventing	  transcription	  of	  IFN-­‐β.	  E5	  
protein	  reduces	  antigen	  presentation	  through	  selective	  down	  regulation	  of	  
components	  of	  the	  MHC/HLC	  Class	  I	  such	  that	  cytotoxic	  T	  lymphocytes	  antigen	  
presentation	  is	  diminished	  whilst	  natural	  killer	  cell	  inhibitory	  ligands	  are	  still	  
apparent31.	  
Although	  there	  is	  a	  survival	  advantage	  to	  the	  virus	  being	  able	  to	  evade	  the	  host	  
immune	  response,	  this	  advantage	  is	  not	  preserved	  once	  development	  of	  
malignancy	  has	  occurred	  and	  completion	  of	  the	  viral	  life	  cycle	  fails,	  due	  to	  a	  stalled	  
progression	  to	  late	  phase	  viral	  proteins.	  
	  
2.2 ORAL	  &	  OROPHARYNGEAL	  SQUAMOUS	  CELL	  CARCINOMA	  
Epidemiology	  
Head	  &	  Neck	  Squamous	  Cell	  Carcinoma	  (HNSCC)	  is	  the	  sixth	  commonest	  cancer	  
worldwide	  with	  approximately	  600,000	  new	  cases	  diagnosed	  annually,	  accounting	  
for	  5%	  of	  all	  tumours32.	  Tumours	  from	  oral	  and	  oropharyngeal	  subsites	  account	  for	  
400,000	  of	  these	  malignancies	  and,	  by	  comparison	  to	  other	  head	  and	  neck	  subsites,	  
there	  has	  been	  a	  disproportionate	  increase	  in	  incidence	  over	  recent	  years	  1.	  A	  
similar	  picture	  has	  become	  apparent	  in	  the	  United	  Kingdom;	  indeed	  a	  considerable	  
proportion	  of	  the	  recent	  increase	  in	  HNSCC	  incidence	  is	  due	  directly	  to	  the	  influence	  
of	  changes	  in	  OPSCC	  incidence.	  OPSCC	  incidence	  has	  risen	  from	  a	  direct	  
standardised	  population	  rate	  of	  1:100,000	  to	  2.5:100,000	  in	  the	  period	  from	  1990	  –	  
2006,	  whilst	  in	  the	  same	  period	  Oral	  Squamous	  Cell	  Carcinoma	  (OSCC)	  incidence	  
remained	  relatively	  stable	  between	  2.5	  and	  3:100,0002.	  Data	  released	  from	  the	  US	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National	  Cancer	  Institute’s	  Surveillance,	  Epidemiology,	  and	  End	  Results	  (SEER)	  
indicate	  a	  similar	  steady	  rise	  in	  OPSCC	  incidence	  since	  1973	  during	  which	  time	  
evidence	  of	  exposure	  to	  tobacco	  smoke	  has	  declined33.	  
	  
Wide	  variation	  in	  rates	  of	  OSCC	  and	  OPSCC	  are	  apparent	  across	  the	  globe,	  with	  
areas	  of	  particularly	  high	  incidence	  centered	  in	  South	  and	  Southeast	  Asia,	  Latin	  
America	  and	  small	  regions	  within	  the	  Eastern	  Europe34,35.	  When	  considered	  in	  a	  
global	  context,	  the	  United	  Kingdom	  has	  comparatively	  low	  rates	  of	  oral	  and	  
oropharyngeal	  SCC	  with	  the	  combined	  diagnoses	  accounting	  for	  approximately	  3%	  
of	  all	  malignancies.	  Table	  1	  demonstrates	  the	  incidence	  in	  absolute	  terms	  for	  the	  
United	  Kingdom	  from	  2009.	  
	  
Number	  of	  UK	  new	  cases	  of	  Oral	  &	  Oropharyngeal	  SCC	  (2009)	  
Site	   	  	   Males	   Females	   Persons	   M:F	  ratio	  
Lip	  (ICD10	  C00)	  	   217	   124	   341	   1.8:1	  
Tongue	  (ICD10	  C01-­‐02)	  	   1239	   675	   1914	   1.8:1	  
Mouth	  (ICD10	  C03-­‐06)	  	   1074	   762	   1836	   1.4:1	  
Oropharynx	  (ICD10	  C09-­‐10)	   989	   357	   1346	   2.8:1	  
Total	  OSCC	  &	  OPSCC	   3,519	   1918	   5,437	   2:1	  
	  
Table	  2:	  United	  Kingdom	  annual	  Incidence	  for	  OSCC	  &	  OPSCC	  	  
(Modified	  from	  Cancer	  Research	  UK	  Cancer	  Stats,	  2009).	  
	  
Until	  relatively	  recently	  survival	  from	  HNSCC	  has	  displayed	  only	  modest	  
improvements36	  despite	  refinement	  to	  surgical	  techniques,	  introduction	  of	  
variations	  in	  radiation	  therapy	  delivery	  and	  the	  advent	  of	  new	  generation	  
chemotherapeutics37.	  As	  will	  be	  discussed	  in	  greater	  depth	  below	  (aetiology)	  the	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contribution	  of	  factors	  influencing	  causation	  other	  than	  tobacco	  and	  alcohol	  usage	  
have	  become	  more	  apparent	  recently.	  The	  evolving	  role	  of	  human	  papillomavirus	  in	  
head	  and	  neck	  cancer	  has	  the	  potential	  to	  drastically	  change	  incidence	  and	  survival	  
particularly	  in	  subsites	  most	  likely	  to	  harbor	  HPV-­‐mediated	  malignancy3,38.	  
	  
Aetiology	  
The	  aetiology	  of	  squamous	  malignancies	  of	  the	  head	  and	  neck	  is	  multifactorial	  
however	  the	  majority	  of	  these	  malignancies	  are	  related	  to	  either	  consumption	  or	  
usage	  of	  tobacco	  in	  its	  various	  forms,	  areca	  nut/betel	  quid	  chewing	  and	  or	  alcohol35.	  	  
There	  is	  also	  mounting	  evidence	  to	  suggest	  that	  deficiency	  in	  particular	  dietary	  
micronutrients	  has	  an	  increasing	  influence	  on	  aetiology,	  a	  trend	  that	  may	  persist	  
particularly	  in	  developing	  countries39.	  	  Factors	  specific	  to	  particular	  sites	  within	  the	  
head	  and	  neck	  have	  also	  been	  reported,	  in	  particular	  UV	  light	  inducing	  malignant	  
change	  particularly	  in	  sun	  exposed	  areas	  (lip)35,	  and,	  within	  the	  main	  oral	  cavity,	  
poor	  oral	  hygiene	  with	  its	  associated	  bacterial	  infections	  with	  or	  without	  chronic	  
trauma	  from	  so	  called	  dental	  factors	  have	  been	  cited40.	  In	  addition	  to	  
environmental	  factors,	  an	  inherited	  genetic	  predisposition	  is	  involved	  in	  a	  small	  
proportion	  of	  upper	  aero-­‐digestive	  cancers35.	  
Awareness	  of	  histological	  similarities	  between	  anogenital	  and	  upper	  aerodigestive	  
mucosal	  surfaces	  combined	  with	  an	  increasing	  understanding	  of	  the	  aetiological	  
role	  of	  HPV	  in	  anogenital	  malignancy,	  particularly	  in	  cervical	  cancer,	  lead	  
investigators	  to	  explore	  the	  role	  of	  HPV	  in	  head	  and	  neck	  mucosal	  malignancy	  and	  
premalignancy41-­‐43.	  In	  2009,	  the	  International	  Agency	  for	  Research	  on	  Cancer	  (IARC)	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published	  an	  important	  monograph44	  summarising	  those	  infectious	  agents	  for	  
which	  causation	  has	  been	  established	  beyond	  doubt.	  Consistent	  with	  a	  mounting	  
body	  of	  evidence,	  the	  IARC	  found	  Human	  papillomavirus	  type	  16	  (HPV-­‐16)	  to	  be	  
causal	  in	  squamous	  cell	  cancer	  (SCC)	  of	  the	  oral	  cavity	  and	  oropharynx.	  	  
At	  a	  molecular	  level,	  head	  and	  neck	  carcinogenesis	  is	  a	  complex	  multistep,	  
multifactorial	  process	  containing	  a	  myriad	  of	  genetic	  and	  epigenetic	  abnormalities	  
in	  DNA	  repair,	  cell	  signaling,	  cellular	  differentiation,	  angiogenesis,	  apoptosis	  and	  cell	  
cycle	  regulation45.	  	  Whilst	  recognising	  the	  considerable	  role	  that	  genetic	  alterations	  
play,	  this	  research	  sought	  to	  explore	  the	  key	  epigenetic	  alterations	  in	  HPV	  mediated	  
HNSCC	  which	  to	  date	  have	  received	  little	  attention.	  
	  
Regional	  Anatomy	  
Oral	  and	  Oropharyngeal	  Squamous	  Cell	  Carcinoma	  (OSCC	  and	  OPSCC)	  describes	  the	  
squamous	  malignancies	  arising	  from	  mucosal	  surfaces	  of	  the	  lip,	  tongue	  and	  mouth	  
(oral	  cavity	  [ICD-­‐10:	  C00,	  C02-­‐06])	  and	  oropharynx	  [ICD-­‐10:	  C01,	  C09-­‐10]46,47.	  This	  
subgroup	  of	  head	  and	  neck	  cancer	  excludes	  salivary	  malignancies	  and	  tumours	  
arising	  within	  other	  subsites	  of	  the	  pharynx.	  	  	  
Despite	  the	  close	  physical	  proximity	  and	  similar	  embryological	  development48,49,	  the	  
distinction	  between	  oral	  cavity	  and	  oropharynx	  is	  important	  when	  considering	  the	  
role	  of	  virally	  mediated	  malignancy.	  A	  considerable	  proportion,	  although	  by	  no	  
means	  all,	  of	  the	  evidence	  for	  HPV	  positive	  malignancy	  in	  the	  head	  and	  neck	  refers	  
to	  the	  oropharynx50-­‐52.	  The	  oral	  cavity	  is	  the	  mucosal	  lined	  region	  extending	  from	  
the	  lips	  anteriorly	  to	  the	  junction	  of	  the	  anterior	  2/3	  and	  posterior	  1/3	  of	  the	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tongue	  posteriorly,	  the	  palatoglossal	  arch	  posterolaterally	  and	  the	  soft	  palate	  
superiorly49.	  	  The	  oropharynx	  is	  bounded	  by	  the	  soft	  palate	  superiorly,	  the	  base	  of	  
the	  tongue	  (posterior	  1/3	  of	  the	  tongue)	  to	  the	  level	  of	  the	  epiglottis	  inferiorly	  and	  
the	  palatoglossal	  and	  palatopharyngeal	  arches	  laterally.	  Posteriorly,	  it	  is	  enclosed	  by	  
the	  posterior	  pharyngeal	  wall49.	  A	  particularly	  important	  constituent	  part	  of	  the	  
oropharynx,	  which	  contrasts	  markedly	  with	  the	  oral	  cavity,	  is	  the	  inclusion	  of	  
abundant	  lymphoid	  tissue	  arranged	  in	  an	  incomplete	  ring	  or	  arch	  superiorly	  –	  
Waldeyer’s	  ring49.	  It	  has	  been	  suggested	  that	  regional	  variation	  in	  HPV	  related	  
malignancy	  within	  the	  head	  and	  neck	  may,	  at	  least	  in	  part,	  be	  related	  to	  the	  
lymphoid	  tissue	  of	  the	  oropharynx53.	  The	  palatine	  tonsils	  in	  particular	  seem	  to	  be	  
disproportionally	  effected	  by	  HPV	  positive	  tumours	  as	  will	  be	  discussed	  in	  greater	  
depth	  below	  (2.3	  Epidemiology	  of	  HPV-­‐mediated	  Malignancy).	  These	  collections	  of	  
lymphoid	  tissue,	  on	  each	  side	  of	  the	  oropharynx	  in	  the	  interval	  or	  intertonsillar	  cleft	  
between	  the	  palatoglossal	  and	  palatopharyngeal	  arches,	  are	  covered	  by	  stratified	  
squamous	  epithelium	  and	  incorporate	  multiple	  invaginations	  or	  crypts.	  The	  reticular	  
crypts	  greatly	  increase	  the	  tonsils	  surface	  area	  and,	  importantly,	  are	  composed	  of	  
specialised	  epithelia	  with	  both	  immune	  and	  secretory	  features54	  that	  may	  facilitate	  
access	  of	  oral	  pathogens,	  including	  HPV,	  to	  the	  basement	  membrane55.	  	  
Functionally,	  both	  the	  oral	  cavity	  and	  the	  oropharynx	  play	  critical	  roles	  in	  speech,	  
mastication	  and	  swallowing.	  The	  detrimental	  influence	  on	  these	  functions	  caused	  
by	  both	  the	  tumour	  and	  subsequent	  cancer	  treatment	  varies,	  with	  more	  anterior	  
lesions	  altering	  speech	  and	  mastication	  to	  a	  larger	  extent	  and	  more	  posterior	  
lesions	  causing	  greater	  swallowing	  impairment56,57.	  
	   	  
	  	  
18	  
2.3 EPIDEMIOLOGY	  OF	  HPV-­‐MEDIATED	  MALIGNANCY	  
Global	  Incidence	  &	  Subsites	  
Global	  cancer	  incidence	  in	  2008	  was	  estimated	  to	  exceed	  12.7	  million	  new	  cases	  
accounting	  for	  7.6	  million	  cancer	  related	  deaths58.	  Although	  there	  is	  considerable	  
global	  inter-­‐regional	  variation,	  an	  estimated	  16%	  of	  all	  human	  malignancies	  result	  
from	  chronic	  infection,	  one	  third	  of	  which	  are	  attributable	  directly	  to	  HPV	  infection.	  
In	  addition	  to	  the	  human	  costs	  of	  HPV	  related	  malignancy,	  there	  is	  also	  a	  substantial	  
and	  mounting	  financial	  cost	  to	  tax	  payers	  for	  HPV	  related	  medical	  care.	  In	  2000	  
alone,	  the	  direct	  costs	  associated	  with	  HPV	  infection	  approached	  US$3	  billion,	  the	  
majority	  of	  which	  was	  spent	  on	  monitoring	  and	  initial	  management	  of	  HPV-­‐related	  
cervical	  premalignant	  and	  malignant	  disease59.	  
As	  described	  above,	  HPV	  induces	  malignancy	  in	  both	  cutaneous	  and	  mucosal	  
surfaces.	  	  
At	  present,	  the	  greatest	  burden	  of	  HPV	  related	  malignancy	  is	  cervical	  cancer,	  which	  
is	  the	  second	  most	  common	  cancer	  amongst	  women	  with	  approximately	  500,000	  
new	  cases	  and	  274,000	  deaths	  annually60.	  Cancers	  of	  the	  vagina	  and	  the	  external	  
genitalia,	  namely	  the	  penis	  and	  vulva,	  are	  likewise	  frequently	  virally	  mediated	  
however	  by	  comparison	  to	  the	  cervix,	  where	  virtually	  all	  cases	  are	  HPV	  DNA	  
positive,	  vaginal	  cancer	  is	  64-­‐91%	  HPV	  positive	  and	  only	  40-­‐60%	  of	  all	  penile	  and	  
vulval	  cancers	  HPV	  positive60.	  Cancer	  of	  the	  mucosal	  lining	  of	  the	  anal	  canal	  have	  a	  
similarly	  strong	  association	  with	  HPV	  DNA	  infection,	  with	  88-­‐94%	  of	  these	  cancers	  
proving	  positive	  for	  HPV1661,62.	  HPV	  positive	  malignancy	  in	  the	  head	  and	  neck	  
region	  is	  greatest	  in	  the	  oropharynx	  (OPSCC)	  where	  approximately	  40%	  of	  all	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tumours	  globally	  are	  HPV	  positive	  albeit	  with	  considerable	  regional	  variation3.	  
Although	  presently	  cervical	  cancer	  is	  the	  largest	  group	  of	  HPV	  positive	  malignancy	  
by	  number,	  extrapolations	  of	  current	  trends	  in	  HPV	  positive	  OPSCC	  incidence	  
suggest	  that	  this	  group	  may	  exceed	  cervical	  cancer	  by	  202063.	  In	  head	  and	  neck	  
subsites	  outwith	  the	  oropharynx	  the	  incidence	  and	  role	  of	  HPV	  in	  cancers	  remains	  
contentious	  and	  controversial52,64	  however	  it	  was	  deemed	  sufficient	  by	  the	  
International	  Agency	  for	  Research	  on	  Cancer	  (IARC)	  to	  conclude	  that	  HPV	  was	  
causative	  in	  both	  oral	  and	  oropharyngeal	  cancer65.	  
Evidence	  for	  HPV	  as	  an	  aetiological	  factor	  in	  cutaneous	  malignancy	  has	  been	  
available	  for	  more	  than	  30	  years,	  particularly	  within	  those	  individuals	  with	  pre-­‐
existing	  immunosuppression,	  however	  a	  direct	  causal	  relationship	  has	  yet	  to	  be	  
formally	  established66.	  It	  may	  be	  that	  the	  influence	  of	  HPV	  in	  skin	  malignancy	  comes	  
as	  a	  co-­‐carcinogen	  with	  UV	  radiation	  or	  immunosuppression62.	  
	  
Of	  the	  15	  high	  risk	  subtypes	  of	  HPV,	  HPV16	  &	  HPV18	  are	  the	  two	  most	  common	  
subtypes	  involved	  in	  mucosal	  malignancy.	  It	  is	  generally	  accepted	  that	  all	  cervical	  
cancers	  are	  HPV	  positive	  and	  HPV16	  &	  HPV18	  are	  found	  in	  70-­‐75%	  of	  cases62.	  
Within	  HPV	  positive	  anal,	  oropharyngeal,	  vulval,	  vaginal	  and	  penile	  malignancies	  the	  
dominant	  subtype	  is	  invariably	  HPV16	  although	  there	  is	  some	  evidence	  for	  the	  role	  
of	  HPV18	  in	  vulval,	  anal	  and	  penile	  cancer	  and	  to	  lesser	  extent	  OPSCC62.	  	  Remaining	  
high-­‐risk	  subtypes	  have	  variable	  influence	  by	  site	  and,	  in	  the	  head	  and	  neck	  in	  




HPV	  Carriage,	  Clearance	  and	  Consequences	  of	  Persistence.	  	  
The	  prevalence	  of	  genital	  HPV	  infection	  in	  women	  within	  the	  US	  population	  has	  
been	  estimated	  at	  greater	  than	  40%	  for	  all	  subtypes	  and	  4.7%	  specifically	  for	  
HPV1667.	  Although	  it	  is	  without	  question	  that	  HPV	  infection	  is	  a	  fundamental	  
necessity	  for	  the	  development	  of	  HPV-­‐related	  malignancy,	  the	  relationship	  between	  
HPV	  carriage,	  HPV	  clearance	  or	  persistence	  and	  malignancy	  is	  yet	  to	  be	  elucidated	  
fully	  in	  all	  sites.	  	  	  
The	  greatest	  clarity	  exists	  in	  cervical	  cancer	  where	  it	  is	  considered	  that	  in	  virtually	  
all	  cases,	  cancer	  arises	  in	  a	  sequential	  or	  step-­‐wise	  fashion;	  acute	  viral	  infection	  is	  
followed	  by	  detectable	  viral	  persistence	  that	  over	  decades	  leads	  to	  cervical	  
precancer	  and	  invasion68.	  	  
	  
	  
Figure	  3	  The	  Natural	  History	  of	  Cervical	  HPV	  infection	  and	  Carcinogenesis	  
Representation	  of	  the	  risk	  associated	  with	  viral	  persistence	  and	  progression.	  Left	  graph	  
demonstrates	  proportional	  population	  based	  viral	  infection	  outcomes	  from	  infection	  to	  either	  
clearance	  or	  cervical	  dysplasia.	  Right	  graph	  depicts	  the	  implications	  of	  virally	  induced	  dysplasia	  




However,	  viral	  clearance	  by	  half	  of	  newly	  infected	  individuals	  interrupts	  this	  process	  
within	  the	  first	  6	  months,	  and	  90%	  of	  women	  will	  be	  clear	  of	  HPV	  infection	  by	  12	  
months68.	  As	  Figure	  3	  indicates,	  the	  rate	  of	  HPV	  clearance	  from	  the	  cervix	  of	  
infected	  women	  does	  subsequently	  diminish	  over	  time	  and,	  by	  contrast	  to	  
infections	  that	  clear,	  cancer	  risk	  increases	  substantially	  for	  the	  5%	  of	  women	  whose	  
infection	  persists.	  	  
Infection	  with	  high-­‐risk	  HPV	  is	  almost	  ubiquitous	  for	  the	  sexually	  active	  
population69,70	  as	  HPV	  infections	  are	  easily	  transmitted	  by	  a	  variety	  of	  sexual	  
contacts,	  either	  to	  or	  from	  the	  anogenital	  tract	  to	  the	  oral	  cavity.	  Gillison	  et	  al71	  
reported	  the	  first	  population-­‐based	  study	  to	  concurrently	  examine	  the	  
epidemiology	  of	  oral	  HPV	  infection	  among	  both	  men	  and	  women	  following	  analysis	  
of	  data	  from	  the	  National	  Health	  and	  Nutrition	  Examination	  Survey	  (NHANES).	  The	  
authors	  found	  infection	  with	  any	  HPV	  type	  amongst	  men	  and	  women	  aged	  14	  –	  69	  
was	  6.9%	  and	  for	  HPV16	  specifically,	  only	  1%.	  Of	  particular	  interest	  was	  a	  5-­‐fold	  
increase	  in	  HPV16	  prevalence	  in	  the	  oral	  cavity	  of	  men	  and	  a	  bimodal	  distribution	  of	  
incidence	  by	  age,	  with	  peaks	  early	  in	  the	  forth	  decade	  of	  life	  and	  again	  in	  the	  early	  
seventh	  decade71.	  The	  oral	  infection	  rate	  is	  considerably	  lower	  than	  that	  seen	  in	  the	  
genital	  tract	  and	  it	  remains	  to	  be	  seen	  whether	  these	  static	  data	  collections	  are	  
stable	  or	  more	  dynamic,	  as	  such	  reflecting	  a	  fundamental	  change	  in	  global	  infection	  
and	  carriage	  providing	  an	  insight	  into	  the	  mechanisms	  behind	  rising	  HPV	  positive	  
OPSCC	  rates.	  	  It	  is	  similarly	  unclear	  why	  males	  have	  a	  significantly	  elevated	  oral	  HPV	  
carriage	  rate,	  however	  one	  hypothesis	  centers	  on	  the	  elevated	  burden	  of	  viral	  copy	  
number	  within	  an	  infected	  cervix	  by	  comparison	  to	  the	  penis,	  and	  follows	  therefore	  
that	  viral	  transmission	  via	  oral	  sex	  is	  more	  likely	  from	  a	  woman	  to	  a	  man	  (cervix	  to	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mouth)	  than	  visa	  versa	  (penis	  to	  mouth).	  Evidence	  of	  increased	  HPV	  transmission	  
amongst	  heterosexuals	  from	  cervix	  to	  penis,	  rather	  than	  penis	  to	  cervix	  would	  seem	  
to	  support	  this	  hypothesis72.	  
An	  increasing	  body	  of	  evidence	  suggests	  that	  oral	  HPV	  infection	  is	  unlikely	  to	  be	  
associated	  with	  casual	  non-­‐sexual	  contact.	  Infection	  seems	  consistently	  associated	  
with	  sexual	  behavior,	  exemplified	  by	  an	  8-­‐fold	  increase	  in	  infection	  in	  sexually	  
experienced	  individuals	  and	  a	  significant	  increase	  in	  infection	  rates	  as	  number	  of	  
sexual	  partners	  increases71.	  
The	  natural	  history	  of	  oral	  HPV	  infection	  is	  similar	  to	  that	  of	  anogential	  disease	  with	  
most	  prevalent	  infections	  having	  been	  cleared	  within	  the	  first	  12	  months73,74.	  	  Due	  
to	  the	  lack	  of	  a	  clinically	  apparent	  dysplastic	  lesion	  in	  HPV	  positive	  OPSCC,	  
analogous	  to	  that	  seen	  in	  the	  cervix	  (cervical	  intraepithelial	  neoplasia,	  CIN),	  it	  is	  
difficult	  to	  describe	  a	  temporal	  relationship	  between	  persistent	  infection	  and	  
neoplastic	  change.	  As	  is	  the	  case	  for	  the	  natural	  history	  of	  HPV	  infection,	  much	  of	  
the	  understanding	  of	  viral	  persistence	  and	  epithelial	  transformation	  therefore	  is	  
gleaned	  from	  cervical	  cancer	  data.	  	  	  
Analysis	  of	  pooled	  data	  from	  eight	  large	  observation	  studies	  comprising	  5642	  cases	  
of	  HNSCC	  and	  6069	  controls	  demonstrated	  that	  the	  risk	  of	  oropharynx	  cancer	  in	  
particular	  was	  associated	  with	  six	  or	  more	  lifetime	  sexual	  partners	  (odds	  ratio	  1.25;	  
95%	  CI	  1.01	  –	  1.54)	  and	  of	  greater	  significance,	  four	  or	  more	  oral	  sex	  partners	  of	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Several	  case-­‐series	  conducted	  in	  the	  late	  1990s	  and	  early	  2000s	  evaluated	  the	  point	  
prevalence	  of	  HPV	  infection	  within	  oropharyngeal	  cancers	  and	  culminated	  in	  a	  
systematic	  review	  by	  Kreimer	  et	  al.76	  in	  2005	  that	  concluded	  that	  over	  one	  third	  
(35.6%)	  of	  OPSCC	  contained	  HPV	  DNA	  (87%	  of	  which	  were	  HPV16).	  	  In	  addition	  to	  
viral	  DNA	  presence,	  several	  studies	  have	  added	  to	  the	  burden	  of	  proof	  necessary	  to	  
conclude	  that	  HPV	  has	  a	  causal	  relationship	  in	  these	  tumours.	  These	  studies	  
demonstrated	  localization	  of	  HPV	  DNA	  to	  the	  cell	  nucleus77,	  evidence	  of	  viral	  DNA	  
integration77,78,	  elevated	  viral	  copy	  number	  in	  malignancy79	  and,	  perhaps	  most	  
importantly,	  evidence	  of	  viral	  oncogene	  expression80.	  
Outwith	  the	  oropharynx,	  HPV	  DNA	  presence	  in	  HNSCC	  cases	  was	  reported	  to	  be	  
lower	  yet	  still	  a	  significant	  minority	  of	  cases.	  In	  the	  systematic	  review	  mentioned	  
previously,	  23.5%	  of	  Oral	  SCC	  and	  24%	  of	  laryngeal	  SCC	  were	  similarly	  HPV	  DNA	  
positive76.	  To	  date,	  the	  same	  supporting	  molecular	  evidence	  as	  is	  available	  for	  the	  
oropharynx	  has	  been	  lacking.	  In	  addition	  to	  sample	  testing	  inadequacies,	  there	  has	  
been	  a	  recognised	  failure	  to	  adhere	  to	  strict	  site	  classification64.	  	  The	  literature	  has	  a	  
variety	  of	  HNSCC	  site	  terms	  that	  are	  applied	  differently	  by	  different	  authors	  leading	  
to	  potential	  confusion;	  oral	  SCC	  (OSCC)	  can	  be	  used	  to	  imply	  the	  oral	  cavity	  or	  the	  
wider	  oral	  and	  oropharyngeal	  region	  and	  similarly	  OSCC	  has	  been	  used	  in	  specific	  
reference	  to	  the	  oropharynx	  alone.	  There	  is	  therefore,	  an	  understandable	  potential	  
for	  misclassification	  of	  some	  HPV	  positive	  oropharynx	  cancers	  as	  “oral”	  either	  
clinically	  or	  literally	  in	  publication64.	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As	  such,	  additional	  molecular	  and	  epidemiologic	  studies	  with	  strict	  site	  classification	  
have	  been	  called	  for	  to	  further	  evaluate	  the	  association	  of	  HPV	  infection	  with	  oral	  
cavity	  cancer	  and	  larynx	  cancer38.	  This	  carries	  particular	  relevance	  when	  
consideration	  is	  given	  to	  the	  substantial	  contribution	  that	  these	  subsites	  make	  to	  
total	  global	  HNSCC	  cases.	  Even	  a	  modest	  HPV-­‐attributable	  proportion	  to	  either	  oral	  
or	  larynx	  cancer	  would	  translate	  to	  a	  substantial	  tumour	  burden.	  
Whilst	  the	  proportion	  of	  HNSCC	  cases	  that	  are	  HPV	  positive	  varies	  by	  head	  and	  neck	  
subsite,	  the	  same	  is	  also	  true	  more	  generally	  between	  different	  populations	  and	  
global	  geographical	  regions38.	  A	  case	  control	  study	  conducted	  in	  Latin	  America	  and	  
Central	  Europe	  between	  1998	  and	  2003	  reported	  HPV	  prevalence	  in	  OPSCC	  of	  
4.4%81	  whilst	  Scandinavian	  data	  from	  2006-­‐7	  indicated	  that	  OPSCC,	  specifically	  from	  
the	  tonsil,	  demonstrated	  HPV	  positive	  malignancy	  in	  93%	  of	  cases82.	  When	  
considered	  collectively,	  HPV	  prevalence	  in	  OPSCC	  from	  North	  American	  studies	  was	  
47%,	  whilst	  in	  Asia	  this	  was	  46%	  and	  28%	  for	  Western	  Europe.	  This	  geographical	  
heterogeneity	  in	  HPV	  positive	  OPSCC	  rates	  is	  likely	  to	  be	  influenced	  both	  by	  sexual	  
practices	  in	  the	  differing	  ethnic	  and	  cultural	  groups	  and	  also	  the	  extent	  to	  which	  
tobacco	  and	  other	  traditional	  HNSCC	  risk	  factors	  play	  in	  populations38.	  	  
Despite	  variations	  in	  the	  HPV	  positive	  fraction	  of	  OPSCC	  in	  various	  regions,	  there	  is	  
consistency	  in	  the	  trend	  of	  increasing	  overall	  OPSCC	  incidence	  over	  time	  
irrespective	  of	  geography63,83-­‐90.	  The	  combination	  of	  falling	  tobacco	  consumption	  in	  
combination	  with	  evidence	  of	  increasing	  HPV	  proportions	  coinciding	  with	  the	  
incidence	  rise	  has	  lead	  to	  use	  of	  the	  term	  “virus-­‐related	  epidemic”82.	  Certainly	  
retrospective	  analyses	  of	  OPSCC	  cohorts	  in	  the	  USA63,	  Australia84	  and	  Sweden82	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would	  support	  this	  suggestion,	  each	  demonstrating	  substantial,	  sustained	  
elevations	  in	  HPV	  positive	  OPSCC.	  
	  
Clinical	  Implications	  of	  HPV-­‐positive	  OPSCC	  
Clinical	  Features	  
The	  clinical	  features	  of	  HPV	  positive	  OPSCC	  are	  distinct	  from	  HPV	  negative	  
counterparts.	  HPV	  positive	  tumours	  tend	  to	  present	  at	  a	  more	  advanced	  stage,	  
typically	  with	  a	  small	  primary	  tumour	  with	  advanced	  nodal	  disease	  in	  the	  neck3,91,92,	  
a	  significant	  proportion	  of	  which	  display	  cystic	  degeneration	  within	  cervical	  
metastatic	  deposits93.	  Individuals	  with	  HPV	  positive	  OPSCC	  display	  differing	  
sociodemographic	  and	  behavioral	  characteristics.	  HPV	  positive	  patients	  tend	  to	  be	  
5-­‐10	  years	  younger	  than	  HPV	  negative	  individuals	  and	  are	  less	  likely	  to	  drink	  alcohol	  
or	  smoke	  tobacco94,	  whilst	  having	  had	  a	  higher	  number	  of	  sexual	  partners	  (both	  
generally	  and	  for	  oral	  sex)95.	  In	  developed	  nations,	  individuals	  are	  more	  likely	  to	  be	  
of	  white	  ethnicity	  than	  any	  other95.	  
	  
Prognostic	  Significance	  of	  HPV	  positive	  OPSCC	  
Tumour	  HPV	  status	  is	  an	  important	  and	  independent	  predictor	  of	  both	  disease	  free	  
survival	  and	  overall	  survival	  in	  OPSCC.	  The	  first	  indications	  of	  such	  a	  survival	  
advantage	  became	  apparent	  in	  a	  single-­‐institution	  case	  series	  of	  tonsillar	  SCC96.	  At	  3	  
years,	  survival	  for	  HPV	  positive	  individuals	  was	  65.3%	  compared	  with	  31.5%	  in	  the	  
HPV	  negative	  group	  (odds	  ration	  4.18).	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This	  level	  III	  evidence	  was	  subsequently	  supported	  by	  a	  meta-­‐analysis	  of	  several	  
individual	  case	  series97	  and	  importantly	  by	  analysis	  of	  outcomes	  of	  individuals	  
stratified	  by	  HPV	  status	  in	  the	  Eastern	  Cooperative	  Oncology	  Group	  (ECOG)	  2399	  
phase	  II	  trial98.	  The	  latter	  indicating	  that	  following	  a	  median	  survival	  of	  39	  months,	  
HPV	  positive	  individuals	  demonstrated	  a	  73%	  (HR,	  0.27;	  95%	  CI,	  0.1	  –	  0.75)	  
reduction	  in	  risk	  of	  progression	  and	  64%	  (HR,	  0.36;	  95%	  CI,	  0.15	  –	  0.85)	  reduction	  in	  
risk	  of	  mortality	  by	  comparison	  to	  HPV	  negative	  individuals	  following	  adjustment	  for	  
age,	  tumour	  stage	  and	  performance	  status.	  
The	  potential	  for	  differential	  survival	  benefit	  beyond	  the	  confines	  of	  an	  aggressive,	  
multimodality	  therapeutic	  trial	  has	  been	  demonstrated	  for	  surgically	  treated	  
patients	  with	  or	  without	  postoperative	  radiotherapy99,	  conventional	  radiotherapy	  
alone100	  and	  chemoradiation	  (in	  a	  large	  phase	  III	  trial	  with	  variation	  of	  radiotherapy	  
delivery;	  fractionated	  and	  accelerated	  fractionation)91.	  Interestingly	  the	  evidence	  
from	  Ang	  et	  al91,	  in	  reporting	  the	  results	  of	  the	  RTOG0129	  trial,	  suggests	  that	  
further	  stratification	  of	  disease	  outcomes	  can	  be	  made	  when	  consideration	  of	  both	  
HPV	  status	  and	  tobacco	  exposure	  is	  made.	  They	  demonstrated	  that	  tobacco	  
smoking	  was	  independently	  associated	  with	  overall	  survival	  and	  progression-­‐free	  
survival	  in	  both	  HPV	  subgroups	  and	  the	  magnitude	  of	  tobacco	  effect	  was	  similar	  in	  
both	  groups	  with	  a	  resultant	  survival	  classification	  (high,	  intermediate	  and	  low	  risk	  
categories)	  based	  on	  HPV	  status,	  tobacco	  consumption	  and	  tumour	  stage.	  The	  
authors	  concluded	  that	  this	  evidence	  suggested	  HPV	  status	  and	  tobacco	  smoking	  
are	  major	  independent	  risk	  factors	  in	  OPSCC	  and	  go	  on	  to	  infer	  that	  the	  observed	  
survival	  differences	  are	  a	  consequence	  of	  differing	  molecular	  profiles	  and	  the	  





In	  the	  broader	  context	  of	  all	  HPV	  positive	  OPSCC,	  a	  biological	  rationale	  for	  the	  
improved	  survival	  outcomes	  has	  yet	  to	  be	  defined.	  It	  is	  conceivable	  that	  the	  
presence	  of	  wild	  type	  p53	  and	  Rb	  tumour	  suppressor	  genes	  in	  HPV-­‐transformed	  
cells	  makes	  them	  more	  susceptible	  to	  treatments	  which	  induce	  additional	  cellular	  
stress,	  sufficient	  to	  tip	  the	  sensitive	  balance	  between	  p53/Rb	  production	  and	  their	  
sequestration	  through	  the	  effects	  of	  E6	  or	  E7.	  This	  would	  in	  turn	  reactivate	  
apoptotic	  and	  cell	  cycle	  regulatory	  pathways	  in	  a	  way	  not	  generally	  possible	  in	  
tobacco-­‐	  or	  alcohol	  carcinogen-­‐transformed	  cells	  with	  mutated	  p53	  and	  or	  Rb	  
genes55.	  
The	  absence	  of	  field	  cancerisation	  in	  HPV	  positive	  cohorts	  may	  have	  reduced	  the	  
incidence	  of	  second	  primary	  tumours	  with	  resultant	  improvement	  in	  outcomes99.	  
Furthermore,	  HPV	  positive	  tumours	  have	  been	  shown	  to	  demonstrate	  reduced	  
expression	  of	  prognostic	  biomarkers	  of	  poor	  outcome	  such	  as	  epidermal	  growth	  
factor	  receptor	  (EGFR),	  although	  this	  may	  be	  a	  function	  of	  reduced	  tobacco-­‐usage	  
associated	  tissue	  hypoxia	  rather	  than	  a	  direct	  HPV-­‐associated	  effect101.	  
Finally,	  activation	  of	  the	  host	  immune	  response	  by	  unexplained	  treatment	  
associated	  factors	  may	  also	  contribute	  to	  improved	  outcomes102.	  
	   	  
	  	  
28	  
2.4 HPV-­‐MEDIATED	  TUMOURGENESIS	  
Molecular	  Pathogenesis	  	  
HPV	  is	  reliant	  on	  the	  host	  cells	  replication	  machinery	  to	  copy	  its	  own	  DNA	  however	  
the	  cellular	  proteins	  necessary	  for	  this	  replication	  are	  only	  apparent	  in	  actively	  
dividing	  cells.	  As	  a	  consequence	  HPV	  encodes	  proteins	  of	  its	  own	  to	  maintain	  the	  
host	  cell	  in	  a	  dividing	  state	  but	  in	  doing	  so	  the	  potential	  for	  cell	  cycle	  disregulation	  
and	  inappropriate	  cell	  division	  becomes	  a	  possibility.	  
The	  viral	  proteins	  responsible	  for	  this	  alteration	  of	  cellular	  homeostasis	  are	  the	  
transforming	  oncoproteins	  E6	  and	  E74	  and	  to	  a	  lesser	  extent	  E5103.	  As	  previously	  
discussed	  (above)	  they	  are	  also	  of	  importance	  in	  immune	  evasion,	  being	  involved	  in	  
both	  innate	  and	  adaptive	  immune	  response.	  
	  
The	  oncogenic	  role	  of	  the	  HPV	  E5	  protein	  occurs	  early	  in	  the	  course	  of	  infection,	  as	  
it	  promotes	  cellular	  proliferation	  through	  binding	  to	  the	  epidermal	  growth	  factor	  
receptor	  (EGFR),	  platelet	  derived	  growth	  factor	  β	  receptor	  and	  colony	  stimulating	  
factor	  1	  receptor103.	  The	  coding	  sequence	  for	  this	  protein	  is	  frequently	  deleted	  or	  
disrupted	  in	  the	  process	  of	  viral	  DNA	  integration	  in	  established	  or	  later	  infection,	  
leading	  to	  the	  presumption	  that	  its	  persistent	  expression	  is	  not	  fundamental	  
requirement	  or	  necessity	  for	  ongoing	  oncogenesis4.	  The	  maintenance	  of	  the	  
malignant	  phenotype	  is	  predominantly	  a	  function	  therefore	  of	  the	  major	  oncogenes	  




HPV	  E6	  protein	  facilitates	  proteosomal	  degredation	  of	  p53	  leading	  to	  loss	  of	  cell	  
cycle	  arrest	  and	  apoptosis	  in	  response	  to	  DNA	  damage104.	  The	  formation	  of	  a	  
complex	  between	  E6	  and	  the	  ubiquitin	  ligase,	  E6-­‐associated	  protein	  (E6AP),	  initially	  
facilitates	  ubiquitination	  of	  p53	  causing	  its	  rapid	  degredation	  and	  removes	  the	  cell	  
cycle	  checkpoint	  control	  (G1/S	  and	  G2/M)	  usually	  afforded	  by	  p53.	  As	  a	  result,	  DNA	  
damage	  and	  other	  cellular	  stresses	  have	  an	  increased	  opportunity	  to	  be	  translated	  
into	  persistent	  genomic	  instability	  through	  loss	  of	  p53-­‐mediated	  DNA	  repair	  or,	  
where	  replication	  of	  damaged	  DNA	  has	  already	  occurred,	  the	  loss	  of	  p53-­‐induced	  
apoptosis105	  	  (Figure	  4D).	  Interestingly,	  E6	  from	  low	  risk	  HPV	  types	  also	  binds	  E6-­‐AP	  
and	  p53	  however	  the	  low	  risk	  type	  have	  the	  capacity	  to	  produce	  only	  a	  single	  
variant	  of	  E6,	  whilst	  high	  risk	  types	  such	  as	  HPV16	  and	  HPV18	  produce	  both	  the	  full	  
E6	  transcript	  and	  two	  splice	  variants	  (E6^I	  and	  E6^II).	  It	  is	  through	  these	  E6	  variants	  
that	  high	  risk	  HPV	  mediates	  its	  fundamentally	  different,	  transformative	  impact	  on	  
cells9,14.	  
p53-­‐independent	  anti-­‐apoptotic	  influence	  occurs	  through	  a	  variety	  of	  mechanisms	  
including	  E6’s	  downregulation	  of	  BAK-­‐induced	  apoptosis.	  BAK,	  a	  member	  of	  the	  Bcl-­‐
2	  family	  normally	  highly	  expressed	  in	  fully	  differentiated	  cells,	  will	  induce	  a	  caspase	  
apoptotic	  cascade,	  however	  E6	  mediates	  its	  degredation	  via	  ubiquitination14.	  	  This	  
would	  clearly	  be	  of	  benefit	  to	  the	  virus	  in	  completing	  its	  life	  cycle	  in	  differentiated	  
cells	  but	  similarly	  reduces	  opportunities	  for	  exclusion	  of	  damaged	  DNA	  from	  further	  
replication.	  
E6	  also	  contributes	  to	  induction	  of	  telomerase	  activity	  through	  activation	  of	  hTERT	  
and	  in	  doing	  so	  promotes	  cellular	  immortalization	  though	  telomere	  length	  
maintenance	  and	  indefinite	  proliferation14.	  	  hTERT,	  in	  normal	  conditions,	  is	  under	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the	  transcriptional	  repressive	  control	  of	  NFX-­‐91	  however	  the	  E6-­‐E6AP	  promotes	  
NFX-­‐91	  degredation	  leading	  to	  hTERT	  transcription.	  
Interactions	  of	  E6	  with	  several	  other	  cellular	  factors	  have	  been	  documented106,107.	  
These	  interactions	  affect	  the	  keratinocytes	  transcription	  and	  differentiation,	  induce	  
telomerase	  activation	  and/or	  lengthen	  cell	  life	  span	  thus	  maximizing	  HPV	  
amplification	  but	  also	  contributing	  to	  conditions	  favoring	  malignant	  
change/progression.	  
	  
The	  HPV	  E7	  protein	  binds	  to	  the	  cullin	  2	  ubiquitin	  ligase	  complex	  and	  causes	  
ubiquitination	  of	  the	  retinoblastoma	  protein	  (pRb)	  tumour	  suppressor	  through	  
proteosomal	  degredation108.	  The	  consequence	  is	  once	  more	  seen	  in	  disregulation	  of	  
cell	  cycle	  control,	  on	  this	  occasion	  resulting	  in	  unrestricted	  progression	  through	  the	  
G1/S	  cell	  cycle	  checkpoint4.	  Without	  pRb,	  the	  transcription	  factors	  from	  the	  E2F	  
family	  of	  proteins	  induce	  transcription	  of	  S	  phase	  promoting	  genes	  that	  leads	  to	  
further	  cellular	  proliferation4	  (Figure	  4).	  	  
E7	  from	  low	  risk	  HPV	  type	  will	  still	  also	  bind	  to	  pRB	  although	  generally	  with	  
significantly	  reduced	  affinity.	  This	  reduced	  affinity	  to	  low	  risk	  types	  is	  not	  exclusive	  
however,	  as	  HPV1	  E7	  displays	  binding	  comparable	  to	  that	  of	  HPV16,	  indicating	  that	  
mechanisms	  other	  than	  pRB	  binding	  are	  of	  importance	  in	  HPV-­‐mediated	  cellular	  
transformation9.	  
	  
E7	  interacts	  with	  pRb-­‐related	  pocket	  proteins,	  p107	  and	  p130,	  and	  the	  cyclin-­‐
dependent	  kinase	  (CDK)	  inhibitors	  having	  a	  further	  inhibitory	  effect	  on	  cell	  cycle	  
arrest4	  (Figure	  4B	  &	  C).	  Under	  normal	  cellular	  conditions,	  cyclin	  dependent	  kinase	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activity	  maintains	  control	  over	  phosphorylation	  of	  pRb	  and	  reducing	  resultant	  
release	  of	  pRB	  from	  the	  pRB/E2F	  complex.	  E7	  binds	  to	  the	  pocket	  proteins	  and	  in	  a	  
similar	  fashion	  to	  CDKs,	  results	  in	  active	  E2F	  release	  that	  in	  turn	  promotes	  
transcription	  of	  cell	  cycle	  proteins	  such	  as	  cyclin	  E	  &	  A.	  The	  process	  of	  positive	  
feedback	  ensues	  driving	  the	  cell	  through	  the	  G1/S	  restriction	  point14.	  
E7	  targeting	  of	  the	  CDK	  inhibitors	  p21	  and	  p27	  causes	  neutralization	  of	  their	  normal	  
inhibitory	  effects	  on	  cell	  cycle,	  once	  again	  promoting	  cell	  cycle	  progression.	  
In	  addition	  to	  their	  individual	  autonomous	  impact	  on	  the	  cell,	  the	  viral	  proteins	  also	  
work	  in	  concert	  to	  compliment	  one	  and	  other.	  Whilst	  the	  impact	  of	  E7	  on	  the	  cell	  
may	  ordinarily	  increase	  the	  likelihood	  of	  apoptosis,	  E6	  counteracts	  this	  through	  
p53-­‐dependent	  and	  –independent	  anti-­‐apoptotic	  influence.	  Similarly	  E7	  rescues	  E6	  
from	  CDKN2A	  (p16)	  inhibition	  that	  follows	  Rb	  knockdown,	  by	  direct	  activation	  of	  
cyclins	  A	  and	  E	  and	  functional	  inactivation	  of	  p16,	  bypassing	  its	  cell	  cycle	  
regulation4.	  It	  is	  this	  marked,	  albeit	  ineffective,	  upregulation	  of	  p16	  expression109,	  
occurring	  as	  a	  cellular	  feedback	  mechanism	  intended	  to	  restrict	  cell	  cycle	  
progression	  in	  the	  face	  of	  pRb	  function	  loss,	  that	  has	  been	  used	  as	  a	  surrogate	  for	  





Figure	  4:	  Cellular	  influences	  of	  HPV	  oncoproteins	  in	  the	  malignant	  transformation	  of	  keratinocyte	  
From	  clockwise	  inferiorly,	  A	  –	  ubiquitination	  of	  pRb	  thought	  the	  actions	  E7	  and	  the	  cullin	  2	  ubiquitin	  
ligase	  complex	  (CUL2);	  B	  and	  C	  –	  interaction	  between	  E7	  and	  p27	  &	  p21	  (respectively)	  with	  resultant	  
inhibition	  of	  cell	  cycle	  arrest	  contributing	  to	  carcinogenesis;	  D	  –	  ubiquitination	  of	  p53	  by	  E6	  and	  the	  
ubiquitin	  ligase	  E6AP	  leading	  to	  p53	  degredation;	  E	  –	  overexpression	  of	  p16	  in	  response	  to	  
downregulation	  of	  pRb	  and	  F	  –	  degredation	  of	  the	  hTERT	  transcriptional	  repressor,	  NFX1,	  following	  
the	  association	  of	  E6	  and	  E6AP.	  Consequently	  hTERT	  is	  activated	  leading	  in	  turn	  to	  cellular	  
immortalization.	  	  
(Modified	  from	  Chung,	  CH	  and	  Gillison,	  ML4)	  
	  
E6	  and	  E7	  expression	  is	  primarily	  under	  tight	  self	  control	  through	  the	  regulatory	  
influence	  of	  the	  early	  viral	  gene	  transcriptional	  repressor	  E215.	  	  	  	  
The	  function	  of	  the	  E2	  gene	  is	  frequently	  disrupted	  during	  the	  process	  of	  
carcinogenesis	  as	  the	  circular	  HPV	  genome	  linearises	  and	  inserts	  into	  the	  host	  
genome110.	  Although	  the	  point	  of	  insertion	  into	  the	  host	  genome	  appears	  to	  be	  
relatively	  random,	  with	  a	  predilection	  for	  chromosomal	  fragile	  sites,	  within	  the	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circular	  viral	  genome	  the	  E1/2	  region	  of	  HPV	  appears	  to	  be	  preferentially	  
interrupted110.	  The	  consequence	  of	  which	  is	  release	  of	  the	  viral	  oncogenes,	  E6	  and	  
E7,	  from	  transcriptional	  repression	  by	  E2	  leading	  to	  E6/7-­‐mediated	  alteration	  of	  key	  
tumour	  suppressor	  pathways,	  as	  already	  discussed.	  In	  vitro	  evidence	  would	  suggest	  
that,	  rather	  than	  merely	  an	  inconsequential	  event,	  integration	  appears	  to	  be	  a	  
fundamental	  step	  in	  cervical	  oncogenesis.	  Restoration	  of	  E2	  expression,	  in	  integrant	  
cell	  lines,	  results	  in	  repression	  of	  E6	  and	  E7	  expression	  and	  a	  detrimental	  effect	  on	  
cell	  proliferation	  via	  induction	  of	  arrest	  in	  the	  cell	  cycle	  in	  G1111,112.	  Additionally,	  E2	  
produces	  an	  apoptotic	  effect	  independent	  of	  the	  E6-­‐p53	  interaction	  well	  as	  both	  
cellular	  senescence	  and	  apoptosis113.	  As	  will	  be	  discussed	  in	  greater	  detail	  (7.1),	  
there	  remains	  conflict	  within	  the	  literature	  as	  to	  the	  true	  rate	  of	  viral	  integration	  
and	  relevance	  of	  integration	  where	  oncogene	  expressing	  episomal	  transcripts	  exists	  
in	  malignant	  HNSCC97.	  	  	  
	  
Despite	  the	  potential	  to	  induce	  substantial	  perturbations	  in	  both	  DNA	  repair	  and	  
cell	  cycle	  regulation,	  HPV	  E6	  and	  E7	  proteins	  are	  not	  sufficient	  to	  induce	  malignancy	  
alone,	  however	  additional	  genetic	  events	  are,	  as	  yet,	  unclear4.	  	  
	  
Immune	  system	  response	  in	  HPV-­‐positive	  OPSCC	  
It	  is	  clear	  from	  previous	  studies	  of	  HNSCC	  as	  a	  whole,	  that	  evidence	  of	  immune	  
response,	  in	  particular	  cytotoxic	  T	  cell	  infiltration	  at	  the	  tumour-­‐stromal	  interface	  
correlates	  with	  improved	  outcome	  measures	  such	  as	  risk	  of	  recurrence	  and	  
death114.	  Recently,	  using	  a	  HNSCC	  cohort	  of	  limited	  size,	  Jung	  et	  al.	  produced	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evidence	  of	  greater	  infiltration	  by	  cytotoxic	  CD8+	  T	  cells	  within	  HPV	  positive	  
tumours	  than	  was	  seen	  in	  HPV	  negative	  tumours115.	  Other	  studies	  have	  shown	  
circulating	  markers	  of	  heightened	  immune	  response	  (raised	  CD8+	  T	  cells	  and	  a	  
lower	  CD4+/CD8+	  ratio)	  in	  pretreatment	  HPV	  positive	  OPSCC,	  features	  seen	  in	  
common	  with	  improved	  tumour	  response	  following	  induction	  chemotherapy116.	  It	  
has	  therefore	  been	  suggested	  that	  such	  responses	  might	  play	  a	  part	  in	  the	  
improved	  outcomes	  seen	  in	  HPV	  positive	  cohorts.	  	  Further	  there	  is	  evidence	  that	  
within	  HPV	  positive	  HNSCC	  levels	  of	  expression	  of	  immune	  response	  genes	  are	  
statistically	  higher	  by	  comparison	  to	  HPV	  negative	  cohorts,	  although	  the	  functional	  
significance	  of	  this	  finding	  is	  yet	  to	  be	  fully	  elucidated115.	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2.5 HPV	  DETECTION	  TECHNIQUES	  IN	  HNSCC	  
As	  the	  recognition	  and	  understanding	  of	  the	  involvement	  of	  HPV	  in	  OPSCC	  has	  
evolved,	  its	  importance	  as	  a	  prognostic	  biomarker	  has	  been	  clearly	  
demonstrated98,100.	  	  
Outwith	  the	  Oropharynx,	  the	  role	  that	  HPV	  plays	  has	  been	  a	  source	  of	  controversy	  
both	  in	  malignant	  and	  premalignant	  mucosal	  disease52,64,117.	  This	  has	  been	  in	  part	  
due	  to	  a	  lack	  of	  stringent	  site	  classification	  of	  included	  samples	  for	  analysis52	  but	  
also	  as	  a	  consequence	  of	  considerable	  variability	  in	  the	  testing	  regimes	  
applied118,119.	  Understandably	  calls	  have	  been	  made	  to	  standardise	  the	  definitions	  
and	  clarify	  the	  best	  test	  or	  combination	  of	  tests	  for	  accurate	  diagnosis118,120.	  	  
Recently,	  evidence-­‐based	  clinical	  management	  guideline	  documents	  have	  been	  
published	  detailing	  a	  recommendation	  that	  HPV	  testing	  be	  undertaken	  for	  head	  and	  
neck	  squamous	  cell	  carcinomas;	  specifically	  for	  those	  arising	  in	  the	  oropharynx	  and	  
where	  metastatic	  squamous	  cell	  carcinoma	  of	  unknown	  origin	  is	  evident	  (National	  
Comprehensive	  Cancer	  Network,	  USA;	  College	  of	  American	  Pathologists;	  ENT	  UK;	  
Royal	  College	  of	  Pathologists,	  UK).	  	  Of	  note	  however,	  is	  the	  fact	  that	  the	  guidelines	  
are	  not	  prescriptive	  when	  detailing	  the	  laboratory	  tests	  required	  to	  establish	  HPV	  
status	  since	  an	  ‘international	  standard’	  for	  HPV	  testing	  in	  head	  and	  neck	  cancer	  is	  
yet	  to	  be	  defined118. Currently,	  a	  variety	  of	  detection	  methods	  are	  available119,	  each	  
with	  specific	  benefits	  and	  detractions. 
	  
Detection	  techniques	  vary	  according	  to	  the	  tissue	  source	  being	  analysed.	  In	  clinical	  
practice,	  diagnostic	  specimens	  are	  typically	  placed	  into	  fixative	  agents	  to	  preserve	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the	  cellular	  morphology	  and	  tissue	  architecture	  primarily,	  although	  not	  exclusively,	  
to	  allow	  histopathological	  analysis119.	  The	  fixation	  and	  embedding	  process	  induces	  
undesirable	  degradation	  of	  nucleic	  acid,	  particularly	  RNA,	  resulting	  in	  considerably	  
lower	  quality	  nucleic	  acid	  by	  comparison	  with	  fresh	  frozen	  tissue121-­‐123.	  Additionally,	  
duration	  of	  fixation,	  processing	  temperatures	  and	  post	  fixation/embedding	  storage	  
my	  also	  contribute	  to	  reduced	  nucleic	  acid	  stability122,124.	  
An	  alterative	  to	  FFPE	  tissue	  is	  fresh	  frozen	  tissue,	  either	  collected	  into	  protective	  
media123	  or	  frozen	  directly	  to	  temperatures	  below	  -­‐75	  °C	  to	  protect	  nucleic	  integrity	  
thus	  allowing	  extended	  storage	  times	  and	  utilisation	  at	  a	  later	  date,	  however	  an	  
inability	  to	  conduct	  conventional	  histopathological	  assessment	  is	  a	  significant	  
drawback123.	  	  	  
It	  is	  unsurprising,	  given	  the	  reliance	  of	  routine	  histopathology	  services	  on	  FFPE	  
samples,	  that	  the	  majority	  of	  HPV	  diagnostic	  test	  developments	  have	  focused	  on	  
these	  samples	  rather	  than	  fresh	  frozen	  tissue	  resources.	  	  This	  reliance	  on	  FFPE	  has,	  
to	  date,	  had	  the	  effect	  of	  precluding	  the	  use	  of	  the	  gold	  standard	  or	  reference	  test	  
for	  HPV	  diagnostics;	  evidence	  of	  expression	  of	  viral	  oncogenes	  witnessed	  directly	  
within	  tumour	  tissue,	  which	  is	  believed	  to	  require	  fresh	  tissue	  derived	  samples125.	  
This	  introduction	  details	  the	  present	  understanding	  of	  HPV	  diagnostics	  in	  HNSCC	  
and	  explores	  the	  clinical	  applicability	  of	  those	  tests,	  both	  diagnostic	  and	  prognostic.	  
	  
Viral	  Oncogene	  Expression	  (HPV	  mRNA	  qPCR)	  –	  The	  “Gold	  Standard”	  
Sustained	  and	  persistent	  expression	  of	  high-­‐risk	  HPV	  E6/E7	  viral	  oncogene	  is	  a	  
fundamental	  requirement	  for	  both	  the	  initiation	  and	  the	  maintenance	  of	  an	  HPV-­‐
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driven	  malignant	  phenotype3.	  	  It	  is	  known	  that	  the	  oncogenic	  effects	  of	  high-­‐risk	  
HPV	  E6/E7	  driving	  OPSCC	  correlate	  with	  cellular	  genotoxic	  damage	  and	  gene	  
expression	  changes	  which	  are	  the	  hallmarks	  of	  cancer126.	  	  As	  a	  consequence,	  
demonstration	  of	  transcriptionally	  active	  oncogenic	  viral	  infection	  on	  samples	  
derived	  from	  fresh	  tissue	  has	  been	  considered	  to	  be	  the	  reference	  or	  gold	  standard	  
test.	  The	  practical	  application	  of	  this	  test	  is	  usually	  by	  means	  of	  quantitative	  reverse	  
transcriptase	  polymerase	  chain	  reaction	  (qRT-­‐PCR)	  amplifying	  high-­‐risk	  HPV	  E6/E7	  
mRNA	  transcripts127,128.	  Such	  an	  approach	  is	  capable	  of	  providing	  precise	  
quantitative	  assessment	  of	  both	  the	  viral	  oncogene	  transcript	  abundance	  within	  a	  
single	  sample,	  by	  comparison	  to	  a	  constitutively	  expressed	  endogenous	  
‘housekeeping’	  gene,	  and	  also	  relative	  expression	  levels	  between	  references	  (cell	  
line	  samples)	  or	  other	  clinical	  samples.	  	  
Although	  its	  application	  to	  routine	  clinical	  diagnostic	  samples	  is	  limited,	  the	  use	  of	  
HPV	  qRT-­‐PCR	  in	  HNSCC	  samples	  was	  fundamental	  in	  framing	  the	  causal	  relationship	  
of	  HPV16	  in	  HNSCC127,128.	   
	  
Viral	  DNA	  Detection	  (DNA	  PCR,	  DNA	  in	  situ	  hybridisation)	  
Polymerase	  Chain	  Reaction	  (PCR)	  for	  HPV	  DNA	  target	  amplification	  can	  rely	  on	  
either	  non-­‐quantitative	  post	  amplification	  recognition	  of	  the	  target	  sequence	  or	  
simultaneous	  quantitative	  detection	  utilising	  in-­‐built	  reporting	  systems.	  Such	  a	  
process	  can	  utilise	  type-­‐specific	  primers	  or	  degenerate	  primers	  capable	  of	  
recognising	  multiple	  subtypes	  in	  combination	  with	  a	  further	  step	  of	  type	  specific	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PCR	  or	  hybridisation	  to	  custom	  array	  chips	  containing	  probes	  for	  a	  specific	  HPV	  
types129.	  	  
Given	  the	  high	  analytical	  sensitivity	  of	  PCR	  techniques	  there	  is	  a	  significant	  prospect	  
of	  assays	  detecting	  HPV	  DNA	  presence	  that	  is	  merely	  a	  transient	  opportunistic	  
contaminant	  rather	  than	  a	  driver	  of	  malignancy,	  this	  may	  particularly	  be	  the	  case	  
for	  non-­‐quantitative	  techniques130.	  Quantitative	  PCR	  (qPCR)	  has	  the	  specific	  
advantage	  of	  reporting	  sequence	  presence	  in	  relation	  to	  concurrently	  amplified	  
endogenous	  genes,	  for	  example	  β-­‐actin.	  This	  allows	  reporting	  of	  viral	  detection	  in	  
terms	  of	  copy	  number,	  from	  which	  a	  biologically	  relevant	  threshold	  can	  be	  
applied119.	  This	  however,	  does	  not	  necessarily	  reflect	  the	  biological	  relevance	  of	  the	  
viral	  DNA	  that	  is	  present,	  as	  has	  been	  highlighted	  in	  a	  combined	  analysis	  of	  both	  
DNA	  detection	  and	  viral	  gene	  expression	  in	  clinical	  samples	  which	  found	  50%	  
(12/24)	  of	  cases	  with	  HPV	  DNA	  present	  lacked	  evidence	  of	  viral	  expression	  128.	  
A	  further	  limitation	  of	  PCR-­‐based	  techniques,	  when	  applied	  to	  HPV	  diagnostics,	  is	  
the	  arbitrary	  nature	  of	  the	  diagnostic	  threshold	  for	  a	  positive	  test.	  Although	  these	  
thresholds	  can	  be	  accommodated	  into	  a	  logical	  biological	  rationale	  (for	  example	  1	  
viral	  copy	  per	  host	  genome)	  PCR	  is	  not	  capable	  of	  differentiating	  between	  detected	  
copies	  originating	  from	  cells	  with	  multiple	  copies	  of	  virus	  (eg.	  productive	  HPV	  
infection)	  or,	  the	  intended,	  single	  copy	  per	  malignant	  cell130.	  
	  
The	  application	  of	  DNA	  in	  situ	  hybridisation	  (DNA	  ISH)	  technology	  to	  FFPE	  tissues	  is	  
a	  commonly	  utilised	  and	  clinically	  validated	  technique	  for	  HPV	  diagnostics131.	  Using	  
nucleic	  acid	  probes	  which	  are	  specific	  for	  HPV	  sequences	  of	  interest	  (either	  for	  
specific	  viral	  subtypes	  or	  groupings	  such	  as	  high-­‐risk	  subgroups),	  viral	  DNA	  can	  be	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detected	  at	  a	  cellular	  and	  subcellular	  level	  (localization	  to	  cytoplasm	  or	  nucleus)123.	  
Introduction	  of	  various	  signal	  amplification	  steps	  have	  further	  increased	  the	  
sensitivity	  of	  this	  technique,	  such	  that	  visualization	  of	  a	  single	  target	  sequence	  per	  
cell	  is	  feasible131.	  Primarily	  the	  sensitivity,	  but	  also	  specificity	  of	  this	  test	  has	  been	  
questioned	  given	  that	  probes	  may	  in	  certain	  conditions	  bind	  to	  similar	  sequences	  
that	  are	  not	  a	  prefect	  match	  and	  it	  is	  difficult	  to	  exclude	  potential	  probe	  cross-­‐
reactivity123.	  	  	  
	  
p16	  immunohistochemistry	  (p16	  IHC)	  as	  a	  Surrogate	  Marker	  of	  HPV-­‐
mediated	  Malignancy.	  
The	  use	  of	  p16	  immunohistochemistry	  to	  infer	  HPV	  status	  in	  tonsillar	  SCC	  was	  first	  
described	  in	  2003	  by	  Klussmann	  et	  al.132.	  At	  a	  molecular	  level,	  p16	  protein	  
accumulates	  in	  HPV	  positive	  cells	  as	  a	  consequence	  of	  the	  effect	  of	  the	  viral	  E7	  
protein	  on	  Rb	  (Figure	  4).	  In	  response	  to	  sequestered	  Rb,	  p16	  is	  released	  from	  
transcriptional	  repression	  with	  a	  consequent	  elevation	  of	  protein	  levels	  within	  HPV	  
positive	  cells.	  Using	  standard	  immunohistochemistry	  techniques,	  the	  ensuing	  
elevated	  protein	  levels	  are	  detectable.	  	  
The	  main	  advantage	  of	  p16	  IHC	  is	  the	  applicability	  to	  FFPE	  specimens	  using	  
techniques	  common	  to	  most	  clinical	  pathology	  laboratories.	  However,	  its	  analytical	  
performance	  has	  been	  highlighted	  as	  suboptimal	  by	  some	  authors125,133	  and	  off	  
target	  effects,	  such	  as	  staining	  in	  histologically	  normal	  tissues,	  have	  called	  into	  
question	  its	  clinical	  utility	  as	  a	  stand	  alone	  HPV	  diagnostic	  test.	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Despite	  concerns	  such	  as	  those	  detailed	  above,	  p16	  IHC	  remains	  a	  frequently	  
applied	  test	  both	  in	  routine	  clinical	  practice	  and	  it	  is	  the	  sole	  HPV	  diagnostic	  test	  
used	  to	  determine	  case	  inclusion	  for	  several	  major	  clinical	  trails	  designed	  to	  analyse	  
therapeutic	  regimes	  in	  HPV	  positive	  OPSCC*.	  	  
Recent	  attempts	  have	  been	  made	  to	  refine	  the	  diagnostic	  stringency	  of	  p16	  IHC	  
through	  the	  application	  of	  scoring	  or	  grading	  systems	  based	  on	  staining	  features	  
such	  as	  intracellular	  stain	  localisation134	  or	  novel	  staining	  scores	  such	  as	  the	  p16	  H	  
score	  validated	  by	  Jordan	  et	  al133	  which	  uses	  the	  cross	  product	  of	  the	  proportion	  of	  
cells	  stained	  and	  the	  intensity	  with	  which	  they	  stain.	  It	  is,	  as	  yet,	  unclear	  whether	  
such	  an	  application	  of	  p16	  can	  correct	  for	  concerns	  surrounding	  test	  specificity.	  
	  
Diagnostic	  Algorithms	  	  
Alternative	  techniques	  to	  overcome	  variation	  in	  sensitivity	  and	  specificity	  of	  single	  
tests,	  combined	  tests	  and	  diagnostic	  algorithms,	  have	  been	  proposed125,135,136.	  
Smeets	  et	  al.125	  classified	  HPV	  status	  in	  48	  HNSCC	  cases	  by	  detectable	  viral	  
oncogene	  RNA	  (RTqPCR	  for	  HPV16	  E6	  and	  E7)	  derived	  from	  fresh	  frozen	  tissue	  
samples	  and	  gauged	  performance	  of	  fixed	  tissue	  based	  tests	  on	  corresponding	  FFPE	  
samples	  for	  each	  case.	  Using	  the	  fixed	  tissue	  results,	  they	  were	  able	  to	  generate	  an	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
*	  RTOG	  1016:	  Radiation	  Therapy	  Oncology	  Group	  Phase	  III	  Trial	  of	  Radiotherapy	  Plus	  
Cetuximab	  Versus	  Chemoradiotherapy	  in	  HPV-­‐Associated	  Oropharynx	  Cancer;	  	  
De-­‐ESCALaTE	  HPV:	  Determination	  of	  Epidermal	  growth	  factor	  receptor	  inhibitor	  
(cetuximab)	  versus	  Standard	  Chemotherapy	  (cisplatin)	  early	  And	  Late	  Toxicity	  Events	  in	  
Human	  Papillomavirus	  positive	  oropharyngeal	  squamous	  cell	  carcinoma,	  NCRN	  Portfolio	  
Study	  ID:	  11723;	  	  
ECOG	  3311:	  Eastern	  Cooperative	  Oncology	  Group	  Low	  Risk	  OPSCC:	  Personalized	  adjuvant	  




algorithm	  capable	  of	  achieving	  reliable	  HPV	  status	  detection,	  100%	  sensitivity	  and	  
specificity	  for	  each	  case	  using	  a	  combination	  of	  p16	  IHC	  and	  GP5+/6+	  HPV	  DNA	  PCR.	  
Subsequent	  validation	  of	  this	  algorithm	  was	  undertaken	  on	  an	  independent	  series	  
(n=86)	  from	  within	  the	  same	  institution	  using	  matched	  FFPE	  and	  frozen	  tumour	  
confirming	  sensitivity	  of	  96%	  and	  specificity	  of	  98%.	  90	  	  
Based	  on	  broad	  experience	  of	  epidemiological	  studies	  in	  HSNCC	  and	  clinical	  trial	  
design,	  the	  John	  Hopkins	  Institution	  published	  their	  diagnostic	  hierarchy136,	  which	  
was	  simplified	  to	  diagrammatical	  form	  subsequently119	  (Figure	  5).	  
	  
Figure	  5:	  Algorithm	  for	  detection	  of	  HPV	  in	  FFPE	  head	  and	  neck	  biopsies	  
(Modified	  from	  Robinson	  et	  al119	  as	  previously	  described	  by	  Westra136)	  
	  
Currently	  there	  is	  insufficient	  evidence	  to	  recommend	  one	  particular	  testing	  
algorithm	  over	  another,	  however,	  the	  combination	  of	  p16	  IHC	  with	  either	  an	  HPV	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DNA	  directed	  PCR	  amplification	  technique	  or	  HPV	  DNA	  detection	  with	  signal	  
amplification	  methods	  (ISH)	  have	  been	  suggested125,131,135,137.	  The	  basis	  upon	  which	  
such	  recommendations	  have	  been	  made	  varies	  and	  only	  one	  study	  measures	  




2.6 DNA	  METHYLATION	  IN	  HNSCC	  
Epigenetics	  refers	  to	  those	  heritable	  changes	  in	  gene	  expression	  that	  do	  not	  result	  
from	  an	  alteration	  in	  the	  DNA	  sequence138.	  Four	  particular	  modifications	  or	  
mechanisms	  are	  presently	  considered	  together	  under	  the	  umbrella	  term	  
epigenetics;	  DNA	  methylation,	  covalent	  histone	  modification,	  nucleosome	  
positional	  remodeling	  and	  microRNA.	  Although	  considered	  as	  discrete	  entities,	  they	  
interact	  closely	  in	  order	  to	  impact	  upon	  gene	  expression139.	  
Whilst	  contributing	  to	  the	  facilitation	  of	  appropriate	  gene	  expression	  in	  healthy	  
cells,	  epigenetic	  control	  also	  contributes	  to	  dysregulated	  gene	  expression	  in	  a	  
variety	  of	  disease	  states,	  including	  human	  malignancy139,140.	  
	  
DNA	  methylation	  occurs	  almost	  exclusively	  when	  a	  methyl	  group	  is	  added	  to	  the	  5’	  
position	  of	  cytosine	  rings	  that	  immediately	  precede	  guanine	  nucleotides	  in	  the	  
linear	  DNA	  sequence	  (so	  called	  CpG	  dinucleotide	  or	  sites).	  CpGs	  are	  not	  distributed	  
randomly	  throughout	  the	  genome	  and	  tend	  to	  cluster	  in	  regions	  called	  CpG	  islands	  
regions	  of	  more	  than	  200	  bases	  which	  are	  particularly	  GC	  rich	  and	  have	  an	  observed	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to	  expected	  ratio	  of	  CpGs	  of	  greater	  than	  0.6139.	  CpG	  islands	  can	  be	  found	  within	  
60-­‐70%	  of	  human	  gene	  promoters	  and,	  in	  contrast	  to	  the	  generally	  sparsely-­‐
distributed	  and	  hypermethylated	  CpGs	  in	  repetitive	  genomic	  sequences	  (intergenic	  
regions	  and	  transposable	  elements),	  CpG	  islands	  are	  typically	  hypomethylated	  
under	  normal	  conditions	  in	  order	  to	  facilitate	  gene	  expression141.	  	  
Increases	  in	  DNA	  methylation	  are	  associated	  with	  chromatin	  remodeling	  and	  a	  
subsequent	  reduction	  in	  transcriptional	  activity.	  In	  addition	  to	  the	  implications	  in	  
normal	  biological	  processes,	  both	  specific	  and	  complimentary	  epigenetic	  alterations	  
contribute	  to	  disease	  pathogenesis;	  in	  particular,	  epigenetic	  aberrations	  appear	  to	  
be	  of	  increasing	  relevance	  in	  specific	  human	  malignancies140,142.	  	  
	  
DNA	  methylation	  in	  malignancy	  
Evidence	  of	  the	  frequent	  epigenetic	  aberrations	  apparent	  in	  human	  
malignancy142,143	  raises	  the	  possibility	  of	  exploiting	  of	  these	  changes	  for	  clinical	  
benefit;	  diagnostic	  (both	  early	  detection	  and	  definitive	  diagnosis),	  predictive	  and	  
prognostic	  biomarker	  evaluation,	  therapeutic	  stratification	  and	  disease	  monitoring.	  	  
	  
Two	  patterns	  of	  DNA	  methylation	  are	  specifically	  observed	  in	  malignancy;	  firstly,	  
global	  or	  genome-­‐wide	  hypomethylation,	  a	  large	  proportion	  of	  which	  is	  confined	  to	  
repetitive	  DNA	  elements,	  and	  secondly	  gene	  specific	  hypermethylation	  of	  CpG	  
island	  within	  the	  promoter	  regions	  of	  particular	  genes,	  which	  may	  in	  turn	  result	  in	  




Generation	  of	  global	  DNA	  methylation	  has	  been	  hypothesised	  to	  have	  evolved	  from	  
initial	  host	  attempts	  to	  silence	  exogenous	  DNA	  from	  pathogens	  such	  as	  viruses146.	  
Reduction	  in	  genome-­‐wide	  methylation,	  or	  global	  hypomethylation,	  in	  malignancy	  
is	  thought	  to	  increase	  genomic	  instability147,	  loss	  of	  imprinting	  and	  activation	  of	  
oncogenes148	  and	  as	  such	  alter	  clinical	  outcomes,149-­‐151	  which	  is	  clearly	  of	  particular	  
clinical	  relevance.	  These	  observations	  are	  supported	  from	  a	  mechanistic	  standpoint	  
by	  the	  observation	  that	  global	  hypomethylation	  becomes	  more	  pronounced	  during	  
neoplastic	  transformation	  from	  initial	  dysplastic	  lesions	  to	  invasive	  malignancy148.	  	  
	  
Attention	  towards	  site-­‐specific	  hypermethylation	  in	  human	  cancers	  has	  focused	  on	  
the	  CpG	  islands	  of	  promoter	  regions	  of	  genes,	  particularly	  those	  of	  tumour	  
suppressor	  genes,	  which	  may	  become	  functionally	  silenced	  by	  elevation	  in	  
methylation148.	  There	  is	  an	  extensive	  catalogue	  of	  such	  genes	  that	  have	  been	  
demonstrated	  to	  be	  functionally	  inactivated	  in	  cancer	  by	  promoter	  methylation	  
(Table	  3)	  impacting	  on	  a	  variety	  of	  cellular	  pathways	  involved	  in	  oncogenesis;	  cell	  
cycle	  control,	  apoptosis,	  DNA	  repair,	  cellular	  adhesion	  &	  invasion,	  angiogenesis143.	  
Although	  not	  an	  exhaustive	  list,	  it	  does	  draw	  attention	  to	  the	  variability	  in	  the	  




Table	  3:	  Selective	  list	  of	  gene	  previously	  reported	  to	  be	  silenced	  by	  promoter	  hypermethylation	  in	  
malignancy	  




Regulation	  of	  DNA	  methylation	  
Both	  in	  normal	  physiology	  and	  in	  pathological	  situations,	  establishment	  of	  de	  novo	  
methylation	  and	  maintenance	  of	  the	  pre-­‐existing	  methylation	  pattern	  is	  the	  
function	  of	  the	  DNA	  methyltransferases	  (DNMTs)	  and	  to	  a	  lesser	  extent	  related	  
proteins	  responsible	  for	  recruiting	  DNMTs	  to	  positions	  requiring	  their	  action,	  for	  
example	  UHRF-­‐1.	  
DNMT1	  is	  predominantly	  responsible	  for	  maintenance	  of	  methylation	  patterns	  
during	  both	  DNA	  replication	  and	  repair.	  It	  displays	  a	  marked	  preference	  (x30)	  for	  
hemimethylated	  DNA	  by	  comparison	  to	  unmethylated	  form152,	  yet	  its	  action	  is	  not	  
exclusively	  maintenance	  as	  it	  also	  demonstrates	  de	  novo	  methylation	  capacity153.	  	  
DNMT3a	  and	  3b	  are	  primarily	  viewed	  as	  de	  novo	  methylators,	  in	  effect	  establishing	  
the	  pattern	  of	  DNA	  methylation	  in	  embryonic	  development,	  however	  their	  role	  is	  
not	  strictly	  confined	  and	  they	  too	  undertake	  an	  element	  of	  methylation	  
maintenance153.	  	  
The	  UHRF1	  protein	  has	  recently	  been	  shown	  to	  play	  a	  supporting	  role	  in	  
methylation	  maintenance	  through	  a	  strong	  affinity	  for	  binding	  to	  hemimethylated	  
DNA	  and	  subsequent	  recruitment	  of	  DNMT1154.	  This	  has	  been	  evidenced	  by	  
significant	  reductions	  in	  methylation	  levels	  in	  UHRF1	  knock	  out	  mice154.	  Once	  bound	  
to	  DNA,	  UHRF1	  extrudes	  targeted	  cytosines	  from	  the	  double	  helix	  into	  an	  active	  site	  
when	  upon	  a	  methyl	  group	  transfer	  takes	  place	  from	  DNMT1	  via	  UHRF1	  to	  the	  
cytosine153.	  	  Additionally,	  a	  facilitative	  role	  for	  UHRF1	  in	  DNMT3a	  and	  3b	  
methylation	  has	  also	  been	  proposed153.	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In	  reality,	  the	  role	  of	  DNMTs	  and	  their	  related	  proteins	  in	  DNA	  methylation	  is	  likely	  
to	  be	  more	  collaborative	  in	  nature,	  where	  DNMTs	  act	  in	  concert	  with	  one	  and	  other	  
rather	  than	  in	  exclusivity153.	  
	  
The	  significance	  of	  DNMTs	  in	  cancer	  biology	  lies	  with	  the	  implications	  they	  may	  
have	  in	  silencing	  of	  tumour	  suppressor	  genes.	  Accumulating	  evidence	  indicates	  
elevated	  levels	  of	  DNMTs	  in	  a	  variety	  of	  tumour	  types155-­‐157	  and	  that	  this	  elevation	  
frequently	  correlates	  with	  hypermethylation	  of	  key	  TSGs	  and	  statistically	  significant	  
worse	  clinical	  outcomes158-­‐161.	  
In	  a	  similar	  fashion	  to	  DNMTs,	  UHRF1	  has	  been	  shown	  to	  be	  a	  key	  epigenetic	  switch,	  
which	  controls	  cell	  cycle	  progression	  in	  Non-­‐Small	  Cell	  Lung	  Carcinoma	  through	  its	  
ability	  to	  induce	  transcriptional	  silencing	  of	  tumour	  suppressor	  genes	  by	  
maintaining	  their	  promoters	  in	  a	  state	  of	  hypermethylation161.	  	  
Within	  HPV	  driven	  malignancy	  the	  role	  that	  DNMTs	  may	  play	  in	  viral	  methylation	  
state	  has	  not	  been	  explored	  and	  it	  remains	  of	  particular	  interest	  given	  that	  the	  virus	  
lacks	  its	  own	  methylation	  machinery	  and	  must	  therefore	  come	  under	  the	  influence	  
of,	  or	  potentially	  direct,	  the	  hosts’	  methylation	  machinery.	  
	  
DNA	  Methylation	  in	  HNSCC	  
As	  in	  other	  malignancies,	  DNA	  methylation	  in	  HNSCC	  acts	  through	  either	  global	  or	  
site	  specific	  methylation	  change	  to	  induce	  both	  genomic	  instability	  and	  TSG	  
repression	  respectively.	  Methylation	  therefore	  plays	  an	  important	  role	  in	  both	  
tumour	  initiation	  and	  progression.	  HNSCC	  is	  not	  dissimilar	  to	  other	  malignancies	  in	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that	  it	  is	  a	  heterogenous	  disease	  and	  therefore	  methylation	  states	  and	  implications	  
vary	  according	  to	  a	  variety	  of	  factors	  such	  as	  tumour	  site	  and	  aetiology	  (viral	  or	  
otherwise)145.	  	  	  
Exploration	  of	  methylation	  changes	  has	  received	  increasing	  interest	  due,	  at	  least	  in	  
part,	  to	  their	  potential	  as	  early	  predictive	  biomarkers	  in	  premalignant	  lesions	  or	  as	  
diagnostic	  biomarkers	  within	  surrogates	  such	  as	  such	  as	  saliva145.	  Also	  of	  relevance	  
is	  the	  changing	  aetiology	  of	  HNSCC	  brought	  about	  the	  impact	  of	  HPV-­‐mediated	  
oncogenesis	  in	  the	  oropharynx	  and	  the	  implications	  that	  this	  may	  have	  on	  the	  host	  
methylome162.	  Early	  data	  suggests	  a	  picture	  of	  variation	  in	  the	  methylation	  marks	  
seen	  in	  different	  tumours	  based	  on	  HPV	  status	  alone144,163,164.	  This	  variation	  extends	  
to	  include	  HNSCC	  and	  in	  particular	  HPV	  positive	  OPSCC	  
Although	  a	  variety	  of	  genes,	  selected	  via	  both	  candidate	  gene	  approaches	  and	  
genome	  wide	  association	  studies,	  have	  demonstrated	  variations	  in	  specific	  TSG	  
methylation	  levels	  when	  comparing	  tumours	  and	  normal	  pairs,	  there	  remains	  
considerable	  variation	  reported145.	  	  Tumour	  heterogeneity	  may	  influence	  this,	  
however	  a	  failure	  to	  differentiate	  between	  the	  varying	  head	  and	  neck	  subsites,	  and,	  
by	  inference,	  HPV	  status,	  in	  some	  studies	  almost	  certainly	  contributes	  to	  variability	  
in	  results138.	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2.7 HPV16	  INTEGRATION	  STATE	  IN	  MALIGNANCY	  
Following	  viral	  infection	  of	  the	  keratinocyte,	  HPV	  DNA	  is	  thought	  to	  remain	  in	  a	  
circular	  episomal	  form	  within	  the	  mucosal	  basal	  cell	  layer.	  Typically,	  there	  is	  
maintenance	  of	  50-­‐100	  copies	  of	  the	  virus	  during	  this	  latent	  cellular	  infection	  and	  
remains	  so	  until	  the	  virally	  infected	  cell	  progresses	  through	  routine	  cellular	  
differentiation	  to	  reach	  the	  upper	  layers	  of	  the	  stratified	  squamous	  epithelium.	  	  
In	  contrast	  to	  the	  permissive	  infection	  of	  squamous	  epithelium	  where,	  upon	  
terminal	  cellular	  differentiation,	  the	  viral	  life	  cycle	  completes	  with	  shedding	  of	  
encapsidated	  virions,	  the	  transforming	  oncogenic	  infection	  results	  in	  non-­‐
productive	  infection	  and	  progressive	  cellular	  abnormality165.	  The	  factors	  
discriminating	  between	  permissive	  and	  transforming	  infections	  remain	  particularly	  
unclear,	  however	  viral	  integration	  has	  been	  suggested	  as	  an	  important	  potential	  
mechanism	  in	  this	  process166.	  	  	  
In	  cancer	  samples,	  HPV	  can	  be	  found	  in	  episomal	  (extra-­‐chromosomal)	  form,	  
integrated	  into	  the	  host	  genome,	  or	  in	  a	  mixed	  form	  constituting	  variable	  
proportions	  of	  both	  episomal	  and	  integrated.	  Clinical	  studies	  of	  HPV	  integration	  in	  
cervical	  neoplasia	  show	  that	  proportions	  of	  viral	  integrant	  and	  episome	  vary	  
significantly,	  however	  there	  is	  a	  consistent	  trend	  towards	  increasing	  frequency	  of	  
the	  former	  as	  the	  severity	  of	  cervical	  lesion	  increases	  (from	  early	  dysplasia	  to	  
invasive	  malignancy)110,167-­‐169.	  This	  observation	  would	  suggest	  that	  integration	  is	  a	  




Several	  particular	  consequences	  of	  viral	  integration	  have	  been	  considered	  of	  
marked	  importance	  in	  oncogenesis5;	  
1. Viral	  E2	  gene	  disruption	  
2. Altered	  E6/E7	  expression	  and	  or	  stabilization	  
3. Insertional	  mutagenesis	  
4. Numerical	  and	  structural	  chromosomal	  alteration	  
	  
Viral	  E2	  gene	  Disruption	  
In	  the	  majority	  of	  cervical	  malignancies,	  disregulation	  of	  viral	  early	  gene	  function,	  in	  
particular	  the	  oncogene	  transcriptional	  repressor	  E2170,	  occurs	  through	  cleavage	  of	  
the	  circular	  viral	  genome	  and	  insertion	  into	  the	  host	  DNA6.	  Cells	  in	  which	  this	  occurs	  
are	  thought	  to	  hold	  a	  selective	  growth	  advantage171	  although	  conversely,	  the	  
integration	  event	  inhibits	  the	  viruses	  natural	  life	  cycle	  by	  removing	  key	  early	  genes	  
necessary	  for	  synthesis	  of	  an	  infectious	  virus6.	  The	  implied	  importance	  of	  a	  
disrupted	  E2	  gene	  in	  oncogenesis	  has	  been	  supported	  by	  observations	  from	  cell	  
culture	  experiments	  in	  which	  reintroduction	  of	  an	  intact	  viral	  E2	  gene	  to	  established	  
cervical	  carcinoma	  cell	  lines	  induced	  growth	  arrest	  and	  senescence	  due	  to	  
reactivation	  of	  the	  p53	  and	  Rb	  pathways172,173	  
 
In	  addition	  to	  the	  uncontrolled	  expression	  of	  viral	  oncogenes,	  integration-­‐related	  
loss	  of	  E2	  removes	  its	  inhibition	  of	  hTERT	  expression112,	  potentiating	  the	  effect	  of	  E6	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on	  telomerase	  activation14	  and	  therefore	  increasing	  opportunities	  for	  cellular	  
immortalization	  (Figure	  6).	  	  
Altered	  viral	  oncogene	  expression	  and	  stabilization	  
Depending	  upon	  the	  site	  of	  integration	  into	  the	  host	  genome,	  cis-­‐acting	  host	  
sequences	  may	  potentiate	  viral	  oncogene	  expression174	  and,	  further,	  those	  
integrant	  derived	  E6	  and	  E7	  transcripts	  may	  be	  stabilized	  by	  co-­‐transcribed	  cellular	  
sequences,	  enhancing	  oncogenic	  potential171,175	  (Figure	  6).	  	  
Insertion	  mutagenesis	  
It	  has	  been	  suggested	  that	  integration	  of	  the	  HPV	  genome	  may	  activate	  cellular	  
oncogenes176,177	  or	  disrupt	  key	  tumour	  suppressor	  genes178	  such	  that	  an	  additional	  
neoplastic	  selective	  pressure	  becomes	  apparent.	  A	  systematic	  review	  of	  genomic	  
integration	  sites	  within	  cervical	  squamous	  intraepithelial	  lesions	  (SIL)	  and	  invasive	  
cervical	  malignancy	  by	  Wentzensen	  et	  al.110	  failed	  to	  provide	  evidence	  of	  frequent	  
gene	  specific	  integration.	  Indeed	  they	  demonstrated	  that	  integration	  is	  an	  
apparently	  randomly	  distributed	  across	  the	  human	  genome	  albeit	  with	  a	  clear	  
predilection	  for	  chromosomal	  fragile	  sites	  (CFSs).	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To	  date	  there	  is	  insufficient	  evidence	  to	  substantiate	  a	  definitive	  or	  essential	  role	  
for	  insertional	  mutagenesis	  in	  HPV-­‐induced	  carcinogenesis.	  It	  has	  been	  speculated	  
that	  the	  absence	  of	  a	  viral	  integrase	  indicates	  that	  integration	  is	  a	  chance	  




Figure	  6:	  Molecular	  Consequences	  of	  Viral	  integration	  
Typically	  viral	  DNA	  insertion	  contains	  the	  viral	  oncogenes	  (E6	  and	  E7)	  and	  the	  upstream	  regulator	  
(URR)	  that	  is	  the	  start	  site	  for	  early	  gene	  transcription	  (dotted	  line).	  The	  blue	  text	  boxes	  represent	  
the	  viral	  gene	  alterations	  and	  implications	  on	  host	  genes	  with	  subsequent	  implications	  for	  cellular	  
disregulation	  (green	  boxes).	  
Viral	  integration	  can	  also	  dissociate	  the	  viral	  polyadenylation	  signal	  from	  early	  gene	  transcription,	  
however	  leading	  to	  utilisation	  of	  host	  poly(A)	  signals	  once	  integrated,	  produce	  fusion	  transcripts	  
with	  greater	  stability.	  	  
Less	  commonly,	  multiple	  viral	  integrants	  are	  inserted	  back	  to	  back,	  including	  intact	  E2	  genes.	  Host	  
methylation	  of	  the	  URR,	  limiting	  the	  functional	  significance	  of	  the	  multiple	  inserts	  is	  a	  speculative	  




Integration	  in	  HPV	  positive	  HNSCC	  
Although	  the	  progressive	  impact	  of	  viral	  integration	  in	  cervical	  cancer	  has	  been	  
described	  at	  length,	  the	  understanding	  within	  HPV	  positive	  HNSCC	  is	  somewhat	  
different.	  Coupled	  with	  the	  obvious	  lack	  of	  a	  detectable	  analogous	  dysplastic	  lesion	  
in	  the	  oropharynx,	  there	  seems	  to	  be	  a	  significantly	  different	  level	  of	  integrative	  
events	  in	  the	  final	  invasive	  malignancy.	  In	  the	  cervix	  integration	  is	  evident	  in	  the	  
vast	  majority	  of	  invasive	  lesions5,167,168	  whilst	  in	  OPSCC	  this	  level	  is	  markedly	  lower,	  
ranging	  from	  14	  –	  60%,	  depending	  on	  analytical	  method	  and	  tissue	  specimen	  type	  
being	  analysed96,179,180.	  	  Explanations	  for	  this	  variation	  have	  yet	  to	  be	  advanced	  nor	  
experimentally	  explored.	  
There	  are	  several	  techniques	  described	  to	  facilitate	  detection	  of	  HPV	  integration.	  
They	  can	  be	  divided	  into	  those	  analyses	  that	  classify	  integration	  on	  the	  basis	  of	  
implied	  evidence	  or	  those	  which	  allow	  direct	  detection,	  typically	  by	  means	  of	  
sequencing	  techniques.	  	  
Implied	  evidence	  extends	  primarily	  from	  experimental	  data	  that	  suggests	  there	  is	  an	  
integration-­‐dependent	  disruption	  of	  the	  HPV	  E2	  gene	  when	  any	  integration	  event	  
occurs	  and	  hence	  detection	  of	  E2	  status,	  integrity	  or	  expression	  informs	  integration	  
state181-­‐183.	  	  One	  weakness	  of	  such	  techniques	  surrounds	  the	  inference	  that	  
detection	  of	  episomal	  viral	  DNA	  is	  absolute	  however	  such	  a	  finding	  belies	  the	  




Direct	  detection	  of	  integration	  differs	  in	  that	  fewer	  assumptions	  are	  made	  and	  
evidence	  of	  integration	  is	  sought	  directly.	  Once	  again,	  several	  techniques	  have	  been	  
described,	  ranging	  from	  Southern	  Blot	  analysis,	  with	  or	  without	  subsequent	  
fragment	  sequencing,	  to	  the	  more	  recently	  described	  HPV	  specific	  techniques	  of	  
Amplification	  of	  Papillomavirus	  Oncogene	  Transcripts	  PCR	  (APOT-­‐PCR)	  and	  
Detection	  of	  Integrated	  Papillomavirus	  Sequences	  PCR	  	  (DIPS-­‐PCR)	  for	  detection	  of	  
transcripts	  or	  genomic	  sequence	  respectively.	  
An	  ideal	  integration	  detection	  technique	  would	  provide	  direct	  evidence	  of	  viral	  
cleavage	  position(s)	  within	  the	  circular	  viral	  DNA	  and	  accompanying	  host	  
chromosomal	  integration	  position(s).	  Although	  a	  single	  viral	  copy	  could	  be	  all	  that	  is	  
necessary.	  Additionally,	  the	  technique	  would	  allow	  detection	  of	  relative	  viral	  load,	  
be	  applicable	  to	  clinical	  samples	  for	  biologically	  relevant	  analysis.	  Finally,	  it	  should	  
involve	  a	  step	  that	  demonstrates	  active	  viral	  transcription,	  as	  this	  remains	  the	  
prerequisite	  for	  defining	  a	  virally	  mediated	  malignancy	  as	  opposed	  to	  a	  potentially	  
innocuous	  viral	  infection	  irrespective	  of	  copy	  number.	  	  	  
A	  novel	  approach	  to	  integration	  analysis	  is	  utilisation	  of	  next	  generation	  sequencing	  
technologies	  with	  capture	  of	  HPV	  and	  host	  sequence	  at	  the	  position	  of	  viral	  
cleavage/host	  insertion.	  To	  date,	  such	  an	  application	  of	  technique	  has	  yet	  to	  be	  
adopted	  for	  integration	  analysis	  in	  HPV	  positive	  malignancy.	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3 MATERIAL	  &	  METHODS	  
3.1 HUMAN	  TISSUE	  PROCUREMENT	  &	  CHARACTERISATION	  
Ethical	  Agreements	  for	  Clinical	  Sample	  &	  Data	  Collection	  
Fresh	  Frozen	  Tissue	  Samples	  
Tissue	  samples	  utilised	  in	  this	  research	  were	  sourced	  from	  patients	  treated	  at	  two	  
sites	  within	  the	  Merseyside	  region,	  namely	  the	  Royal	  Liverpool	  &	  Broadgreen	  
University	  Hospital	  Trust	  (1988	  –	  1996)	  and	  University	  Hospital	  Aintree	  NHS	  
Foundation	  Trust	  (1992	  –	  present).	  Tissue	  collection	  was	  undertaken	  following	  the	  
granting	  of	  ethical	  approval	  by	  the	  South	  Sefton	  Research	  Ethics	  Committee	  (EC	  
47.01),	  the	  Liverpool	  (Adult)	  Research	  Ethics	  Committee	  (REC	  07/Q1505/15)	  and	  
North	  West	  5	  Research	  Ethics	  Committee	  (REC	  09.H1010.54).	  	  
Utilisation	  of	  tissue	  resources	  collected	  under	  the	  latter	  two	  of	  these	  agreements	  
was	  made	  possible	  following	  the	  granting	  of	  approval	  from	  the	  North	  West	  3	  –	  
Liverpool	  East	  Research	  Ethics	  Committee	  (REC	  10/H1002/53). 
	  	  
Tumours	  and	  adjacent	  normal	  uninvolved	  marginal	  tissue	  (where	  additionally	  
available)	  was	  sourced	  from	  one	  hundred	  and	  eight	  (n=108)	  Oropharyngeal	  
Squamous	  Cell	  Carcinomas	  (n=53	  matched	  normal).	  
	  
Formalin	  Fixed	  Paraffin	  Embedded	  Tissue	  Samples	  
Formalin	  fixed	  paraffin	  embedded	  (FFPE)	  tissue	  samples	  corresponding	  to	  the	  above	  
fresh	  tissue	  samples	  were	  collected	  in	  parallel	  under	  the	  ethical	  agreements	  already	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noted.	  Ninety-­‐seven	  such	  samples	  were	  available	  for	  utilisation	  in	  TMA	  
construction.	  	  
To	  quantify	  the	  potential	  contribution	  of	  stromal,	  inflammatory	  and	  adjacent,	  non-­‐
involved	  epithelial	  cells	  within	  the	  non-­‐microdissected	  tissue	  samples	  a	  tumour	  cell	  
burden	  analysis	  was	  performed	  by	  analysis	  of	  the	  tumour	  cell	  proportion	  within	  
Haematoxylin	  and	  Eosin	  (H&E)	  stained,	  fixed	  tissue	  slides	  corresponding	  to	  the	  fresh	  
frozen	  samples	  of	  20	  randomly	  selected	  cases.	  	  
	  
Alternatively	  Sourced	  DNA	  &	  RNA	  Samples	  
Nucleic	  acids	  (DNA	  and	  RNA)	  extracted	  from	  20	  OPSCC	  at	  source	  by	  a	  collaborator	  
conducting	  the	  PREDICT-­‐TPF	  Trial	  (Primary	  Investigator;	  Dr	  B	  Lallemant,	  Faculty	  of	  
Medicine	  Montpellier-­‐Nîmes,	  CHU	  de	  Nîmes,	  France)	  was	  kindly	  offered	  for	  
analysis.	  All	  nucleic	  acid	  extraction	  was	  undertaken	  from	  fresh	  frozen	  samples	  using	  
the	  same	  techniques	  detailed	  below	  for	  locally	  sourced	  samples	  (page	  63),	  with	  
DNA	  and	  RNA	  quality	  assurance	  also	  following	  identical	  processes	  (page	  67).	  	  
Complimentary	  DNA	  synthesis	  was	  undertaken	  alongside	  all	  other	  OPSCC	  samples	  
detailed	  in	  this	  research	  using	  the	  techniques	  detailed	  below	  (page	  67).	  
	  
DNA	  from	  Lymphoctyes	  derived	  from	  whole	  blood	  samples	  of	  healthy	  controls,	  
sourced	  under	  ethical	  agreements	  granted	  to	  the	  Liverpool	  Lung	  Project	  &	  the	  Roy	  
Castle	  Lung	  Cancer	  Foundation,	  was	  kindly	  provided	  by	  Dr	  George	  Nikolaidas.	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3.2 TISSUE	  MICROARRAY	  (TMA)	  CONSTRUCTION	  &	  UTILISATION	  
TMA	  Construction	  
Tissue	  microarrays	  (TMAs)	  were	  constructed	  from	  formalin-­‐fixed	  paraffin-­‐
embedded	  (FFPE)	  tissue	  blocks	  of	  OPSCC	  using	  a	  manual	  tissue	  arrayer	  (MTA-­‐I,	  
Beecher	  Instruments,	  USA),	  as	  previously	  described184.	  	  
Recipient	  paraffin	  blocks	  were	  constructed	  from	  paraffin	  wax,	  melted	  in	  a	  wax	  bath,	  
and	  subsequently	  poured	  into	  metal	  frame	  moulds,	  to	  reduce	  the	  incidence	  of	  air	  
bubble	  entrapment	  that	  might	  subsequently	  affect	  TMA	  section	  integrity.	  Once	  set,	  
blocks	  were	  inspected	  and	  any	  evident	  impurity	  or	  flaws	  in	  the	  block	  resulted	  in	  its	  
rejection	  before	  use.	  
Array	  construction	  followed	  the	  procedure	  as	  detailed	  by	  Parsons	  et	  al184.	  Briefly,	  
haematoxylin	  and	  eosin	  (H&E)	  stained	  sections	  were	  reviewed	  by	  a	  consultant	  Head	  
&	  Neck	  histopathologist	  to	  identify	  areas	  of	  representative	  tumour	  and	  adjacent	  
normal	  mucosa	  within	  each	  donor	  block.	  Triplicate	  tumour	  cores	  and	  solitary	  
matched	  normal	  mucosal	  cores	  (height	  4mm,	  diameter	  0.6mm)	  were	  transferred	  
from	  individual	  donor	  blocks	  to	  the	  recipient	  block	  employing	  a	  predetermined	  
asymmetrical	  distribution.	  The	  asymmetrical	  core	  distribution	  was	  intended	  to	  
ensure	  that	  the	  chance	  of	  confounding	  results	  due	  to	  positional	  staining	  artifacts	  
were	  minimized	  for	  any	  individual	  case.	  Spacing	  between	  cores	  was	  1.2	  mm	  on	  the	  
x-­‐axis	  and	  1.0	  mm	  on	  the	  y-­‐axis	  to	  increase	  core	  retention	  and	  minimise	  the	  chance	  
of	  block	  fracture	  during	  construction.	  	  
Following	  completion	  of	  TMA	  construction,	  blocks	  were	  incubated	  at	  40	  °C	  
overnight	  to	  facilitate	  bonding	  of	  the	  donor	  cores	  with	  the	  paraffin	  wax	  of	  the	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recipient	  block.	  5µm	  H&E	  stained	  sections	  of	  the	  TMAs	  were	  subsequently	  
examined	  by	  a	  two	  consultant	  pathologists,	  blinded	  to	  the	  core	  tissue	  origin,	  to	  
confirm	  accurate	  sampling	  of	  tumour	  bearing	  (or	  conversely	  normal)	  tissue.	  	  
	  
TMA	  Utilisation	  
5	  µm	  sections	  of	  recipient	  blocks	  were	  cut	  on	  a	  microtome	  and	  floated	  on	  a	  water	  
bath	  at	  or	  below	  42	  °C	  before	  immediate	  transfer	  and	  mounting	  on	  4%	  APES	  coated	  
Superfrost	  Plus	  glass	  slides	  (Fisher	  Scientific,	  Leicestershire,	  UK).	  Slides	  were	  dried	  
at	  37	  °C	  overnight	  before	  storage	  or	  usage.	  	  
	  
3.3 p16	  IMMUNOHISTOCHEMISTRY	  
p16INK4A	  Immunohistochemistry	  (p16	  IHC)	  was	  carried	  out	  on	  5	  µm	  sections	  of	  TMA	  
or	  whole	  mount	  blocks,	  prepared	  as	  detailed	  above.	  A	  proprietary	  kit	  (CINtec	  
Histology;	  Roche	  mtm	  laboratories	  AG,	  Heidelberg,	  Germany)	  was	  utilised	  on	  a	  
Ventana	  Benchmark	  autostainer	  (Ventana	  Medical	  Systems	  Inc,	  Tucson,	  AZ,	  USA).	  A	  
tonsil	  squamous	  cell	  carcinoma	  with	  previously	  demonstrated	  high	  p16	  expression	  
was	  used	  as	  a	  positive	  control	  during	  slide	  staining.	  Omission	  of	  the	  proprietary	  
primary	  antibody	  for	  p16	  staining	  (E6H4™)	  was	  made	  for	  the	  purposes	  of	  negative	  
control.	  p16	  staining	  was	  scored	  as	  positive	  if	  there	  was	  strong	  diffuse	  nuclear	  and	  
cytoplasmic	  staining	  present	  in	  greater	  than	  70%	  of	  malignant	  cells131.	  All	  other	  
staining	  patterns	  were	  scored	  as	  negative.	  Details	  of	  observer	  scoring	  and	  




3.4 HIGH	  RISK	  HPV	  DNA	  IN	  SITU	  HYBRIDISATION	  
High	  Risk	  HPV	  DNA	  in	  situ	  hybridisation	  (HR	  HPV	  DNA	  ISH)	  was	  carried	  out	  using	  
proprietary	  reagents	  (Inform	  III	  Family	  16	  Probe	  (B),	  Ventana	  Medical	  Systems	  Inc.,	  
Tucson,	  AZ,	  USA)	  on	  a	  Benchmark	  Autostainer	  (Ventana	  Medical	  Systems	  Inc.)	  
applied	  to	  5	  µm	  sections	  of	  TMA	  or	  whole	  mount	  blocks,	  prepared	  as	  detailed	  
above.	  The	  Inform	  III	  Family	  Probe	  (B)	  detects	  high	  risk	  HPV	  genotypes	  HPV16,	  -­‐18,	  -­‐
31,	  -­‐33,	  -­‐35,	  -­‐39,	  -­‐45,	  -­‐51,	  -­‐52,	  -­‐56,	  -­‐58,	  -­‐66.	  Three	  control	  samples	  were	  included	  
with	  each	  slide;	  formalin	  fixed	  paraffin	  embedded	  samples	  of	  CaSki	  cells	  (HPV16	  
positive,	  approximately	  870	  copies	  per	  diploid	  genome,	  or	  approximately	  1700	  
copies	  per	  near-­‐tetraploid	  cell185),	  HeLa	  cells	  (HPV18	  positive,	  10-­‐50	  copies	  per	  cell)	  
and	  C-­‐33A	  (HPV	  negative	  control,	  Ventana	  Medical	  Systems	  Inc.).	  The	  HR	  HPV	  DNA	  
ISH	  test	  was	  scored	  as	  positive	  if	  there	  was	  any	  blue	  reaction	  product	  colocalizing	  to	  
the	  cell	  nucleus	  of	  malignant	  cells	  (either	  punctate	  or	  diffuse)131.	  Cases	  with	  
specifically	  punctate	  nuclear	  staining	  cases	  were	  recorded	  in	  accordance	  with	  
previously	  published	  reference	  to	  possibility	  of	  such	  staining	  pattern	  corresponding	  
to	  genomic	  integration	  of	  viral	  DNA186.	  
Details	  of	  observer	  scoring	  and	  interpretation	  of	  test	  results	  are	  detailed	  below.	  
	  
3.5 HIGH	  RISK	  HPV	  RNA	  IN	  SITU	  HYBRIDISATION	  (RNAscope)	  
Detection	  of	  High	  Risk	  HPV	  E6/E7	  mRNA	  on	  5	  µm	  sections	  of	  TMA	  sections,	  
prepared	  as	  detailed	  above,	  or,	  where	  necessary,	  on	  5	  µm	  representative	  whole	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mount	  sections,	  was	  performed	  using	  the	  High	  Risk	  HPV	  RNAscope	  kit	  (Advanced	  
Cell	  Diagnostics,	  Inc.,	  Hayward,	  CA,	  USA)	  as	  previously	  described187	  by	  the	  product	  
manufacturers	  in	  their	  own	  research	  facility	  (Advanced	  Cell	  Diagnostics).	  	  
Briefly,	  5	  µm	  TMA	  sections	  were	  deparaffinised	  and	  pretreated	  with	  heat	  and	  
protease	  before	  hybridisation	  with	  target-­‐specific	  probes	  for	  the	  E6	  and	  E7	  genes	  of	  
seven	  High	  Risk	  HPV	  genotypes	  (HPV-­‐16,	  -­‐18,	  -­‐31,	  -­‐33,	  -­‐35,	  -­‐52,	  -­‐58).	  Ubiquitin	  C	  
(UBC,	  a	  constitutively	  expressed	  endogenous	  gene)	  and	  the	  bacterial	  gene,	  dapB	  
were	  used	  as	  positive	  and	  negative	  controls	  respectively.	  
Whole	  tissue	  sections	  for	  selected	  cases	  were	  stained	  for	  HR	  HPV	  RNA,	  UBC	  and	  
dapB	  by	  a	  fully	  automated	  RNAscope	  assay	  (RNAscopeVS)	  using	  the	  Ventana	  
Discovery	  XT	  slide	  autostaining	  system	  (Ventana	  Medical	  Systems	  Inc,	  USA).	  
Application	  of	  analysis	  to	  full	  sections	  of	  tumour	  specimens	  was	  deemed	  necessary	  
where	  there	  was	  inter-­‐observer	  discrepancy	  in	  the	  TMA	  analysis	  reporting	  process.	  	  
The	  UBC	  test	  was	  used	  to	  assess	  the	  presence	  of	  hybridisable	  RNA	  and	  was	  defined	  
as	  adequate	  if	  there	  was	  strong	  staining	  in	  the	  majority	  of	  cells	  in	  the	  section.	  The	  
dapB	  test	  was	  used	  to	  assess	  non-­‐specific	  staining;	  only	  those	  cases	  that	  were	  
negative	  or	  weakly	  stained	  were	  considered	  for	  HPV	  scoring.	  A	  positive	  HPV	  test	  
result	  was	  defined	  as	  punctate	  staining	  that	  co-­‐localised	  to	  the	  cytoplasm	  and/or	  
nucleus	  of	  any	  of	  the	  malignant	  cells.	  Where	  staining	  was	  detected	  in	  the	  dapB	  
negative	  control,	  a	  positive	  HPV	  result	  was	  only	  recorded	  if	  staining	  was	  at	  least	  
twice	  as	  strong	  as	  the	  dapB	  test.	  With	  respect	  to	  HR	  HPV	  RNA	  ISH	  test	  controls,	  the	  
UBC	  test	  was	  used	  to	  assess	  the	  presence	  of	  hybridisable	  RNA	  and	  was	  defined	  as	  




3.6 HIGH	  RISK	  HPV	  TEST	  INTERPRETATION	  TECHNIQUES	  
The	  TMA	  section	  analysis	  was	  conducted	  for	  each	  test	  and	  involved	  assessment	  of	  
individual	  cores,	  with	  assessor	  remaining	  blind	  to	  the	  core	  sample	  origin.	  Scoring	  
was	  conduced	  by	  two	  consultant	  pathologists	  (Dr	  Max	  Robinson	  &	  Professor	  Philip	  
Sloan,	  Newcastle	  University,	  UK)	  using	  a	  binary	  classification	  (positive	  vs.	  negative).	  	  
Following	  collation	  of	  the	  independent	  staining	  interpretation,	  discordant	  scores	  
were	  re-­‐examined	  at	  a	  meeting	  between	  the	  pathologists	  to	  establish	  a	  consensus	  
interpretation.	  In	  order	  to	  quality	  assure	  the	  results,	  cases	  that	  had	  discordant	  
scores	  between	  the	  pathologists	  and/or	  variable	  scores	  between	  cores	  from	  the	  
same	  tumour	  were	  additionally	  subjected	  to	  analysis	  of	  whole	  tumour	  sections.	  Test	  
analysis	  for	  whole	  sections	  was	  identical	  to	  that	  of	  the	  TMA	  sections.	  
	  
3.7 CELL	  LINES	  
All	  cell	  lines	  were	  grown	  and	  maintained	  in	  plastic	  culture	  dishes	  in	  media	  
appropriate	  to	  their	  growth	  requirements	  at	  37	  °C	  in	  an	  atmosphere	  of	  5%	  CO2.	  
Cells	  were	  split	  as	  required	  (usually	  60-­‐80%	  confluent)	  by	  detachment	  with	  trypsin	  
(0.25%	  w/v)/EDTA	  (5mM)	  prewarmed	  to	  37	  °C.	  Briefly,	  the	  culture	  medium	  was	  
removed	  from	  the	  flask	  and	  cells	  were	  washed	  with	  sterile	  PBS	  for	  30	  seconds	  
before	  discarding	  from	  the	  flask.	  Trypsin	  was	  added	  and	  allowed	  to	  coat	  the	  cells	  
before	  being	  incubated	  for	  5	  minutes	  at	  37	  °C.	  Detachment	  of	  cells	  was	  confirmed	  
by	  tapping	  the	  flask	  (and	  incubation	  time	  increased	  if	  detachment	  not	  apparent)	  
before	  neutralizing	  the	  effects	  of	  trypsin	  with	  serum	  containing	  media	  in	  an	  equal	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volume.	  The	  cell	  population,	  suspended	  within	  media/trypsin	  was	  pipetted	  from	  the	  
flask	  and	  centrifuged	  at	  1200	  rpm	  for	  5	  minutes.	  Supernatant	  was	  subsequently	  
removed	  and	  the	  cell	  pellet	  used	  in	  onward	  processes.	  
Established	  Cell	  Lines	  
CaSki	  
The	  Human	  Caucasian	  cervical	  epidermoid	  carcinoma	  derived	  cell	  line	  was	  procured	  
from	  ATCC	  (Middlesex,	  UK).	  CaSki	  cells	  contain	  600-­‐800	  integrated	  copies	  of	  HPV16	  
per	  cell185.	  CaSki	  was	  maintained	  in	  RPMI	  1640,	  2nM	  Glutamine	  and	  10%	  Foetal	  
Bovine	  Serum.	  
SiHa	  
The	  Human	  Caucasian	  cervical	  squamous	  cell	  carcinoma	  derived	  cell	  line	  was	  
procured	  from	  ATCC	  (Middlesex,	  UK).	  SiHa	  cells	  contain	  between	  1	  and	  2	  integrated	  
copies	  of	  HPV16	  per	  cell188.	  Cell	  growth	  is	  maintained	  in	  Eagle’s	  Minimum	  Essential	  
Medium,	  2nM	  Glutamine	  and	  10%	  Foetal	  Bovine	  Serum.	  
HeLa	  
The	  Human	  Negroid	  cervical	  epitheloid	  carcinoma	  derived	  cell	  line	  was	  procured	  
from	  ATCC	  (Middlesex,	  UK).	  HeLa	  contains	  approximately	  50	  copies	  of	  HPV18	  per	  
cell.	  Cell	  growth	  was	  maintained	  in	  Eagle’s	  Minimum	  Essential	  Medium,	  2nM	  




3.8 NUCLEIC	  ACID	  EXTRACTION	  	  
Fresh	  Frozen	  Tissue	  Samples	  
The	  AllPrep	  DNA/RNA	  Mini	  Kit	  (Qiagen®,	  Crawley,	  UK)	  was	  used	  to	  purify	  genomic	  
DNA	  and	  total	  RNA	  simultaneously	  from	  fresh	  frozen	  tissue	  specimens	  which	  had	  
been	  maintained	  at	  -­‐80°C	  since	  time	  of	  surgical	  resection.	  Briefly,	  2mm3	  portions	  of	  
tumour	  tissue	  were	  divided	  from	  main	  tissue	  sample	  blocks	  within	  a	  class	  II	  
biological	  safety	  cabinet	  with	  new	  sterile	  disposable	  consumables	  to	  avoid	  cross-­‐
contamination.	  	  Tissue	  samples	  were	  placed	  directly	  into	  350	  µl	  of	  Buffer	  RLT	  Plus	  
(with	  1:100	  ß-­‐mercaptoethanol)	  and	  homogenized	  within	  Precellys	  soft	  tissue	  
homogenizing	  tubes	  containing	  1.4mm	  ceramic	  (zirconium	  oxide)	  beads	  (Bertin	  
Technologies,	  Montigny-­‐le-­‐Bretonneaux,	  France).	  Homogenization	  was	  undertaken	  
in	  the	  Precellys®	  24	  using	  2	  x	  20s	  cycles	  at	  6500rpm	  (Bertin	  Technologies,	  Montigny-­‐
le-­‐Bretonneaux,	  France).	  Samples	  were	  centrifuged	  at	  10,000g	  for	  3	  minutes	  before	  
transfer	  to	  the	  AllPrep	  DNA	  spin	  column	  for	  further	  centrifuging	  for	  30s	  at	  10,000g.	  
The	  flow-­‐through	  product	  was	  retained	  for	  RNA	  extraction	  as	  below.	  The	  samples	  
were	  washed	  once	  with	  500μl	  buffer	  AW1	  and	  centrifuged	  at	  10,000g	  before	  being	  
washed	  again	  with	  500μl	  buffer	  AW2.	  After	  centrifugation	  at	  10,000g,	  50μl	  of	  EB	  
buffer	  was	  added	  to	  each	  sample	  and	  following	  incubation	  at	  room	  temperature	  for	  
1	  min,	  DNA	  was	  recovered	  by	  centrifugation	  at	  10,000g	  for	  1	  min.	  	  A	  subsequent	  
elution	  of	  remaining	  DNA	  was	  made	  as	  above	  for	  retention	  of	  a	  “B-­‐sample”.	  




RNA	  extraction	  was	  undertaken	  using	  the	  flow-­‐through	  product	  from	  AllPrep	  DNA	  
spin	  column	  (above)	  according	  to	  the	  manufacturers	  protocol	  and	  including	  DNase	  
digestion	  using	  a	  Qiagen	  RNase-­‐Free	  DNase	  set	  (Qiagen,	  Crawley)	  to	  eliminate	  DNA	  
carryover	  in	  the	  RNA	  preparations.	  Briefly,	  350µl	  of	  70%	  ethanol	  was	  mixed	  with	  
the	  flow-­‐through	  and	  transferred	  to	  an	  RNeasy	  spin	  column	  for	  centrifuging	  at	  
10,000g	  for	  15s.	  The	  sample	  was	  washed	  with	  buffer	  RW1	  before	  on-­‐column	  DNase	  
digestion	  with	  DNase	  I	  stock	  solution	  in	  Buffer	  RDD.	  The	  samples	  were	  incubated	  at	  
room	  temperature	  (20-­‐30°C)	  for	  30	  minutes	  before	  a	  further	  wash	  with	  Buffer	  RW1.	  	  
The	  samples	  were	  centrifuged	  for	  15s	  at	  10,000g,	  washed	  with	  Buffer	  RPE	  and	  
centrifuged	  repeatedly	  until	  the	  spin	  column	  was	  dry	  (2	  x	  2min	  at	  10,000g).	  	  
Purified	  RNA	  was	  eluted	  in	  50uL	  of	  RNase-­‐free	  water	  and	  stored	  at	  -­‐80°C	  until	  
required.	  
	  
Cell	  Line	  Derived	  Samples	  
For	  the	  DNA	  extraction	  from	  cell	  lines	  the	  DNeasy	  kit	  (Spin	  column	  protocol)	  
(Qiagen)	  was	  used.	  A	  maximum	  of	  5x106	  cells	  were	  pelleted	  at	  300	  x	  g	  for	  5	  minutes	  
and	  the	  pellet	  was	  re-­‐suspended	  in	  200	  μl	  PBS.	  20	  μl	  proteinase	  K	  and	  4	  μl	  of	  RNase	  
A	  (100	  mg/ml)	  (Qiagen)	  were	  added,	  the	  lysate	  was	  then	  mixed	  by	  vortexing	  and	  
incubated	  at	  room	  temperature	  for	  10	  minutes.	  Subsequently	  200	  μl	  Buffer	  AL	  were	  
added	  and	  the	  lysate	  was	  mixed	  thoroughly	  by	  vortexing	  and	  incubated	  at	  56°C	  for	  
10	  min.	  200	  μl	  of	  ethanol	  (96–100%)	  were	  added	  to	  the	  sample	  which	  was	  mixed	  
thoroughly	  by	  vortexing.	  The	  mixture	  was	  transferred	  into	  the	  DNeasy	  Mini	  spin	  
column	  (which	  carries	  a	  silica	  based	  membrane)	  placed	  in	  a	  2	  ml	  collection	  tube,	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and	  was	  centrifuged	  at	  6000	  x	  g	  for	  1	  min.	  500	  μl	  of	  Buffer	  AW1	  were	  added,	  and	  
the	  sample	  was	  centrifuged	  for	  1	  min	  at	  6000	  x	  g.	  500	  μl	  of	  Buffer	  AW2	  were	  then	  
added	  and	  the	  sample	  was	  centrifuged	  for	  3	  min	  at	  20,000	  x	  g	  to	  dry	  the	  DNeasy	  
membrane.	  The	  DNeasy	  mini	  spin	  column	  was	  then	  placed	  in	  a	  1.5	  ml	  
microcentrifuge	  tube	  and	  the	  DNA	  was	  recovered	  into	  200	  μl	  Buffer	  AE	  with	  
centrifuging	  at	  6000	  x	  g	  for	  1	  min.	  DNA	  quality	  and	  quantity	  was	  assessed	  by	  
spectrophotometry	  at	  260/280	  nm	  wavelength.	  	  
	  
DNA	  &	  RNA	  from	  the	  HPV	  negative	  human	  bronchial	  epithelial	  cell	  line,	  HBEC-­‐3KT,	  
was	  kindly	  provided	  by	  Dr	  George	  Nikolaidis.	  These	  samples	  were	  utilised	  as	  an	  
important	  HPV	  negative	  control	  and	  source	  of	  DNA	  and	  RNA	  for	  qPCR	  assay	  
optimization.	  
	  
Cell	  Line	  Verification	  Procedure	  
The	  identities	  of	  all	  cell	  lines	  utilised	  were	  confirmed	  following	  initial	  culturing	  and	  
subsequent	  preparation	  of	  nucleic	  acids.	  Using	  the	  Cell	  ID	  System	  (Promega,	  
Madison,	  WI,	  USA),	  confirmation	  of	  previously	  determined	  short	  tandem	  repeat	  
(STR)	  loci	  profiles	  for	  each	  cell	  line	  was	  made.	  Briefly	  2ng	  of	  sample	  DNA	  (or	  positive	  
control	  K562	  DNA)	  was	  combined	  with	  Cell	  ID	  Enzyme	  Mix	  (x5)	  and	  Primer	  Pair	  Mix	  





Temperature	  (oC)	   Time	   No	  of	  cycles	  
96	   2	  min	   	  
94	   30	  sec	   	  
60	   30	  sec	   10	  
70	   45	  sec	   	  
90	   30	  sec	   	  
60	   30	  sec	   22	  
70	   45	  sec	   	  
60	   30	  min	   	  
	  
Table	  4:	  Thermal	  Cycling	  Conditions	  for	  Cell	  ID	  System	  
	  
Detection	  of	  amplified	  fragments	  in	  samples	  was	  conducted	  on	  an	  Applied	  
Biosystems	  3130	  Genetic	  Analyser	  (Applied	  Biosystems)	  using	  GeneMapper	  4.0	  
software.	  Briefly	  1µL	  of	  PCR	  product	  was	  combined	  with	  10µL	  of	  highly	  deionized	  
formamide	  (HDF)	  and	  1µL	  of	  the	  Internal	  Lane	  Standard	  (ILS	  600)	  and	  denatured	  at	  
95°C	  for	  3	  minutes	  before	  returning	  to	  ice	  then	  immediately	  loading	  for	  capillary	  
electrophoresis	  as	  detailed	  by	  the	  manufacturer.	  Comparison	  of	  STR	  loci	  results	  was	  
made	  with	  those	  published	  by	  the	  cell	  line	  procurement	  source	  (ATCC,	  Middlesex,	  
UK)	  and	  are	  detailed	  below	  in	  Table	  5.	  
	  	  
STR	  Locus	   CaSki	   SiHa	   HeLa	  
	  
Database	   Actual	   Database	   Actual	   Database	   Actual	  
Amelogenin	   X	   X	   X	   X	   X	   X	  
CSF1PO	   10	   10	   12	   12	   9,10	   9,10	  
D13S317	   8,12	   8,12	   11	   11	   12,13.3	   12,13.3	  
D16S539	   11,12	   11,12	   12	   12	   9,10	   9,10	  
D5S818	   13	   13	   9	   9	   11,12	   11,12	  
D7S820	   8,11	   8,11	   10	   10	   8,12	   8,12	  
THO1	   7	   7	   6,9	   6,9	   7	   7	  
TPOX	  	   8	   8	   8	   8	   8,12	   8,12	  
vWA	   17	   17	   14,17	   14,17	   16,18	   16,18	  
	  
Table	  5:	  Reported	  and	  Actual	  STR	  Profiles	  for	  Cell	  Lines	  Utilised	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3.9 NUCLEIC	  ACID	  QUANTIFICATION	  
The	  purified	  DNA	  &	  RNA	  samples	  were	  quantified	  by	  spectrophotometry	  using	  a	  
NanoDrop	  1000™	  (NanoDrop	  Technologies,	  Thermo	  Fischer	  Scientific,	  Wilmington,	  
DE,	  USA).	  Nucleic	  acid	  extraction	  was	  repeated	  where	  sample	  purity	  fell	  outside	  
expected	  normal	  range,	  as	  determined	  by	  the	  ratio	  of	  absorption	  at	  260	  and	  280nm	  
(A260:280).	  For	  DNA	  samples	  repeat	  extraction	  was	  conducted	  for	  A260:280	  less	  than	  
1.75	  and	  for	  RNA	  samples	  when	  A260:280	  fell	  below	  1.90.	  	  
	  
3.10 COMPLIMENTARY	  DNA	  SYNTHESIS	  
Complimentary	  DNA	  synthesis	  (cDNA)	  was	  undertaken	  using	  the	  QuantiTect	  
Reverse	  Transcription	  Kit	  (Qiagen®,	  Crawley,	  UK)	  according	  to	  the	  manufacturers	  
protocol.	  	  
Briefly,	  following	  thawing	  on	  ice,	  500-­‐600ng	  of	  Total	  RNA	  was	  combined	  with	  2	  µL	  
of	  gDNA	  wipe-­‐out	  buffer	  and	  a	  variable	  volume	  of	  RNase	  free	  water	  to	  make	  a	  final	  
volume	  of	  14	  µL.	  Samples	  were	  incubated	  at	  42°C	  for	  2	  min	  then	  placed	  
immediately	  on	  ice.	  	  
A	  reverse-­‐transcription	  master	  mix	  of	  Quantiscript	  reverse	  transcriptase	  (1	  µL	  per	  
sample),	  Quantiscript	  RT	  buffer	  (4	  µL	  per	  sample)	  and	  RT	  primer	  mix	  (1	  µL	  per	  
sample)	  was	  made	  on	  ice.	  6	  µL	  of	  the	  prepared	  master	  mix	  was	  combined	  with	  each	  
sample,	  mixed	  by	  pipetting	  and	  incubated	  at	  42	  °C	  for	  15	  min	  with	  a	  final	  incubation	  
at	  95°C	  for	  3	  min	  to	  inactivate	  Quantiscript	  reverse	  transcriptase.	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Each	  finished	  reverse-­‐transcription	  reaction	  sample	  was	  diluted	  1:5	  with	  RNAse	  free	  
water	  before	  storing	  at	  -­‐20°C	  until	  required.	  
	  
3.11 QUANTITATIVE	  REAL-­‐TIME	  PCR	  ANALYSIS	  
For	  the	  detection	  of	  viral	  and	  host	  gene	  DNA	  presence	  and	  gene	  expression,	  
quantitative	  real-­‐time	  PCR	  assays	  were	  used.	  These	  constituted	  either	  custom	  
designed	  assays	  (HPV16	  E2,	  E6	  &	  E7	  and	  HPV	  18	  E6)	  or	  commercially	  available	  
assays	  (HPV	  33	  E6)	  as	  detailed	  below.	  	  Analysis	  was	  undertaken	  for	  a	  cohort	  of	  96	  
OPSCC	  and	  where	  available	  adjacent	  matched	  normal	  pairs	  (n=53).	  
Additionally,	  proprietary	  gene	  expression	  assays	  were	  utilised	  to	  determine	  
differential	  gene	  expression	  levels	  based	  on	  HPV	  status	  for	  the	  key	  determinants	  of	  
DNA	  methylation,	  DNA	  methyltransferases	  (DNMT-­‐1,	  -­‐3a	  &	  -­‐3b)	  and	  UHRF1.	  
	  
HR	  HPV	  qPCR	  Assays	  Design	  and	  Optimisation	  
The	  defined	  gold	  standard	  test	  for	  this	  research	  was	  HR	  HPV	  RNA	  qPCR	  which	  
included	  assays	  for	  HPV16	  E6	  and	  E7	  genes,	  HPV18	  E6	  gene	  and	  HPV33	  E6	  gene.	  The	  
aggregation	  of	  results	  from	  these	  four	  assays	  was	  deemed	  appropriate	  to	  correctly	  
classify	  HPV	  status	  in	  over	  99%	  of	  HPV	  positive	  OPSCC	  in	  accordance	  with	  the	  






HPV16	  E2,	  E6	  &	  E7,	  HPV18	  E6	  Assays	  
Using	  the	  Primer	  Express	  v2.0	  Software	  (Applied	  Biosystems),	  primers	  and	  probes	  
were	  designed	  for	  the	  HPV	  E2,	  E6,	  E7,	  and	  the	  HPV18	  E6.	  Reference	  sequences	  
utilised	  were	  as	  follows;	  Genebank	  NCBI	  Reference	  Sequence	  NC_001526.2	  &	  
AY262282.1	  respectively.	  	  All	  primer	  sequences	  passed	  Basic	  Local	  Alignment	  Seach	  
Tool	  (BLAST)	  analysis	  to	  ensure	  an	  absence	  of	  human	  genome	  target	  sequence	  
homology.	  	  
Probes	  were	  FAM-­‐labeled	  MGB	  Taqman	  probes	  synthesized	  by	  Applied	  Biosystems,	  
whilst	  primers	  were	  synthesized	  by	  MWG	  (Ebersberg,	  Germany).	  Details	  of	  the	  
primer	  and	  probe	  sequences	  are	  contained	  in	  Table	  6.	  	  
Commercially	  available	  primers	  and	  a	  VIC-­‐TAMRA	  labeled	  probe	  for	  the	  single-­‐copy	  
gene	  RNase	  P	  (Taqman	  RNase	  P	  Control	  Reagents,	  Applied	  Biosystems)	  were	  used	  
as	  an	  endogenous	  reference	  in	  each	  multiplex	  reaction.	  This	  served	  to	  demonstrate	  
availability	  and	  quantitative	  adequacy	  of	  detectable	  human	  genomic	  DNA	  within	  
each	  reaction.	  	  
	  
	  
Table	  6:	  Primer	  and	  probe	  sequences	  for	  HPV-­‐16	  &	  -­‐18	  gene	  specific	  assays	  
	  
Target	   Forward	  Sequence	   Reverse	  Sequence	   Probe	  Sequence	  
HPV16	  E2	   GATGGAGACATATGCAATACAATGC	   CACAGTTACTGATGCTTCTTCACAAA	   TACAAACTGGACACATATAT	  
HPV16	  E6	   CTGCGACGTGAGGTATATGACTTT	   ACATACAGCATATGGATTCCCATCT	   CTTTTCGGGATTTATGC	  
HPV16	  E7	   TTCGGTTGTGCGTACAAGC	   AGTGTGCCCATTAACAGGTCTTC	   CACGTAGACATTCGTACTT	  
HPV18	  E6	   AAACCGTTGAATCCAGCAGAA	   GTCGTTCCTGTCGTGCTCG	   TTGCAGCACGAATGG	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Optimisation	  of	  HPV16	  qPCR	  assays	  was	  conducted	  with	  CaSki	  and	  SiHa	  cell	  line	  
derived	  DNA	  as	  positive	  controls	  and,	  in	  the	  case	  of	  CaSki,	  as	  an	  important	  
threshold	  determiner.	  The	  positive	  control	  for	  HPV18	  E6	  qPCR	  assay	  optimization	  
was	  HeLa	  derived	  DNA.	  
In	  addition	  to	  non-­‐template	  controls,	  Hela	  was	  included	  as	  a	  negative	  control	  when	  
CaSki	  was	  the	  target	  positive	  control	  and	  vice	  versa.	  	  
As	  Figure	  7	  demonstrates,	  the	  capacity	  to	  detect	  HPV	  viral	  sequence	  was	  preserved	  
in	  concentrations	  as	  low	  as	  1:10,000	  of	  CaSki,	  whilst	  remaining	  reliably	  quantifiable	  
to	  a	  level	  of	  1:1,000	  (Figure	  8).	  	  
	  
	  
Figure	  7:	  HPV16	  Assay	  Detection	  Sensitivity	  
Serial	  dilution	  experiment	  of	  CaSki	  cDNA	  in	  ddH2O	  to	  assess	  the	  reliability	  of	  the	  designed	  qPCR	  
assay.	  The	  mean	  ∆Ct	  for	  relevant	  HPV16	  target	  (E2,	  E6	  &	  E7)	  is	  represented	  on	  the	  Y	  axis	  while	  X-­‐axis	  
shows	  the	  dilution	  factor.	  The	  almost	  straight	  lines	  across	  dilutions	  demonstrate	  reliability	  over	  5	  





Figure	  8:	  Establishment	  of	  the	  Linear	  Dynamic	  Range	  of	  the	  HPV16	  Assay	  	  
Establishement	  of	  the	  Linear	  Dynamic	  Range	  of	  the	  HPV16	  Assay.	  Mean	  ∆Ct	  for	  relevant	  HPV16	  
target	  (E2,	  E6	  &	  E7)	  of	  the	  HPV	  positive	  CaSki	  RNA	  in	  serial	  dilution	  with	  the	  HPV	  negative	  HBEC-­‐3KT	  
RNA	  with	  subsequent	  reverse	  transcription	  prior	  to	  qPCR	  assay.	  The	  results	  demonstrate	  a	  linear	  
relationship	  of	  detection	  down	  to	  a	  dilution	  of	  10-­‐3	  with	  HPV	  negative	  RNA.	  
	  
Optimisation	  of	  each	  assay	  (HPV-­‐16	  and	  -­‐18)	  lead	  to	  defined	  qPCR	  thermal	  
conditions,	  as	  detailed	  in	  Table	  7	  and	  Table	  8.	  	  
Each	  sample	  was	  run	  in	  duplicate	  with	  an	  ultimate	  reaction	  volume	  of	  25µL	  
consisting	  of	  1x	  Taqman	  Gene	  Expression	  Master	  Mix	  (Applied	  Biosystems),	  
500nmol/l	  of	  relevant	  primer	  and	  250nmol/L	  of	  appropriate	  probe,	  1x	  endogenous	  
reference	  primer/probe	  mix	  (VIC-­‐TAMRA-­‐labeled	  probe	  for	  single	  copy	  gene	  
RNaseP	  for	  DNA	  qPCR	  (Taqman	  RNase	  P	  Control	  Reagents,	  Applied	  Biosystems)	  or	  
Human	  VIC-­‐MGB-­‐labeled	  Actin	  ß	  (ACTB)	  primers	  and	  probe	  (Applied	  Biosystems,	  
Carlsbad,	  CA;	  assay	  ID:	  4352935E)	  for	  expression	  analysis)	  and	  100ng	  of	  genomic	  






Step	   Temperature	  (oC)	   Time	   No	  of	  cycles	  
UDG	  Incubation	   50	   2	  min	   	  
Activation	   95	   10	  min	   	  
Denaturation	   95	   15	  sec	   	  
Annealing/Extension	   61	   60	  sec	   45	  
	  
Table	  7:	  HPV16	  E2,	  E6	  &	  E7	  qPCR	  Thermal	  Conditions	  
	  
Step	   Temperature	  (oC)	   Time	   No	  of	  cycles	  
UDG	  Incubation	   50	   2	  min	   	  
Activation	   95	   10	  min	   	  
Denaturation	   95	   15	  sec	   	  
Annealing/Extension	   60	   60	  sec	   45	  
	  
Table	  8:	  HPV18	  E6	  qPCR	  Thermal	  Conditions	  
	  
Assays	  were	  run	  on	  an	  Applied	  Biosystems	  7500	  real	  time	  PCR	  machine.	  Reactions	  
were	  set	  up	  in	  a	  duplicate	  volume	  and	  reactions	  split	  to	  final	  25	  μl	  volume	  
duplicates.	  Reaction	  duplicates	  were	  run	  on	  the	  same	  PCR	  cycling	  machine	  in	  
immediate	  time	  sequence.	  
	  
HPV33	  E6	  Assay	  
Detection	  of	  HPV33	  E6	  expression	  was	  undertaken	  using	  a	  proprietary	  assay	  
(Human	  papillomavirus	  33	  E6	  gene,	  Genesig,	  Southampton,	  UK).	  qPCR	  Assay	  
preparation	  and	  amplification	  was	  conducted	  in	  accordance	  with	  the	  manufacturers	  
protocol.	  Briefly,	  in	  a	  reaction	  volume	  of	  20µL,	  template	  cDNA,	  genesig	  2x	  qPCR	  
MasterMix	  and	  HPV33	  Primer/Probe	  mix	  was	  amplified	  under	  the	  conditions	  
detailed	  in	  Table	  9.	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A	  serial	  dilution	  of	  HPV33	  positive	  control	  was	  prepared	  and	  run	  simultaneously	  for	  
relative	  quantification	  of	  detected	  target.	  
	  	  
Step	   Temperature	  (oC)	   Time	   No	  of	  cycles	  
UDG	  Incubation	   37	   15	  min	   	  
Activation	   95	   15	  min	   	  
Denaturation	   95	   10	  sec	   	  
Annealing/Extension	   60	   60	  sec	   50	  
	  
Table	  9:	  Genesig	  HPV33	  qPCR	  Thermal	  Conditions	  
	  
DNA	  qPCR	  Assays	  
DNA	  qPCR	  Detection	  Threshold	  
The	  detection	  threshold	  for	  HPV	  positive	  status	  was	  set	  in	  accordance	  with	  the	  
previously	  reported	  frequency	  of	  E6	  gene	  copies	  per	  diploid	  genome	  for	  CaSki	  (869	  
copies)185.	  Assuming	  an	  HPV16	  driven	  tumour	  is	  composed	  of	  a	  dominant	  clonal	  
population	  of	  cells,	  we	  scored	  as	  positive	  those	  samples	  with	  ≥1	  E6	  gene	  
copy/diploid	  genome.	  A	  sample	  was	  only	  deemed	  positive	  if	  the	  threshold	  was	  met	  
in	  both	  of	  the	  duplicate	  runs.	  
	  
Expression	  (mRNA	  qPCR)	  Assays	  
HPV	  Expression	  Assays	  
The	  HPV	  genome	  is	  intronless	  and,	  as	  such,	  primers	  and	  probes	  designed	  for	  
amplification	  of	  DNA	  sequences	  can	  be	  utilised	  for	  expression	  analysis.	  Removal	  of	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DNA,	  however,	  is	  therefore	  an	  absolute	  requirement	  to	  ensure	  detected	  
amplification	  is	  from	  mRNA	  (cDNA)	  origin	  rather	  than	  from	  either	  residual	  DNA	  or	  
contamination	  with	  DNA.	  To	  achieve	  this,	  DNase	  treatment	  occurred	  both	  in	  the	  
RNA	  preparation	  from	  tissue	  and	  as	  an	  essential	  component	  of	  reverse	  
transcriptase	  generation	  of	  cDNA.	  
Subsequent	  to	  the	  DNase	  treatment	  and	  reverse	  transcription,	  eight	  cDNA	  samples	  
(selected	  at	  random)	  were	  subjected	  to	  microsatellite	  marker	  analysis	  of	  non-­‐exonic	  
areas	  of	  two	  human	  genes	  that	  would	  therefore	  be	  present	  in	  gDNA	  yet	  absent	  in	  
RNA	  (or	  cDNA).	  Primers	  were	  selected	  from	  the	  LMS	  High	  Density	  Panel	  5	  set	  
(Applied	  Biosystems);	  D9S161	  (9p21.2)	  and	  D17S938	  (17p13.2),	  and	  synthesized	  
with	  fluorescent-­‐labelled	  reverse	  primers	  (FAM).	  Microsatellite	  marker	  reactions	  
were	  carried	  out	  in	  a	  multiplex	  manner	  using	  the	  Qiagen	  Multiplex	  Master	  Mix	  
(Qiagen,	  UK),	  50ng	  of	  cDNA	  and	  ddH20	  to	  a	  volume	  of	  20µL.	  The	  thermal	  conditions	  
for	  the	  subsequent	  PCR	  are	  detailed	  below	  (Table	  10).	  	  
	  
Step	   Temperature	  (oC)	   Time	   No	  of	  cycles	  
Taq	  Activation	   95	   15	  min	   	  
Denaturation	   94	   30	  sec	   	  
Annealing	   56	   90	  sec	   30	  
Extension	   72	   60	  sec	   	  
Final	  extension	   72	   30	  min	   	  
	  
Table	  10:	  Microsatellite	  Marker	  Analysis	  PCR	  Thermal	  conditions	  
	  
2µL	  of	  the	  resultant	  PCR	  products	  were	  dissolved	  in	  10µL	  of	  Highly	  Deionized	  
Formamide	  (HDF)	  with	  0.5µL	  of	  the	  proprietary	  Genescan	  600	  LIZ	  Size	  Standard	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(Applied	  Biosystems).	  For	  maximal	  sensitivity	  of	  detection	  of	  gDNA	  carrover,	  
analysis	  was	  undertaken	  on	  a	  3130	  sequencer	  (Applied	  Biosystems).	  	  	  
	  
DNMT1,	  3A,	  3B	  &	  UHRF1	  Expression	  Assays	  
Determination	  of	  expression	  levels	  of	  DNA	  Methyltransferases	  1,	  3A	  and	  3B	  
(DNMT1,	  -­‐3A	  and	  -­‐3B)	  and	  the	  UHRF1	  gene	  in	  tumour	  tissue	  samples,	  associated	  
matched	  normal	  pairs	  and	  HPV	  positive	  cell	  lines,	  was	  undertaken	  using	  
commercially	  available	  assays	  (Applied	  Biosystems).	  The	  relevant	  assays	  are	  
detailed	  in	  Table	  11.	  	  
	  
GENE	   Assay	  Id	   DYE	   Unigene	  Id	   Amplicon	  length	  (bp)	  
DNMT1	   Hs00154749_m1	   FAM	   Hs.202672	   77	  
DNMT3A	   Hs01027166_m1	   FAM	   Hs.515840	   79	  
DNMT3B	   Hs00171876_m1	   FAM	   Hs.713611	   55	  
UHRF1	   Hs00273589_m1	   FAM	   Hs.108106	   105	  
ACTB	   4326315E	   VIC	   Hs.520640	   171	  
	  
Table	  11	  Identification	  and	  additional	  information	  for	  proprietary	  gene	  expression	  assays	  DNMT1,	  -­‐
3A,	  -­‐3B	  &	  UHRF1	  
	  
The	  proprietary	  endogenous	  control,	  Human	  VIC-­‐MGB-­‐labeled	  Actin	  ß	  (ACTB)	  
primers	  and	  probe	  (Applied	  Biosystems,	  Carlsbad,	  CA;	  assay	  ID:	  4352935E),	  was	  
utilised	  in	  each	  multiplex	  reaction.	  By	  comparison	  to	  target	  genes,	  ACTB	  had	  a	  
greater	  amplicon	  length	  and	  as	  such	  its	  inclusion	  enabled	  use	  as	  an	  internal	  control	  
for	  cDNA	  integrity.	  	  
Each	  final	  reaction	  volume	  of	  20μl	  contained	  10	  μl	  of	  2x	  TaqMan®	  Gene	  Expression	  
Master	  Mix	  (Applied	  Biosystems),	  900	  nmol/L	  of	  each	  primer	  and	  250	  nmol/L	  probe,	  
	  	  
76	  
1µL	  of	  endogenous	  control	  ACTB-­‐VIC	  (Applied	  Biosystems)	  and	  approximately	  100	  
ng	  of	  cDNA	  following	  the	  thermal	  cycling	  conditions	  detailed	  below	  in	  Table	  12.	  
	  
Step	   Temperature	  (oC)	   Time	   No	  of	  cycles	  
UDG	  Incubation	   50	   2	  min	   	  
Activation	   95	   10	  min	   	  
Denaturation	   93	   30	  sec	   	  
Annealing/Extension	   60	   45	  sec	   45	  
	  
Table	  12:	  DNMT	  &	  UHRF1	  qPCR	  Thermal	  Conditions	  
	  	  
Reactions	  were	  set	  up	  with	  duplicate	  volumes	  and	  subsequently	  split	  to	  reach	  final	  
20	  μl	  reactions.	  Using	  an	  Applied	  Biosystems	  7500	  real	  time	  PCR	  machine	  reactions	  
were	   run	   in	   immediate	   time	   sequence.	   Using	   the	   7500	   Software	   v2.0.1	   (Applied	  
Biosystems),	  qPCR	  data	  was	  analysed	  with	  post-­‐assay	  expression	  levels	  expressed	  as	  
relative	   quantification	   values	   (RQ,	   where	   RQ=2(-­‐ΔΔCt))189.	   Average	   RQ	   values	   were	  
determined	  from	  the	  duplicated	  runs	  for	  subsequent	  analysis.	  	  
	  
3.12 BISULPHITE	  TREATMENT	  OF	  DNA	  
1	  µg	  DNA	  was	  bisulphite	  treated	  using	  the	  EZ-­‐96	  DNA	  Methylation-­‐Gold™	  Kit,	  
(Shallow-­‐Well	  Format)	  (Zymo	  Research,	  Irvine,	  CA,	  USA)	  following	  the	  
manufacturer’s	  protocol.	  	  	  
Preparation	  of	  the	  CT	  Conversion	  Reagent	  was	  made	  by	  the	  addition	  of	  9	  ml	  of	  
water,	  500	  μl	  of	  M-­‐Dissolving	  Buffer,	  and	  3	  ml	  of	  M-­‐Dilution	  buffer.	  It	  was	  then	  
mixed	  at	  room	  temperature	  by	  constant	  shaking	  for	  15	  minutes.	  The	  M-­‐Wash	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Buffer	  was	  prepared	  by	  adding	  144	  ml	  of	  100%	  ethanol	  to	  the	  36	  ml	  M-­‐Wash	  Buffer	  
concentrate.	  	  
Each	  sample	  containing	  1	  µg	  of	  DNA	  was	  made	  up	  to	  20	  µL	  with	  water	  before	  
combining	  with	  130	  μl	  of	  the	  CT	  Conversion	  Reagent	  in	  a	  Conversion	  Plate.	  All	  
samples	  were	  mixed	  by	  pipetting	  action	  before	  sealing	  the	  plate	  prior	  to	  thermal	  
cycling	  as	  follows;	  98°C	  for	  10	  minutes,	  64°C	  for	  2.5	  hours.	  The	  samples	  were	  
subsequently	  transferred	  to	  individual	  wells	  of	  the	  Silicon-­‐A™	  Binding	  Plate	  
mounted	  on	  a	  Collection	  Plate	  together	  with	  400	  μl	  of	  M-­‐Binding	  Buffer.	  The	  plate	  
was	  centrifuged	  at	  3,000	  x	  g	  for	  5	  minutes	  and	  the	  flow-­‐through	  discarded.	  400	  μl	  
of	  M-­‐Wash	  Buffer	  was	  added	  to	  each	  well	  and	  the	  plate	  re-­‐centrifuged	  at	  3,000	  x	  g	  
for	  5	  minutes.	  200	  μl	  of	  M-­‐Desulphonation	  Buffer	  was	  then	  added	  to	  each	  well	  and	  
incubated	  at	  room	  temperature	  (20	  °C	  –	  30	  °C)	  for	  20	  minutes.	  Following	  
incubation,	  the	  plate	  was	  centrifuged	  at	  3,000	  x	  g	  for	  5	  minutes	  and	  the	  pursuant	  
flow-­‐through	  discarded.	  400	  μl	  of	  M-­‐Wash	  Buffer	  was	  added	  to	  each	  well	  of	  the	  
plate	  and	  the	  plate	  centrifuged	  at	  3,000	  x	  g	  for	  5	  minutes	  with	  the	  flow-­‐through	  
discarded	  once	  more.	  A	  final	  400	  μl	  of	  M-­‐Wash	  Buffer	  was	  added	  and	  the	  plate	  and	  
centrifuged	  at	  3,000	  x	  g	  for	  10	  minutes.	  	  
The	  Silicon-­‐A™	  Binding	  Plate	  was	  then	  placed	  onto	  an	  Elution	  Plate	  and	  50μl	  of	  M-­‐
Elution	  Buffer	  were	  added	  directly	  to	  each	  well.	  After	  5	  minutes	  incubation	  at	  room	  
temperature	  (20	  °C	  –	  30	  °C),	  it	  was	  centrifuged	  at	  3,000	  x	  g	  for	  3	  minutes	  to	  elute	  
the	  DNA.	  Storage	  of	  samples	  following	  bisulphite	  treatment	  was	  at	  -­‐20°C	  until	  use	  





3.13 PYROSEQUENCING	  METHYLATION	  ANALYSIS	  
Pyrosequencing	  (PSQ)	  was	  utilised	  to	  detect	  and	  quantify	  variation	  in	  methylation	  
levels	  within	  target	  sequences	  from	  clinical	  samples.	  	  
LINE-­‐1	  Assay	  
LINE-­‐1	   methylation	   status	   determination	   was	   undertaken	   using	   the	   previously	  
described	   Pyrosequencing	  Methylation	   Assay	   (PMA)190.	   Briefly,	   this	   assay	   detects	  
methylation	  of	  6	  CpGs	  contained	  within	  the	  CpG	  island	  of	  the	  5’	  internal	  promoter.	  
All	  primers	  were	  synthesized	  by	  MWG	  (Germany)	  in	  accordance	  with	  the	  previously	  
published	  sequences190	  (Table	  13).	  
	  
Promoter	   Forward	  primer	  	  (5’→3’)	   Reverse	  primer	  (5’→3’)	   Sequencing	  primer	  (5’→3’)	  
LINE-­‐1	   BIO-­‐TAGGGAGTGTTAGATAGTGG	   AACTCCCTAACCCCTTAC	   CAAATAAAA	  CAATACCTC	  
	  
Table	  13:	  LINE-­‐1	  Primer	  Sequences	  
	  (BIO:	  biotinylated	  primer)	  
	  
PCR	   reaction	   set	   up	   was	   undertaken	   with	   the	   following	   components;	   Qiagen	  
HotStarTaq	  Plus	  Master	  Mix	  Kit,	  5μΜ	  biotinylated	  primer,	  10	  μΜ	  non-­‐biotinylated	  
primer	   and	   2.5	   μl	   (approximately	   50ng)	   of	   bisulphite	   treated	   DNA.	   All	   reactions	  
were	  setup	  in	  duplicate	  with	  sequencing	  runs	  conducted	  consecutively.	  An	  excess	  of	  
non-­‐biotinylated	   primer	  was	   included	   to	   reduce	   residual	   biotinylated	   primer	   that	  
may	  otherwise	  impact	  on	  sequencing	  reaction	  fidality.	  The	  PCR	  thermal	  profile	  for	  




Step	   Temperature	  (oC)	   Time	   No	  of	  cycles	  
Taq	  Activation	   95	   5	  min	   	  
Denaturation	   94	   30	  sec	   	  
Annealing	   58	   45	  sec	   40	  
Extension	   72	   45	  sec	   	  
Final	  extension	   72	   10	  min	   	  
	  
Table	  14:	  PCR	  conditions	  for	  LINE-­‐1	  Assay	  
	  
The	   quality	   and	   quantity	   of	   resultant	   PCR	   product	   was	   confirmed	   by	   agarose	   gel	  
(2%)	  electrophoresis	  and	  UV	  visualisation	  on	  a	  UVP	  VisionWorks	  LS	  instrument	  prior	  
to	  progression	  to	  Pyrosequencing	  analysis.	  	  
For	  the	  pyrosequencing	  workflow,	  proprietary	  PyroGold	  reagents	  were	  used	  
following	  the	  suppliers’	  protocol	  (Qiagen),	  with	  sequencing	  performed	  in	  the	  
PSQ96MA	  pyrosequencer	  (Qiagen,	  Crawley,	  UK)	  instrument.	  	  
As	  above,	  duplicate	  PCR	  reactions	  for	  each	  sample	  were	  sequenced	  and	  the	  mean	  
methylation	  levels	  recorded	  from	  the	  average	  of	  both	  sample	  runs	  (where	  positive	  
results	  were	  apparent	  in	  both	  instances).	  
Briefly,	  PCR	  products	  were	  combined	  with	  binding	  buffer	  that	  contained	  both	  buffer	  
and	  sepharose	  streptavidin	  beads.	  Once	  transferred	  to	  a	  96	  well	  plate	  the	  samples	  
were	  agitated	  using	  a	  vortex	  plate	  at	  350rpm	  for	  10	  minutes	  to	  allow	  for	  template	  
binding	   to	   streptavidin	   beads.	   Bound	   template	   was	   then	   transferred,	   using	   a	  
vacuum	  tool,	  to	  successive	  washes	  of	  70%	  Ethanol	  for	  10	  seconds,	  0.2M	  NaOH	  for	  
20	  seconds	  and	  then	  proprietary	  wash	  buffer	  for	  a	  further	  10	  seconds.	  Templates,	  
whilst	   still	   retained	  on	   the	  vacuum	  tool	  were	   transferred	   to	  annealing	  buffer	   that	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contains	  sequencing	  primer.	  The	  samples	  were	  heated	  to	  80°C	  for	  2	  minutes	  before	  
being	  returned	  to	  room	  temperature	  for	  2	  minutes.	  Samples	  then	  entered	  the	  PSQ	  
96MA	  for	  sequencing.	  
	  
HPV16	  Gene	  Methylation	  Assays	  
To	  explore	  the	  effect	  of	  viral	  genome	  methylation	  in	  OPSCC,	  pyrosequencing	  
methylation	  assays	  were	  designed	  for	  the	  most	  CpG	  rich	  regions	  of	  the	  E2	  gene	  and	  
two	  regions	  within	  the	  HPV16	  long	  control	  region	  (LCR).	  	  
The	  reference	  HPV16	  genome	  sequence	  utilised	  was	  Genebank	  NC_001526.2.	  	  All	  
PMA	  primers	  were	  designed	  using	  the	  Assay	  Design	  Software	  (Qiagen)	  and	  
synthesized	  by	  WMG	  (Germany).	  Primer	  sequences	  are	  listed	  below	  (Table	  15).	  
	  
Target	   Forward	  primer	  	  (5’→3’)	   Reverse	  primer	  (5’→3’)	   Sequencing	  primer	  (5’→3’)	   Product	  Size	  (bp)	  
HPV	  E2	   GTGAAATTATTAGGTAGTATTTGG	   BIO-­‐CAACAACTTAATAATATAACAAAAA	   GTGAAATTATTAGGTAGTA	   148	  
LCR	  1	   BIO-­‐ATTGTATTATGTGTAATTATTGAA	   CCAAAAATATATACCTAACAAC	   CCAAAAATATATACCTAACAAC	   104	  
LCR	  2	   GTAAAATTGTATATGGGTGT	   BIO-­‐	  TAAAATATCTACTTTTATACTAACC	   TAATTTATGTATAAAATTAAGG	   157	  
	  
Table	  15:	  HPV16	  Pyrosequencing	  Methylation	  Assay	  Primer	  Sequences	  
(BIO:	  biotinylated	  primer)	  
	  
The	  LCR	  2	  PMA	  was	  designed	  to	  include	  five	  CpGs,	  of	  which	  four	  fell	  within	  the	  E2	  
protein	  binding	  sites	  3	  and	  4	  (E2BS3	  and	  E2BS4).	  Within	  each	  binding	  site	  there	  
were	  two	  corresponding	  CpGs.	  The	  relevant	  components	  of	  the	  LCR	  and	  PMA	  
primer	  locations	  are	  graphically	  represented	  on	  Figure	  9	  (below).	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PCR	  amplifications	  were	  performed	  using	  Qiagen	  Hotstar	  Plus	  Master	  Mix	  Kit,	  5uM	  
biotinylated	  primer,	  10uM	  non-­‐biotinylated	  primer	  and	  2.5µL	  of	  bisulphite	  treated	  
DNA.	  As	  before,	  excess	  non-­‐biotinylated	  primer	  was	  included	  and	  PCR	  cycling	  was	  
increased	  to	  40	  cycles	  to	  reduce	  carryover	  of	  unused	  biotinylated	  primer	  into	  the	  
sequencing	  reaction.	  
	  
Figure	  9:	  Schematic	  representation	  of	  HPV	  genome	  with	  detailed	  LCR	  and	  Pyrosequencing	  
Methylation	  Assay	  sites.	  
Specific	  genes	  and	  LCR	  sequence	  start	  points	  are	  highlighted.	  The	  single	  E1	  binding	  site	  and	  four	  E2	  
binding	  sites	  are	  highlighted.	  Also	  depicted	  are	  the	  PMA	  target	  locations.	  LCR	  2	  PMA	  analyses	  five	  
CpG	  including	  four	  that	  fall	  within	  E2BS3	  (nt	  37	  &	  43)	  and	  E2BS4	  (nts	  52	  &	  58).	  
(Modified	  from	  Snellenberg	  et	  al191)	  
	  
Thermal	  profiles	  for	  E2,	  LCR	  1	  and	  LCR	  2	  reactions	  are	  detailed	  below	  in	  Table	  16,	  






Step	   Temperature	  (oC)	   Time	   No	  of	  cycles	  
Taq	  Activation	   95	   5	  min	   	  
Denaturation	   94	   30	  sec	   	  
Annealing	   48	   40	  sec	   40	  
Extension	   72	   30	  sec	   	  
Final	  extension	   72	   10	  min	   	  
	  
Table	  16:	  HPV16	  E2	  PMA	  Thermal	  Conditions	  
	  
Step	   Temperature	  (oC)	   Time	   No	  of	  cycles	  
Taq	  Activation	   95	   5	  min	   	  
Denaturation	   94	   30	  sec	   	  
Annealing	   46	   60	  sec	   40	  
Extension	   72	   20	  sec	   	  
Final	  extension	   72	   10	  min	   	  
	  
Table	  17:	  HPV16	  Long	  Control	  Region	  1	  PMA	  Conditions	  
	  
Step	   Temperature	  (oC)	   Time	   No	  of	  cycles	  
Taq	  Activation	   95	   5	  min	   	  
Denaturation	   94	   30	  sec	   	  
Annealing	   46	   35	  sec	   40	  
Extension	   72	   15	  sec	   	  
Final	  extension	   72	   10	  min	   	  
	  
Table	  18:	  HPV16	  Long	  Control	  Region	  2	  PMA	  Conditions	  
	  
Following	  thermal	  cycling,	  PCR	  products	  were	  run	  on	  a	  2%	  agarose	  gel	  and	  
visualised	  using	  UV	  visualisation	  on	  a	  UVP	  VisionWorks	  LS	  instrument	  to	  ensure	  
sufficient	  product	  quality	  and	  quantity.	  As	  for	  LINE-­‐1	  PMA	  sequencing,	  products	  
were	  sequenced	  in	  a	  96MA	  Pyrosequencer	  (Qiagen)	  (as	  above,	  LINE-­‐1	  Assay).	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3.14 METHYLATION	  MICROARRAY	  ANALYSIS	  
To	  analyse	  differences	  in	  gene	  promoter	  methylation	  between	  HPV	  positive	  and	  
HPV	  negative	  OPSCC,	  the	  recently	  validated192	  Infinium	  HumanMethylation450	  
BeadChip	  microarray	  analysis	  (Illumina,	  San	  Diego,	  CA,	  USA)	  was	  utilised.	  	  
A	  separate	  cohort	  of	  24	  OPSCC	  was	  submitted	  for	  analysis	  of	  differential	  promoter	  
sequence	  methylation	  status	  on	  the	  basis	  of	  HPV	  status.	  The	  Infinium	  platform	  is	  
designed	  to	  provide	  analytical	  coverage	  of	  96%	  of	  CpG	  islands	  and	  associated	  
flanking	  island	  scores.	  Of	  the	  approximate	  450,000	  CpG	  sites	  included	  in	  the	  assay,	  
just	  over	  150,000	  (30.9%)	  are	  deemed	  to	  be	  from	  within	  CpG	  islands.	  When	  
considered	  in	  a	  functional	  setting,	  41%	  (200,339)	  CpGs	  are	  in	  proximal	  gene	  
promoter	  regions	  however	  at	  varying	  distances	  upstream	  of	  the	  relevant	  
transcriptional	  start	  site.	  
Sample	  preparation	  and	  processing	  on	  the	  Infinium	  Methylation	  Assay	  was	  
conducted	  by	  a	  third	  party	  technical	  provider	  (Gen-­‐Probe,	  Manchester,	  UK).	  Briefly	  
500ng	  of	  gDNA	  was	  outsourced	  to	  the	  third	  party	  for	  bisulphite	  treatment,	  with	  
subsequent	  utilisation	  of	  4µL	  of	  the	  resultant	  bisulphite	  treated	  DNA	  according	  to	  
the	  Infinium	  HD	  Methylation	  Assay	  protocol.	  	  
HPV16	  status	  determination	  was	  undertaken	  for	  all	  samples	  using	  the	  HPV16	  E6	  




Bioinfomatic	  Analysis	  &	  Validation	  Pyrosequencing	  Methylation	  Assay	  
Design	  
Raw	  data	  delivered	  from	  the	  third	  party	  were	  initially	  assessed	  for	  quality	  
assurance.	  No	  outliers	  were	  detected.	  All	  data	  originating	  from	  the	  X	  chromosome	  
were	  excluded	  from	  further	  analysis	  to	  exclude	  potential	  bias	  on	  the	  basis	  of	  
gender.	  	  
With	  knowledge	  of	  the	  previously	  determined	  HPV	  status	  of	  the	  24	  samples	  (HPV	  
positive	  n=6,	  HPV	  negative	  n=18),	  R	  statistical	  package,	  version	  2.14.1	  (Lucent	  
Technologies,	  2012),	  was	  utilised	  to	  perform	  Wilcoxon	  signed-­‐rank	  and	  Wilcoxon	  
rank	  sum	  tests.	  Where	  the	  average	  Beta	  score	  for	  any	  individual	  gene	  was	  greater	  
than	  0.2	  or	  less	  than	  -­‐0.2	  and	  where	  there	  were	  4	  or	  more	  probes	  included	  on	  the	  
array	  that	  fell	  within	  the	  promoter	  region	  for	  that	  specific	  gene,	  it	  was	  shortlisted	  
for	  technical	  validation.	  	  
From	  the	  top	  ranked	  methylation	  variable	  positions,	  14	  genes	  met	  the	  above	  
criteria	  (13	  differentially	  hypermethylated	  in	  HPV	  positive	  tumours	  and	  1	  gene	  
hypomethylated).	  Following	  mapping	  of	  probes	  to	  the	  relevant	  gene	  sequence,	  
PMA	  primer	  design	  was	  undertaken	  using	  PyroMark	  Assay	  Design	  Software	  2.0	  
(Qiagen,	  Crawley,	  UK).	  PMA	  assay	  design	  was	  unlikely	  to	  provide	  satisfactory	  PCR	  
products	  capable	  of	  meeting	  the	  stringent	  requirements	  for	  pyrosequencing	  in	  the	  
case	  of	  6	  genes.	  In	  the	  case	  of	  the	  8	  genes	  for	  which	  PMA	  design	  was	  successful,	  it	  
was	  ensured	  that	  coverage	  of	  sequence	  containing	  a	  minimum	  of	  three	  CpGs	  
corresponding	  to	  the	  probes	  was	  adhered	  to.	  Primer	  sequences	  (Table	  19)	  and	  PCR	  
conditions	  are	  listed	  below	  for	  each	  of	  the	  genes,	  along	  with	  details	  of	  the	  number	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of	  CpGs	  covered	  by	  both	  the	  Infinium	  array	  probes	  and	  the	  PMA	  (Table	  20	  and	  
Table	  21).	  
As	  above,	  all	  target	  genes	  for	  validation	  had	  originally	  been	  demonstrated	  to	  be	  
differentially	  hypermethylated	  in	  HPV	  positive	  OPSCC	  using	  the	  Infinium	  analysis.	  
	  
Target	  Gene	   Forward	  primer	  	  (5’→3’)	   Reverse	  primer	  (5’→3’)	   Sequencing	  primer	  (5’→3’)	  
GalR1	   GGGGTGAGGGTGGGATTA	   BIO-­‐	  CTCCTCCCCAAAATAACTATCC	   GGTGAGGGTGGGATT	  
C12	  orf42	   BIO-­‐	  AGTATTTTGTTGGGTTTTGG	   CACAAAACAACCCCATTATA	   AAACAACCCCATTATAATTA	  
HOXA7	   BIO-­‐	  ATTTTAGTAGTTTTTATAGGTGGT	   AAACCTCTTACCCTTCCAT	   CTTACCCTTCCATTCTAA	  
FLJ26850	   GGTGGTTATTAGAGAATTGAAT	   BIO-­‐	  ACTCAATATAAAAATTCTCAAAAC	   AGAGAATTGAATTTAGGAGG	  
SYN2	   BIO-­‐	  GGAAGGATAAGAGGTGTTAG	   TTCCTCCTCACTACAAAATAT	   CCTCACTACAAAATATTC	  
KCNA1	   BIO-­‐	  GGATTTGATTATTTTTAATGTG	   AACTCTACTTCCCCTATAACC	   ACTCTACTTCCCCTATA	  
SLCo4C1	   AGTGTTTGGGTTTAAGGG	   BIO-­‐	  AAAATTCTCACCCCACAA	   TGTTTGGGTTTAAGGGAG	  
CCNA1	   GATAGAGTTGGGGTTTGGG	   BIO-­‐	  CAAAAACTCCTCTCCCCAC	   AGAGTTGGGGTTTGGGA	  
	  
Table	  19:	  Infinium	  Technical	  Validation	  PMA	  Primer	  Sequences	  
(BIO:	  biotinylated	  primer)	  
	  
Step	   Temperature	  (oC)	   Time	   No	  of	  cycles	  
Taq	  Activation	   95	   5	  min	   	  
Denaturation	   94	   30	  sec	   	  
Annealing	   *	   30	  sec	   40	  
Extension	   72	   30	  sec	   	  
Final	  extension	   72	   10	  min	   	  
	  
Table	  20:	  Infinium	  Technical	  Validation	  PMA	  Conditions	  










Probes	  Covered	  	  
GalR1	   60	   5	   4	  
C12	  orf42	   56	   7	   4	  
HOXA7	   52	   4	   3	  
FLJ26850	   52	   4	   3	  
SYN2	   54	   4	   3	  
KCNA1	   50	   9	   3	  
SLCo4C1	   51	   7	   5	  
CCNA1	   60	   8	   5	  
	  
Table	  21:	  Infinium	  PMA	  Gene	  Specific	  Annealing	  Temperatures	  &	  CpG	  Inclusions	  
For	  each	  gene,	  the	  number	  of	  CpGs	  is	  listed	  and	  the	  corresponding	  number	  of	  CpGs	  correlating	  to	  
the	  Infinium	  array	  probes.	  	  
	  
	  
PMA	  PCR	  amplifications	  were	  performed	  using	  Qiagen	  Hotstar	  Plus	  Master	  Mix	  Kit,	  
5uM	  biotinylated	  primer,	  10uM	  non-­‐biotinylated	  primer	  and	  2.5µL	  of	  bisulphite	  
treated	  DNA.	  As	  before,	  excess	  non-­‐biotinylated	  primer	  was	  included	  and	  PCR	  
cycling	  was	  increased	  to	  40	  cycles	  to	  reduce	  carryover	  of	  unused	  biotinylated	  
primer	  into	  the	  sequencing	  reaction.	  
	  
Following	  thermal	  cycling,	  PCR	  products	  were	  run	  on	  a	  2%	  agarose	  gel	  and	  
visualised	  using	  UV	  visualisation	  on	  a	  UVP	  VisionWorks	  LS	  instrument	  to	  ensure	  
sufficient	  product	  quality	  and	  quantity.	  Once	  more,	  as	  for	  LINE-­‐1	  PMA	  sequencing,	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products	  were	  sequenced	  in	  a	  96MA	  Pyrosequencer	  (Qiagen)	  (as	  above,	  LINE-­‐1	  
Assay).	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3.15 DNA	  ARTIFICIALLY	  METHYLATED	  CONTROLS	  
Leukocytes	  from	  a	  healthy	  individual	  previously	  shown	  not	  to	  harbor	  HPV16	  DNA,	  
were	  methylated	  in	  vitro	  with	  excess	  SssI	  methyltransferase	  (New	  England	  Biolabs)	  
to	  generate	  completely	  methylated	  DNA,	  as	  per	  the	  manufacturers	  protocol.	  
Briefly,	  160	  μM	  S-­‐adenosylmethionine	  (SAM,	  2µL)	  was	  combined	  with	  10x	  NEBuffer	  
2	  (2µL),	  1µg	  of	  lymphocyte	  gDNA	  and	  SssI	  methylase	  (CpG	  Methyltransferase,	  1µL)	  
before	  mixing	  by	  pipetting.	  
The	  reaction	  volume	  was	  incubated	  for	  one	  hour	  at	  37ºC	  before	  stopping	  the	  
reaction	  by	  heating	  to	  65ºC	  for	  20	  minutes.	  
	  
Subsequently,	  a	  serial	  dilution	  of	  the	  artificially	  methylated	  DNA	  was	  made	  for	  the	  
purposes	  of	  PMA	  calibration/reference	  methylation	  analysis.	  
	  
Samples	  corresponding	  to	  unmethylated	  5%,	  10%,	  20%,	  40%,	  80%	  and	  100%	  
methylated	  lymphocyte	  DNA	  were	  bisulphite	  treated	  as	  detailed	  in	  section	  3.12.	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3.16 HPV16	  INTEGRATION	  ANALYSIS	  
Analysis	  of	  a	  cohort	  of	  HPV	  positive	  OPSCC	  (n=43)	  and	  control	  cell	  lines	  (CaSki	  &	  
SiHa)	  was	  undertaken	  to	  determine	  the	  presence	  or	  otherwise	  of	  viral	  integration	  
into	  the	  host	  genome.	  	  This	  analysis	  was	  undertaken	  using	  direct	  PCR	  based	  analysis	  
of	  the	  E2	  gene	  integrity.	  
Additionally,	  a	  pilot	  series	  of	  OPSCC	  sourced	  from	  the	  above	  cohort	  (n=9)	  and	  the	  
control	  cell	  lines	  (CaSki	  &	  SiHa)	  were	  further	  interrogated	  using	  a	  recently	  described	  
technique	  coupled	  with	  massively	  parallel	  sequencing.	  
	  
E2	  Gene	  Integrity	  Analysis	  
To	  determine	  the	  integrity	  of	  the	  HPV16	  E2	  gene,	  the	  previously	  modified	  and	  
optimised	  approach	  described	  by	  Collins	  et	  al	  was	  employed182.	  The	  technique	  
utilised	  sets	  of	  overlapping	  sequence-­‐specific	  primers	  for	  the	  E2	  gene	  (Figure	  10).	  
Determination	  of	  integration	  state	  relies	  on	  the	  assumption	  that	  integration	  occurs	  
exclusively	  in	  the	  E2	  gene	  and	  that	  failure	  of	  amplification	  of	  a	  component	  (or	  
components)	  of	  the	  E2	  gene	  implies	  integration.	  Conversely,	  detection	  of	  all	  





Figure	  10:	  Schematic	  Diagram	  of	  HPV16	  E2	  Integrity	  Overlapping	  Primer	  Analysis	  
Location	  of	  primer	  sets	  detailed	  with	  respect	  to	  the	  E2	  gene.	  Nucleotide	  numbers	  are	  according	  to	  
the	  whole	  HPV16	  genome.	  (Modified	  from	  Collins	  et	  al182)	  
	  
Briefly,	  60ng	  of	  DNA	  samples	  from	  each	  case	  was	  amplified	  using	  Hotstart	  
Mastermix	  with	  0.4umol/L	  of	  the	  appropriate	  primer	  set.	  Thermal	  cycling	  conditions	  
are	  detailed	  in	  Table	  22	  and	  Table	  23,	  the	  only	  alteration	  from	  the	  conditions	  
described	  by	  Collins	  et	  al.	  is	  a	  reduction	  in	  number	  of	  cycles	  from	  60	  to	  40.	  
	  
Step	   Temperature	  (oC)	   Time	   No	  of	  cycles	  
Taq	  Activation	   95	   5	  min	   	  
Denaturation	   95	   30	  sec	   	  
Annealing	   57	   60	  sec	   40	  
Extension	   72	   120	  sec	   	  
Final	  extension	   72	   10	  min	   	  
	  
Table	  22:	  Thermal	  Cycling	  Conditions	  for	  HPV16	  E2	  Whole	  Gene	  
	  
Step	   Temperature	  (oC)	   Time	   No	  of	  cycles	  
Taq	  Activation	   95	   5	  min	   	  
Denaturation	   95	   30	  sec	   	  
Annealing	   54	   60	  sec	   40	  
Extension	   72	   120	  sec	   	  
Final	  extension	   72	   10	  min	   	  
	  




Following	  thermal	  cycling,	  PCR	  products	  were	  run	  on	  a	  2%	  agarose	  gel	  and	  
visualised	  using	  UV	  visualisation	  on	  a	  UVP	  VisionWorks	  LS	  instrument	  to	  
demonstrate	  product	  presence	  (or	  absence).	  Controls	  included	  DNA	  samples	  from	  
CaSki	  and	  SiHa	  cell	  lines,	  which	  had	  previously	  been	  demonstrated	  to	  contain	  
complete	  head-­‐to-­‐tail	  complete	  viral	  gene	  integrants193	  (hence	  positive	  control	  for	  
all	  primer	  pairs)	  and	  a	  solitary	  integrant	  with	  loss	  of	  the	  E2	  gene	  respectively194	  
(integration	  positive	  control	  with	  expectation	  of	  primer	  set	  2	  amplicon	  failure).	  
The	  negative	  controls	  were	  DNA	  derived	  from	  the	  known	  HPV16	  negative	  cell	  line	  
HBEC-­‐3KT	  and	  DNA	  from	  the	  HPV	  negative	  OPSCC	  (sample	  No.11).	  
	  
Next	  Generation	  Sequencing	  (NGS)	  Analysis	  	  
Prior	  to	  commencement	  of	  the	  project,	  options	  for	  both	  target	  sequence	  
acquisition	  and	  sequencing	  were	  subject	  to	  collaborative	  discussion	  with	  the	  third	  
party	  organization	  chosen	  to	  undertake	  sample	  preparation	  and	  sequencing;	  Centre	  
for	  Genomics	  Research,	  University	  of	  Liverpool,	  Liverpool,	  UK.	  
Due	  to	  the	  previous	  success	  of	  Depledge	  et	  al195,	  target	  capture	  and	  library	  
preparation	  was	  undertaken	  using	  the	  previously	  validated	  SureSelectXT	  Target	  
Enrichment	  System	  for	  extraction	  of	  the	  sequences	  of	  interest	  and	  generation	  of	  an	  
Illumina	  Paired-­‐End	  Sequencing	  Library	  (Agilent,	  Santa	  Clara,	  CA,	  USA)(Figure	  11).	  	  
Once	  more,	  selection	  of	  the	  platform,	  best	  suited	  to	  specifics	  of	  the	  project,	  was	  
made	  in	  response	  to	  guidance	  provided	  by	  the	  third	  party	  collaborator	  and	  in	  
keeping	  with	  project	  goals.	  Paired-­‐end	  sequencing	  of	  all	  target	  sequences	  was	  
completed	  using	  the	  HiSeq	  2000	  (Illumina,	  San	  Diego,	  USA)195.	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Figure	  11:	  Overall	  sequencing	  sample	  preparation	  workflow	  
(Modified	  from	  Agilent	  SureSelect	  XT	  Protocol)	  *	  indicates	  correlation	  with	  hybridisation	  workflow	  
(Figure	  12).	  	  
	  




Figure	  12:	  Sample	  Hybridisation	  Schematic	  
(Modified	  from	  Agilent	  SureSelect	  XT	  Protocol)	  *	  indicates	  input	  point	  of	  prepared	  and	  purified	  
sample	  libraries.	  
	  
Selection	  of	  cases	  for	  analysis	  was	  undertaken,	  ensuring	  adequate	  available	  DNA	  
(3µg)	  and	  sample	  quality	  as	  detected	  by	  Nanodrop	  analysis	  (A260/280	  and	  A260/230	  
rations	  ensured	  to	  be	  ≥1.8	  and	  1.9,	  respectively).	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The	  sample	  preparation,	  hybridisation	  and	  sequencing	  were	  outsourced	  to	  a	  third	  
party	  organisation;	  Centre	  for	  Genomics	  Research,	  University	  of	  Liverpool,	  
Liverpool,	  UK.	  The	  workflow	  for	  sample	  preparation	  is	  graphically	  represented	  in	  
Figure	  11	  and	  the	  simplified	  graphical	  representation	  of	  the	  target	  sequence	  
hybridisation,	  portrayed	  in	  Figure	  12.	  	  
	  
Briefly,	  the	  protocol	  entailed	  shearing	  of	  3ug	  of	  gDNA	  for	  each	  of	  9	  HPV16	  positive	  
OPSCC	  samples	  and	  2	  HPV16	  positive	  cell	  lines	  (CaSki	  and	  SiHa)	  using	  the	  Covaris	  
300	  programme	  to	  a	  target	  size	  of	  300bp.	  The	  sheared	  and	  size-­‐selected	  DNA	  was	  
analysed	  on	  a	  DNA	  1000	  chip.	  Samples	  were	  compared	  to	  optimal	  DNA	  shearing	  
profiles	  to	  ensure	  accurate	  shearing	  prior	  to	  proceeding	  to	  hybridisation	  (Figure	  13).	  	  
	  
Figure	  13:	  Optimal	  DNA	  shearing	  profile	  from	  Agilent	  2100	  Bioanalyzer	  electropherogram	  (12k	  chip)	  
Target	  fragment	  size	  300bp.	  Peaks	  at	  extreme	  left	  (15bp)	  and	  extreme	  right	  of	  profile	  (1500bp)	  
represent	  reference	  control	  fragments.	  	  
	  
Following	  confirmation	  of	  satisfactory	  shearing	  profiles,	  samples	  underwent	  end	  
repair,	  non-­‐templated	  addition	  of	  3’-­‐A,	  adaptor	  ligation,	  hybridisation,	  enrichment	  
PCR	  and	  related	  sample	  purification	  steps	  according	  to	  the	  SureSelect	  Illumina	  
Paired-­‐End	  Sequencing	  Library	  protocol	  (version	  1.2,	  May	  2011).	  The	  SureSelect	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capture	  library	  or	  “baits”	  were	  customized	  for	  the	  HPV	  genome	  and	  the	  RNAse	  P	  
human	  gene	  as	  follows.	  Overlapping	  120-­‐mer	  RNA	  baits	  allowing	  x5	  coverage	  of	  the	  
entire	  HPV16	  genome	  was	  designed	  with	  the	  Agilent	  eArray	  software	  and	  then	  
synthesized	  by	  Agilent	  Biotechnologies	  (NCBI	  Reference	  Sequence:	  NC_001526.2).	  
Bait	  design	  paid	  additional	  attention	  to	  the	  circular	  nature	  of	  the	  genome	  to	  ensure	  
coverage	  (x5)	  at	  the	  extremes	  of	  linearized	  text	  sequence,	  resulting	  in	  a	  total	  of	  335	  
baits	  for	  the	  HPV16	  genome.	  
Additionally,	  baits	  were	  designed	  and	  synthesized	  for	  the	  host	  gene,	  RNaseP	  and	  
multiplexed	  with	  HPV16	  baits.	  As	  before	  coverage	  was	  x5	  for	  the	  341bp	  RNase	  P	  
gene	  (NCBI	  Reference	  Sequence:	  NC_000014.8).	  Inclusion	  of	  this	  gene	  was	  intended	  
to	  serve	  two	  purposes;	  firstly,	  it	  would	  allow	  direct	  validation	  of	  the	  sequencing	  
method	  with	  previously	  determined	  quantitative	  PCR	  results	  for	  each	  sample,	  and	  
secondly	  allow	  calculation	  of	  relative	  HPV	  viral	  load	  between	  samples	  with	  RNaseP	  
reads	  being	  the	  equilibrator	  for	  input	  DNA.	  
Sequencing	  was	  performed	  on	  the	  Illumina	  HiSeq	  platform	  in	  accordance	  with	  
standard	  manufacturers	  protocols.	  Raw	  data	  management	  and	  bioinformatic	  
analysis	  was	  provided	  by	  the	  third	  party.	  Bioinfomatic	  outputs	  were	  predetermined	  
with	  the	  third	  party	  to	  ensure	  specific	  research	  targets	  and	  data	  were	  both	  
realistically	  achievable	  and	  delivered	  to	  allow	  interpretation	  in	  keeping	  with	  the	  
project	  aims.	  Specific	  reporting	  features	  were	  paired-­‐end	  read	  origin	  (host	  or	  viral),	  
mapping	  positioning,	  viral-­‐host	  read	  analysis	  with	  specific	  interpretation	  of	  chimeric	  
reads	  to	  report	  viral	  and	  host	  genomic	  break	  point/insertion	  locations	  and	  relative	  
viral	  load.	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4 EVALUATION	  OF	  DIAGNOSTIC	  TESTING	  IN	  
OROPHARYNGEAL	  SQUAMOUS	  CELL	  CARCINOMA	  
4.1 INTRODUCTION	  
Human	  Papillomavirus-­‐16	  (HPV16)	  is	  the	  causative	  agent	  in	  a	  biologically	  distinct	  
subset	  of	  oropharyngeal	  squamous	  cell	  carcinoma	  (OPSCC).	  HPV	  status	  has	  been	  
demonstrated	  to	  be	  an	  important	  prognostic	  biomarker	  in	  OPSCC98,100	  with	  a	  hazard	  
ratio	  for	  overall	  survival	  around	  0.4	  from	  systematic	  reviews	  of	  clinical	  trials50	  (2.3).	  	  	  
In	  the	  design	  and	  introduction	  of	  new	  clinical	  trials,	  HPV16	  status	  has	  become	  an	  
essential	  inclusion	  or	  stratification	  parameter,	  highlighting	  the	  importance	  of	  
accurate	  status	  determination.	  Understandably	  calls	  have	  been	  made	  to	  
standardise	  the	  definitions	  and	  clarify	  the	  best	  test	  or	  combination	  of	  tests	  for	  
accurate	  diagnosis120.	  Currently,	  a	  variety	  of	  detection	  methods	  are	  available119,	  
each	  with	  specific	  benefits	  and	  detractions	  (2.5).	  Additionally,	  considerable	  
variation	  in	  sensitivity	  and	  specificity	  exists	  between	  the	  tests	  defining	  HPV	  
status118,	  such	  that	  the	  utility	  of	  some	  has	  been	  questioned.	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4.2 DIAGNOSTIC	  TEST	  ANALYSIS	  AIMS	  &	  METHODS	  
Hypotheses	  
In	  keeping	  with	  previous	  evidence125,	  detection	  of	  viral	  mRNA	  expression	  carried	  
out	  by	  quantitative	  PCR	  (qPCR)	  techniques	  on	  fresh-­‐frozen	  tissue	  samples	  can	  be	  
considered	  the	  gold	  standard	  for	  HPV	  tumour	  diagnostics.	  Although	  invaluable	  in	  
the	  research	  setting	  this	  gold	  standard	  has	  several	  logistical	  and	  practical	  difficulties	  
that	  have	  ensured	  a	  reliance	  on	  alterative	  tests	  for	  routine	  clinical	  pathology	  
services.	  	  
It	  is	  hypothesised	  that	  the	  tests	  currently	  used	  or	  advocated	  in	  routine	  clinical	  
practice	  are	  less	  than	  optimal	  when	  directly	  compared	  to	  the	  gold	  standard.	  
	  
Against	  this	  standard,	  this	  research	  aimed	  to	  determine	  the	  diagnostic	  and	  
prognostic	  capacity	  of	  the	  frequently	  applied	  or	  advocated	  clinical	  tests	  (or	  
combination	  tests);	  p16	  IHC,	  HR	  HPV	  DNA	  ISH,	  combined	  p16	  IHC/HR	  HPV	  DNA	  ISH,	  
HPV16	  DNA	  qPCR,	  and	  combined	  p16	  IHC/HPV16	  DNA	  qPCR.	  Such	  an	  application	  of	  
a	  comprehensive	  diagnostic	  test	  panel	  to	  strictly	  classified	  OPSCC	  samples	  had	  not	  
been	  conducted	  previously	  and	  sought	  to	  define	  a	  single	  clinical	  standard	  for	  HPV	  
diagnostic	  testing	  in	  OPSCC.	  	  
In	  addition,	  the	  analysis	  aimed	  to	  provide	  data	  to	  clarify	  the	  role	  of	  HPV	  within	  a	  
cohort	  of	  OPSCC	  patients	  from	  the	  United	  Kingdom,	  a	  region	  from	  which	  a	  the	  
combination	  of	  both	  incidence	  and	  prognostic	  data	  had	  yet	  to	  be	  published.	  In	  
doing	  so	  this	  would	  test	  the	  hypothesis	  that	  reported	  increases	  in	  HPV	  positive	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OPSCC	  incidence,	  whilst	  being	  apparent,	  are	  overstated	  due	  to	  a	  lack	  of	  diagnostic	  
stringency	  by	  virtual	  of	  suboptimal	  testing	  techniques.	  
	  	  
Testing	  Methods	  &	  Statistical	  Analyses	  
The	  analysis	  cohort	  contained	  108	  OPSCC	  all	  of	  which	  had	  been	  strictly	  classified	  
according	  to	  site46,47	  to	  ensure	  only	  tumours	  from	  the	  oropharynx	  were	  included	  
(2.2).	  Samples	  originated	  from	  3	  distinct	  time	  periods	  (1988-­‐1997,	  2004-­‐2007	  &	  
2008-­‐2009),	  allowing	  analysis	  of	  relative	  HPV	  positive	  tumour	  incidence	  over	  time.	  
FFPE	  based	  analyses	  were	  conducted	  using	  triplicate	  fixed	  tissue	  tumour	  cores	  
mounted	  on	  a	  tissue	  microarray	  (TMA)	  whilst	  DNA	  and	  RNAqPCR	  testing	  was	  
conducted	  on	  relevant	  nucleic	  acid	  samples	  (DNA	  or	  cDNA)	  on	  a	  real	  time	  PCR	  
platform	  as	  detailed	  previously	  in	  material	  and	  methods	  (3.11).	  Due	  to	  a	  hiatus	  in	  
sample	  collection	  in	  the	  period	  from	  1997-­‐2004,	  cases/samples	  were	  not	  available	  
for	  inclusion	  in	  the	  research	  project.	  This	  precluded	  analysis	  of	  a	  cohort	  of	  samples	  
that	  spanned	  the	  entire	  period	  1988	  –	  2009.	  
HPV	  status,	  as	  defined	  by	  the	  gold	  standard	  test,	  was	  only	  deemed	  positive	  where	  
positive	  results	  were	  apparent	  in	  both	  of	  duplicate	  runs	  of	  RNA	  qPCR	  and	  as	  such	  a	  
tumour	  would	  therefore	  be	  deemed	  as	  a	  reliably	  HPV-­‐	  driven	  malignancy.	  The	  chi-­‐
squared and	  Kruskal–Wallis	  tests	  were	  used	  for	  comparison	  of	  demographic	  and	  
tumor-­‐specific	  features	  between	  periods	  of	  sample	  collection	  and	  HPV	  positive	  and	  
-­‐negative	  subgroups.	  Kaplan–Meier	  estimates	  for	  survival	  analysis	  and	  
determination	  of	  testing	  sensitivity	  and	  specificity	  of	  the	  7	  alternative	  tests	  (p16	  
IHC;	  HR	  HPV	  ISH;	  DNA	  qPCR;	  and	  combined	  analysis	  tests:	  p16	  IHC/HR	  HPV	  ISH;	  p16	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IHC/DNA	  qPCR;	  DNA/	  RNA	  qPCR;	  and	  p16	  IHC/RNA	  qPCR)	  were	  carried	  out.	  The	  log-­‐
rank	  (Mantel–Cox)	  test	  was	  used	  for	  comparison	  between	  survival	  curves	  according	  
to	  each	  of	  the	  detection	  methods.	  	  
Disease-­‐specific	  survival	  was	  defined	  as	  death	  from	  or	  due	  to	  OPSCC,	  and	  overall	  
survival	  was	  defined	  as	  death	  resulting	  from	  any	  cause.	  Both	  disease-­‐specific	  
survival	  and	  overall	  survival	  were	  calculated	  at	  36	  months	  follow-­‐up	  beyond	  the	  
date	  of	  initial	  diagnosis.	  
	  
Tissue	  procurement	  was	  undertaken	  across	  an	  extended	  period	  (1988	  –	  2009),	  
therefore,	  to	  ensure	  that	  era	  of	  collection	  did	  not	  impact	  upon	  detection	  rates,	  the	  
quality	  of	  both	  DNA	  and	  RNA	  (cDNA)	  was	  assessed	  by	  a	  Kruskal–Wallis	  test	  of	  the	  
cycle	  threshold	  (CT)	  of	  the	  relevant	  reference	  gene	  (RNase	  P	  for	  DNA	  qPCR	  and	  β	  
Actin	  for	  RNA	  qPCR).	  
It	  is	  appreciated	  that	  oropharyngeal	  SCC	  typically	  contains	  an	  inflammatory	  cell	  
infiltrate196,	  particularly	  tumour	  infiltrating	  lymphocytes,	  and	  as	  such	  detection	  of	  
HPV16	  DNA/RNA	  in	  samples	  prepared	  from	  non-­‐microdissected	  tissues	  may	  be	  
reduced.	  Quantification	  of	  any	  potential	  reduction	  in	  tumour	  purity	  was	  undertaken	  
through	  analysis	  of	  20	  randomly	  selected	  fixed	  tissue	  slides	  corresponding	  to	  the	  
fresh	  frozen	  samples,	  from	  which	  DNA	  &	  RNA	  were	  extracted.	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4.3 DIAGNOSTIC	  &	  PROGNOSTIC	  CAPACITY	  RESULTS	  
Cohort	  characteristics	  
The	  characteristics	  of	  the	  overall	  group	  and	  comparisons	  between	  samples	  derived	  
from	  the	  three	  periods	  of	  collection	  are	  demonstrated	  in	  Table	  24.	  Whilst	  
comparison	  was	  made	  between	  the	  numbers	  of	  cases	  collected	  in	  each	  era	  and	  the	  
clinical	  and	  demographic	  characteristics	  of	  those	  cases,	  no	  evidence	  of	  significant	  
differences	  was	  detected.	  Tobacco	  consumption	  proved	  to	  be	  the	  sole	  exception	  in	  
this	  instance,	  as	  there	  was	  a	  demonstrable	  increase	  in	  the	  proportion	  of	  non-­‐
smokers	  in	  latter	  years	  (p=0.018).	  As	  would	  be	  expected	  in	  a	  cohort	  of	  head	  and	  
neck	  cancer	  patients,	  a	  male	  to	  female	  ratio	  of	  approximately	  3:1	  was	  consistently	  
observed.	  The	  majority	  of	  tumours	  originated	  from	  within	  the	  tonsillar	  subsite	  
however	  the	  contributions	  to	  the	  cohort	  from	  soft	  palate	  and	  base	  of	  tongue	  
subsites	  remained	  meaningful.	  




Table	  24:	  Cohort	  Characteristics	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Availability	  for	  testing,	  sample	  quality	  and	  consistency	  between	  repeats.	  
DNA	  and	  RNA	  qPCR	  
98/108	  (91%)	  and	  95/108	  (88%)	  of	  samples	  were	  evaluable	  for	  HPV	  status	  
determination	  by	  DNA	  and	  RNA	  qPCR	  respectively,	  and	  importantly	  with	  all	  samples	  
providing	  analysable	  results	  from	  duplicate	  qPCR	  runs.	  
A	  Kruskal-­‐Wallis	  test	  was	  applied	  to	  the	  mean	  CT	  of	  the	  relevant	  reference	  gene	  by	  
year	  of	  sample	  collection	  (RNase	  P	  for	  DNA	  qPCR	  and	  β	  Actin	  for	  RNA	  qPCR).	  There	  
was	  no	  evidence	  of	  statistically	  significant	  change	  in	  DNA	  quality	  as	  determined	  by	  
mean	  CT	  for	  RNase	  P	  across	  the	  period	  of	  collection	  of	  samples	  (p=0.87)	  (Figure	  14).	  
Whilst	  there	  was	  an	  apparent	  difference	  in	  the	  mean	  CT	  for	  β	  Actin	  amongst	  cDNA	  
samples	  (RNA)	  (p=0.01),	  the	  graphical	  representation	  below	  demonstrates	  variation	  
to	  be	  in	  a	  non-­‐linear	  fashion	  and	  therefore	  appears	  not	  to	  relate	  to	  increasing	  age	  
of	  samples	  (Figure	  15).	  It	  was	  concluded	  therefore	  that	  there	  was	  no	  conclusive	  





Figure	  14:	  DNA	  Quality	  Over	  Time	  	  
	  (as	  reflected	  by	  mean	  CT	  of	  reference	  gene,	  RNase	  P	  for	  each	  sample)	  p=0.87	  
	  
	  
Figure	  15:	  RNA	  Quality	  Over	  Time	  	  
	  (as	  reflected	  by	  mean	  CT	  of	  reference	  gene,	  β	  Actin	  for	  each	  sample).	  p=0.01	  
	  
It	  is	  acknowledged	  that	  oropharyngeal	  SCC	  typically	  contains	  an	  inflammatory	  cell	  
infiltrate,	  particularly	  tumour	  infiltrating	  lymphocytes,	  and	  as	  such	  detection	  of	  
HPV16	  DNA/RNA	  in	  samples	  prepared	  from	  non-­‐microdissected	  tissues	  may	  be	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reduced.	  Quantification	  of	  any	  potential	  reduction	  in	  tumour	  purity	  was	  undertaken	  
through	  analysis	  of	  20	  randomly	  selected	  fixed	  tissue	  slides	  corresponding	  to	  the	  
fresh	  frozen	  samples	  from	  which	  DNA	  &	  RNA	  were	  extracted.	  This	  analysis	  
demonstrated	  a	  tumour	  cell	  proportion	  of	  greater	  than	  50%	  in	  all	  cases,	  and	  greater	  
than	  2/3	  in	  16	  (80%)	  samples.	  Given	  the	  sensitivity	  of	  the	  assays	  (as	  detailed	  
previously,	  3.11)	  failure	  to	  detect	  HPV,	  if	  present,	  would	  not	  be	  expected	  with	  a	  
tumour	  cell	  proportion	  of	  50%	  or	  more.	  
	  
TMA:	  P16	  IHC	  &	  HR	  HPV	  ISH	  
FFPE	  blocks	  were	  available	  for	  tissue	  microarray	  inclusion	  for	  97/108	  cases.	  p16	  IHC	  
and	  HR	  HPV	  ISH	  results	  were	  analysable	  from	  at	  least	  one	  or	  more	  representative	  
tumour	  core	  for	  each	  case	  (97/97,	  100%).	  	  Upon	  consideration	  of	  cases	  with	  
positive	  staining	  results,	  complete	  consistency	  of	  p16	  IHC	  and	  HR	  HPV	  ISH	  results	  
between	  all	  tumour	  cores	  originating	  from	  the	  same	  FFPE	  block	  was	  seen	  in	  36/41	  
(88%)	  and	  20/29	  (69%)	  cases	  respectively.	  A	  combined	  threshold	  of	  ≥2/3	  core	  
concordance	  for	  combined	  p16	  IHC	  and	  HR	  HPV	  ISH	  was	  achieved	  by	  97/97	  (100%)	  
cases.	  	  	  
In	  appreciation	  of	  the	  limitations	  of	  sampling	  which	  apply	  when	  undertaking	  TMA	  
analysis,	  it	  was	  felt	  important	  to	  undertake	  additional	  p16	  IHC	  of	  whole	  sections	  for	  
5	  cases	  where	  a	  complete	  absence	  of	  staining	  in	  the	  TMA	  cores	  in	  the	  face	  of	  HPV	  
positive	  tests.	  This	  internal	  control	  confirmed	  true	  negative	  scores	  for	  p16	  IHC	  in	  
each	  case	  by	  virtue	  of	  the	  presence	  of	  p16	  IHC	  staining	  within	  adjacent	  normal	  






The	  proportion	  of	  HPV	  positive	  cases	  within	  each	  time	  period	  or	  era,	  and	  the	  overall	  
total,	  is	  expressed	  as	  a	  trend	  1988-­‐2009	  in	  Table	  25.	  	  The	  percentage	  of	  cases	  
considered	  HPV	  positive	  as	  defined	  by	  RNA	  qPCR	  increased	  from	  14%	  (5/36)	  within	  
the	  era	  1988-­‐1997,	  to	  57%	  (17/30)	  for	  cases	  originating	  from	  2008-­‐2009	  (P=0.001).	  
The	  overall	  tumour	  HPV	  positive	  rate	  for	  the	  sample	  cohort	  irrespective	  of	  era	  of	  
tissue	  collection	  was	  36%	  (34/95).	  	  
The	  increase	  in	  incidence	  remained	  statistically	  significant	  irrespective	  of	  the	  test	  
used	  although	  the	  2008/9	  measures	  of	  HPV	  rates	  varied	  markedly	  between	  52%	  for	  
combined	  DNA/RNA	  qPCR	  and	  77%	  for	  p16	  IHC	  reflecting	  the	  variable	  sensitivity	  of	  
tests.	  	  	  
In	  comparison	  to	  the	  defined	  gold	  standard	  test,	  the	  sensitivity	  of	  the	  seven	  tests,	  
and	  combinations	  of	  tests,	  ranged	  from	  88%	  to	  97%	  and	  the	  specificity	  from	  82%	  to	  
100%	  (Table	  25).	  
With	  the	  exception	  of	  a	  single	  case	  (case	  87,Table	  27)	  all	  samples	  that	  were	  positive	  
by	  RNA	  qPCR	  were	  also	  positive	  by	  DNA	  qPCR,	  however	  8	  DNA	  qPCR	  positive	  cases	  
were	  negative	  by	  RNA	  qPCR,	  a	  feature	  reflected	  in	  the	  consequent	  reduction	  in	  
specificity	  for	  DNA	  qPCR	  (87%).	  
3/95	  (3%)	  of	  cases	  were	  positive	  for	  either	  HPV18	  (1/95)	  or	  HPV33	  (2/95)	  E6	  
expression.	  Of	  the	  latter,	  one	  of	  these	  cases	  demonstrated	  a	  multiple	  HPV	  infection	  
with	  evidence	  of	  both	  HPV16	  and	  HPV33	  E6	  gene	  expression.	  	  FFPE	  tissue	  was	  not	  
available	  for	  this	  case,	  however	  the	  second	  HPV33	  positive	  case	  did	  demonstrate	  a	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positive	  result	  for	  HR	  HPV	  ISH	  yet	  this	  positive	  result	  occurred	  in	  the	  absence	  of	  p16	  
IHC	  staining.	  	  
The	  single	  case	  shown	  to	  be	  positive	  for	  HPV18	  was	  p16	  IHC/HR	  HPV	  ISH	  positive	  
whilst	  negative	  by	  both	  HPV16	  DNA	  and	  RNA	  qPCR.	  
A	  series	  of	  cases	  (n=5)	  were	  subjected	  to	  full	  section	  analysis	  of	  HR	  HPV	  ISH	  due	  to	  
conflicting	  HPV	  status	  reporting	  between	  FFPE	  results	  and	  those	  of	  the	  gold	  
standard.	  Full	  section	  analysis	  was	  undertaken	  to	  ensure	  sure	  conflict	  was	  due	  to	  
the	  testing	  regime	  rather	  than	  the	  effects	  of	  tumour	  sampling.	  	  
1/5	  cases	  was	  reclassified	  to	  exclude	  HR	  HPV	  ISH	  staining	  following	  the	  same	  criteria	  
and	  as	  such	  brought	  fixed	  tissue	  and	  frozen	  tissue	  derived	  results	  into	  accord	  with	  
one	  and	  other.	  The	  remaining	  4/5	  cases	  correlated	  with	  the	  TMA	  results.	  Of	  these	  
one	  of	  the	  conflicting	  HR	  HPV	  ISH	  cases	  was	  positive	  for	  HPV33	  by	  RNA	  qPCR,	  
however	  3/5	  cases	  remain	  in	  conflict	  with	  the	  expression	  results	  for	  three	  HR	  HPV	  
types	  (HPV-­‐16,	  -­‐18	  &	  -­‐33).	  Results	  (summarized	  in	  Table	  25)	  were	  amended	  to	  










Table	  26:	  Patient	  &	  Tumour	  Individual	  Case	  Diagnostic	  Analysis	  	  





Table	  27:	  Patient	  &	  Tumour	  Individual	  Case	  Diagnostic	  Analysis	  	  




Implications	  of	  Diagnostic	  Thresholds	  
The	  diagnostic	  threshold	  for	  positive	  status	  was	  predetermined	  to	  be	  equivalent	  to	  
a	  single	  HPV-­‐16	  E6	  gene	  copy	  per	  diploid	  genome	  
(by	  reference	  to	  CaSki	  copy	  number,	  869	  integrated	  copies).	  As	  Figure	  16	  clearly	  
demonstrates,	  HPV16	  DNA	  qPCR	  provided	  a	  continuous	  variable	  without	  clear	  
delineation	  around	  the	  threshold.	  In	  contrast,	  HR	  HPV	  RNA	  qPCR	  was	  unequivocal	  
by	  classifying	  samples	  in	  a	  binary	  fashion.	  It	  is	  the	  variability	  around	  the	  threshold	  
that	  has,	  at	  least	  in	  part,	  led	  to	  variation	  in	  specificity	  of	  DNA	  qPCR	  as	  a	  diagnostic	  
test.	  
	  
Figure	  16:	  Plot	  of	  Individuals	  case	  HPV16	  ∆CT	  DNA	  qPCR	  results	  by	  HPV	  status	  
Where	  HPV	  status	  is	  determined	  by	  RNA	  qPCR	  for	  HPV16	  E6.	  Horizontal	  blue	  dash	  line	  represents	  the	  




HPV16	  Status	  in	  Tumours	  &	  Adjacent	  Normal	  Marginal	  Tissues	  
A	  subcohort	  of	  samples	  (n=53)	  had	  available	  matched	  normal	  tissue,	  resected	  
following	  completion	  of	  tumour	  specimens	  intraoperatively	  and	  therefore	  beyond	  
both	  the	  clinical	  macroscopic	  extent	  of	  disease	  and	  the	  traditional	  surgical	  clinical	  
margins	  (typically	  1cm	  or	  more	  for	  the	  majority	  of	  samples).	  
Table	  28	  depicts	  the	  relative	  HPV	  positive	  and	  negative	  proportions	  within	  the	  
tumour	  and	  normal	  samples	  both	  in	  terms	  of	  HPV16	  DNAqPCR	  (E6)	  and	  also	  
RNAqPCR	  (E6	  and	  or	  E7).	  The	  rate	  of	  coincident	  HPV	  positivity	  in	  both	  the	  primary	  
tumour	  and	  its	  adjacent	  marginal	  specimen	  was	  44%	  (11/25)	  when	  assessed	  using	  
the	  gold	  standard	  test	  on	  fresh	  frozen	  samples.	  Evidence	  of	  E2	  gene	  expression	  in	  
the	  absence	  of	  viral	  oncogene	  expression	  was	  apparent	  in	  a	  single	  tumour	  sample	  
(without	  any	  detectable	  viral	  expression	  in	  the	  matched	  normal	  tissue)	  and	  similarly	  
E2	  expression	  in	  normal	  tissue	  samples	  of	  two	  further	  cases	  was	  detected	  without	  




Table	  28:	  HPV	  Status	  in	  Matched	  Tumour	  and	  Adjacent	  Normals	  
Sample	  HPV	  status	  classified	  by	  DNAqPCR	  and	  RNAqPCR	  with	  percentage	  of	  cases	  in	  brackets.	   	  
Diagnostic	  Test	   Tumour	   Normal	  
	  	   Positive	   Negative	   Total	   Positive	   Negative	   Total	  
DNA	  E6	   27	  (51)	   26	  (49)	   53	  (100)	   15	  (28)	   38	  (72)	   53	  (100)	  
RNA	  E6+/orE7	   25	  (47)	   29	  (53)	   53	  (100)	   11	  (21)	   42	  (79)	   53	  (100)	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HPV16	  status	  vs.	  clinical	  characteristics	  	  
Individuals	  with	  HPV	  positive	  malignancy	  were	  younger	  than	  the	  HPV	  negative	  
group	  (mean	  53.3	  vs.	  60.8	  yrs,	  p=0.003).	  	  The	  age	  of	  patients	  at	  the	  time	  of	  
diagnosis	  conformed	  to	  a	  normal	  distribution	  (1-­‐sample	  Kolmogorov-­‐Smirnov	  test,	  
p=0.997)	  and,	  significantly,	  the	  modest	  7.5	  yrs	  difference	  seen	  between	  mean	  ages	  
exceeded	  the	  6.8	  yrs	  difference	  seen	  between	  the	  median	  ages.	  	  The	  other	  notable	  
clinical	  characteristic	  correlating	  with	  HPV	  status	  was	  smoking	  history.	  Of	  the	  82	  
patients	  for	  whom	  reliable	  smoking	  history	  could	  be	  determined,	  the	  non-­‐smokers	  
and	  those	  smoking	  <20	  pack	  years	  were	  more	  common	  in	  the	  HPV	  positive	  group	  
(Pearson’s	  chi	  square,	  p=0.007).	  There	  were	  no	  significant	  differences	  between	  the	  
groups	  when	  gender,	  tumour	  site,	  cervical	  lymph	  node	  stage	  or	  alcohol	  




Table	  29:	  Clinical	  Characteristics	  by	  HPV	  status	  	  
(As	  defined	  by	  RNA	  qPCR)	  
	  
HPV	  testing	  methods	  as	  prognostic	  biomarkers:	  survival	  analysis	  
Kaplan-­‐Meier	  survival	  curves,	  segregating	  cases	  by	  HPV	  status	  (as	  assigned	  by	  the	  
gold	  standard	  RNA	  qPCR	  test)	  showed	  a	  significant	  prognostic	  benefit	  in	  both	  
Overall	  Survival	  (OS,	  p=	  0.003)	  and	  Disease	  Specific	  Survival	  (DSS,	  p=0.005)	  (Figure	  
17).	  Kaplan-­‐Meier	  estimates	  of	  mean	  survival	  for	  the	  other	  tests	  are	  shown	  in	  Table	  
30.	  	  Although	  very	  similar	  to	  the	  gold	  standard	  RNA	  qPCR	  outcome	  measures,	  the	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test	  combination	  demonstrating	  a	  prognostic	  benefit	  of	  greatest	  significance	  for	  
both	  disease	  specific	  and	  overall	  survival	  was	  combined	  p16	  IHC/	  DNA	  qPCR	  	  (OS,	  
p=0.002	  and	  DSS,	  p=0.005).	  The	  least	  satisfactory	  tests	  in	  this	  regard	  were	  p16	  IHC	  
or	  HR	  HPV	  ISH,	  either	  alone	  or	  in	  combination.	  Although	  remaining	  statistically	  
significant,	  the	  differences	  in	  OS	  (p=0.021,	  0.011	  &	  0.016	  respectively)	  vary	  by	  an	  
order	  of	  magnitude	  by	  comparison	  with	  the	  gold	  standard.	  All	  tests	  using	  target	  
amplification	  of	  DNA	  and	  RNA,	  performed	  relatively	  well	  in	  differentiating	  survival	  
outcomes	  for	  both	  OS	  and	  DSS,	  although	  it	  is	  important	  to	  note	  that	  DNA	  qPCR	  




Table	  30:	  Kaplan-­‐Meier	  estimates	  of	  survival	  at	  36	  Months	  by	  HPV	  status	  





Figure	  17:	  36	  Month	  Kaplan-­‐Meir	  Plots	  of	  Disease	  Specific	  Survival	  and	  Overall	  Survival	  by	  HPV	  status	  




4.4 DISCUSSION	  &	  IMPLICATIONS	  FOR	  CLINICAL	  PRACTICE	  
The	  results	  of	  this	  research	  provide	  the	  first	  evidence	  of	  relative	  incidence	  of	  HPV	  
driven	  OPSCC,	  with	  associated	  prognostic	  implications,	  from	  a	  United	  Kingdom	  
cohort.	  	  
Reflecting	  trends	  seen	  in	  other	  developed	  countries,	  the	  proportion	  of	  HPV	  
mediated	  OPSCC	  cases	  has	  increased	  from	  14%	  to	  57%	  between	  1998	  and	  2009	  
within	  the	  Liverpool	  cohort.	  	  Although	  there	  was	  variation	  in	  this	  rate	  depending	  on	  
diagnostic	  test	  used	  (52	  to	  77%,	  2008-­‐9),	  these	  results	  show	  that	  there	  has	  been	  a	  
substantial	  rise	  in	  relative	  incidence	  of	  HPV	  positive	  OPSCC.	  Although	  choice	  of	  test	  
will	  influence	  the	  final	  HPV	  positive	  rate,	  these	  data	  are	  comparable	  to	  published	  
rates	  from	  Western	  Europe	  and	  North	  America3,51,76,90,197-­‐200.	  	  
It	  remains	  to	  be	  seen	  whether	  the	  trend	  of	  increasing	  HPV	  positive	  OPSCC,	  and	  
indeed	  OPSCC	  as	  a	  whole,	  continues,	  however	  speculative	  extrapolations	  of	  current	  
rates	  suggest	  that	  by	  2020	  in	  a	  comparable	  US	  population,	  HPV-­‐positive	  OPSCC	  
cases	  alone	  will	  exceed	  those	  of	  cervical	  cancer	  for	  the	  first	  time63.	  Whether	  or	  not	  
rates	  exceed	  their	  present	  state,	  the	  data	  generated	  here	  will	  provide	  more	  
evidence	  in	  support	  of	  calls	  to	  strengthen	  primary	  and	  secondary	  prevention	  
through	  prophylactic	  vaccination	  &	  education.	  	  
In	  keeping	  with	  the	  substantially	  improved	  outcomes,	  individuals	  with	  HPV	  positive	  
OPSCC	  typically	  have	  improved	  locoregional	  control	  and	  reduced	  incidence	  of	  
second	  primaries	  of	  the	  aerodigestive	  tract91,201.	  Evidence	  has	  previously	  suggested	  
a	  link	  between	  genetic	  or	  epigenetic	  alterations	  within	  otherwise	  normal	  marginal	  
tissues	  adjacent	  to	  HPV	  negative	  HNSCC	  and	  potential	  for	  disease	  recurrence202,203.	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In	  keeping	  with	  this	  it	  would	  be	  conceivable	  that	  the	  oncogenic	  drivers	  of	  HPV	  
OPSCC,	  namely	  E6	  and	  E7	  expression,	  would	  be	  absent	  in	  marginal	  normal	  tissues.	  
This	  however,	  did	  not	  appear	  to	  be	  the	  case,	  with	  almost	  half	  (44%)	  of	  normal	  
samples	  matched	  to	  HPV	  positive	  OPSCC	  demonstrating	  viral	  oncogene	  expression.	  	  
Clearly,	  inclusion	  of	  tumour	  cells	  within	  normal	  samples	  cannot	  be	  excluded	  in	  the	  
absence	  of	  a	  full	  sectional	  histological	  analysis	  of	  the	  sample	  prior	  to	  nucleic	  acid	  
extraction.	  Reliance	  on	  FFPE	  sourced	  material	  with	  microdissection	  may	  provide	  
greater	  clarity;	  however	  there	  would	  therefore	  be	  a	  reliance	  on	  RNAqPCR	  results	  
derived	  from	  FFPE	  rather	  than	  fresh	  frozen	  samples.	  	  
	  
HPV	  analysis	  of	  OPSCC	  in	  clinical	  practice	  is	  becoming	  a	  fundamental	  requirement	  in	  
the	  provision	  of	  both	  adequate	  prognostic	  information	  but	  also	  to	  facilitate	  entry	  
into	  appropriately	  stratified	  clinical	  trials,	  including	  those	  investigating	  the	  potential	  
to	  de-­‐escalate	  the	  intensity	  of	  curative	  therapies.	  Paradoxically,	  there	  remains	  no	  
‘international	  standard’	  for	  defining	  HPV	  related	  OPSCC	  in	  clinical	  practice118.	  	  
Through	  the	  analysis	  of	  the	  currently	  applied	  diagnostic	  tests	  and	  test	  algorithms,	  
these	  results	  highlight	  the	  compromises	  that	  have	  been	  necessary	  in	  terms	  of	  
sensitivity	  and	  specificity,	  to	  achieve	  a	  test	  which	  can	  be	  used	  in	  a	  clinical	  setting.	  
Van	  Houten	  et	  al128	  alluded	  to	  the	  inherent	  variability	  in	  the	  sensitivity	  of	  tests	  that	  
may	  lead	  to	  potential	  overestimation	  of	  the	  role	  of	  HPV	  in	  OSPCC.	  Clearly	  the	  
implications	  of	  reduced	  specificity	  for	  individuals	  recruited	  to	  trials	  aiming	  to	  de-­‐
escalate	  therapeutic	  intensity	  on	  the	  basis	  of	  HPV	  status	  could	  be	  critical.	  
p16	  IHC	  was	  initially	  described	  as	  a	  surrogate	  for	  HPV	  status	  by	  Klussmann	  et.	  al.132	  
and	  was	  later	  applied	  in	  OPSCC	  survival	  analysis	  by	  Lassen	  et	  al.	  100	  in	  their	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description	  of	  HPV	  status	  within	  the	  Danish	  Head	  and	  Neck	  Cancer	  Group	  
(DAHANCA)	  5	  Trial.	  When	  used	  in	  isolation,	  p16	  IHC	  will	  identify	  tumours	  with	  
excess	  p16	  protein	  due	  to	  both	  the	  effects	  of	  viral	  E7	  protein	  but	  also	  through,	  as	  
yet	  unexplained,	  non	  HPV-­‐mediated	  mechanisms204.	  In	  addition,	  the	  strength	  of	  
stain	  and	  proportion	  of	  tumour	  specimen	  stained	  in	  a	  given	  FFPE	  sample	  will	  vary	  
leading	  to	  ongoing	  debate	  surrounding	  the	  best	  p16	  threshold	  and	  an	  ever-­‐present	  
potential	  for	  inaccurate	  classification131,133,136.	  	  
The	  inclusion	  of	  HPV	  DNA	  testing	  (by	  PCR	  or	  ISH)	  in	  combination	  with	  p16	  has	  been	  
advocated	  to	  improve	  testing	  specificity,	  with	  such	  combined	  tests	  allowing	  
classification	  into	  one	  of	  four	  groups205	  depending	  on	  a	  score	  for	  the	  two	  
components.	  Robinson	  et.	  al.’s	  review119	  of	  	  HPV	  testing	  included	  a	  pooling	  of	  
results	  from	  six	  studies	  examining	  496	  tumours	  using	  such	  a	  classification	  and	  found	  
p16	  positive/HPV	  negative	  in	  5%	  of	  cases	  and	  p16	  negative/HPV	  positive	  results	  in	  
8%.	  	  	  Based	  on	  our	  current	  series	  of	  108	  cases,	  the	  p16	  IHC/HR	  HPV	  ISH	  classification	  
demonstrates	  a	  p16	  positive/HPV	  negative	  rate	  of	  8%	  and	  p16	  negative/HPV	  
positive	  status	  in	  2%	  of	  cases.	  Both	  of	  the	  p16	  negative/HPV	  positive	  cases	  were	  
negative	  by	  both	  DNA	  qPCR	  and	  RNA	  qPCR,	  however	  one	  sample	  was	  positive	  by	  
HPV33	  RNAqPCR	  analysis.	  Of	  particular	  interest	  however	  is	  the	  finding	  that	  RNA	  
qPCR	  results	  highlight	  2/97	  cases	  (2%)	  that	  were	  p16	  positive/HR	  HPV	  ISH	  negative.	  
Such	  a	  finding	  of	  false	  negative	  results	  reflects	  reduced	  sensitivity	  for	  the	  combined	  
p16	  IHC/HR	  HPV	  ISH	  test	  in	  determining	  tumour	  HPV16	  status.	  By	  comparison,	  
combined	  p16	  IHC/DNA	  qPCR	  showed	  6/88	  (7%)	  cases	  that	  were	  p16	  positive/HPV	  
negative,	  none	  of	  which	  demonstrated	  HPV16	  E6	  expression	  (RNA	  qPCR).	  The	  
presence	  of	  HPV16	  DNA	  was	  detected	  in	  8	  cases	  (20%	  of	  DNA	  qPCR	  positive	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samples)	  where	  expression	  was	  not	  evident.	  Given	  the	  stringent	  efforts	  employed	  
to	  avoid	  contamination	  at	  each	  step	  in	  this	  analysis,	  it	  is	  likely	  that	  this	  reflects	  
detection	  of	  an	  innocent	  bystander	  viral	  infection	  in	  the	  absence	  of	  true	  virally	  
mediated	  malignancy.	  Clearly	  the	  reduced	  specificity	  of	  DNA	  qPCR	  alone	  limits	  its	  
utility	  in	  most	  settings.	  The	  threshold	  applied	  to	  DNAqPCR	  could	  however	  be	  
questioned	  in	  this	  situation,	  yet	  the	  determined	  cut	  off	  was	  in	  keeping	  with	  a	  
biological	  rationale	  for	  a	  truly	  HPV-­‐driven	  malignancy185	  and	  indeed	  was	  more	  
stringent	  than	  previous	  publications	  would	  suggest130.	  Although	  these	  results	  would	  
suggest	  that	  the	  threshold	  is	  somewhat	  arbitrary,	  the	  level	  prescribed	  in	  this	  setting	  
was	  made	  with	  a	  sound	  biological	  basis	  and	  indeed	  it	  would	  be	  hard	  to	  defend	  a	  
threshold	  that	  falls	  below	  the	  level	  of	  a	  single	  viral	  copy	  per	  cell.	  The	  problem	  of	  
threshold	  establishment	  is	  problematic	  and	  has	  been	  highlighted	  in	  the	  literature	  
previoulsy130	  and	  it	  remains	  far	  from	  resolved	  leading	  one	  to	  question	  the	  use	  of	  
DNA	  PCR	  based	  analysis	  in	  clinical	  practice.	  Once	  more,	  we	  recognise	  the	  
implication	  that	  non-­‐microdissected	  fresh	  frozen	  tissue	  samples	  may	  have	  on	  the	  
potential	  for	  altered	  proportion	  of	  HPV	  to	  genomic	  DNA	  where	  tumour	  cell	  
percentage	  is	  reduced.	  In	  an	  attempt	  to	  quantify	  any	  reduction	  in	  tumour	  cell	  
percentage	  in	  fresh	  frozen	  samples,	  matched	  FFPE	  histopathological	  analysis	  was	  
undertaken	  in	  a	  representative	  sample	  subcohort.	  This	  indicated	  tumour	  cell	  
burden	  to	  be	  over	  50%	  in	  all	  cases	  and	  greater	  the	  2/3	  in	  80%	  of	  cases.	  
Detection	  of	  target	  signal	  for	  HPV	  in	  all	  samples,	  albeit	  below	  the	  threshold,	  was	  a	  
curious	  finding	  which	  defied	  stringent	  attempts	  to	  exclude	  cross-­‐contamination	  at	  
all	  steps	  from	  sample	  procurement	  through	  to	  laboratory	  analysis	  (disposable	  
instruments	  at	  time	  of	  tumour	  sectioning,	  fume	  cupboard	  isolation,	  separate	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laboratory	  space,	  refrigeration	  and	  tools	  (pipettes	  etc).	  Indeed,	  at	  all	  times,	  non-­‐
template	  controls	  remained	  free	  from	  signal,	  making	  PCR	  setup	  errors	  unlikely.	  By	  
its	  very	  nature	  PCR	  has	  potential	  for	  specificity	  weakness	  depending	  on	  the	  assay	  
design	  (eg.	  sequence	  specificity	  or	  mispriming)	  or	  technique	  (eg.	  PCR	  cycle	  number	  
for	  detection)	  however	  the	  possibility	  of	  a	  transcriptionally	  inactive	  remnant	  of	  viral	  
DNA	  sequence	  (conceivably	  following	  HPV	  infection)	  should	  be	  considered.	  The	  
results	  of	  the	  HPV16	  E6	  assay	  were	  paralleled	  by	  HPV16	  E2	  and	  E7	  DNAqPCR	  assays	  
lending	  some	  support	  to	  this	  explanation.	  
	  	  
The	  Ventana	  Inform	  III	  HR	  HPV	  ISH	  probe	  detects	  twelve	  high	  risk	  HPV	  types	  
including	  HPV16,	  18	  &	  33.	  In	  this	  instance	  the	  ISH	  analysis	  defined	  a	  small	  subset	  of	  
HPV	  negative	  cases	  as	  being	  positive,	  although	  by	  inclusion	  of	  a	  combined	  analysis	  
with	  p16	  IHC	  this	  group	  was	  reduced.	  It	  is	  possible	  that	  the	  HR	  HPV	  cocktail	  is	  
detecting	  HPV	  types	  other	  than	  those	  tested	  using	  RNA	  qPCR,	  however	  contribution	  
to	  OPSCC	  of	  other	  HR	  HPV	  types	  (beyond	  HPV16	  &	  -­‐18)	  in	  isolation	  is	  unlikely65,76.	  
Unfortunately	  genotype	  specific	  probes	  are	  not	  available	  for	  diagnostic	  use	  in	  
Europe	  due	  to	  licensing	  restrictions	  (Dako	  and	  Ventana	  Medical	  Systems	  Inc).	  	  
To	  date	  there	  is	  no	  published	  data	  that	  compares	  the	  genotype	  specific	  probes	  with	  
cocktail	  probes	  however	  the	  probe	  utilised	  in	  this	  research	  has	  been	  shown	  to	  
compare	  favorably	  when	  analysed	  against	  the	  detection	  of	  HPV16	  E7/E6	  mRNA137.	  
	  
If	  the	  calls	  for	  inclusion	  of	  OPSCC	  patients	  into	  appropriately	  designed	  and	  stratified	  
clinical	  trials	  are	  to	  be	  met50,120,206,	  then	  it	  is	  vital	  that	  accurate	  classification	  of	  HPV	  
status	  be	  made	  prior	  to	  enrolment,	  and	  with	  a	  validated,	  clinically	  appropriate	  test.	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This	  is	  now	  more	  than	  a	  theoretical	  problem,	  as	  several	  trials	  focussing	  towards	  de-­‐
escalation	  of	  treatment	  for	  individuals	  with	  HPV	  positive	  tumour	  and	  in	  early	  phase	  
trials	  of	  HPV	  directed	  agents	  or	  immunotherapy,	  have	  recently	  opened.	  	  Our	  data	  
suggests	  that	  HPV16	  status	  determination	  with	  the	  p16	  IHC/DNA	  qPCR	  combination	  
test	  offers	  a	  valuable	  alternative	  to	  viral	  expression	  analysis	  on	  fresh	  tissue	  samples,	  
and	  retains	  excellent	  prognostic	  value	  along	  with	  97%	  sensitivity	  /	  94%	  specificity.	  	  
Such	  a	  test,	  although	  feasible,	  does	  carry	  with	  it	  logistical	  constraints	  for	  a	  routine	  
pathology	  practice.	  The	  combination	  of	  p16	  IHC/	  HR	  HPV	  ISH	  is	  worthy	  of	  
consideration	  as	  an	  alternative,	  consistent	  with	  the	  diagnostic	  algorithms	  suggested	  
by	  Westra	  et.	  al.	  136.	  In	  our	  data,	  specificity	  for	  p16	  IHC/	  HR	  HPV	  ISH,	  albeit	  with	  a	  
HPV	  high	  risk	  cocktail	  probe	  rather	  than	  a	  type	  specific	  probe,	  was	  acceptable	  (90%)	  
but	  did	  come	  at	  the	  expense	  of	  sensitivity	  (88%)	  such	  that	  the	  test	  may	  be	  deemed	  
undesirable.	  
	  
Clinical	  trials	  in	  HNSCC	  frequently	  struggle	  to	  adequately	  recruit207,	  and	  in	  those	  
focussing	  within	  one	  anatomical	  sub-­‐site,	  this	  difficulty	  may	  be	  exaggerated.	  In	  
order	  to	  maximise	  sensitivity	  i.e.	  potential	  recruitment	  whilst	  maintaining	  specificity	  
i.e.	  patient	  safety,	  the	  choice	  of	  satisfactory	  test	  is	  more	  limited.	  Faced	  with	  the	  
potential	  “loss”	  of	  approximately	  10%	  of	  eligible	  patients	  using	  tests	  such	  as	  p16	  
IHC/	  HR	  HPV	  ISH,	  the	  benefits	  to	  sensitivity	  of	  employing	  DNA	  or	  RNA	  PCR	  assays	  
appear	  to	  easily	  balance	  the	  additional	  logistic	  costs.	  
	  
The	  contribution	  and	  clinical	  importance	  of	  high	  risk	  HPV	  subtypes	  other	  than	  
HPV16,	  appears	  to	  be	  minimal	  by	  comparison	  with	  gynaecological	  and	  anogenital	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malignancy44.	  	  Consequently,	  we	  feel	  that	  the	  use	  of	  “consensus”	  HPV	  PCR	  primers	  
in	  HNSCC	  cases	  is	  difficult	  to	  justify,	  not	  least	  as	  this	  would	  merely	  confirm	  presence	  
of	  viral	  DNA	  rather	  than	  the	  stronger	  burden	  of	  proof	  that	  viral	  oncogene	  
expression	  bares	  when	  considering	  virally	  mediated	  malignancy.	  Kreimer	  et	  al76	  in	  
their	  systematic	  review	  of	  prevalence	  and	  HPV	  type	  distribution	  in	  the	  head	  and	  
neck	  found	  86.7%	  of	  OPSCC	  were	  HPV16	  positive	  whilst	  HPV18	  and	  HPV33	  positive	  
cases,	  the	  subsequent	  largest	  percentage	  of	  types,	  accounted	  for	  only	  1%	  each.	  
Using	  viral	  oncogene	  expression,	  our	  findings	  are	  comparable;	  with	  HPV16	  
accounting	  for	  94%	  of	  all	  HPV	  positive	  cases	  and	  HPV18	  &	  33	  representing	  a	  small	  
subset	  (3%	  and	  6%	  respectively).	  	  
	  
	  
With	  respect	  to	  survival,	  this	  research	  reinforces	  previously	  reported	  favourable	  
outcomes	  for	  individuals	  with	  HPV	  positive	  tumours50,91,97,98,	  as	  demonstrated	  by	  
both	  improved	  DSS	  and	  OS.	  It	  is	  apparent	  that,	  with	  the	  exception	  of	  p16	  IHC	  or	  HR	  
HPV	  ISH	  in	  isolation,	  most	  of	  the	  other	  assays	  available	  provide	  a	  reasonable	  
prognostic	  guide.	  
Debate	  remains	  as	  to	  whether	  tobacco	  usage	  further	  stratifies	  HPV	  positive	  and	  
negative	  malignancies	  into	  a	  third,	  middle,	  tier	  for	  prognostic	  value91,208.	  	  
Due	  to	  the	  small	  numbers	  of	  non-­‐smokers	  in	  this	  cohort,	  limiting	  meaningful	  
analysis,	  the	  additional	  prognostic	  value	  of	  combining	  HPV16	  and	  smoking	  history	  
has	  not	  been	  assessed.	  We	  speculate	  that	  the	  addition	  of	  smoking	  data	  has	  added	  
accuracy	  to	  some	  other	  published	  HPV	  typing	  methods	  that	  have	  inherent	  and	  
proven	  inaccuracies	  (e.g.	  p16	  IHC).	  In	  such	  a	  setting,	  non-­‐smoking	  behaviour	  will	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doubtless	  be	  strongly	  correlated	  with	  an	  HPV-­‐16	  positive	  category.	  
	  
In	  conclusion,	  the	  presented	  data	  reflects	  a	  rigorous	  analysis	  of	  diagnostic	  tests,	  
judging	  their	  value	  against	  the	  most	  clinically	  relevant	  demands	  of	  diagnostic	  
accuracy	  and	  prognostic	  relevance.	  It	  is	  anticipated	  that	  the	  design	  of	  forthcoming	  
clinical	  trials,	  aimed	  at	  both	  de-­‐escalating	  therapy	  in	  HPV	  mediated	  OPSCC	  and,	  
conversely,	  intensifying	  therapy	  for	  HPV	  negative	  cases,	  will	  be	  informed	  and	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5 IS	  THE	  REFERENCE	  “GOLD	  STANDARD”	  TEST	  RESTRICTED	  
TO	  FRESH	  FROZEN	  SAMPLES?	  
5.1 INTRODUCTION	  
Whilst	  there	  has	  been	  an	  increasing	  consensus	  surrounding	  the	  use	  of	  viral	  
oncogene	  expression	  as	  a	  reference	  test,	  for	  reasons	  of	  RNA	  instability,	  such	  testing	  
has	  both	  relied	  on	  the	  analysis	  of	  fresh	  frozen	  tissue,	  and	  upon	  utilisation	  of	  
specialist	  research	  laboratory	  techniques.	  This	  has	  inevitably	  limited	  the	  potential	  
translation	  of	  RNA-­‐based	  tests	  into	  routine	  clinical	  diagnostics.	  For	  clinical	  utility	  
therefore,	  HPV	  testing	  strategies	  have	  necessarily	  focused	  on	  formalin-­‐fixed	  
paraffin-­‐embedded	  (FFPE)	  tissue	  (2.5),	  but	  this	  has	  been	  at	  the	  expense	  of	  reduced	  
sensitivity	  and	  specificity	  for	  oncogenic	  HPV125. Further,	  the	  inclusion	  of	  multiple	  
analytical	  stages	  to	  achieve	  an	  accurate	  and	  reliable	  HPV	  status	  is	  technically	  
cumbersome,	  may	  produce	  discordant	  results	  across	  the	  different	  tests	  employed	  
and	  inevitably	  increases	  costs.	  
Limited	  recent	  evidence	  has	  suggested	  that	  a	  novel	  RNA-­‐based	  chromogenic	  in	  situ	  
hybridisation	  (ISH)	  technique	  (RNAscope,	  Advanced	  Cell	  Diagnostics,	  Hayward,	  CA)	  
is	  capable	  of	  reliably	  detecting	  transcriptionally	  active	  genes,	  including	  High	  Risk	  
HPV	  E6/E7	  oncogenes,	  in	  FFPE	  tissue	  samples209.	  	  
The	  RNA	  ISH	  techniques	  have	  been	  applied	  previously	  for	  detection	  of	  HPV	  
transcripts	  in	  cervical	  neoplasia,	  genital	  condylomas	  and	  sinonasal	  papillomas,	  
however	  the	  application	  of	  radioactively	  labelled	  probes	  and	  associated	  protracted	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exposure	  times,	  or	  problems	  associated	  with	  variable	  RNA	  control	  detection	  limited	  
or	  precluded	  routine	  clinical	  use210-­‐212.	  	  
This	  more	  recently	  described	  chromogenic	  RNA	  ISH	  technique	  has	  shown	  promising	  
results	  in	  comparison	  to	  other	  FFPE-­‐based	  HPV	  diagnostic	  tests	  both	  in	  a	  large	  
(n=196)	  cohort	  of	  OPSCC213	  and	  on	  samples	  from	  head	  and	  neck	  subsites	  outwith	  
the	  oropharynx214	  however,	  validation	  against	  the	  gold	  standard	  of	  fresh	  tissue	  
derived	  mRNA	  qPCR	  has	  not	  been	  conducted	  in	  either	  of	  these	  clinical	  cohort	  
studies.	  Although	  a	  test	  capable	  of	  detecting	  viral	  oncogene	  expression	  holds	  
considerable	  promise,	  without	  formal	  validation	  against	  the	  previously	  described	  
gold	  standard,	  clinical	  acceptance	  would	  be	  unlikely	  to	  be	  forthcoming.	  
	  
High	  Risk	  HPV	  RNA	  In	  situ	  Hybridisation	  Aims	  
It	  was	  hypothesised	  that	  HR	  HPV	  ISH	  was	  capable	  of	  reaching	  a	  standard	  
comparable	  to	  that	  displayed	  by	  the	  best	  performing	  test(s)	  currently	  applied	  in	  
routine	  clinical	  practice,	  when	  measured	  against	  the	  current	  gold	  standard,	  
evidence	  of	  viral	  oncogene	  expression	  derived	  from	  fresh	  tissue	  samples.	  
	  
Test	  Methods,	  Interpretation	  &	  Analysis	  
Validation	  of	  the	  HR	  HPV	  RNAscope	  test	  was	  undertaken	  on	  a	  subcohort	  of	  TMA	  
mounted	  FFPE	  cores	  from	  the	  previously	  described,	  well-­‐characterised	  OPSCC	  cases	  




Test	  assessment	  for	  all	  tissue-­‐based	  analyses	  was	  conducted	  independently,	  by	  two	  
experienced	  Head	  &	  Neck	  Pathologists.	  Previously	  generated	  results	  for	  HR	  HPV	  
DNA	  ISH,	  HPV16	  DNA	  qPCR	  &	  the	  reference	  test,	  HPV16	  E6/7,	  HPV18	  E6	  and	  HPV33	  
E6	  expression,	  were	  correlated	  to	  relevant	  cases	  but	  not	  reinterpreted.	  
However	  p16	  IHC	  status	  reanalysis	  was	  undertaken	  with	  the	  aim	  of	  allowing	  
interpretation	  by	  two	  separate	  means,	  firstly	  using	  the	  threshold	  of	  strong	  and	  
diffuse	  nuclear	  and	  cytoplasmic	  staining	  in	  ≥70%	  of	  the	  tumour	  131	  and	  also	  by	  
means	  of	  the	  recently	  proposed	  and	  validated	  H	  score	  for	  p16	  IHC133.	  	  The	  latter	  of	  
these	  two	  scoring	  techniques	  reflects	  the	  cross-­‐product	  (H	  score)	  of	  p16	  staining	  
intensity	  (scored	  from	  0	  to	  3)	  and	  the	  percentage	  of	  tumour	  cells	  staining	  (from	  0	  to	  
100%	  in	  5%	  increments),	  with	  an	  H	  score	  of	  >60	  defined	  as	  p16	  positive.	  	  
Statistical	  analysis	  was	  conducted	  in	  the	  same	  fashion	  as	  detailed	  previously	  (4.2)	  
	  
5.2 RESULTS	  
Tissue	  sample	  quality	  and	  consistency	  
From	  the	  full	  cohort	  of	  OSPCC	  (4.3),	  matched	  FFPE	  tissue	  and	  correlating	  fresh	  
tissue	  derived	  test	  results	  were	  available	  for	  79	  cases.	  
Interpretable	  results	  were	  available	  79	  cases,	  however	  one	  case	  had	  insufficient	  
staining	  for	  ubiquitin	  C	  (positive	  control)	  and	  was	  therefore	  excluded	  from	  further	  
analysis,	  leaving	  78	  of	  79	  (99%)	  cases	  for	  HPV	  analysis.	  	  Seventeen	  cases	  (22%)	  had	  
discordant	  scores	  following	  TMA	  interpretation,	  due	  either	  to	  inter-­‐observer	  
variation	  or	  inter-­‐core	  variation,	  and	  were	  subjected	  to	  further	  testing	  and	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independent	  scoring	  using	  whole	  FFPE	  sections.	  A	  resultant	  Kappa	  scope	  of	  0.948	  




The	  entire	  cohort	  had	  a	  median	  follow	  up	  of	  27	  months	  (95%	  CI	  27-­‐37).	  The	  
characteristics	  of	  the	  OPSCC	  cohort	  as	  a	  whole	  and	  subdivided	  by	  HPV	  status,	  
defined	  by	  High	  Risk	  HPV	  qRTPCR,	  are	  shown	  in	  Table	  31.	  
As	  would	  be	  expected	  from	  a	  subcohort	  of	  the	  original	  study	  cohort,	  these	  results	  
are	  generally	  comparable.	  	  
The	  age	  of	  patients	  at	  diagnosis	  conformed	  to	  a	  normal	  distribution	  as	  signified	  by	  a	  
one-­‐sample	  Kolmogorov-­‐Smirnov	  test	  (p=0.999).	  Individuals	  within	  the	  HPV	  positive	  
group	  were	  statistically	  significantly	  younger	  than	  those	  in	  the	  HPV	  negative	  group	  
(mean	  54.2	  vs.	  61.3	  years	  of	  age	  at	  diagnosis,	  p=0.003).	  Of	  the	  69	  cases	  for	  which	  
reliable	  risk	  factor	  data	  was	  available,	  those	  individuals	  who	  were	  either	  non-­‐
smokers	  or	  who	  had	  smoked	  less	  than	  20	  pack-­‐years	  were	  statistically	  more	  likely	  to	  
have	  HPV	  positive	  OPSCC	  (p=0.004).	  Similarly,	  there	  was	  a	  trend	  towards	  lower	  
alcohol	  exposure	  in	  the	  HPV	  positive	  group.	  	  There	  were	  no	  statistical	  differences	  
between	  the	  groups	  by	  sex,	  tumour	  subsite	  or	  nodal	  category.	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HPV	  Status	  by	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
HR	  HPV	  qRTPCR	  
Analysis	   Total	  
Statistical	  
Significance	  
	  	   	  	   Negative	   Positive	   p	  =	  
Patient/Tumour	  Data	   	  	   	  	   	  	   	  	  
No.	  of	  Patients	   45	  (58%)	   33	  (42%)	   78	  (100%)	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
Age	  at	  Diagnosis	  (years)	   	  	   	  	   	  	   	  	  
Mean	     61.3	   54.2	   58.3	   0.003	  
S.E.	  of	  Mean	     1.6	   1.7	   1.2	   	  	  
Sex	   	  	   	  	  
	   	  
	  	  
Female	   	  	   12	  (67%)	   6	  (33%)	   18	  (23%)	   NS	  
Male	   	  	   33	  (55%)	   27	  (45%)	   60	  (77%)	   	  	  
Tumour	  
Site	   	  	   	  	  
	   	  
	  	  
Tonsil	   	  	   21	  (49%)	   22	  (51%)	   43	  (55%)	   	  	  
Soft	  Palate	   	  	   9	  (69%)	   4	  (31%)	   13	  (17%)	   	  	  
Base	  of	  Tongue	   8	  (62%)	   5	  (38%)	   13	  (17%)	   	  	  
Oropharynx	  (not	  further	  
spec.)	   7	  (78%)	   2	  (22%)	   9	  (11%)	   	  	  
	  	   Total	   45	  (58%)	   33	  (42%)	   78	  (100%)	   NS	  
Nodal	  
Stage	   	  	   	  	  
	   	  
	  	  
N0	  	   	  	   13	  (59%)	   9	  (41%)	   22	  (31%)	   	  	  
N1	  without	  ECS	   6	  (67%)	   3	  (33%)	   9	  (13%)	   	  	  
N2/3	  or	  N1	  with	  ECS	   20	  (50%)	   20	  (50%)	   40	  (56%)	   	  	  
	  	   Total	   39	  (55%)	   32	  (45%)	   71	  (100%)	   NS	  
Smoking	   	  	   	  	  
	   	  
	  	  
Non-­‐
smoker	   	  	   6	  (32%)	   13	  (68%)	   19	  (28%)	   	  	  
<20	  pack-­‐year	  Hx	   9	  (43%)	   12	  (57%)	   21	  (31%)	   	  	  
≥20	  pack-­‐year	  Hx	   21	  (78%)	   6	  (22%)	   27	  (41%)	   	  	  
	  	   Total	   36	  (54%)	   31	  (46%)	   67	  (100%)	   0.004	  
Alcohol	  Consumption	   	  	  
	   	  
	  	  
Non-­‐
drinker	   	  	   5	  (50%)	   5	  (50%)	   10	  (14%)	   	  	  
<28	  Units/Week	   11	  (38%)	   18	  (62%)	   29	  (42%)	   	  	  
≥28	  Units/Week	   21	  (70%)	   9	  (30%)	   30	  (44%)	   	  	  
	  	   Total	   37	  (54%)	   32	  (46%)	   69	  (100%)	   0.05	  
	  




High	  Risk	  HPV	  Detection	  in	  Normal	  Tissues	  
Of	  the	  seventy-­‐nine	  FFPE	  cores,	  sampled	  from	  histologically	  normal	  mucosal	  tissue	  
directly	  adjacent	  to	  related	  tumour	  resection	  specimens,	  seventy	  cores	  were	  
available	  for	  analysis	  (70/79;	  89%).	  	  Four	  of	  these	  cores	  displayed	  insufficient	  
staining	  for	  ubiquitin	  C	  (positive	  control)	  and	  were	  therefore	  excluded	  from	  
analysis.	  Within	  the	  remaining	  normal	  tissue	  cores	  there	  was	  no	  evidence	  of	  
staining	  for	  HR	  HPV	  (0/66;	  0%).	  
	  
Oropharyngeal	  SCC	  Test	  Analysis	  
Photomicrographs	  of	  cases	  classified	  as	  HPV	  positive	  by	  High	  Risk	  HPV	  RNAscope	  
are	  shown	  in	  Figure	  18.	  The	  High	  Risk	  HPV	  RNAscope	  test	  had	  a	  sensitivity	  of	  97%	  
and	  a	  specificity	  of	  93%	  against	  the	  reference	  test,	  with	  positive	  and	  negative	  
predictive	  values	  of	  91%	  and	  98%	  respectively	  (Table	  31).	  	  
Sensitivity	  values	  for	  other	  HPV	  tests	  when	  used	  as	  single	  tests	  were	  comparable	  to	  
RNAscope;	  p16	  IHC	  97%,	  HR	  HPV	  ISH	  94%	  and	  to	  a	  lesser	  extent	  HPV-­‐16	  DNA	  qPCR	  
91%,	  however,	  lower	  levels	  of	  specificity	  for	  oncogenic	  HPV	  were	  apparent	  for	  two	  
of	  these	  tests;	  p16	  IHC	  82%,	  HPV-­‐16	  DNA	  qPCR	  87%.	  Interpretation	  of	  more	  than	  
one	  test	  per	  sample,	  in	  a	  diagnostic	  algorithm,	  appeared	  to	  improve	  specificity,	  but	  
at	  the	  expense	  of	  sensitivity,	  exemplified	  by	  combined	  p16	  IHC/HPV-­‐16	  DNA	  qPCR;	  
sensitivity	  91%	  and	  specificity	  93%.	  	  
A	  comparison	  of	  the	  two	  p16	  IHC	  scoring	  techniques	  revealed	  complete	  
concordance	  with	  no	  difference	  in	  p16	  status	  (positive	  or	  negative)	  either	  at	  the	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level	  of	  individual	  TMA	  cores	  or	  specific	  tumour	  cases.	  As	  a	  result	  all	  reporting	  of	  
p16	  IHC	  testing	  performance	  can	  be	  considered	  to	  refer	  to	  either	  testing	  technique.	  	  




Figure	  18:	  Photomicrographs	  of	  OPSCC	  cases	  stained	  using	  RNAscope	  
The	  cases	  demonstrate	  a	  range	  of	  positive	  staining	  patterns	  for	  high-­‐risk	  HPV.	  Panels	  (left	  to	  right)	  
represent	  the	  test	  result	  (HR	  HPV	  RNA	  ISH),	  negative	  control	  (dapB)	  and	  positive	  control	  (UBC).	  Scale	  
bars	  are	  equivalent	  to	  200	  µm	  for	  cases	  109	  and	  87,	  and	  50	  µm	  for	  cases	  97	  and	  95	  
Cases	  109	  and	  97	  showed	  strong	  and	  moderate	  staining	  respectively,	  and	  contained	  HPV-­‐16	  E6/E7	  
mRNA	  by	  qRT–PCR.	  Case	  87	  showed	  strong	  staining	  and	  contained	  HPV-­‐18	  E6	  mRNA	  by	  qRT–PCR.	  
Case	  95	  (identified	  as	  case	  101	  on	  Table	  27)	  showed	  weak	  staining	  and	  was	  negative	  for	  HPV-­‐16	  




The	  Kaplan-­‐Meier	  survival	  estimates	  illustrated	  in	  Figure	  19	  and	  detailed	  in	  Table	  32	  
&	  33	  show	  the	  prognostic	  capacity	  of	  all	  HPV	  tests.	  High	  Risk	  HPV	  RNAscope	  
displayed	  an	  encouraging	  capacity	  to	  discriminate	  survival,	  both	  in	  terms	  of	  overall	  
survival	  (p=0.004)	  and	  disease	  specific	  survival	  (p=0.017),	  and	  this	  was	  comparable	  
to	  the	  reference	  test	  (OS	  p=0.008,	  DSS	  p=0.025).	  
p=0.017
p=0.004	  
Figure	  19:	  Kaplan-­‐Meier	  Survival	  plots	  by	  HPV	  status	  as	  determined	  by	  HR	  HPV	  RNA	  ISH	  (RNAscope)	  





Table	  32:	  Kaplan-­‐Meier	  survival	  estimates	  of	  Disease	  Specific	  Survival	  with	  associated	  Hazard	  Ratios	  
Results	  segregated	  according	  to	  individual	  diagnostic	  tests	  or	  combination	  tests.	  
 
Table	  33:	  Kaplan-­‐Meier	  survival	  estimates	  of	  Overall	  Survival	  with	  associated	  Hazard	  Ratios	  





False	  positive	  and	  false	  negative	  reporting	  
High	  Risk	  HPV	  RNAscope	  conferred	  positive	  results	  for	  three	  cases	  (4%)	  where	  there	  
was	  an	  absence	  of	  detectable	  HPV	  mRNA	  by	  qRTPCR.	  Corresponding	  test	  results	  for	  
these	  cases	  indicated	  that	  they	  were	  also	  positive	  by	  p16	  IHC,	  HR	  HPV	  DNA	  ISH,	  
HPV-­‐16	  DNA	  qPCR,	  and	  consequently	  combinations	  of	  these	  tests.	  
High	  Risk	  HPV	  RNAscope	  classified	  as	  negative,	  one	  case	  (1%)	  which	  displayed	  
evidence	  of	  HPV-­‐16	  transcripts	  by	  qRTPCR.	  The	  case	  was	  also	  classified	  as	  negative	  




Table	  34:	  Diagnostic	  capabilities	  of	  individual	  tests	  by	  comparison	  to	  HR	  HPV	  qPCR	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5.3 DISCUSSION	  &	  IMPLICATIONS	  FOR	  CLINICAL	  PRACTICE	  
HPV	  analysis	  of	  OPSCC	  in	  clinical	  practice	  is	  swiftly	  becoming	  a	  fundamental	  
requirement.	  Definitive	  HPV	  testing	  aims	  to	  provide	  both	  adequate	  prognostic	  
information	  for	  patients	  and	  also	  facilitate	  entry	  into	  appropriately	  stratified	  clinical	  
trials,	  including	  those	  investigating	  the	  potential	  to	  de-­‐escalate	  the	  intensity	  of	  
curative	  therapies.	  Paradoxically,	  there	  remains	  no	  ‘international	  standard’	  for	  
defining	  HPV	  related	  OPSCC	  in	  clinical	  practice	  and	  an	  adequately	  validated	  
diagnostic	  standard	  for	  FFPE	  tissue	  has	  yet	  to	  be	  defined	  118.	  
To	  demonstrate	  the	  efficacy	  of	  any	  test	  it	  must	  be	  appraised	  against	  a	  “reference”	  
or	  “gold	  standard”	  test.	  As	  already	  detailed	  (2.4),	  in	  the	  context	  of	  HPV-­‐driven	  
malignancy,	  viral	  oncogenes	  expression	  is	  the	  prerequisite	  for	  carcinogenesis	  and	  its	  
detection	  is	  therefore	  the	  most	  appropriate	  analytical	  standard125.	  Whilst	  
acknowledging	  that	  HPV	  oncogene	  expression	  is	  only	  part	  of	  a	  complex	  process	  of	  
altered	  molecular	  pathways	  in	  viral-­‐driven	  cancer,	  it	  is	  against	  quantitative	  
detection	  of	  transcriptionally	  active	  virus	  that	  the	  novel	  HPV	  test,	  High	  Risk	  HPV	  
RNAscope,	  was	  measured.	  
High	  Risk	  HPV	  RNAscope	  has	  previously	  shown	  promising	  capability	  when	  compared	  
to	  other	  HPV	  diagnostic	  tests	  213,215	  yet	  validation	  against	  an	  analytical	  standard	  had	  
not	  been	  possible	  to	  date.	  	  
As	  has	  already	  been	  highlighted	  (2.3),	  previous	  evaluations	  of	  clinical	  outcomes	  in	  
OPSCC	  based	  on	  HPV	  status	  have	  clearly	  demonstrated	  the	  survival	  advantage	  for	  
individuals	  with	  HPV	  positive	  malignancy	  by	  comparison	  to	  their	  HPV	  negative	  
counterparts	  50,91,98,100,216,217.	  In	  keeping	  with	  other	  clinically	  applicable	  tests,	  High	  
	  	  
137	  
Risk	  HPV	  RNAscope	  has	  been	  shown	  to	  be	  capable	  of	  replicating	  this	  prognostic	  
discrimination	  and	  indeed	  demonstrated	  a	  similar	  capacity	  to	  predict	  outcomes	  to	  
the	  “gold	  standard”.	  	  
It	  is	  however	  the	  high	  sensitivity	  (97%)	  and	  specificity	  (93%)	  of	  High	  Risk	  HPV	  
RNAscope	  that	  offers	  considerable	  potential	  as	  a	  diagnostic	  test	  for	  HPV	  related	  
OPSCC.	  This	  carries	  particular	  relevance	  given	  the	  fact	  that	  this	  diagnostic	  
discrimination	  is	  achieved	  on	  FFPE	  tissue	  samples	  in	  a	  solo	  test	  format.	  	  The	  
incorporation	  of	  control	  tests	  (UBC	  and	  dapB)	  on	  parallel	  sections	  enhances	  the	  
quality	  control	  of	  test	  interpretation	  purposes.	  	  
The	  only	  other	  single	  test	  to	  have	  demonstrated	  comparable	  sensitivity	  in	  previous	  
comparison	  to	  viral	  oncogene	  expression	  is	  p16	  IHC	  (94-­‐100%)	  125,218.	  	  The	  level	  of	  
specificity	  (79-­‐82%)	  demonstrated	  by	  p16	  under	  the	  same	  conditions	  however,	  is	  
considerably	  lower,	  due	  mostly	  to	  alternative,	  and	  as	  yet	  unexplained,	  elevations	  of	  
p16	  expression	  in	  HPV	  negative	  malignancy	  204,215.	  	  Diagnostic	  algorithms	  or	  
combination	  tests	  (2.5)	  have	  been	  validated	  and	  as	  such	  are	  advocated	  to	  maximise	  
diagnostic	  capability.	  In	  the	  context	  of	  these	  results	  however,	  it	  would	  appear	  that	  
RNAscope	  is	  capable	  of	  outperforming	  combination	  tests	  by	  virtue	  of	  comparable	  
specificity	  whilst	  displaying	  superior	  sensitivity.	  	  
	  
Investigation	  of	  the	  potential	  differences	  between	  p16	  IHC	  scoring	  techniques	  was	  
undertaken	  by	  application	  of	  both	  the	  currently	  applied	  standard	  for	  p16	  IHC	  
analysis	  131,	  strong	  and	  diffuse	  nuclear	  and	  cytoplasmic	  staining	  in	  >70%	  of	  the	  
tumour,	  and	  the	  recently	  described	  H	  score	  analysis	  133,	  derived	  from	  the	  cross	  
product	  of	  staining	  intensity	  and	  proportion	  of	  tumour.	  Interestingly,	  both	  of	  the	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p16	  IHC	  scoring	  techniques	  gave	  identical	  results	  and	  therefore	  had	  no	  apparent	  
bearing	  on	  either	  the	  sensitivity/specificity	  of	  p16	  IHC	  or	  its	  prognostic	  capacity.	  	  It	  
is	  appreciated	  that	  the	  modest	  cohort	  size	  may	  impact	  up	  on	  the	  ability	  to	  discern	  
significant	  differences	  between	  scoring	  techniques	  however	  it	  would	  seem	  that	  
neither	  test	  is	  capable	  of	  improving	  upon	  reduced	  levels	  of	  specificity	  previously	  
reported125,	  which	  remains	  the	  limiting	  factor	  of	  p16	  IHC†	  219.	  
	  
High	  Risk	  HPV	  RNAscope	  classified	  three	  cases	  as	  HPV	  positive	  in	  the	  absence	  of	  
detectable	  HPV	  mRNA.	  It	  is	  conceivable	  that	  the	  samples	  might	  harbour	  other	  High	  
Risk	  HPV	  genotypes	  not	  included	  in	  the	  reference	  test,	  which	  was	  restricted	  to	  the	  
analysis	  of	  the	  three	  most	  common	  HPV	  genotypes	  isolated	  from	  OPSCC	  (HPV-­‐16,	  -­‐
18,	  -­‐33)	  or	  indeed	  potential	  heterogeneity	  for	  HPV	  within	  the	  tumour	  as	  suggested	  
previously	  by	  Rietbergen	  et	  al90.	  	  It	  is	  interesting	  to	  note	  that	  one	  of	  the	  three	  cases	  
had	  high	  levels	  of	  HPV-­‐16	  E2	  expression	  detected	  by	  qRTPCR	  (6.2).	  	  E2	  is	  a	  known	  
transcriptional	  repressor	  of	  E6	  and	  E7	  genes,	  and	  its	  influence	  may	  have	  been	  
sufficient	  to	  reduce	  E6	  and	  E7	  transcript	  levels	  below	  the	  detection	  threshold	  of	  
qRTPCR	  whilst	  remaining	  within	  the	  detection	  range	  of	  High	  Risk	  HPV	  RNAscope.	  
Alternatively,	  the	  mismatch	  between	  the	  qRTPCR	  result	  and	  the	  tests	  on	  FFPE	  raises	  
the	  possibility	  of	  methodological	  flaws,	  despite	  the	  use	  of	  stringent	  experimental	  
design	  and	  detection	  protocols	  to	  quality	  assure	  test	  results.	  A	  further	  possibility	  to	  
explain	  discordant	  results	  between	  the	  novel	  test	  and	  the	  gold	  standard	  would	  be	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
†	  In	  contrast	  to	  several	  previous	  publications,	  Schlect	  et	  al	  were	  able	  produce	  specificity	  of	  
93%	  when	  comparing	  p16	  IHC	  to	  fresh	  tissue	  derived	  mRNA	  from	  OPSCC.	  However,	  this	  
research	  was	  undertaken	  utilising	  a	  p16	  monoclonal	  antibody	  with	  markedly	  different	  
performance	  profile,	  such	  that	  sensitivity	  was	  only	  56%.	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sample	  allocation	  errors	  such	  that	  FFPE	  cores	  and	  fresh	  frozen	  sourced	  sample	  
results	  were	  for	  different	  samples.	  Attempts	  were	  made	  in	  stages	  of	  sample	  
preparation	  and	  assay	  setup	  to	  avoid	  such	  an	  eventuality	  however	  it	  remains	  a	  
possibility.	  Although	  not	  undertaken,	  and	  therefore	  potentially	  limiting	  the	  
interpretation	  of	  these	  results,	  microsatellite	  marker	  analysis	  could	  have	  proven	  
useful	  to	  discount	  such	  an	  eventuality.	  	  	  
The	  solitary	  HPV	  positive	  case	  reported	  as	  negative	  by	  High	  Risk	  HPV	  RNAscope,	  
demonstrated	  an	  E6	  and	  E7	  expression	  level	  that	  was	  low	  by	  comparison	  with	  other	  
samples,	  however	  it	  was	  not	  the	  lowest	  and	  remained	  well	  within	  the	  threshold	  for	  
detection	  set	  prior	  to	  analysis	  of	  the	  samples.	  Interestingly,	  this	  case	  was	  similarly	  
‘misclassified’	  by	  both	  p16	  IHC	  and	  HR	  HPV	  DNA	  ISH.	  This	  therefore	  raises	  a	  
possibility	  that	  fixation	  and	  processing	  parameters	  may	  have	  resulted	  in	  suboptimal	  
preservation	  of	  the	  target	  molecules,	  however,	  given	  that	  the	  FFPE	  samples	  were	  all	  
derived	  from	  the	  same	  diagnostic	  service,	  with	  storage	  in	  exactly	  the	  same	  
conditions,	  this	  seems	  unlikely.	  
	  
These	  results	  demonstrate	  that	  High	  Risk	  HPV	  RNAscope	  is	  capable	  of	  maintaining	  a	  
high	  degree	  of	  accuracy	  against	  the	  most	  appropriate	  analytical	  gold	  standard	  and	  
was	  the	  best	  discriminator	  of	  disease	  specific	  and	  overall	  survival.	  	  By	  comparison	  to	  
the	  results	  presented	  in	  Chapter	  4,	  RNAscope	  is	  capable	  of	  performing	  at	  a	  standard	  
comparable	  to	  the	  best	  combination	  test	  p16	  IHC/DNA	  qPCR	  whilst	  requiring	  only	  a	  
single	  test	  which	  is	  confined	  to	  FFPE	  tissue	  resources	  alone.	  
Before	  adoption	  of	  HR	  HPV	  RNAscope	  into	  clinical	  practice	  could	  be	  formally	  
advocated,	  this	  test	  requires	  mandatory	  approval	  as	  an	  in	  vitro	  diagnostic	  device	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(IVD),	  however,	  the	  impending	  application	  and	  availability	  of	  High	  Risk	  HPV	  
RNAscope	  to	  a	  widely	  available	  automated	  staining	  platform	  (Ventana	  Medical	  
Systems	  Inc,	  USA)	  will	  facilitate	  standardisation	  of	  test	  conditions	  and	  
reproducibility	  between	  laboratories.	  	  These	  features	  raise	  the	  possibility	  that	  High	  
Risk	  HPV	  RNAscope	  could	  be	  developed	  to	  provide	  the	  “clinical	  standard”	  for	  
assigning	  a	  diagnosis	  of	  HPV-­‐related	  OPSCC.	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6 EPIGENETIC	  REGULATION	  THROUGH	  DNA	  METHYLATION	  
IN	  HPV	  MEDIATED	  OROPHARYNGEAL	  SQUAMOUS	  CELL	  
CARCINOMA	  (OPSCC)	  
6.1 INTRODUCTION	  
Analysis	  of	  Epigenetic	  Regulation	  in	  HPV	  positive	  OPSCC	  Aims	  
Whilst	  virally	  mediated	  oncogenesis	  is	  relatively	  well	  understood,	  the	  influence	  that	  
DNA	  methylation,	  and	  the	  key	  regulators	  of	  that	  methylation,	  have	  in	  this	  process	  
remains	  unclear.	  	  
Viral	  oncogene	  expression	  has	  been	  considered	  to	  be	  under	  the	  repressive	  control	  
of	  the	  early	  viral	  gene	  E2220	  and	  it	  has	  been	  believed	  therefore	  that	  loss	  of	  E2	  
expression,	  through	  mechanisms	  such	  as	  viral	  integration171,	  is	  key	  to	  halting	  this	  
repression	  with	  consequent	  potential	  for	  oncogenesis.	  	  
It	  was	  hypothesised	  that,	  within	  the	  HPV	  genome,	  methylation	  of	  either	  the	  E2	  gene	  
or	  its	  binding	  sites	  (E2BS)	  may	  be	  an	  alternative	  means	  of	  disruption	  of	  E2	  gene	  
expression	  or	  its	  downstream	  effects	  in	  the	  long	  control	  region	  (LCR),	  that	  would	  
otherwise	  be	  seen	  following	  the	  process	  of	  integration.	  If	  this	  were	  true,	  E2	  
methylation	  would	  directly	  influence	  E2	  expression	  levels	  and,	  as	  a	  consequence,	  
result	  in	  an	  elevation	  of	  levels	  of	  the	  viral	  oncogenes,	  E6	  and	  E7,	  normally	  under	  E2	  
repressive	  control.	  A	  similar	  resultant	  increase	  in	  E6	  and	  E7	  expression	  would	  be	  
expected	  if	  methylation	  in	  the	  LCR,	  and	  more	  particularly	  the	  E2BSs,	  were	  to	  
increase	  through	  restriction	  of	  E2	  binding.	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The	  impact	  of	  DNA	  methylation	  within	  the	  host	  genome	  was	  also	  explored	  in	  OPSCC	  
samples.	  It	  was	  postulated	  that	  the	  differences	  in	  global	  DNA	  hypomethylation,	  
previously	  reported	  between	  HPV	  positive	  and	  negative	  cells	  lines	  would	  also	  be	  
evident	  in	  clinical	  tumour	  specimens.	  Similarly	  it	  was	  proposed	  that	  HPV	  positive	  
malignancy	  holds	  a	  distinct	  DNA	  methylation	  profile	  within	  gene	  promoter	  
sequences	  and	  that	  this	  may	  have	  biological	  relevance	  in	  terms	  of	  oncogenesis.	  
Finally	  it	  was	  hypothesised	  that	  distinct	  variations	  in	  DNA	  methylation	  within	  virally	  
mediated	  tumours	  are	  directly	  influenced	  by	  fundamental	  differences	  in	  the	  key	  
drivers	  or	  regulators	  of	  methylation,	  DNA	  methyltransferases	  and	  UHRF1,	  when	  
comparing	  HPV	  positive	  and	  negative	  OPSCC.	  
	  
	   	  
	  	  
143	  
6.2 HPV	  E2	  &	  LONG	  CONTROL	  REGION	  METHYLATION	  STATUS	  AND	  
IMPLICATIONS	  FOR	  VIRAL	  ONCOGENE	  EXPRESSION	  
Analysis	  of	  Epigenetic	  Regulation	  in	  HPV	  positive	  OPSCC	  Methods	  
Pyrosequencing	  methylation	  assays	  (PMAs)	  were	  designed	  for	  the	  viral	  E2	  gene	  and	  
two	  CpGs	  within	  the	  long	  control	  region	  (LCR)	  of	  the	  HPV	  genome	  to	  determine	  
methylation	  status.	  Within	  the	  target	  sequence	  of	  one	  of	  the	  LCR	  assays	  (LCR	  
Region	  2),	  lie	  the	  E2	  binding	  sites	  E2BS3	  and	  E2BS4.	  These	  sites	  have	  previously	  
been	  shown	  to	  directly	  influence	  viral	  oncogene	  expression	  (E6	  &	  E7)	  through	  E2	  
protein	  binding221.	  
Pyrosequencing	  methylation	  assay	  (PMA)	  analysis	  was	  undertaken	  on	  a	  cohort	  of	  
HPV	  positive	  OPSCC	  (n	  =	  43)	  and	  the	  two	  HPV16	  positive	  cell	  lines,	  CaSki	  and	  SiHa.	  
qPCR	  was	  utilised	  to	  quantify	  viral	  oncogene	  RNA	  expression	  levels	  for	  the	  HPV-­‐16	  
early	  genes	  E2,	  E6	  and	  E7.	  RNA	  levels	  were	  expressed	  as	  relative	  quantification	  
values	  (RQ=2(-­‐ΔΔCt))	  with	  calibration	  against	  the	  HPV16	  positive	  cervical	  cancer	  cell	  
line	  CaSki.	  Mean	  RQ	  values	  for	  each	  of	  the	  three	  analysed	  genes	  were	  collated	  with	  
mean	  CpG	  percentage	  methylation	  results.	  PMA	  methylation	  levels	  are	  calculated	  
as	  an	  average	  of	  the	  methylation	  proportions	  at	  each	  individual	  CpG	  within	  the	  
target	  sequence.	  The	  final	  methylation	  value	  reflects	  the	  mean	  of	  duplicated	  sample	  
runs	  consecutively	  on	  the	  pyrosequencing	  platform.	  The	  threshold	  for	  scoring	  
hypermethylated	  samples	  was	  conservatively	  set	  to	  10%,	  which	  is	  higher	  than	  our	  




Non-­‐parametric	  statistical	  tests	  were	  applied	  to	  determine	  correlation	  between	  
detected	  methylation	  state	  and	  viral	  gene	  expression.	  
	  
Epigenetic	  Regulation	  in	  HPV	  positive	  OPSCC	  Results	  
Analysis	  of	  the	  control	  cell	  lines	  is	  depicted	  below.	  In	  keeping	  with	  a	  previously	  
described	  disruption	  of	  the	  viral	  E2	  gene,	  SiHa	  showed	  no	  evidence	  of	  E2	  expression	  
and	  the	  PMA	  analysis	  of	  E2	  methylation	  failed	  to	  amplify	  target	  sequence.	  CaSki	  
expression	  was	  the	  reference	  against	  which	  all	  other	  samples	  were	  compared,	  and	  
is	  therefore	  further	  relative	  expression	  analysis	  is	  precluded.	  In	  terms	  of	  viral	  
methylation,	  CaSki	  showed	  high	  levels	  of	  methylation	  in	  both	  the	  E2	  gene	  and	  also	  
LCR	  regions.	  The	  proportion	  of	  tumour	  samples	  reaching	  the	  threshold	  for	  positive	  
methylation	  is	  detailed	  in	  Table	  36	  for	  comparison	  with	  control	  cell	  lines	  
	  
Sample	  
Average	  Methylation	  Analysis	  (PMA,	  %)	   Viral	  Gene	  Expression	  (RNAqPCR)	  







SiHa	   NR	   3	   12	   0	   0.905	   0.376	  
CaSki	   84	   67	   94	   1	   1	   1	  
	  
Table	  35:	  Control	  Sample	  Compiled	  Viral	  Expression	  and	  Methylation	  Analysis	  Results	  
All	  expression	  was	  relative	  with	  respect	  to	  CaSki	  (RQ).	  Viral	  methylation	  is	  recorded	  as	  a	  percentage.	  







PMA	  Target	   Proportion	  of	  Samples	  Methylation	  Positive	  	  
E2	   33/37	  (89%)	  
LCR	  Region	  1	   4/40	  (10%)	  
LCR	  Region	  2	   11/41	  (27%)	  
	  
Table	  36:	  Proportion	  of	  HPV	  samples	  displaying	  positive	  methylation	  at	  viral	  targets.	  
Positive	  methylation	  threshold	  set	  at	  ≥10%.	  Proportions	  refer	  to	  samples	  for	  which	  duplicate	  PMA	  
results	  were	  available	  for	  analysis.	  
	  
Within	  tumour-­‐derived	  samples,	  there	  was	  a	  generalised	  lack	  of	  direct	  relationship	  
between	  viral	  genome	  methylation	  and	  expression	  of	  key	  viral	  genes.	  Table	  37	  
summarises	  the	  apparent	  relationships.	  E2	  methylation	  and	  E2	  expression	  
demonstrated	  the	  relationship	  with	  greatest	  strength,	  however	  the	  correlation	  
(negative)	  was	  only	  modest	  (correlation	  coefficient	  -­‐0.362).	  There	  was	  no	  evidence	  
of	  a	  relationship	  between	  methylation	  of	  either	  of	  the	  portions	  of	  the	  LCR	  (including	  
E2BS3	  or	  E2BS4)	  and	  the	  expression	  of	  E6	  and	  E7	  genes.	  	  
	  
Figure	  20	  graphically	  represents	  the	  relative	  correlations	  between	  E2	  gene	  










Figure	  20:	  Correlation	  between	  methylation	  of	  viral	  regions	  and	  related	  viral	  gene	  expression	  
Top	  Scatterplot:	  Correlation	  between	  viral	  E2	  gene	  promoter	  methylation	  and	  relative	  E2	  gene	  
expression.	  A	  negative	  weak	  correlation	  was	  observed	  (R2=0.08)	  
Bottom	  Scatterplot:	  Correlation	  between	  viral	  long	  control	  region	  2	  (LCR)	  and	  HPV16	  E6	  gene	  
expression.	  Long	  control	  region	  2	  includes	  the	  E2	  binding	  sites	  E2BS3	  and	  E2BS4.	  No	  evidence	  of	  
correlation	  was	  apparent	  (R2=0.01).	  
	  
	  
	   	  	  	  Viral	  Gene	  Expression	  (RQ)	  	  	  	  







	   	   	   	  
Correlation	  
Coefficient	   -­‐0.362	   -­‐0.243	   -­‐0.147	  
Sig.	  (2-­‐tailed)	   0.03	   0.153	   0.393	  




	   	   	   	   	  
Correlation	  
Coefficient	   0.145	   0.059	   0.061	   	  
Sig.	  (2-­‐tailed)	   0.385	   0.725	   0.714	   	  




	   	   	   	   	  
Correlation	  
Coefficient	   -­‐0.046	   0.071	   -­‐0.055	   	  
Sig.	  (2-­‐tailed)	   0.780	   0.668	   0.738	   	  
N	   39	   39	   39	   	  
	  
Table	  37:	  Correlation	  between	  Viral	  methylation	  and	  Viral	  Gene	  Expression	  
	  
Analysis	  also	  sought	  to	  determine	  the	  relationship	  between	  E2	  and	  E6/E7.	  Whilst	  
levels	  of	  E6	  and	  E7	  expression	  showed	  predictable	  strong	  positive	  correlation	  (Table	  
38;	  r=0.956,	  p<0.0001),	  a	  positive	  correlation	  was	  also	  seen	  between	  E2	  expression	  
and	  E6/E7	  expression,	  contrary	  to	  expectation	  for	  a	  known	  transcriptional	  repressor	  





Figure	  21:	  Scatter	  plot	  of	  correlation	  between	  HPV16	  E2	  and	  E6	  gene	  expression	  (RQ)	  
Positive	  correlation	  is	  reflected	  in	  R2=0.533	  	  
Target	  Gene	   	  	  	  Viral	  Gene	  Expression	  (RQ)	  	  	  	  








	   	   	   	  
Correlation	  
Coefficient	   	   0.864	   0.871	  
Sig.	  (2-­‐tailed)	   	   <0.0001	   <0.0001	  
N	   	   103	   103	  
HPV16	  
E6	  
	   	   	   	   	  
Correlation	  
Coefficient	   0.864	   	   0.956	   	  
Sig.	  (2-­‐tailed)	   <0.0001	   	   <0.0001	   	  
N	   103	   	   103	   	  
HPV16	  
E7	  
	   	   	   	   	  
Correlation	  
Coefficient	   0.871	   0.956	   	   	  
Sig.	  (2-­‐tailed)	   <0.0001	   <0.0001	   	   	  
N	   103	   103	   	   	  
	  




6.3 COMPARATIVE	  HOST	  GENOME-­‐WIDE	  METHYLATION	  STATE	  IN	  
HPV	  POSITIVE	  AND	  HPV	  NEGATIVE	  OPSCC	  
Genome-­‐wide	  Methylation	  Analysis	  Methods	  
To	  quantify	  the	  extent	  of	  host	  genome-­‐wide	  methylation	  in	  OPSCC	  clinical	  samples	  
and,	  where	  available,	  their	  matched	  normal	  tissue	  samples,	  the	  LINE-­‐1.2	  retro-­‐
transposable	  element	  was	  used	  as	  a	  representative	  sequence	  region	  for	  analysis.	  
Because	  LINE-­‐1	  retrotransponson	  constitutes	  a	  substantial	  proportion	  of	  the	  human	  
genome	  (in	  excess	  of	  17%)	  its	  methylation	  status	  has	  been	  suggested	  to	  be	  a	  robust	  
and	  representative	  reflector	  of	  overall	  global	  methylation	  state.224	  LINE-­‐1	  
methylation	  status	  analysis	  was	  undertaken	  using	  a	  previously	  published	  assay	  
CpG190	  as	  detailed	  in	  (3.13),	  on	  a	  cohort	  of	  65	  OPSCC	  including	  34	  HPV	  positive	  cases	  
and	  31	  HPV	  negative	  cases.	  In	  addition,	  matched	  normal	  samples	  for	  25	  OPSCC	  
were	  analysed.	  	  A	  reference	  methylation	  score	  was	  determined	  by	  analysis	  of	  the	  
variability	  of	  LINE-­‐1	  methylation	  in	  normal	  samples	  analysed	  simultaneously	  	  
	  
Genome-­‐wide	  Methylation	  Analysis	  Results	  
LINE-­‐1	  promoter	  was	  highly	  methylated,	  with	  a	  minimal	  degree	  of	  variability	  in	  
normal	  oropharyngeal	  tissues	  (average	  normal	  sample	  LINE-­‐1	  methylation;	  69.6%	  ±	  
2.8%,	  2sd),	  however	  tumour	  derived	  samples	  displayed	  considerably	  greater	  




LINE-­‐1	  promoter	  (average	  LINE-­‐1	  methylation;	  62.0%	  ±	  16%).	  Using	  a	  paired	  T-­‐test,	  
LINE-­‐1	  methylation	  was	  demonstrated	  to	  be	  statistically	  significantly	  higher	  in	  
normal	  tissues	  when	  compared	  to	  tumours	  (p=0.008)	  	  (Figure	  22).	  	  
When	  tumour	  samples	  were	  segregated	  on	  the	  basis	  of	  HPV16	  status	  (as	  
determined	  by	  RNAqPCR),	  HPV	  positive	  OPSCC	  had	  LINE-­‐1	  methylation	  profile,	  
similar	  to	  mean	  normal	  tissue	  levels	  (average	  LINE-­‐1	  methylation;	  64.2%	  ±	  10.8%)	  
whilst	  HPV	  negative	  OPSCC	  displayed	  significant	  global	  hypomethylation	  (average	  
LINE-­‐1	  methylation;	  55.3%	  ±	  12.0%,	  paired	  t-­‐test	  p<0.001)	  (Figure	  23).	  
	  
Figure	  22:	  Boxplot	  representation	  of	  Average	  LINE-­‐1	  Methylation	  values	  in	  
OPSCC	  and	  Adjacent	  Normal	  Tissues.	  	  
Tumours	  demonstrate	  significantly	  increased	  degree	  of	  hypomethylation.	  Average	  values	  are	  derived	  








Figure	  23:	  Boxplot	  representations	  of	  Average	  LINE-­‐1	  Methylation	  values	  in	  
OPSCC	  stratified	  by	  HPV	  status.	  
HPV	  positive	  tumours	  demonstrate	  significantly	  increased	  global	  hypomethylation	  (p<0.0001).	  
Average	  values	  are	  derived	  from	  duplicate	  sample	  runs	  of	  LINE-­‐1	  PMA.	  	  
	  
Exposure	  to	  tobacco	  smoking	  has	  previously	  been	  shown	  to	  strongly	  influence	  
levels	  of	  global	  hypomethylation	  in	  head	  and	  neck	  cancers225,	  therefore	  a	  further	  
analysis	  of	  OPSCC	  tumour	  samples	  was	  undertaken	  to	  exclude	  smoking	  or	  any	  other	  
demographic/clinicopathologcial	  feature	  as	  confounding	  factors.	  No	  significant	  
association,	  however,	  was	  found	  between	  either	  smoking	  history	  or	  any	  other	  




6.4 DETECTION	  OF	  DIFFERENTIAL	  HOST	  GENE	  PROMOTER	  
METHYLATION	  IN	  HPV	  POSTIVE	  &	  HPV	  NEGATIVE	  OPSCC	  	  
Detection	  of	  Promoter	  Methylation	  State	  in	  OPSCC:	  Methods	  
A	  cohort	  of	  24	  OPSCC	  cases,	  not	  previously	  examined,	  was	  analysed	  using	  the	  
Infinium	  HumanMethylation450	  Beadarray	  previously	  detailed	  in	  Chapter	  3	  (3.14).	  
An	  initial	  shortlist	  of	  potential	  candidate	  genes,	  differentially	  methylated	  in	  OPSCC	  
on	  the	  basis	  of	  HPV	  status,	  was	  established	  before	  pyrosequencing	  methylation	  
assay	  design	  and	  technical	  validation.	  Candidate	  genes	  were	  selected	  on	  the	  basis	  
of	  statistical	  and	  pragmatic	  means	  as	  detailed	  previously	  (3.14).	  
	  
Host	  Tumour	  Suppressor	  Gene	  promoter	  sequence	  hypermethylation	  in	  
HPV	  Positive	  &	  HPV	  Negative	  OPSCC:	  Results	  
Differential	  promoter	  hypo-­‐	  and	  hypermethylation	  was	  apparent	  in	  the	  methylation	  
array	  raw	  results	  following	  initial	  statistical	  analysis.	  Following	  ranking	  of	  promoter	  
methylation	  variable	  positions	  stratified	  by	  HPV	  status,	  31	  genes	  with	  apparent	  
hypermethylation	  and	  13	  genes	  differentially	  hypomethylated	  in	  HPV	  positive	  
samples	  were	  highlighted.	  A	  subsequent	  screen	  to	  exclude	  candidate	  genes	  with	  
less	  than	  4	  probes	  per	  gene	  promoter	  confirmed	  a	  shortlist	  of	  14	  genes,	  one	  of	  
which	  was	  hypomethylated	  and	  the	  remainder	  hypermethylated	  in	  HPV	  positive	  
disease.	  
From	  this	  initial	  shortlist,	  feasible	  pyrosequencing	  methylation	  assays	  (PMA)	  design	  
was	  possible	  for	  eight	  genes.	  An	  explanation	  of	  the	  current	  evidence	  for	  potential	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roles	  of	  all	  genes	  meeting	  the	  inclusion	  criteria,	  including	  the	  eight	  genes	  suitable	  
for	  PMA	  validation,	  is	  presented	  in	  Table	  39.	  
Three	  genes	  included	  (C12	  orf42,	  SYN2	  and	  FLJ26850)	  have	  not	  previously	  been	  
reported	  to	  have	  a	  role	  or	  potential	  role	  in	  either	  malignancy	  or	  virally	  mediated	  
disease.	  	  
	  
Target	  Gene	   Evidence	  for	  role	  in	  viral	  infection	  or	  oncogenesis	   Ref	  	  
	   PROMOTER	  HYPOMETHYLATION	  IN	  HPV	  POSITIVE	  OPSCC	   	  
DERL-­‐3	  
Required	  for	  degredation	  of	  misfolded	  proteins,	  
upregulated	  by	  unfolded	  protein	  response.	  Prolonged	  
activation	  of	  UPR	  implicated	  in	  sensitivity	  to	  platinum	  
chemotherapy	  
Ma	  et	  al.226	  
	   PROMOTER	  HYPERMETHYLATION	  IN	  HPV	  POSITIVE	  OPSCC	   	  
CTNND2	  
Delta-­‐Catenin	  (CTNND2)	  is	  a	  cadherin-­‐associated	  protein	  
involved	  in	  cell	  adhesion.	  Overexpressed	  in	  cancer	  and	  
associated	  with	  progression	  in	  malignancy	  
Lu	  et	  al.227	  
GALR1	   Epigenetic	  inactivation	  evidence	  in	  HNSCC	  suggesting	  a	  
role	  as	  a	  TSG	  
Misawa	  et	  al228	  
	  
Putative	  regulator	  of	  resistance	  to	  chemotherapy	  in	  
Colorectal	  cancer.	  Silencing	  induced	  apoptosis	  and	  
synergistically	  enhanced	  effects	  of	  5-­‐FU	  or	  oxaliplatin	  
Stevenson	  et	  al229	  
C12	  orf42	   -­‐	   -­‐	  
HOXA7	   Frequently	  methylation	  target	  in	  early	  stage	  lung	  cancer.	  
Putative	  diagnostic	  biomarker	  in	  lung	  cancer.	  	  
Rauch	  et	  al230	  
	   Associated	  with	  a	  malignant	  phenotype	  in	  meningioma.	  
Putative	  diagnostic	  biomarker	  for	  malignant	  behavior	  
Di	  Vinci	  et	  al231	  
FLJ26850	   -­‐	   -­‐	  
SYN2	   -­‐	   -­‐	  
KCNA1	   Identified	  as	  key	  regulator	  of	  oncogene-­‐induced	  
senescence	  (OIS).	  Down	  regulation	  induces	  OIS	  escape.	  
Lallet-­‐Daher	  et	  al232	  
LMO3	  
Transcription	  factor	  that	  interacts	  with	  p53	  to	  regulate	  
function.	  Hypermethylation	  and	  reduced	  expression	  in	  lung	  
cancer	  
Kwon	  2012	  et	  al.233	  
MYOCD	   Recognised	  promoter	  of	  smooth	  muscle	  cellular	  
differentiation,	  overexpressed	  in	  sarcomas.	  




Organic	  cation/anion	  transporters	  known	  to	  affect	  
platinum	  uptake	  and	  clearance.	  Proposed	  association	  in	  
HNSCC	  
Ziliak	  et	  al235	  
STK32B	   Gene	  product	  necessary	  for	  KRAS-­‐dependent	  cell	  lines.	  
Proposed	  target	  for	  small	  molecule	  inhibitors.	  
Babij	  et	  al.236	  
RPS6KA2	   Putative	  tumour	  suppressor	  gene	  in	  Ovarian	  Malignancy	   Bignone	  et	  al.
237	  
CCNA1	   Component	  of	  PI3	  kinase	  pathway.	  Improved	  disease-­‐free	  
survival	  in	  HNSCC	  
Tan	  et	  al238	  
	  
Evidence	  of	  hypermethylation	  in	  HNSCC	  using	  other	  
methylation	  array	  platforms	  –	  Illumina	  GoldenGate	  &	  
illumina	  infinium	  HumanMethylation27	  beadarray	  
	  
Jithesh	  et	  al239	  
Sator163	  
	  
Table	  39:	  Evidence	  for	  role	  of	  Target	  Genes	  in	  Oncogenesis	  (HPV	  related	  or	  otherwise)	  
Highlighted	  genes	  (red)	  were	  suitable	  for	  custom	  PMA	  design	  and	  subsequent	  validation	  	  
	  	  
Analysis	  of	  HPV	  positive	  methylation	  controls	  provided	  internal	  validation	  of	  the	  
pyrosequencing	  assays	  employed.	  A	  representative	  plot,	  with	  line	  of	  best	  fit	  and	  
correlation	  coefficient	  (C12orf42),	  is	  demonstrated	  in	  Figure	  24	  and	  the	  complete	  
validation	  gene	  panel	  correlation	  coefficients	  are	  detailed	  in	  Table	  40.	  
The	  correlation	  coefficients	  were	  such	  that	  it	  was	  concluded	  that	  detection	  of	  





Figure	  24:	  Representation	  Internal	  Validation	  Plot	  for	  C12orf42	  Pyrosequencing	  Methylation	  Assay.	  
Detection	  of	  artificially	  methylated	  DNA	  control	  samples	  	  
	  
X	  axis:	  Artificially	  Methylated	  DNA	  Standards	  (%);	  y	  axis:	  PMA	  average	  methylation	  detection	  (%).	  
Line	  of	  best	  fit	  and	  correlation	  coefficient	  (R2).	  





	   	   C12orf42	   0.9967	  
	   	   CCNA1	   0.97106	  
	   	   FLJ26850	   0.97228	  
	   	   GARL1	   0.98187	  
	   	   HOXA7	   0.99855	  
	   	   KCNA1	   0.94874	  
	   	   SLCO4Cl	   0.99051	  
	   	   SYN2	   0.98823	  
	  
Table	  40:	  PMA	  Internal	  validation	  analysis	  -­‐	  Correlation	  Coefficients	  for	  Individual	  PMAs	  using	  




Raw	  data	  compiled	  from	  average	  gene	  probe	  methylation	  from	  the	  Infinium	  array	  is	  
tabulated	  adjacent	  to	  technical	  validation	  results	  from	  individual	  gene	  PMA	  analysis	  
(Figure	  25).	  Results	  are	  conditionally	  formatted	  to	  highlight	  the	  differential	  
methylation	  between	  HPV	  negative	  tumours	  (above	  table	  division)	  and	  HPV	  positive	  
tumours	  (below	  table	  division).	  The	  table	  demonstrates	  the	  hypermethylation	  of	  
target	  gene	  promoters	  in	  HPV	  positive	  tumour	  samples	  by	  comparison	  to	  the	  HPV	  
negative	  samples.	  
Additionally,	  comparison	  of	  methylation	  values	  for	  each	  test	  was	  performed	  using	  
Spearman’s	  correlation	  test	  for	  non-­‐parametric	  values.	  A	  positive	  correlation	  was	  
seen	  for	  each	  of	  the	  gene	  assays	  as	  listed	  in	  Table	  41,	  albeit	  the	  strength	  of	  
correlation	  was	  only	  convincing	  for	  C12	  orf42.	  Remaining	  correlations	  were	  weak	  to	  
moderate	  (seven	  gene	  targets).	  
	  Graphic	  representations	  of	  correlation	  scatter	  plots	  for	  two	  of	  the	  best	  correlating	  









Figure	  25:	  Comparative	  Methylation	  Analysis:	  Average	  Methylation	  in	  promoter	  sequence	  of	  eight	  
differentially	  methylated	  genes.	  
Technical	  Validation	  Raw	  Data	  comparing	  Infinium	  HumanMethylation450	  Beadchip	  Array	  data	  and	  
Pyrosequencing	  Methylation	  Assay	  results	  for	  8	  gene	  promoters	  determined	  to	  be	  differentially	  
methylated	  on	  the	  basis	  of	  HPV	  status.	  Individual	  values	  reflect	  the	  average	  methylation	  (either	  
between	  probes	  for	  Array	  data	  or	  between	  duplicate	  runs	  for	  PMA.	  Samples	  1,	  2,	  7,	  13,	  21	  &	  22	  are	  
HPV	  positive	  whilst	  the	  remaining	  cases	  are	  HPV	  negative.	  Conditional	  formatting	  has	  been	  applied	  





	  	  	  	   Correlation	  between	  Infinium	  (450K)	  Array	  and	  PMA	  Methylation	  Results	   	  
	   C12orf42	   CCNA1	   FLJ26850	   GARL1	   HOXA7	   KCNA1	   SLCO4Cl	   SYN2	   	  
Correlation	  
Coefficient	   0.649	   0.353	   0.442	   0.125	   0.563	   0.445	   0.249	   0.484	  
	  
Sig.	  (2-­‐tailed)	   0.001	   0.091	   0.031	   0.570	   0.081	   0.084	   0.251	   0.022	   	  
N	   23	   24	   24	   23	   24	   16	   23	   22	   	  
	  
Table	  41:	  Spearman's	  Correlation	  Coefficients	  for	  Methylation	  Status	  (%)	  between	  Infinium	  







Figure	  26:	  Scatter	  plots	  depicting	  correlation	  between	  Infinium	  Array	  methylation	  results	  and	  
Pyrosequencing	  Methylation	  Array	  average	  methylation	  values.	  	  
FLJ26850	  (above)	  &	  C12	  orf42	  (below)	  demonstrated	  correlation	  coefficients	  of	  0.442	  (p=0.031)	  and	  
0.649	  (p=0.001)	  respectively	  (line	  of	  best	  fit	  identified,	  dotted	  line).	  Methylation	  values	  represent	  the	  
average	  of	  contributory	  probe	  on	  the	  Infinium	  array	  for	  each	  gene	  and	  the	  average	  values	  of	  




6.5 EXPRESSION	  OF	  KEY	  REGULATORS	  OF	  METHYLATION	  STATE	  IN	  
HPV	  POSITIVE	  HNSCC	  
To	  determine	  the	  significance	  of	  the	  regulators	  of	  DNA	  methylation	  in	  OPSCC	  
stratified	  by	  HPV	  status,	  the	  expression	  of	  DNMTs	  and	  UHRF	  was	  determined	  within	  
the	  cohort	  of	  oropharynx	  SCC	  samples	  (n=	  103),	  and,	  where	  available,	  their	  
corresponding	  matched	  normal	  pairs	  (n=53)(Table	  42).	  	  
HPV	  status	  for	  each	  case	  had	  already	  been	  established	  using	  HPV	  mRNA	  (E6	  &	  E7)	  
expression	  as	  detailed	  previously	  (3.11).	  
It	  was	  hypothesized	  that	  different	  expression	  levels	  would	  be	  apparent	  depending	  
upon	  HPV	  status	  and	  this	  would	  in	  turn	  correlate	  with	  a	  global	  methylation	  state	  
that	  was	  fundamentally	  different.	  
	  
	  	   Tumour	  Cohort	   T/N	  Pairs	  





Oropharynx	   103	   46/103	  (45%)	   53	   11/53	  (21%)	  
	  
Table	  42:	  Regulation	  of	  DNA	  Methylation	  Analysis	  Cohort	  
	  
The	  mRNA	  expression	  levels	  of	  DNMTs	  (1,	  3a	  &	  3b)	  and	  UHRF1	  mRNA	  were	  
determined	  for	  each	  sample	  using	  quantitative	  PCR	  	  (qPCR).	  In	  addition,	  for	  a	  
proportion	  of	  cases,	  matched	  normal	  sample	  derived	  RNA	  was	  available	  for	  
concurrent	  analysis.	  Normalisation	  of	  expression	  levels	  was	  conducted	  by	  reference	  
to	  the	  average	  expression	  level	  from	  the	  pooled	  normal	  sample	  cohort	  (calibrator)	  
to	  determine	  a	  relative	  expression	  level.	  This	  relative	  expression	  level	  is	  expressed	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as	  a	  relative	  quantification	  value	  (RQ).	  Statistical	  comparison	  of	  expression	  levels	  
between	  tumours	  and	  their	  adjacent	  normal	  tissue	  samples	  was	  undertaken	  using	  a	  
non-­‐parametric	  test	  for	  paired	  analysis	  (Wilcoxon’s).	  	  
	  
DNA	  Methyltransferase	  &	  UHRF1	  Expression	  Results	  
Variation	  in	  expression	  of	  DNMTs	  or	  UHRF1	  between	  tumours	  and	  adjacent	  normal	  
tissue	  within	  the	  53	  paired	  samples	  demonstrated	  a	  highly	  significant	  increased	  
UHRF1	  expression	  within	  tumours	  (p<0.0001)	  (Figure	  27)	  and	  similarly	  increased	  
levels	  of	  DNMT3b	  expression	  (p=0.01).	  	  
	  
Figure	  27:	  Comparative	  expression	  for	  UHRF1	  between	  paired	  OPSCC	  tumour	  and	  adjacent	  normal	  
tissues.	  
Outliers	  (normal	  =1,	  tumours	  =5)	  excluded	  from	  above	  figure.	  	  
A	  bivariate	  analysis	  of	  the	  detected	  expression	  levels	  in	  the	  cohort	  of	  103	  tumour	  
samples	  alone	  demonstrated	  moderate	  correlation	  between	  DNMT1	  and	  UHRF1,	  
and	  to	  a	  lesser	  extent	  between	  DNMT1	  and	  DNMT3a	  (Table	  43).	  	  









	  	  	  
Target	  Gene	   DNMT1	   DNMT3A	   DNMT3B	  
UHRF1	   0.731*	   0.467	   0.471	  
	  
<0.001§	   <0.001	   <0.001	  
DNMT1	  
	  
0.660	   0.457	  
	   	  
<0.001	   <0.001	  
DNMT3A	  
	   	  
0.295	  
	   	   	  
0.002	  
DNMT3B	  
	   	   	  
	   	   	   	  
	  
Table	  43:	  Correlation	  in	  levels	  of	  expression	  of	  DNMTs/UHRF1	  within	  OPSCC	  tumour	  samples.	  	  
*	  Spearman’s	  Correlation	  Coefficient;	  §	  p	  value	  
	  
Further	  analysis	  of	  correlation	  in	  DNMT	  and	  UHRF1	  expression	  within	  tumours	  was	  
made	  following	  stratification	  on	  the	  basis	  of	  HPV	  status.	  HPV	  negative	  tumours	  
displayed	  a	  greater	  degree	  of	  correlation	  for	  each	  of	  the	  four	  genes	  than	  was	  seen	  
for	  the	  whole	  cohort	  analysis.	  This	  was	  not	  the	  case	  for	  HPV	  positive	  tumours	  where	  
correlations	  were	  consistently	  weaker	  than	  for	  the	  whole	  cohort	  (Table	  44).	  




Target	  Gene	   DNMT1	   DNMT3A	   DNMT3B	  












UHRF1	   0.840*	   0.609	   0.615	   0.245	   0.508	   0.464	  
	  
<0.001§	   <0.001	   <0.001	   0.101	   <0.001	   0.001	  
DNMT1	   	  
	  




<0.001	   <0.001	   <0.001	   0.001	  










0.032	   0.048	  













Table	  44:	  Correlation	  in	  levels	  of	  expression	  of	  DNMTs/UHRF1	  within	  OPSCC	  tumour	  samples	  
stratified	  by	  HPV	  status.	  	  
*	  Spearman’s	  Correlation	  Coefficient;	  §	  p	  value	  
	  
When	  comparison	  was	  made	  of	  independent	  gene	  expression	  levels	  within	  OPSCC	  
tumours	  stratified	  on	  the	  basis	  of	  HPV	  status,	  DNMT3b	  expression	  was	  significantly	  
lower	  in	  HPV	  positive	  tumours	  (Mann-­‐Whitney	  test,	  p=0.007).	  Although	  a	  trend	  
towards	  lower	  expression	  of	  the	  other	  analysed	  genes	  (DNMT1,	  -­‐3a	  and	  UHRF1)	  in	  
HPV	  positive	  tumours	  was	  apparent,	  evidence	  of	  altered	  expression	  on	  the	  basis	  of	  
HPV	  status	  was	  not	  statistically	  significant.	  	  
Further	  analysis	  of	  related	  clinical	  outcomes	  measures	  for	  individuals	  cases	  on	  the	  
basis	  of	  DNMT3b	  expression	  demonstrated	  that,	  at	  36	  months	  following	  diagnosis,	  
both	  disease	  specific	  and	  overall	  survival	  were	  significantly	  worse	  for	  individuals	  




Figure	  28:	  Kaplan	  Meier	  Estimates	  of	  Overall	  Survival	  at	  36	  Months	  on	  the	  basis	  of	  DNMT3b	  
expression.	  	  	  
DNMT3b	  expression	  was	  classified	  as	  either	  High	  or	  Low	  with	  respect	  to	  the	  median	  DNMT3b	  RQ	  
value	  (RQ=0.65).	  High	  expression	  levels	  correlated	  with	  a	  significantly	  worse	  overall	  survival	  
(p=0.04).	  
	  
HPV	  lacks	  intrinsic	  viral	  DNA	  methylation	  machinery,	  therefore	  it	  follows	  that	  
induction	  of	  altered	  methylation	  state	  requires	  recruitment	  or	  opportunistic	  
utilisation	  of	  the	  host	  methylation	  machinery.	  To	  determine	  if	  levels	  of	  DNMTs	  or	  
UHRF1	  expression	  influenced	  viral	  methylation	  state	  (E2	  promoter	  or	  LCR	  
methylation)	  non-­‐parametric	  analysis	  was	  undertaken.	  Analysis	  showed	  no	  
evidence	  of	  any	  correlation	  between	  the	  genes	  responsible	  for	  DNA	  methylation	  
and	  the	  methylation	  state	  of	  the	  individual	  viral	  targets	  included.	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Similarly,	  analysis	  of	  correlations	  between	  DNMTs/UHRF1	  expression	  and	  global	  
methylation	  within	  tumours	  stratified	  by	  HPV	  status	  was	  made	  using	  a	  Mann-­‐




The	  understanding	  that	  the	  HPV	  transcriptional	  repressor	  gene,	  E2,	  plays	  a	  
restraining	  influence	  in	  oncogenesis	  has	  been	  widely	  held,	  particularly	  in	  
consideration	  of	  HPV	  mediated	  cervical	  malignancy240.	  On	  this	  basis,	  the	  immediate	  
implication	  of	  its	  disruption	  by	  an	  integration	  process	  is	  release	  of	  the	  viral	  
oncogenes	  (E6	  and	  E7)	  from	  transcriptional	  repression.	  Such	  a	  concept	  fails	  to	  
explain	  the	  reported	  instances	  of	  tumours	  harboring	  intact	  virus	  in	  an	  episomal	  
form	  presumably	  without	  integration5.	  	  
Support	  for	  the	  concept	  of	  E2	  disruption	  playing	  a	  fundamental	  role	  in	  HPV-­‐
mediated	  oncogenesis	  comes	  from	  in	  vitro	  evidence	  of	  the	  growth	  inhibitory	  effect	  
of	  a	  reintroduction	  of	  E2	  gene	  in	  HeLa	  (HPV18	  positive)	  cells	  with	  a	  coincident	  fall	  in	  
E6	  and	  E7	  expression111,220.	  In	  HPV	  positive	  OPSCC,	  integration	  has	  been	  described	  
as	  a	  critical	  and	  necessary	  step78	  yet	  analyses	  of	  viral	  state	  in	  OPSCC	  suggests	  the	  
proportion	  of	  integrated	  cases	  may	  be	  as	  low	  as	  50%179,	  leading	  to	  the	  possibility	  of	  
other	  means	  to	  bring	  about	  E2	  disruption;	  for	  that	  reason,	  the	  role	  of	  viral	  
methylation	  in	  both	  the	  E2	  promoter	  and	  LCR	  was	  analysed.	  
Pyrosequencing	  assays	  proved	  to	  be	  a	  successful	  technique	  for	  the	  detection	  of	  the	  
methylation	  levels	  of	  both	  the	  E2	  gene	  (37/43,	  86%)	  and	  two	  distinct	  regions	  within	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the	  LCR	  (40/43,	  93%;	  41/43,	  95%).	  Although	  there	  was	  a	  trend	  towards	  negative	  
correlation	  between	  E2	  gene	  promoter	  methylation	  and	  expression,	  it	  was	  only	  
modest	  (correlation	  coefficient	  =	  -­‐0.362,	  p=0.03)	  in	  nature.	  Interestingly	  however,	  
was	  the	  finding	  that	  viral	  oncogene	  expression	  (E6	  &	  E7)	  appeared	  not	  to	  be	  
influenced	  by	  LCR	  methylation	  and,	  further,	  that	  it	  showed	  a	  strong	  positive	  
correlation	  to	  E2	  expression	  (E6;	  0.864,	  p<0.001	  &	  E7;	  0.871,	  p<0.001).	  This	  would	  
suggest	  that	  in	  established	  cases	  of	  HPV	  positive	  OPSCC,	  E2	  is	  either	  a	  positive	  
driving	  force	  for	  oncogene	  expression	  or,	  perhaps	  more	  plausibly,	  that	  E6	  and	  E7	  
expression	  occurs	  autonomous	  to	  E2	  expression,	  and	  perhaps	  elevated	  levels	  of	  E2	  
expression	  are	  an	  unsuccessful	  negative	  feedback	  mechanism	  and	  that	  a	  separate	  
event,	  such	  as	  E2	  binding	  site	  blockade,	  negates	  its	  repressive	  influence.	  	  
Also	  of	  note	  in	  this	  analysis,	  is	  the	  frequency	  with	  which	  E2	  expression	  was	  detected	  
in	  HPV	  positive	  OPSCC	  (35/43,	  81%).	  The	  results	  from	  the	  SiHa	  cell	  line	  demonstrate	  
a	  complete	  loss	  of	  detectable	  E2	  expression	  in	  keeping	  with	  previous	  findings	  and	  a	  
well-­‐documented	  disruption	  to	  the	  E2	  open	  reading	  frame194.	  Although	  evidence	  of	  
E2	  expression	  does	  not	  necessary	  exclude	  viral	  integration,	  it	  does	  imply	  the	  E2	  ORF	  
is	  intact	  in	  each	  of	  these	  cases,	  whether	  it	  be	  integrated,	  episomal	  or	  a	  combination	  
of	  both	  forms.	  	  
	  
As	  mentioned	  above,	  the	  assays	  employed	  have	  demonstrated	  excellent	  capability	  
to	  detect	  viral	  methylation	  state.	  In	  support	  of	  the	  capability	  of	  the	  PMA	  analysis	  is	  
the	  comparable	  viral	  methylome	  results	  for	  CaSki	  when	  considered	  alongside	  those	  
reported	  by	  previously241,242.	  Using	  PMA	  analysis	  our	  results	  showed	  high	  levels	  of	  
methylation	  detected	  at	  all	  sites	  for	  CaSki,	  but	  particularly	  in	  the	  E2	  promoter	  and	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the	  LCR	  region	  2	  (immediately	  adjacent	  to	  the	  p97	  promoter).	  Using	  bisulphite	  
sequencing	  of	  the	  entire	  HPV16	  methylome	  in	  CaSki	  samples,	  both	  Fernandez	  et	  
al.242	  and	  Park	  et	  al.241	  gave	  an	  equivalent	  depiction	  at	  these	  sites	  (E2m>50%	  &	  
LCR>80%242	  and	  LCR	  100%241	  respectively).	  Fernandez	  et	  al.	  went	  on	  to	  
demonstrate	  that	  in	  75%	  (6/8)	  of	  cervical	  cancer	  samples,	  methylation	  specific	  PCR	  
demonstrated	  the	  region	  encompassing	  E2BS3	  and	  E2BS4	  to	  be	  methylated.	  By	  
comparison,	  and	  from	  a	  larger	  series	  of	  clinical	  samples,	  our	  results	  showed	  11/41	  
(27%)	  of	  HPV	  positive	  OPSCC	  to	  be	  definitively	  methylated	  (average	  methylation	  
greater	  than	  10%).	  This	  would	  add	  some	  weight	  to	  a	  theory	  of	  induced	  E2	  binding	  
inhibition	  due	  to	  CpG	  methylation	  and,	  therefore,	  an	  alternative	  to	  E2	  disruption	  
through	  integration.	  However,	  our	  analysis	  failed	  to	  demonstrate	  any	  correlation	  
between	  CpG	  methylation	  encompassing	  E2BS3	  and	  E2BS4	  and	  E2	  expression.	  
	  
Without	  a	  means	  to	  accurately	  determine	  the	  integration	  state	  of	  analysed	  target	  
sequences,	  it	  remains	  unclear	  whether	  integration	  is	  a	  prerequisite	  step,	  as	  
suggested	  by	  Park	  et	  al.241,	  in	  rendering	  the	  viral	  genome	  susceptible	  to	  the	  
acquisition	  of	  an	  altered	  methylation	  profile	  in	  sites	  such	  as	  the	  E2BS.	  In	  addition	  to	  
a	  validated	  quantifiable	  integration	  test,	  it	  would	  also	  be	  necessary	  to	  source	  
clinical	  samples	  derived	  from	  individuals	  “at	  risk”	  of	  progression	  from	  transient	  HPV	  
infection	  to	  transformative	  infection;	  as	  yet,	  such	  a	  cohort	  remains	  difficult	  to	  




Genome-­‐wide	  Host	  Methylation	  State	  
The	  characterisation	  of	  genome-­‐wide	  methylation	  state	  by	  LINE-­‐1	  PMA	  has	  been	  
described	  previously	  in	  several	  tumour	  types,	  including	  HNSCC144,148,163,190.	  It	  is	  
apparent	  that	  genome-­‐wide	  hypomethylation	  is	  a	  hallmark	  of	  all	  human	  cancers225,	  
yet	  when	  considering	  differences	  in	  HNSCC	  global	  DNA	  methylation,	  both	  in	  vitro163	  
and	  in	  vivo144	  analyses	  have	  demonstrated	  that	  HPV	  negative	  tumours	  display	  more	  
frequent	  genome	  wide	  hypomethylation	  than	  HPV	  positive	  counterparts.	  Our	  
findings	  in	  a	  larger	  cohort	  of	  OPSCC	  clearly	  support	  this,	  with	  demonstration	  of	  
increased	  hypomethylation	  of	  tumours	  of	  the	  oropharynx	  as	  a	  whole	  group	  when	  
compared	  with	  adjacent	  uninvolved	  margins.	  Additionally	  it	  was	  seen	  that	  
stratification	  on	  the	  basis	  of	  HPV	  status	  highlighted	  HPV	  positive	  tumours	  to	  have	  
global	  methylation	  levels	  more	  comparable	  to	  normal	  than	  HPV	  negative	  disease	  
(69.6%	  vs	  64.2%	  vs	  55.3%	  for	  normal,	  HPV	  positive	  and	  HPV	  negative	  respectively).	  	  	  
Richards	  et	  al144.	  reported	  similar	  findings	  with	  respect	  to	  maintenance	  of	  a	  more	  
normal	  LINE-­‐1	  methylation	  profile	  in	  HPV	  positive	  tumours	  and	  raised	  the	  question	  
if	  the	  this	  reflects	  an	  exuberate	  cellular	  methylation	  response	  to	  HPV	  infection.	  In	  
terms	  of	  evidence	  of	  altered	  expression	  of	  the	  key	  genes	  for	  DNA	  methylation	  
regulation	  (DNMTs	  and	  UHRF1)	  in	  concert	  with	  correlating	  changes	  in	  LINE-­‐1	  




It	  has	  been	  surmised	  that	  the	  raised	  global	  methylation	  levels	  in	  HPV	  positive	  
disease	  are	  a	  result	  of	  host	  defense	  mechanism	  attempting	  to	  silence	  viral	  gene	  
expression	  yet	  mechanistic	  studies	  exploring	  this	  have	  not	  been	  forthcoming144.	  	  
Given	  the	  statistically	  significant	  reduction	  in	  smoking	  history	  amongst	  individuals	  
with	  HPV	  positive	  OPSCC	  and	  previous	  evidence	  of	  its	  impact	  on	  global	  methylation	  
state225,	  we	  explored	  smoking	  exposure	  as	  alternative	  explanation	  for	  reduced	  
hypomethylation	  in	  HPV	  positive	  tumours	  in	  an	  attempt	  to	  exclude	  its	  confounding	  
effect.	  There	  was	  no	  evidence	  to	  support	  smoking	  or	  any	  other	  demographic	  or	  
pathological	  feature	  as	  confounding	  variables	  in	  LINE-­‐1	  methylation	  analysis.	  
	  
Host	  Gene	  Promoter	  Methylation	  in	  OPSCC	  
Methylation	  microarray	  analyses	  depicting	  differences	  in	  promoter	  methylation	  
between	  HPV	  positive	  and	  negative	  clinical	  and	  cell	  line	  derived	  samples	  have	  been	  
conducted	  using	  several	  platforms	  previously,	  with	  increasing	  depth	  as	  the	  
technology	  has	  evolved.	  Applying	  the	  Illumina	  GoldenGate	  Methylation	  Array	  (1505	  
CpG	  loci)	  to	  a	  series	  of	  Oral	  SCC	  (OSCC)	  Jithesh	  et	  al.239	  found	  significant	  
hypermethylation	  for	  HPV	  positive	  lesions	  across	  nine	  probes,	  two	  of	  which	  (CCNA1	  
and	  CTSL1)	  were	  also	  highlighted	  in	  an	  analysis	  of	  HPV	  positive	  and	  negative	  OPSCC	  
using	  the	  Infinium	  HumanMethylation27	  Beadchip	  array	  (over	  27,000	  CpGs	  across	  
almost	  15,000	  genes)163.	  
	  	  
170	  
Interestingly,	  using	  a	  third	  generation	  methylation	  microarray,	  Infinium	  
HumanMethylation450	  Beadchip	  array,	  CCNA1	  (cyclin-­‐A1)	  was	  also	  identified	  as	  
being	  hypermethylated	  in	  HPV	  positive	  OPSCC.	  	  
In	  a	  further	  cohort	  of	  HNSCC	  analysed	  with	  the	  GoldenGate	  array,	  CCNA1	  was	  once	  
more	  highlighted	  as	  being	  hypermethylated	  in	  HPV	  positive	  cases.	  In	  this	  instance	  
the	  findings	  were	  also	  validated	  using	  a	  PMA	  assay	  providing	  corroboration243.	  	  
CCNA1	  is	  an	  important	  promoting	  modulator	  of	  the	  cyclin-­‐dependent	  kinase	  
pathway	  and	  as	  such	  play	  an	  integral	  part	  in	  cell	  cycle	  progression	  from	  S	  phase	  to	  
G2.	  	  	  
It	  is	  interesting	  to	  speculate	  on	  the	  role	  that	  hypermethylation	  of	  CCNA1	  might	  play	  
in	  HPV	  positive	  OPSCC.	  In	  contrast	  to	  HPV	  negative	  OPSCC,	  the	  majority	  of	  HPV	  
postive	  tumours	  display	  a	  p53	  wild-­‐type	  profile244.	  It	  is	  plausible	  in	  HPV	  positive	  
disease	  that	  epigenetic	  downregulation	  of	  CCNA1	  may	  be	  a	  necessary	  step	  in	  viral	  
carcinogenesis,	  which	  is	  not	  readily	  apparent	  in	  HPV	  negative	  HNSCC.	  
Counterintuitive	  to	  such	  a	  premise,	  is	  evidence	  suggesting	  that	  HPV	  positive	  HNSCC	  
consistently	  displays	  CCNA1	  protein	  overexpression245.	  It	  remains	  conceivable	  that	  
these	  two	  events;	  CCNA-­‐1	  hypermethylation	  and	  CCNA-­‐1	  protein	  overexpression,	  
are	  not	  mutually	  exclusive	  events	  and	  that	  protein	  overexpression	  facilitates	  cell	  
cycle	  deregulation	  whilst	  virally	  induced	  promoter	  methylation	  abrogates	  tumour	  
suppressive	  influences	  of	  the	  gene.	  	  
	  
GARL1,	  G-­‐protein-­‐coupled	  Galanin	  Receptor-­‐1,	  is	  also	  a	  gene	  of	  particular	  interest	  in	  
HNSCC	  and	  more	  particularly	  HPV	  positive	  malignancy.	  As	  a	  group,	  G-­‐protein-­‐
coupled-­‐receptors	  (GPCRs)	  have	  emerged	  as	  key	  regulators	  of	  tumour	  growth	  and	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metastasis246,	  more	  specifically,	  GARL1	  has	  been	  highlighted	  previously	  as	  a	  
putative	  tumour	  suppressor	  gene	  (TSG).	  Misawa	  et	  al.228	  demonstrated,	  in	  HNSCC	  
cell	  lines,	  that	  GARL1	  hypermethylation	  lead	  to	  reduction	  in	  gene	  expression	  and,	  
by	  analysis	  of	  methylation	  specific	  PCR	  (MSP),	  that	  positive	  methylation	  
corresponded	  to	  worse	  survival	  in	  HNSCC	  tumours.	  Although	  HPV	  stratification	  had	  
not	  been	  conducted	  in	  this	  cohort,	  the	  clinicopathological	  features	  (increased	  T	  
stage	  and	  poor	  survival)	  could	  be	  used	  as	  construed	  as	  surrogates	  of	  HPV	  negative	  
disease.	  By	  contrast,	  we	  found	  significant	  differential	  hypermethylation	  in	  HPV	  
positive	  OPSCC	  that	  had	  been	  strictly	  defined	  by	  site	  of	  origin	  and	  by	  HPV	  status.	  
Misawa	  et	  al.	  included	  11/38	  (29%)	  OPSCC	  in	  their	  analysis	  but	  there	  was	  no	  
attempt	  to	  analyse	  them	  separately	  to	  oral,	  hypopharyngeal,	  sinonasal	  and	  
laryngeal	  tumours	  and	  as	  such	  has	  significant	  potential	  to	  confound	  results228.	  	  
DNA	  viruses,	  such	  as	  Epstein-­‐Barr	  Virus	  (EBV)	  and	  Kaposi	  sarcoma-­‐associated	  
herpesvirus	  (KSHV),	  have	  been	  shown	  to	  exploit	  host	  GCRPs	  or	  possess	  ORFs	  that	  
encode	  viral-­‐GCRPs	  for	  selective	  growth	  and	  metastatic	  advantage246.	  In	  contrast,	  
the	  evidence	  of	  hypermethylation	  of	  GARL1	  in	  HPV	  positive	  OPSCC	  we	  found,	  may	  
reflect	  a	  host	  response	  to	  viral	  oncogenesis	  or	  a	  lack	  of	  deregulation	  of	  this	  gene	  
within	  HPV	  positive	  tumours	  and,	  in	  keeping	  with	  findings	  of	  increased	  sensitivity	  to	  
chemotherapy	  (5-­‐fluorouricil	  &	  platinum	  based	  agents)	  in	  colorectal	  cancer229,	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Although	  differential	  methylation	  is	  seen	  using	  both	  the	  450K	  array	  and	  PMA	  
analysis	  for	  each	  of	  the	  candidate	  genes,	  strong	  correlation	  of	  quantitative	  
comparison	  between	  methods	  is	  not	  apparent	  and	  could	  be	  seen	  as	  a	  limitation	  of	  
this	  analysis.	  The	  lack	  of	  quantitative	  correlation	  is	  perhaps	  unsurprising	  given	  the	  
differences	  in	  techniques	  and	  in	  individual	  targets;	  450K	  probes	  analyse	  solitary	  
CpGs	  whilst	  corresponding	  PMA	  target	  sequence	  covers	  a	  number	  of	  probe	  CpGs	  
and	  additional	  adjacent	  CpGs	  (for	  example,	  CCNA1	  PMA	  included	  8	  CpGs	  for	  
analysis,	  of	  which	  5	  had	  been	  individually	  analysed	  on	  the	  450K	  platform).	  	  
	  
In	  keeping	  with	  other	  authors192,248,	  our	  validation	  of	  450K	  results	  support	  the	  
application	  of	  this	  array	  but	  as	  yet	  do	  not	  allow	  complete	  exploration	  of	  the	  
changes	  in	  gene	  promoter	  methylation	  as	  the	  cohort	  analysis	  is	  underpowered.	  
However,	  a	  biological	  validation	  on	  a	  large	  separate	  and	  distinct	  cohort	  may	  allow	  
greater	  interpretation.	  	  Any	  further	  validation	  would	  seek	  to	  elucidate	  and	  better	  
define	  predictive	  biomarkers	  in	  the	  transition	  to	  viral	  induced	  malignancy.	  
	  
Regulators	  of	  Methylation	  in	  HPV	  positive	  OPSCC	  
DNMTs	  are	  the	  only	  recognised	  enzymes	  capable	  of	  methyltransferase	  activity,	  
although	  contributory	  elements,	  such	  as	  UHRF1	  can	  act	  as	  facilitators	  though	  
DNMT1	  recruitment	  to	  hemimethylated	  targets154.	  This	  analysis	  sought	  to	  define	  
the	  quantitative	  differences	  in	  expression	  of	  the	  key	  elements	  of	  the	  cellular	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methylation	  machinery	  between	  HPV	  positive	  and	  negative	  OPSCC	  and	  more	  
importantly	  correlate	  findings	  in	  HPV	  positive	  tumours	  to	  the	  viral	  methylome	  
analysis.	  
In	  accordance	  with	  findings	  in	  a	  wide	  variety	  of	  human	  malignancies156,	  we	  
demonstrated	  that	  OPSCC	  overexpressed	  all	  DNMTs,	  in	  particular	  UHRF1	  and	  
DNMT3b,	  when	  compared	  to	  their	  normal	  adjacent	  tissues.	  Underlining	  the	  
divergent	  mechanisms	  of	  HPV	  positive	  and	  negative	  OPSCC,	  Sator	  et	  al.163	  made	  
similar	  observations	  when	  analysing	  DNMT3a	  expression	  alone	  in	  HPV	  positive	  cell	  
lines	  and	  in	  a	  comparative	  gene	  expression	  array,	  Martinez	  et	  al.249	  found	  DNMT1	  
to	  be	  overexpressed	  in	  HPV	  positive	  HNSCC	  by	  comparison	  to	  normal	  tissues.	  	  
It	  is	  recognised	  that	  the	  pRb/E2F	  pathway	  regulates	  expression	  of	  UHRF1	  and	  
DNMT1	  in	  order	  to	  replicate	  DNA	  methylation	  profiles	  during	  the	  transition	  from	  S	  
to	  G2	  phases	  of	  the	  cell	  cycle250.	  We	  demonstrated	  that	  there	  was	  a	  strong	  positive	  
correlation	  between	  DNMT1	  and	  UHRF1	  expression	  in	  OPSCC	  however	  interestingly,	  
the	  strength	  of	  correlation	  was	  greatest	  for	  HPV	  negative	  tumours.	  Daskalos	  et	  al.161	  
had	  previously	  shown	  in	  primary	  lung	  SCC,	  a	  tumour	  with	  similar	  aetiology	  to	  HPV	  
negative	  HNSCC,	  that	  overexpression	  of	  UHRF1	  was	  a	  critical	  feature	  responsible	  for	  
maintenance	  of	  TSG	  hypermethylation.	  Such	  findings	  would	  support	  our	  
observation	  in	  HPV	  negative	  disease.	  	  
Within	  HPV	  positive	  tumours,	  viral	  E7,	  through	  its	  impact	  on	  pRb	  and	  the	  pRb/E2F	  
complex,	  liberates	  E2F	  that	  in	  turn	  acts	  as	  a	  transcriptional	  activator	  of	  both	  UHRF1	  
and	  DNMT1.	  Our	  results	  did	  not	  demonstrate	  a	  collaborative	  expression	  profile	  and,	  
when	  compared	  to	  HPV	  negative	  tumours,	  HPV	  positive	  disease	  had	  a	  trend	  
towards	  lower	  expression	  of	  all	  DNMTs	  and	  UHRF1.	  This	  trend	  was	  most	  profound	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for	  DNMT3b	  (p=0.007)	  and	  when	  outcomes	  for	  individual	  cases	  was	  analysed	  based	  
the	  level	  of	  DNMT3b	  expression,	  a	  clear	  positive	  prognostic	  impact	  was	  seen	  for	  low	  
expressing	  tumours.	  Due	  to	  the	  profound	  survival	  benefit	  of	  HPV	  positive	  status	  it	  
was	  not	  possible	  to	  exclude	  this	  as	  a	  confounding	  variable,	  however	  evidence	  from	  
diffuse	  large	  B-­‐cell	  lymphoma251,	  acute	  myeloid	  leukaemia252	  and	  non-­‐small	  cell	  
lung	  cancer161	  would	  support	  a	  survival	  advantage	  for	  low	  DNMT3b	  expressing	  
tumours.	  In	  HNSCC,	  irrespective	  of	  levels	  of	  expression,	  DNMT3b	  polymorphisms	  
have	  also	  been	  shown	  to	  covey	  a	  negative	  survival	  impact253,254.	  In	  both	  instances,	  
tumours	  were	  not	  subjected	  to	  HPV	  testing	  however	  the	  demographic	  features	  
would	  be	  suggestive	  of	  HPV	  negative	  disease.	  It	  would	  be	  of	  interest	  to	  determine	  
the	  relevance	  or	  proportional	  occurrence	  of	  DNMT3b	  polymorphisms	  in	  HPV	  
positive	  and	  negative	  OPSCC.	  	  
	  
Although	  HPV	  positive	  and	  negative	  OPSCC	  consistently	  display	  fundamentally	  
different	  genetic	  and	  epigenetic	  profiles,	  we	  were	  unable	  to	  define	  consistent	  
mechanistic	  links	  between	  the	  DNA	  methylation	  regulatory	  genes	  and	  either	  
genome-­‐wide	  methylation	  (LINE-­‐1)	  or	  specific	  targets	  within	  the	  viral	  genome	  (E2	  
promoter,	  LCR	  sites	  including	  E2BSs).	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7 VIRAL	  INTEGRATION	  STATE	  IN	  HPV	  POSITIVE	  OPSCC	  
7.1 INTRODUCTION	  	  
Integration	  Analysis	  Aims	  
The	  understanding	  and	  subsequent	  implications	  of	  viral	  integration	  in	  high	  risk	  HPV	  
lesions	  come	  primarily	  from	  analyses	  of	  cell	  lines	  or	  clinical	  samples	  derived	  from	  
cervical	  dysplasia	  or	  neoplasia6,110,174.	  Integration	  appears	  to	  represent	  a	  critical	  
step	  in	  the	  progression	  to	  invasive	  disease	  as	  implied	  by	  the	  increasing	  frequency	  
with	  which	  it	  observed	  from	  early	  cervical	  intraepithelial	  neoplasia	  (CIN)	  through	  
carcinoma	  in	  situ	  to	  cervical	  cancer255.	  
It	  was	  hypothesised	  that	  integration	  plays	  a	  critical	  role	  in	  the	  disruption	  of	  the	  E2	  
gene	  and	  represents	  an	  obligatory	  step	  in	  oncogenesis	  within	  HPV	  positive	  OPSCC	  
and	  as	  such	  could	  demonstrably	  affect	  detectable	  levels	  of	  E2	  gene	  expression.	  
Although	  potentially	  advantageous	  for	  viral	  DNA	  persistence,	  it	  was	  postulated	  that	  
integration	  events	  within	  cellular	  DNA	  in	  HPV	  OPSCC	  are	  random	  in	  nature	  rather	  
than	  targeted	  to	  specific	  cellular	  genes,	  in	  keeping	  with	  findings	  from	  cervical	  
cancer.	  
Integration	  analysis	  aimed	  to	  detect	  the	  presence	  of	  E2	  gene	  integrity	  and	  correlate	  
this	  with	  E2	  gene	  expression.	  	  
Additionally,	  on	  the	  premise	  that	  the	  HPV	  circular	  genome	  cleavage	  position	  might	  
fell	  beyond	  the	  limits	  of	  the	  E2	  gene	  we	  aimed	  to	  test	  a	  recently	  validated	  
hybridisation	  capture	  and	  sequencing	  techniques	  to	  detect	  these	  positions	  and	  the	  
related	  host	  cellular	  insertion	  points	  in	  a	  small	  of	  cohort	  of	  HPV	  positive	  OPSCC	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samples.	  This	  analysis	  also	  aimed	  to	  determine,	  in	  clinical	  OPSCC	  samples,	  whether	  
detection	  of	  integration	  events	  might	  have	  a	  role	  in	  positive	  selection	  bias	  during	  
oncogenesis	  (insertional	  mutagenesis	  events).	  
	  
7.2 VIRAL	  E2	  GENE	  INTEGRITY	  ANALYSIS	  
E2	  Integrity	  Assay	  -­‐	  Methods	  
The	  integrity	  of	  the	  viral	  E2	  gene	  was	  analysed	  in	  cell	  line	  samples	  (CaSki,	  SiHa	  and	  
HBEC-­‐3KT)	  and	  44	  OPSCC	  samples,	  including	  43	  that	  had	  previously	  been	  
demonstrated	  to	  harbor	  HPV16	  DNA	  (4),	  using	  overlapping	  endpoint	  PCR	  primers	  
for	  E2	  ORF	  as	  previously	  described182.	  	  
The	  positive	  control	  utilised	  for	  disrupted	  E2	  gene	  was	  SiHa	  and	  for	  intact	  E2	  gene	  
was	  CaSki.	  The	  negative	  controls	  were	  DNA	  derived	  from	  the	  known	  HPV16	  
negative	  cell	  line	  HBEC-­‐3KT	  and	  DNA	  from	  the	  HPV	  negative	  OPSCC	  (sample	  No.11).	  
Duplicate	  reactions	  were	  run	  for	  all	  samples	  and	  where	  equivocal	  or	  contradictory	  
results	  were	  apparent,	  a	  triplicate	  reaction	  was	  run	  under	  identical	  conditions	  as	  a	  
discriminator.	  
	  
E2	  Integrity	  Assay	  -­‐	  Results	  
From	  the	  cohort	  of	  43	  HPV16	  DNA	  positive	  cases	  E2	  gene	  integrity	  results	  were	  
available	  for	  all	  cases	  analysed.	  For	  38/43	  samples,	  all	  component	  parts	  of	  the	  E2	  
gene	  (E2	  primer	  pairs	  1-­‐5)	  and	  the	  E2	  whole	  gene	  product	  were	  apparent	  by	  gel	  
electrophoresis.	  For	  5/43	  (12%)	  samples,	  PCR	  products	  were	  not	  visualised	  for	  the	  
	  	  
177	  
whole	  E2	  gene	  amplification	  (Table	  45)	  and	  in	  each	  instance,	  one	  or	  more	  of	  the	  
component	  parts	  (p1-­‐p5)	  also	  failed	  to	  amplify	  product.	  	  	  
The	  positive	  control	  CaSki	  displayed	  PCR	  product	  for	  each	  PCR	  E2	  component	  and	  
the	  whole	  gene	  whilst	  for	  SiHa,	  the	  E2	  whole	  gene	  and	  P2	  primer	  set	  (coverage	  nt	  
3086-­‐3388)	  demonstrated	  no	  evidence	  of	  product.	  
The	  negative	  control	  tumour	  and	  HPV16	  negative	  cell	  line	  DNA	  samples	  
demonstrated	  no	  visualised	  product	  for	  any	  assay,	  whole	  gene	  or	  component.	  
Of	  the	  5	  OPSCC	  samples	  with	  disrupted	  E2	  genes,	  two	  also	  failed	  to	  have	  detectable	  
levels	  of	  viral	  E2	  gene	  expression	  (Table	  45).	  As	  expected	  SiHa	  also	  showed	  no	  







Table	  45:	  Relative	  viral	  gene	  expression	  (RQ)	  and	  E2	  gene	  Integrity	  Analysis	  for	  HPV16	  DNA	  positive	  
OPSCC.	  
Gene	  expression	  data	  is	  relative	  to	  CaSki,	  HPV16	  positive	  cervical	  cancer	  cell	  line	  expression	  (grey	  
band	  represents	  no	  available	  data).	  	  
E2	  gene	  integrity	  analysis	  schematic	  for	  results	  of	  end-­‐point	  PCR	  analysis	  of	  E2	  whole	  gene	  assay	  
(E2W)	  and	  overlapping	  sequence	  components	  of	  the	  E2	  gene	  (E2P1	  –	  P5).	  Red	  signifies	  visualised	  
PCR	  product	  of	  expected	  size	  in	  duplicate	  reactions.	  White	  signifies	  no	  PCR	  product.	  
Integration	  Analysis:	  Reflects	  the	  inferred	  integration	  state	  of	  HPV16	  in	  the	  clinical	  sample;	  evidence	  
of	  all	  components	  of	  the	  E2	  gene	  and	  the	  E2	  whole	  gene	  PCR	  suggests	  episomal	  viral	  state	  whilst	  loss	  
of	  one	  or	  more	  component	  of	  E2	  and	  the	  E2	  whole	  gene	  is	  inferred	  to	  suggest	  integrated	  virus.	  
Cell	  Line	  samples	  (CaSki	  &	  SiHa)	  are	  underlined	  by	  red-­‐hashed	  lines,	  HPV	  negative	  OPSCC	  tumour	  
(No.	  11)	  and	  cell	  line	  (HBEC-­‐KT)	  samples	  are	  underlined	  by	  blue-­‐hashed	  lines.	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7.3 SPECIFIC	  VIRAL	  CAPTURE	  &	  NEXT	  GENERATION	  SEQUENCING	  FOR	  
DETERMINATION	  OF	  VIRAL	  CLEAVAGE	  &	  HOST	  INSERTION	  
POSITIONS	  
A	  series	  of	  9	  HPV16	  DNA	  positive	  OPSCC	  and	  the	  HPV16	  positive	  cervical	  cancer	  cell	  
lines,	  CaSki	  and	  SiHa,	  were	  analysed	  using	  a	  recently	  described	  target	  sequence	  
(HPV16)	  hybridisation,	  amplification	  and	  deep	  sequencing	  technique195.	  
With	  an	  appreciation	  of	  the	  potential	  weaknesses	  of	  inferred	  integration	  assays	  
such	  as	  the	  E2	  integrity	  assay,	  detailed	  above	  and	  discussed	  more	  fully	  below,	  this	  
analysis	  sought	  to	  better	  define	  the	  incidence	  of	  viral	  integration	  in	  clinical	  samples,	  
and	  where	  integration	  was	  apparent,	  the	  cleavage	  point	  within	  the	  circular	  viral	  
genome.	  Through	  capture	  of	  the	  viral	  sequences	  abutting	  integration	  sites	  in	  the	  
host	  genome	  it	  was	  intended	  to	  also	  be	  able	  to	  determine	  the	  “recipient”	  sites	  
within	  the	  host	  and	  quantify	  whether	  integration	  appears	  as	  a	  sporadic	  event	  or	  a	  
specific	  driver	  through	  insertional	  mutagenesis.	  	  
	  
Viral	  sequence	  capture	  and	  sequencing	  –	  Results	  
The	  11	  samples,	  including	  9	  clinical	  OPSCC	  DNA	  samples	  and	  2	  reference/control	  
cell	  lines,	  all	  provided	  results	  amenable	  to	  analysis	  results	  following	  library	  
preparation,	  sequence	  capture,	  amplification	  and	  sequencing.	  
All	  samples	  were	  multiplexed	  and	  sequenced	  using	  an	  Illumina	  HiSeq	  platform,	  
yielding	  between	  8x106	  	  –	  9.5x106	  100bp	  paired-­‐end	  reads	  per	  sample	  analysed	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(Appendix	  I),	  although	  following	  removal	  of	  duplicate	  reads	  to	  declare	  unique	  reads	  
only,	  the	  number	  fell	  by	  between	  44	  –	  66%	  (Appendix	  II).	  
When	  considering	  total	  paired-­‐end	  reads	  (Appendix	  I)	  with	  duplicates	  included,	  
reads	  which	  mapped	  to	  human	  genomic	  sequence	  in	  both	  paired	  ends	  represented	  
a	  significant	  proportion	  of	  reads	  (31.23	  –	  92.71%)	  with	  the	  exception	  of	  CaSki,	  for	  
which	  human-­‐human	  paired	  reads	  represented	  only	  4.82%	  of	  the	  total	  reads.	  
Concordance	  in	  terms	  of	  proximity	  of	  the	  paired	  reads	  to	  one	  and	  other	  in	  the	  
human	  genome	  (mapping	  sites	  <500bp	  apart)	  was	  typically	  seen,	  however	  a	  small	  
proportion	  of	  reads	  mapped	  beyond	  proximity	  of	  500bp	  (Human:Human	  mixed	  
pairs	  0.25	  –	  7.32%).	  
Paired	  end	  reads	  that	  contained	  viral	  sequence	  demonstrated	  substantial	  variation	  
between	  samples.	  The	  CaSki	  cell	  line	  sample	  demonstrated	  a	  high	  frequency	  
(91.24%)	  of	  reads	  containing	  one	  or	  more	  pair	  with	  viral	  sequence,	  however	  5	  
tumour	  samples	  demonstrated	  less	  than	  5%	  of	  paired	  end	  reads	  with	  detectable	  
viral	  sequence.	  Concordance	  within	  the	  viral	  read	  pairs	  (mapping	  viral	  sites	  within	  
<500bp	  of	  paired	  reads)	  was	  proportionate	  to	  the	  overall	  viral	  reads	  (86-­‐94%)	  with	  
the	  exception	  of	  one	  sample	  (Sample	  ID	  13)	  that	  showed	  greater	  variation	  (60%)	  
albeit	  from	  a	  significantly	  reduced	  number	  of	  viral	  reads.	  
Hybrid	  reads,	  which	  were	  composed	  of	  viral	  reads	  in	  one	  paired-­‐end	  read	  and	  
human	  sequence	  in	  the	  second	  were	  seen	  infrequently,	  greatest	  in	  a	  tumour	  
sample	  (Sample	  ID	  34)	  and	  the	  CaSki	  cell	  line	  sample	  (3.52%)	  and	  least	  frequently	  in	  
the	  remaining	  tumour	  samples	  (range	  <0.001%	  -­‐	  1.92%).	  
RNaseP	  reads	  were	  consistent	  across	  the	  tumour	  samples,	  however	  CaSki	  
demonstrated	  a	  substantially	  reduced	  total,	  and	  proportionate,	  read	  for	  RNaseP	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pairs	  (Appendix	  I	  –	  bottom	  panel).	  Across	  the	  cohort	  of	  samples	  between	  3	  -­‐	  6%	  of	  
RNaseP	  reads	  lacked	  concordance	  (over	  500bp	  between	  paired	  reads).	  
	  
Comparative	  integration	  results	  (Table	  46)	  highlight	  the	  presence	  of	  detectable	  viral	  
integration	  in	  both	  reference	  cell	  lines	  and	  all	  clinical	  samples.	  As	  detailed	  
previously,	  the	  E2	  integrity	  assay	  inferred	  integration	  to	  be	  present	  in	  only	  3/9	  
samples,	  yet	  NGS	  analysis	  detects	  integration	  in	  all	  9	  clinical	  samples	  and	  the	  two	  
cell	  lines.	  Generalised	  peak	  viral	  cleavage	  position,	  collated	  from	  Human:Viral	  	  
mixed	  pair	  reads,	  demonstrates	  variability	  in	  viral	  break	  points.	  	  
More	  detailed	  analysis	  of	  individual	  samples	  (Appendix	  III-­‐XIII)	  shows	  that	  viral	  
cleavage,	  for	  the	  most	  part,	  is	  pan-­‐genomic,	  with	  the	  exception	  of	  short	  viral	  
regions	  in	  SiHa	  (E2	  gene;	  Appendix	  IV),	  and	  in	  clinical	  samples	  No.	  13	  (E7,	  E2,	  L1,	  L2	  
and	  LCR;	  Appendix	  V),	  No.	  106	  (E2	  –	  E5;	  Appendix	  VII)	  and	  No.	  105	  (L2;	  Addendix	  IX)	  
where	  no	  viral	  reads	  are	  detected	  in	  mixed	  paired	  end	  reads	  (including	  human	  
sequence	  in	  the	  corresponding	  paired	  read).	  
In	  the	  cases	  of	  the	  four	  samples	  that	  had	  undetectable	  E2	  expression	  (3	  clinical	  
samples	  and	  SiHa	  cell	  line),	  a	  peak	  E2	  viral	  cleavage	  position	  was	  not	  apparent.	  
However	  within	  these	  same	  samples,	  absent	  representation	  of	  viral	  reads	  from	  a	  
portion	  of	  the	  E2	  gene	  was	  apparent	  in	  three	  of	  the	  four	  instances,	  SiHa	  and	  
samples	  No.	  13	  and	  106	  (as	  above)	  suggesting	  the	  possibility	  of	  deleted	  sequence.	  
For	  samples	  where	  E2	  expression	  was	  apparent	  (including	  sample	  No.	  101	  which	  
had	  exclusive	  high	  E2	  expression	  without	  detectable	  viral	  oncogene	  expression),	  E2	  




Co-­‐localisation	  of	  paired	  end	  viral	  DNA	  reads	  to	  the	  human	  genome	  (Appendix	  III-­‐
XIII;	  top	  images)	  demonstrated	  specific	  integration	  positions	  in	  5	  samples	  (SiHa	  and	  
tumour	  samples	  106,	  95,	  88	  and	  108;	  Appendix	  VII,	  VIII,	  X	  and	  XI	  respectively).	  Not	  
only	  were	  these	  apparent	  in	  the	  Human/HPV	  mixed	  pairs	  read	  but	  also	  detected	  in	  
chimaeric	  reads	  and	  were	  analysised	  for	  specific	  integration	  site/nucleotide	  (Table	  
46	  &	  Appendix	  V,	  VII,	  VIII,	  X	  &	  XI	  -­‐	  bottom	  schematics).	  
For	  the	  remaining	  samples,	  CaSki,	  and	  clinical	  samples	  Nos.	  13,	  34,	  105,	  87	  &	  101),	  
co-­‐localisation	  to	  the	  human	  genome	  was	  non-­‐specific	  or	  pan-­‐genomic	  in	  nature	  
(Table	  46	  &	  Appendix	  III,	  V,	  VI,	  IX,	  XII	  &	  XIII).	  Interestingly,	  this	  group	  included	  all	  
samples	  that	  had	  low	  frequency	  integrants	  (sample	  Nos.	  13,	  105,	  87	  &	  101)	  as	  
demonstrated	  in	  the	  relatively	  low	  chimaeric	  read	  frequency	  (<250	  total	  chimaeric	  
reads).	  	  
	  
Chimaeric	  read	  interrogation	  revealed	  peak	  human	  insertion	  positions	  in	  each	  
sample.	  Due	  to	  low	  chimaeric	  read	  number,	  samples	  deemed	  to	  be	  low	  frequency	  
integrant	  samples	  were	  not	  further	  analysed	  for	  human	  insertion	  position.	  It	  is	  
apparent	  in	  remaining	  samples	  that	  integration	  position	  is	  not	  conserved	  between	  
samples	  with	  no	  evidence	  of	  repetition	  in	  the	  cohort	  analysed.	  Further,	  sites	  appear	  
to	  be	  primarily	  within	  repetitive	  elements	  of	  the	  human	  genome	  rather	  than	  
specific	  genes	  (Table	  46).	  Specific	  gene	  disruption	  of	  GPR1,	  G-­‐couple-­‐protein	  
receptor	  1,	  was	  noted	  in	  sample	  No.	  95	  (Appendix	  VIII).	  
	  
There	  was	  no	  apparent	  relationship	  between	  viral	  cleavage,	  host	  insertion	  or	  read	  
proportions	  and	  the	  extent	  of	  viral	  oncogene	  expression	  (E6	  &	  E7).	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Table	  46:	  Compiled	  results	  for	  samples	  analysed	  using	  next	  generation	  sequencing	  (NGS)	  
For	  each	  tumour	  or	  cell	  line	  control	  sample,	  details	  of	  the	  viral	  E6	  gene	  DNA	  qPCR	  results	  (∆CT)	  and	  
RNAqPCR	  (∆∆CT,	  ref	  sample	  CaSki)	  results	  for	  gene	  expression	  of	  viral	  E2,	  E6	  and	  E7	  are	  included.	  
Inferred	  E2	  integration	  results	  and	  overall	  NGS	  integration	  state	  is	  listed	  for	  each	  sample.	  
Representative	  host	  insertion	  position	  (table	  centre)	  is	  detailed	  from	  viral/host	  chimaeric	  reads.	  Peak	  
host	  insertion	  position	  (nucleotide	  position,	  cytogenetic	  location)	  and	  where	  apparent	  human	  gene	  
with	  known	  gene	  function.	  Corresponding	  viral	  cleavage	  position	  is	  also	  noted.	  
Schematic	  diagram	  of	  viral	  genome	  (far	  right	  of	  table),	  with	  relative	  viral	  open	  reading	  frame	  size,	  
highlights	  peak	  viral	  cleavage	  positions	  (blue	  fill)	  in	  each	  sample.	  
Cell	  Line	  samples	  (CaSki	  &	  SiHa)	  are	  listed	  above	  red	  dividing	  line,	  OPSCC	  tumour	  samples	  are	  below	  
red	  dividing	  line	  
	  




7.4 DISCUSSION	  	  
Detection	  of	  viral	  integration	  –	  E2	  gene	  integrity	  
Disruption	  of	  the	  E2	  gene	  has	  been	  held	  as	  synonymous	  with	  integrated	  viral	  DNA	  
and,	  by	  implication,	  the	  loss	  of	  E2	  is	  subsequently	  a	  critical	  step	  in	  viral	  mediated	  
oncogenesis.	  Collins	  et	  al.182	  demonstrated	  in	  cervical	  dysplastic	  lesions	  and	  invasive	  
cervical	  disease	  that	  an	  assay	  capable	  of	  detecting	  the	  integrity	  of	  E2,	  will	  highlight	  
progressive	  increases	  in	  inferred	  integration	  of	  viral	  DNA	  as	  severity	  of	  disease	  
advances.	  
In	  HPV16	  positive	  OPSCC,	  this	  assay	  classified	  12%	  of	  cases	  as	  having	  a	  disrupted	  E2	  
ORF,	  suggestive	  of	  integrated	  viral	  DNA.	  The	  positive	  control	  for	  disrupted	  E2	  gene,	  
SiHa	  cell	  line	  DNA,	  gave	  results	  consistent	  with	  previous	  findings	  of	  disruption	  of	  the	  
E2	  gene	  between	  nucleotides	  3132	  –	  3384	  as	  reported	  by	  Baker	  et	  al.194	  and	  
corroborated	  by	  Collins	  et	  al.182	  in	  their	  description	  of	  the	  application	  of	  this	  assay.	  
This	  supports	  the	  capacity	  of	  the	  test	  to	  detect	  a	  disrupted	  E2	  gene,	  at	  least	  when	  
all	  copies	  in	  the	  sample	  are	  similarly	  disrupted.	  
As	  will	  be	  discussed	  further	  below,	  detection	  of	  integration	  using	  the	  sensitive	  
sequencing	  technique	  employed,	  categorised	  all	  samples	  as	  having	  integrated	  viral	  
DNA,	  effecting	  E2	  and	  other	  ORFs,	  and	  therefore	  the	  conflicting	  results	  question	  the	  
capacity	  of	  the	  E2	  integrity	  test	  to	  detect	  all	  cases	  of	  integration	  and	  hence	  its	  
efficacy.	  
Admittedly,	  no	  precursor	  lesion	  was	  available	  for	  inclusion	  in	  this	  analysis	  and	  
therefore	  the	  temporal	  element	  to	  this	  assay’s	  utility	  is	  lost,	  however	  the	  test	  also	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fails	  to	  recognise	  the	  potential	  for	  viral	  cleavage	  events	  beyond	  the	  boundaries	  of	  
the	  E2	  gene	  and,	  in	  common	  with	  many	  indirect	  integration	  analyses,	  fails	  to	  “see	  
past”	  episomal	  viral	  DNA	  when	  detecting	  integration.	  This	  situation	  is	  clearly	  
demonstrated	  in	  the	  cervical	  cancer	  cell	  line,	  CaSki,	  which	  is	  known	  to	  contain	  
multiple	  viral	  integrants185	  and	  yet	  registers	  intact	  E2	  components	  and	  whole	  E2	  
gene,	  therefore	  interpreted	  as	  episomal.	  
	  
E2	  expression	  was	  absent	  in	  five	  samples	  with	  evident	  E6	  and/or	  E7	  expression	  
(SiHa	  and	  4	  OPSCC	  derived	  samples),	  yet	  it	  would	  appear	  that	  complete	  E2	  gene	  
disruption	  can	  only	  be	  implicated	  in	  3	  of	  these	  samples,	  of	  which	  SiHa	  is	  one.	  
Alterative	  means	  of	  disruption	  of	  the	  viral	  E2	  ORF	  are	  possible,	  including	  down	  
regulation	  through	  methylation	  of	  the	  gene	  promoter,	  although	  our	  results	  noted	  
previously	  (6.2)	  do	  not	  support	  such	  a	  finding.	  Similarly	  the	  nature	  of	  end	  point	  PCR	  
assays	  may	  have	  lead	  to	  misinterpretation	  of	  the	  biological	  situation	  through	  assay	  
detection	  issues.	  
	  
Next	  Generation	  Sequencing	  as	  an	  Analytical	  Tool	  	  
Using	  target	  capture	  technology	  and	  high	  throughput	  sequencing	  we	  were	  able	  to	  
produce	  total	  paired-­‐end	  reads	  of	  approximately	  8	  x	  106	  from	  HPV16	  positive	  
tumour	  samples.	  This	  is	  slightly	  lower	  than	  that	  described	  by	  Depledge	  et	  al.	  (4.8	  x	  
107	  –	  7.2	  x	  107)	  when	  analysing	  larger	  viral	  target	  sequences	  in	  from	  clinical	  
preparations.	  Duplicate	  reads	  accounted	  for	  34	  -­‐56%	  of	  paired-­‐end	  reads	  following	  
initial	  analysis.	  It	  is	  recognised	  that	  duplicate	  reads	  can	  occur	  as	  a	  result	  of	  PCR	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amplification,	  however	  independent	  sequencing	  fragments	  are	  also	  likely	  to	  
generate	  identical	  reads	  by	  chance.	  In	  this	  analysis,	  since	  the	  region	  of	  target	  
interest	  is	  small	  and	  resultant	  depth	  of	  sequencing	  in	  greatly	  increased,	  it	  is	  to	  be	  
expected	  a	  limited	  number	  of	  exact	  sequences	  would	  be	  replicated	  resulting	  in	  
numerous	  independent	  reads	  which	  start	  and	  end	  at	  the	  same	  position.	  As	  can	  be	  
seen	  in	  Appendix	  I	  and	  Appendix	  II,	  duplicate	  reads	  follow	  a	  similar	  proportionate	  
distribution	  to	  the	  overall	  reads.	  For	  these	  reasons	  it	  was	  therefore	  decided	  to	  
include	  duplicate	  reads	  in	  the	  mapping	  statistics	  for	  all	  subsequent	  analysis.	  
The	  proportion	  of	  paired-­‐end	  reads	  which	  map	  to	  Human	  sequence	  is	  surprisingly	  
high	  in	  tumour	  samples	  when	  compared	  to	  CaSki,	  which	  is	  know	  to	  have	  a	  high	  
number	  of	  integrants	  per	  genome	  (>800)185.	  In	  the	  initial	  description	  of	  this	  capture	  
and	  sequencing	  technique,	  Depledge	  et	  al195	  was	  able	  to	  generate	  an	  average	  of	  
80%	  (range	  34-­‐99%)	  on	  target	  reads,	  however	  in	  situations	  where	  target	  abundance	  
was	  low	  this	  fell	  to	  18-­‐20%.	  Our	  findings	  for	  CaSki	  demonstrate	  over	  90%	  paired-­‐
end	  reads	  containing	  one	  or	  more	  read	  with	  viral	  sequence	  however	  OPSCC	  tumour	  
samples	  had	  between	  0.02%	  -­‐	  61.66%	  (mean	  15.5%).	  Low	  natural	  abundance	  of	  
target	  reads	  in	  complete	  genomic	  samples	  could	  explain	  this,	  at	  least	  in	  part.	  If	  viral	  
copies	  are	  very	  low,	  then	  following	  complete	  uptake	  of	  viral	  sequence	  the	  baits	  may	  
capture	  targets	  with	  reduced	  homology	  non-­‐specifically.	  
Alternative	  explanations	  generally	  point	  to	  less-­‐than-­‐stringent	  washes	  applied	  post	  
hybridisation	  however	  the	  techniques	  employed	  do	  not	  differ	  from	  previous	  
descriptions	  nor	  the	  manufacturers	  ideals	  and	  it	  is	  felt	  that	  this	  is	  therefore	  an	  less	  
likely	  explanation.	  Also,	  inclusion	  of	  RNaseP	  baits	  in	  the	  process	  could	  impact	  on	  
genomic	  read	  frequency	  and	  a	  proportion	  of	  the	  120mer	  baits	  had	  homology	  of	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other	  human	  sequence	  of	  up	  to	  20bp.	  This	  level,	  however,	  sat	  well	  within	  the	  
confines	  of	  the	  manufacturers	  recommendations	  (<40bp	  homology)	  and	  is	  felt	  likely	  
to	  have	  only	  had	  a	  minor	  contribution	  to	  increased	  human	  paired-­‐end	  read	  
frequency.	  
	  
Analysis	  of	  paired-­‐end	  reads	  that	  include	  viral	  sequence	  suggest	  the	  presence	  of	  
integration	  in	  all	  samples,	  cell	  line	  or	  tumour	  derived.	  Such	  a	  finding	  would	  be	  
expected	  in	  CaSki	  and	  SiHa,	  however	  in	  this	  instance	  all	  tumour	  samples	  
demonstrated	  sequencing	  features	  such	  as	  human:viral	  mixed	  pairs	  and	  chimaeric	  
reads	  (single	  reads	  containing	  viral	  and	  host	  sequence),	  consistent	  with	  integration.	  
Although	  integration	  may	  be	  ubiquitous	  in	  HPV	  positive	  OPSCC,	  sample	  No	  13	  must	  
be	  viewed	  with	  caution	  given	  the	  very	  low	  viral	  read	  number,	  yet	  on	  balance,	  it	  
does	  retains	  a	  high	  HPV	  concordant:mixed	  pair	  ratio	  (0.23)	  despite	  the	  overall	  read	  
number.	  
In	  keeping	  with	  all	  other	  integration	  analysis	  techniques,	  it	  is	  still	  not	  possible	  to	  
quantify	  the	  proportion	  virus	  that	  is	  episomal	  and	  that	  which	  is	  integrated	  for	  any	  
given	  sample.	  In	  support	  of	  the	  analysis	  presented,	  the	  disruptive	  peaks	  for	  SiHa	  
demonstrate	  concordance	  with	  the	  previously	  described	  range	  for	  peak	  cleavage	  (nt	  
3134	  –	  3384)	  both	  published182,188,194	  and	  indicated	  in	  the	  E2	  integrity	  results	  above.	  
Similarly,	  CaSki	  integration	  findings	  are	  in	  keeping	  with	  previous	  results	  of	  multiple	  
tandem	  head	  to	  tail	  nondisrupted	  and	  fragmented	  disrupted	  reads188,	  although	  the	  
interpretation	  is	  difficult	  given	  the	  high	  number	  of	  integrant	  events,	  the	  apparent	  




Viral	  Cleavage	  Position	  Detection	  
This	  analysis	  provides	  evidence	  that	  cleavage	  of	  the	  viral	  genome	  in	  the	  integration	  
process	  is	  pan-­‐genomic	  in	  nature.	  Both	  Human:Viral	  mixed	  reads,	  and	  chimaeric	  
reads	  have	  highlighted	  the	  positions	  of	  cleavage	  broadly	  across	  the	  viral	  genome.	  
Although	  peaks	  of	  cleavage	  frequency,	  particularly	  in	  the	  E1	  and	  E2	  genes,	  are	  
witnessed,	  short	  conserved	  viral	  sequence	  that	  does	  not	  appear	  in	  to	  cleave	  is	  also	  
apparent,	  particularly	  within	  E2	  (in	  SiHa	  and	  in	  2	  tumour	  samples)	  but	  also	  
elsewhere	  in	  the	  genome.	  	  
On	  the	  evidence	  of	  disparate	  cleavage	  position,	  it	  is	  difficult	  to	  support	  the	  concept	  
of	  viral	  E2	  cleavage	  as	  being	  a	  driving	  event	  in	  oncogenesis.	  This	  is	  further	  refuted	  
by	  no	  apparent	  correlation	  between	  integration	  and	  E2	  expression	  and	  the,	  
otherwise	  counterintuitive,	  positive	  correlation	  witnessed	  in	  E6	  and	  E7	  expression	  
(6.2).	  
	  
It	  is	  difficult	  to	  speculate	  on	  the	  significance	  of	  preserved	  regions	  of	  virus,	  not	  
involved	  in	  mixed	  human:virus	  paired	  reads	  given	  their	  frequency	  in	  this	  small	  
cohort	  of	  samples.	  
The	  samples	  that	  provided	  pangenomic	  cleavage	  positions	  fell	  into	  two	  groups;	  
those	  with	  low	  viral	  integrant	  frequency	  (<250	  chimaeric	  reads)	  and	  those	  with	  high	  
integration	  as	  a	  feature	  (>250	  chimaeric	  reads).	  	  Interestingly,	  the	  former	  of	  these	  
two	  groups	  included	  one	  sample	  that	  demonstrated	  high	  E2	  expression	  alone	  (in	  
the	  absence	  of	  detectable	  E6	  or	  E7	  (sample	  No.	  101,	  Appendix	  XIII)	  despite	  
detectable	  viral	  reads	  from	  the	  E6	  and	  E7	  ORF.	  Such	  a	  tumour	  would	  normally	  be	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classified	  as	  being	  HPV	  negative	  using	  the	  gold	  standard	  definition	  (viral	  oncogene	  
expression	  from	  fresh	  frozen	  tissue	  samples)	  and	  as	  such	  could	  merely	  be	  a	  
transient	  infection,	  albeit	  with	  low	  levels	  of	  integration	  present.	  Review	  of	  
RNAscope	  (HR	  HPV	  RNAISH)	  data	  for	  the	  corresponding	  FFPE	  cores	  however,	  
highlighted	  the	  sample	  to	  be	  clearly	  positive	  for	  viral	  E6	  and	  E7	  expression.	  
	  
Host	  Integration	  Position	  
From	  the	  overall	  reads	  and	  the	  chimaeric	  reads	  that	  dictate	  exact	  nucleotide	  
insertion	  positions,	  insertion	  is	  almost	  exclusively	  in	  repetitive	  elements	  rather	  than	  
specific	  genes.	  This	  does	  question	  the	  theory	  of	  insertional	  mutagenesis	  bearing	  a	  
substantial	  or	  obligatory	  stage	  in	  oncogenesis.	  These	  findings	  are	  from	  a	  small	  
cohort	  however	  but	  are	  supported	  by	  a	  previous	  systematic	  review	  of	  viral	  insertion	  
sites	  in	  HPV	  positive	  cell	  lines,	  dysplastic	  epithelial	  cervical	  lesions	  and	  invasive	  
cervical	  cancer110.	  From	  over	  190	  previously	  reported	  loci	  of	  integration	  in	  HPV	  
positive	  samples,	  integration	  appeared	  random	  in	  nature	  but	  with	  a	  predilection	  for	  
reported	  common	  fragile	  sites	  (CFS).	  Two	  sites	  in	  particular	  show	  frequent	  
integration	  hits	  and	  have	  been	  termed	  “hot	  spots”	  for	  integration256.	  From	  the	  
samples	  analysed	  here,	  the	  cell	  line	  SiHa	  fits	  within	  a	  previously	  reported	  HPV	  
related	  CFS	  (13q22.1,	  FRA13B)257	  as	  expected.	  Further,	  tumour	  sample	  No.	  106	  
displayed	  the	  highest	  frequency	  of	  chimaeric	  reads	  within	  the	  CFS	  FRA1H110.	  Given	  
the	  scale	  of	  different	  integrant	  locations	  there	  remains	  considerable	  scope	  to	  
further	  correlate	  known	  and	  putative	  CFS	  with	  integration	  loci.	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It	  is	  not	  yet	  apparent	  if	  integration	  at	  CSF	  occurs	  in	  an	  opportunistic	  fashion	  or	  
whether	  there	  is	  a	  selective	  advantage	  however	  there	  have	  been	  calls	  made	  to	  
better	  define	  CSFs	  in	  the	  context	  of	  HR	  HPV	  integration6.	  	  
	  
In	  a	  comparative	  analysis	  of	  integration	  sites	  and	  genomic	  alterations,	  using	  an	  
array-­‐CGH	  analysis,	  Peter	  et	  al.174	  demonstrated	  that	  at	  particular	  genomic	  
integration	  sites,	  short	  amplifications	  occurred	  in	  multiple	  tumour	  samples	  within	  
the	  test	  cohort.	  In	  our	  analysis,	  Sample	  No.	  34	  demonstrated	  peak	  chimaeric	  
integration	  detection	  at	  the	  loci	  identified	  by	  Peter	  et	  al.	  (8q24.21)	  as	  the	  most	  
frequently	  detected	  recurrent	  amplification	  point.	  Amplifications	  detected	  by	  
Peters	  et	  al	  were	  modest	  in	  nature	  and	  they	  speculated	  that	  it	  was	  the	  integrated	  
viral	  origin	  of	  replication	  that	  directed	  later	  amplification	  through	  co-­‐amplification	  
of	  viral	  and	  host	  sequences.	  	  Despite	  being	  an	  observation	  in	  separate	  cohorts,	  by	  
different	  means,	  it	  is	  unclear	  whether	  this	  observation	  has	  any	  fundamental	  impact	  
on	  the	  process	  of	  virally	  mediated	  tumourgenesis.	  
	  
Evidence	  based	  support	  for	  the	  concept	  of	  insertional	  mutagenesis	  was	  not	  readily	  
apparent	  when	  considering	  the	  peak	  integration	  positions	  detected	  in	  OPSCC	  in	  our	  
analysis.	  	  The	  previously	  mentioned	  sample	  No.	  34	  was	  shown	  to	  have	  peak	  
chimaeric	  reads	  with	  the	  chromosomal	  band	  8q24.21,	  a	  region	  of	  the	  MYC	  gene.	  
This	  has	  been	  seen	  previously,	  in	  particular	  in	  association	  with	  HPV18	  mediated	  
cervical	  malignancy	  and	  has	  raised	  interest	  given	  the	  implications	  MYC	  holds	  for	  
universally	  up	  regulating	  gene	  expression6.	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Sample	  No.	  95	  demonstrated	  a	  large	  frequency	  of	  integration	  into	  the	  G-­‐protein-­‐
coupled	  receptor-­‐1	  (GPR1).	  Part	  of	  the	  G-­‐protein-­‐coupled	  receptor	  superfamily,	  this	  
gene	  has	  not	  featured	  in	  previous	  integration	  sites	  nor	  does	  it	  have	  reported	  links	  to	  
malignancy,	  virally	  mediated	  or	  otherwise.	  
	  
Although	  selection	  bias	  cannot	  directly	  be	  excluded	  within	  these	  results,	  it	  is	  
apparent	  that	  the	  view	  of	  viral	  integration	  occurring	  in	  a	  significant	  minority	  of	  
OPSCC	  should	  be	  reconsidered.	  Although	  this	  represents	  a	  modest	  cohort	  of	  
samples,	  integration	  appears	  to	  be	  ubiquitous	  and	  the	  disruption	  to	  viral	  sequence	  
and	  host	  alike	  does	  not	  fit	  to	  a	  single	  prescription.	  Expansion	  to	  a	  larger	  cohort	  
using	  sensitive	  techniques	  such	  as	  those	  employed	  here	  would	  add	  strength	  to	  the	  
initial	  findings.	  An	  important	  step	  beyond	  observational	  findings	  will	  be	  
corroboration	  via	  alterative	  techniques	  such	  as	  quantitative	  PCR.	  Should	  specific	  
genes,	  such	  as	  MYC,	  appear	  more	  frequently	  on	  a	  list	  of	  insertion	  sites,	  qPCR	  
validation	  might	  prove	  a	  useful	  tool	  to	  differentiate	  incidental	  event	  from	  oncogenic	  
driver.	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8 DISCUSSION	  &	  FUTURE	  DIRECTIONS	  
HPV	  Diagnostics	  in	  HNSCC	  –	  Prognostic	  Biomarker	  &	  Disease	  Stratification	  
Detection	  of	  HPV,	  or	  surrogate	  markers	  of	  its	  presence,	  has	  swiftly	  become	  a	  
fundamental	  requirement	  in	  the	  clinical	  management	  of	  OPSCC	  within	  the	  United	  
Kingdom	  and	  the	  majority	  of	  Western	  health	  care	  systems.	  	  
Although	  therapeutic	  regimes	  do	  not	  as	  yet	  differ	  on	  the	  basis	  of	  HPV	  status,	  testing	  
provides	  the	  basis	  for	  guiding	  discussions	  surrounding	  prognosis	  in	  the	  clinical	  
setting.	  	  
We	  have	  demonstrated	  that	  the	  well-­‐established	  increase	  in	  incidence	  of	  OPSCC	  in	  
United	  Kingdom	  Head	  and	  Neck	  Oncology	  practice	  is	  coincident	  and	  comparable	  to	  
the	  increase	  in	  relative	  incidence	  of	  HPV	  positive	  OPSCC,	  such	  that	  almost	  two	  
thirds	  of	  OPSCC	  are	  now	  likely	  to	  harbor	  transcriptionally	  active	  HPV16.	  Such	  a	  
change	  has	  increasingly	  been	  described	  as	  an	  epidemic	  of	  HPV	  positive	  OPSCC	  and	  
has	  drawn	  the	  attention	  of	  public	  health	  officials	  responsible	  for	  health	  planning	  
and	  vaccination.	  	  
Although	  we	  have	  shown	  that	  the	  clinical	  testing	  regimes	  available	  currently	  are	  
universally	  capable	  as	  prognostic	  biomarkers,	  their	  diagnostic	  capacity	  is	  highly	  
variable,	  in	  part	  due	  to	  a	  necessary	  reliance	  on	  formalin	  fixed	  tissue	  specimens.	  
Where	  sensitivity	  is	  sought,	  for	  example	  in	  the	  application	  of	  p16	  IHC,	  our	  results	  
demonstrate	  it	  to	  be	  at	  the	  expense	  of	  specificity.	  Combination	  tests	  offer	  
opportunities	  to	  improve	  specificity	  but	  in	  doing	  so	  compromise	  sensitivity.	  	  For	  so	  
long	  as	  treatment	  does	  not	  depend	  on	  HPV	  status,	  each	  of	  the	  alternative	  test	  will	  
remain	  fit	  for	  purpose,	  however	  this	  will	  no	  longer	  remain	  acceptable	  should	  clinical	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practice	  evolve	  towards	  de-­‐escalation	  of	  therapeutic	  intensity	  for	  HPV	  positive	  
disease,	  or	  indeed	  the	  converse,	  intensification	  for	  individuals	  with	  locally	  advanced	  
HPV	  negative	  disease.	  Both	  in	  this	  setting	  and	  in	  the	  clinical	  trials	  that	  are	  necessary	  
to	  inform	  this	  practice,	  greater	  diagnostic	  stringency	  will	  be	  essential.	  
	  
The	  research	  detailed	  in	  this	  thesis	  will	  form	  the	  basis	  for	  future	  applications	  to	  
investigate	  the	  prognostic	  significance	  of	  HPV	  positive	  malignancy	  beyond	  the	  
confines	  of	  the	  oropharynx.	  	  
Although,	  only	  briefly	  mentioned,	  data	  from	  small	  cohorts	  of	  tumours	  in	  other	  head	  
and	  neck	  subsites	  (oral	  cavity,	  larynx	  and	  hypopharynx)	  suggest	  that	  only	  a	  small	  
proportion,	  typically	  5-­‐10%,	  are	  HPV	  positive	  (Oral	  4/102	  (4%),	  Larynx	  3/91	  (3.2%),	  
Hypopharynx	  2/28	  (7.1%),	  Overall	  9/221	  (4.1%);	  unpublished	  data	  kindly	  provided	  
by	  Mr	  Nav	  Upile).	  The	  size	  of	  these	  cohorts	  has	  precluded	  meaningful	  analysis	  of	  
outcome	  measures	  to	  determine	  if	  HPV	  status	  outwith	  the	  oropharynx	  has	  
prognostic	  significance.	  Large	  multicentre	  bio-­‐banks	  are	  established	  and	  with	  sound	  
diagnostic	  rigor	  could	  be	  interrogated	  to	  answer	  this	  question.	  
We	  also	  intend	  to	  explore	  further,	  the	  relationship	  between	  smoking	  history	  and	  
HPV	  status	  with	  a	  view	  to	  better	  defining	  any	  apparent	  survival	  difference	  between	  
HPV	  positive	  smokers	  and	  HPV	  positive	  non-­‐smokers.	  It	  remains	  to	  be	  seen	  whether	  
strict	  anatomical	  site	  classification	  coupled	  to	  stringent	  HPV	  status	  determination	  
will	  detract	  from	  previous	  findings	  of	  disease	  specific	  prognostic	  implications	  for	  the	  
HPV	  positive	  smoker.	  
It	  is	  important	  to	  reflect	  upon	  the	  contradictory	  findings	  of	  definitive	  HPV16	  
oncogene	  expression	  in	  a	  significant	  minority	  of	  fresh	  frozen	  adjacent	  marginal	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tissues	  (paired	  to	  HPV	  positive	  tumours),	  whilst	  examination	  of	  FFPE	  samples	  using	  
RNAscope	  demonstrated	  no	  such	  findings.	  Interpretation	  has	  considerable	  
importance	  as	  it	  is	  assumed	  that,	  in	  contrast	  to	  carcinogen-­‐induced	  HPV	  negative	  
malignancy,	  HPV	  positive	  tumours	  lack	  field	  change;	  a	  potential	  contributory	  factor	  
in	  improved	  local	  recurrence	  free	  survival.	  Although	  tumour	  infiltration	  of	  normal	  
samples	  is	  difficult	  to	  completely	  refute	  without	  formal	  histopathological	  review	  
prior	  to	  analysis,	  our	  experience	  in	  such	  circumstances	  would	  consider	  this	  to	  be	  
unlikely.	  A	  more	  convincing	  explanation	  would	  be	  “peri-­‐resection”	  contamination	  of	  
harvested	  samples	  as	  would	  be	  the	  case	  for	  any	  surgically	  resected	  specimen.	  
Although	  tumour	  is	  not	  confined	  to	  the	  normal	  marginal	  tissue	  (harvested	  over	  
10mm	  from	  the	  macroscopic	  tumour	  margin),	  contaminated	  fluids,	  blood	  or	  saliva	  
will	  inevitably	  abut	  all	  tissues.	  The	  high	  sensitivity	  of	  the	  analytical	  tests	  therefore	  
will	  ensure	  positive	  results	  despite	  the	  probability	  of	  no	  active	  transcription	  in	  the	  
normal	  tissue.	  FFPE	  samples	  by	  contrast	  will	  have	  any	  “peri-­‐resection”	  
contamination	  washed	  away	  or	  denatured	  in	  the	  process	  of	  fixation,	  resulting	  in	  the	  
observed	  negative	  results	  for	  HR	  HPV	  in	  any	  normal	  FFPE	  tissue	  core.	  Alternatively,	  
HPV	  positive	  non-­‐tumour	  marginal	  tissue	  may	  occur	  in	  a	  proportion	  of	  HPV	  positive	  
OSPCC.	  This	  would,	  by	  inference	  however,	  call	  into	  question	  the	  sensitivity	  of	  all	  
other	  FFPE	  tests	  applied	  here	  (p16,	  DNA	  ISH	  and	  RNA	  ISH),	  as	  each	  scored	  normal	  
tissues	  as	  negative	  in	  all	  instances.	  	  
Whilst	  a	  definitive	  answer	  cannot	  be	  made	  here	  based	  on	  the	  evidence	  available,	  on	  
balance	  of	  probability	  and	  for	  sound	  scientific	  reasons	  the	  former	  explanation	  is	  




Virally	  mediated	  OPSCC	  has	  both	  distinct	  behavior	  and	  prognosis	  hence,	  as	  
mentioned	  above,	  clinical	  trials	  specifically	  targeting	  HPV	  positive	  OPSCC	  are	  now	  
being	  developed.	  The	  accuracy	  of	  trial	  stratification	  for	  individuals	  on	  the	  basis	  of	  
the	  HPV	  status	  of	  their	  malignancy	  is	  of	  paramount	  importance	  and	  immediate	  
clinical	  impact.	  The	  consequences	  of	  inaccurate	  stratification	  in	  the	  setting	  of	  de-­‐
intensification	  trials	  could	  result	  in	  a	  cohort	  of	  individuals	  receiving	  sub	  therapeutic	  
treatment	  with	  potentially	  devastating	  clinical	  implications.	  Our	  results	  have	  shown,	  
when	  compared	  to	  the	  gold	  standard	  test,	  the	  novel	  RNA	  in	  situ	  hybridisation	  test,	  
High	  Risk	  HPV	  RNAscope,	  has	  diagnostic	  stringency	  better	  than	  any	  other	  single	  test	  
and	  comparable	  to	  tests	  that	  would	  otherwise	  not	  be	  viable	  in	  a	  clinical	  setting.	  The	  
utility	  of	  this	  test	  on	  FFPE	  samples,	  coupled	  with	  excellent	  levels	  of	  interobserver	  
concordance	  imply	  that	  it	  could	  be	  applied	  in	  the	  clinical	  trial	  setting	  once	  through	  
the	  necessary	  national	  and	  international	  in	  vitro	  diagnostic	  regulatory	  frameworks.	  
It	  is	  anticipated	  that	  our	  experience	  with	  this	  diagnostic	  tool	  would	  leave	  us	  well	  
placed	  to	  engage	  with	  such	  future	  works.	  	  
	  
Biomarkers	  for	  HPV	  positive	  OPSCC	  
The	  necessity	  for	  a	  biomarker	  capable	  of	  discriminating	  between	  a	  persistent	  high-­‐
risk	  HPV	  infection	  and	  one	  with	  the	  potential	  to	  become	  transformative	  in	  the	  
oropharynx	  exists.	  On	  the	  evidence	  provided	  in	  this	  research	  it	  appears	  that	  neither	  
genome-­‐wide	  methylation	  analysis	  nor	  viral	  methylome	  characteristics	  can	  be	  
exploited	  to	  this	  end.	  We	  were	  able	  to	  build	  upon	  the	  growing	  evidence	  that	  HPV	  
positive	  OPSCC	  is	  biologically	  distinct	  from	  HPV	  negative	  tumours	  but	  also,	  we	  were	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able	  to	  prove	  the	  hypothesis	  that	  HPV	  positive	  disease	  has	  a	  distinct	  epigenetic	  
profile.	  Using	  clinical	  samples	  we	  have	  corroborated	  findings	  initially	  generated	  in	  
HPV	  positive	  cell	  lines	  and	  through	  array-­‐based	  techniques	  and	  target-­‐specific	  
assays,	  shown	  fundamental	  differences	  that	  warrant	  further	  investigation.	  The	  
results	  generated	  when	  comparing	  promoter	  methylation	  in	  HPV	  positive	  and	  
negative	  OPSCC	  with	  the	  Infinium	  HumanMethylation450	  BeadArray	  were	  
subjected	  to	  technical	  validation	  through	  pyrosequencing	  assays	  yet	  expansion	  to	  a	  
larger	  cohort	  to	  OPSCC	  remains	  necessary	  for	  biological	  validation	  of	  targets.	  It	  
remains	  to	  be	  seen	  whether	  a	  panel	  of	  differentially	  methylated	  genes	  would	  assist	  
biomarker	  development	  prediction	  of	  the	  potentially	  transformative	  viral	  infection.	  
	  
Similarly,	  it	  is	  unclear	  whether	  the	  developing	  understanding	  of	  viral	  integration	  
state	  in	  HPV	  positive	  OPSCC	  can	  be	  exploited	  to	  improve	  either	  diagnostics	  or	  
therapeutic	  intervention.	  Without	  a	  dysplastic	  lesion	  analogous	  to	  that	  seen	  in	  the	  
cervix	  and	  utilised	  to	  great	  effect	  in	  national	  cervical	  screening	  programmes,	  early	  
diagnosis	  in	  HPV	  positive	  OPSCC	  is	  limited	  to	  clinically	  evident	  tumours	  or	  
subsequent	  metastatic	  disease.	  If	  integration	  was	  shown	  to	  be	  a	  critical	  step	  in	  HPV	  
positive	  OPSCC	  oncogenesis	  then	  it	  would	  follow	  that	  investment	  of	  research	  
energy	  and	  resources	  could	  be	  directed	  towards	  investigating	  further,	  saliva	  based	  
screening	  tools	  aimed	  at	  viral	  integration	  detection.	  Such	  advances	  would,	  by	  
necessity,	  need	  to	  differentiate	  between	  latent	  and	  fully	  selected	  transcriptionally	  
active	  integrants,	  conceivably	  through	  downstream	  effects	  on	  cellular	  function	  by	  
E6	  and	  E7.	  Sample	  recruitment	  from	  individuals	  with	  latent	  infection	  is	  needed	  and	  
	  	  
199	  
would	  be	  invaluable	  as	  a	  reference	  to	  compare	  with	  samples	  derived	  from	  
individuals	  with	  HPV	  mediated	  cancer.	  
	  
We	  have	  however	  generated	  data	  that	  would	  suggest	  that	  viral	  integration	  is	  an	  
inescapable	  eventuality	  for	  HPV	  mediated	  OPSCC.	  Additionally,	  we	  have	  brought	  
into	  question	  the	  significance	  of	  the	  viral	  E2	  gene	  following	  the	  establishment	  of	  
malignancy.	  Our	  data	  appears	  in	  indicate	  that	  viral	  cleavage	  events	  span	  the	  HPV	  
genome	  rather	  than	  concentrating	  on	  the	  E2	  ORF.	  Indeed,	  expression	  of	  the	  E2	  
gene,	  at	  whatever	  level,	  seems	  to	  be	  an	  irrelevance	  once	  oncogenesis	  is	  
established,	  supported	  by	  a	  finding	  that	  E6	  and	  E7	  expression	  is	  not	  under	  the	  
transcriptional	  repression	  of	  E2,	  at	  least	  in	  invasive	  disease.	  	  
It	  is	  interesting	  to	  speculate	  whether	  HPV	  mediated	  malignancy	  conforms	  more	  to	  a	  
theory	  of	  hit	  and	  run	  oncogenesis	  rather	  than	  persistent	  viral	  oncogene	  dependent	  
malignancy.	  Certainly,	  the	  role	  that	  E2	  plays	  in	  this	  process	  is	  less	  convincing.	  
Data	  generated	  with	  deep	  sequencing	  technology	  supports	  previous	  findings	  of	  
random	  human	  integration	  sites	  although	  with	  a	  slight	  preponderance	  towards	  
common	  fragile	  sites.	  The	  implications	  of	  viral	  integration	  in	  terms	  of	  insertional	  
mutagenesis	  are	  certainly	  an	  interesting	  avenue	  for	  future	  investigation,	  both	  in	  
terms	  of	  expansion	  of	  the	  number	  of	  tumour	  samples	  subjected	  to	  techniques	  such	  
as	  those	  employed	  here,	  but	  also	  through	  validation	  of	  findings	  at	  particular	  loci	  
such	  as	  MYC,	  a	  transcriptional	  regulator	  known	  to	  be	  constitutively	  expressed	  in	  




In	  conclusion,	  this	  research	  has	  provided	  important	  clarification	  surrounding	  the	  
relative	  utility	  of	  HPV	  diagnostic	  tests	  in	  OPSCC	  whilst	  validating	  a	  novel	  test	  that	  
offers	  considerable	  promise	  when	  addressing	  the	  question	  of	  de-­‐escalation	  of	  
therapeutic	  intensity	  in	  HPV	  positive	  OPSCC.	  	  	  
Although	  new	  understandings	  of	  viral	  integration	  occurrence	  have	  been	  put	  
forward	  in	  this	  thesis,	  uncertainly	  remains	  when	  considering	  potential	  for	  
biomarkers	  for	  the	  progression	  to	  transforming	  viral	  infection.	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%	   Within	  HPV	  pairs	   %	  
CaSki	   9,511,505	   458,537	   4.82%	   430,276	   4.52%	   8,678,529	   91.24%	  
SiHa	   8,386,165	   7,377,237	   87.97%	   6,938,964	   82.74%	   364,594	   4.35%	  
13	   8,045,978	   7,459,666	   92.71%	   7,081,186	   88.01%	   1,466	   0.02%	  
105	   8,817,575	   5,389,265	   61.12%	   5,091,711	   57.75%	   2,797,628	   31.73%	  
101	   8,329,130	   6,910,317	   82.97%	   6,590,243	   79.12%	   850,771	   10.21%	  
106	   8,841,535	   7,880,586	   89.13%	   7,416,594	   83.88%	   221,956	   2.51%	  
34	   8,622,022	   2,692,502	   31.23%	   2,533,755	   29.39%	   5,326,167	   61.77%	  
108	   9,639,841	   6,508,255	   67.51%	   6,146,477	   63.76%	   2,560,347	   26.56%	  
88	   7,978,406	   6,440,880	   80.73%	   6,087,751	   76.30%	   969,477	   12.15%	  
95	   8,335,501	   7,621,955	   91.44%	   7,182,714	   86.17%	   100,866	   1.21%	  
87	   8,844,930	   7,694,502	   86.99%	   7,290,046	   82.42%	   404,606	   4.57%	  
	   	   	   	   	   	   	   	  




%	   Human/HPV	  mixed	  pairs	   %	  
Human:Human	  
mixed	  pairs	   %	  
CaSki	   9,511,505	   8,220,424	   86.43%	   335,243	   3.52%	   22,635	   0.24%	  
SiHa	   8,386,165	   333,691	   3.98%	   28,012	   0.33%	   526,532	   6.28%	  
13	   8,045,978	   883	   0.01%	   259	   0.00%	   520,963	   6.47%	  
105	   8,817,575	   2,523,107	   28.61%	   168,960	   1.92%	   402,077	   4.56%	  
101	   8,329,130	   798,060	   9.58%	   43,371	   0.52%	   460,877	   5.53%	  
106	   8,841,535	   191,711	   2.17%	   19,271	   0.22%	   647,556	   7.32%	  
34	   8,622,022	   4,880,479	   56.60%	   362,182	   4.20%	   208,732	   2.42%	  
108	   9,639,841	   2,375,437	   24.64%	   141,848	   1.47%	   359,279	   3.73%	  
88	   7,978,406	   894,543	   11.21%	   68,215	   0.85%	   435,048	   5.45%	  
95	   8,335,501	   91,657	   1.10%	   6,789	   0.08%	   544,232	   6.53%	  
87	   8,844,930	   377,091	   4.26%	   11,599	   0.13%	   335,302	   3.79%	  
	   	   	   	   	   	   	   	  
Sample	  ID	   Total	  read	  pairs	   RNaseP	  pairs	   %	  
RNaseP	  
mixed	  pair	   %	  
	   	  CaSki	   9,511,505	   474	   0.00%	   15	   0.00%	  
	   	  SiHa	   8,386,165	   12,271	   0.15%	   547	   0.01%	  
	   	  13	   8,045,978	   12,808	   0.16%	   636	   0.01%	  
	   	  105	   8,817,575	   11,072	   0.13%	   670	   0.01%	  
	   	  101	   8,329,130	   11,505	   0.14%	   591	   0.01%	  
	   	  106	   8,841,535	   14,774	   0.17%	   748	   0.01%	  
	   	  34	   8,622,022	   5,643	   0.07%	   311	   0.00%	  
	   	  108	   9,639,841	   12,157	   0.13%	   510	   0.01%	  
	   	  88	   7,978,406	   12,990	   0.16%	   592	   0.01%	  
	   	  95	   8,335,501	   13,163	   0.16%	   709	   0.01%	  
	   	  87	   8,844,930	   8,569	   0.10%	   320	   0.00%	  




Appendix	  I:	  Mapping	  Statistics	  for	  individual	  samples,	  including	  duplicate	  reads	  where	  apparent.	  	  
Human	  within	  chromosome	  pairs:	  Paired	  end	  reads	  mapping	  to	  human	  sequence	  at	  one	  or	  both	  
ends.	  Human	  Concordant	  Pairs:	  Concordant	  Human	  paired-­‐end	  reads,	  mapping	  within	  500bp.	  
Within	  HPV	  Pairs:	  Paired	  end	  reads	  both	  mapping	  to	  HPV	  sequence.	  HPV	  Concordant	  Pairs:	  
Concordant	  Viral	  paired-­‐end	  reads,	  mapping	  within	  500bp.	  Human:Human	  Mixed	  Pairs:	  Paired	  end	  
reads	  mapping	  to	  human	  sequence	  in	  excess	  of	  500bp	  from	  paired	  reads.	  RNaseP	  Pairs:	  Paired	  end	  
reads	  mapping	  to	  the	  341bp	  RNaseP	  gene	  sequence.	  RNaseP	  mixed	  Pair:	  Paired	  end	  reads	  mapping	  
to	  viral	  sequence	  or	  human	  sequence	  in	  excess	  of	  500bp	  from	  opposing	  paired	  read	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%	   Within	  HPV	  pairs	   %	  
CaSki	   3,222,204	   437,504	   13.58%	   410,786	   12.75%	   2,431,180	   75.45%	  
SiHa	   4,361,982	   3,804,007	   87.21%	   3,537,080	   81.09%	   117,570	   2.70%	  
13	   4,113,314	   3,719,781	   90.43%	   3,492,696	   84.91%	   920	   0.02%	  
105	   4,565,928	   3,259,749	   71.39%	   3,057,252	   66.96%	   872,978	   19.12%	  
101	   4,673,491	   3,978,570	   85.13%	   3,770,027	   80.67%	   293,774	   6.29%	  
106	   4,686,207	   4,115,781	   87.83%	   3,829,754	   81.72%	   69,605	   1.49%	  
34	   3,974,592	   1,977,242	   49.75%	   1,854,511	   46.66%	   1,567,167	   39.43%	  
108	   5,046,944	   3,880,349	   76.89%	   3,636,877	   72.06%	   772,022	   15.30%	  
88	   4,307,501	   3,604,753	   83.69%	   3,375,994	   78.37%	   309,955	   7.20%	  
95	   3,959,364	   3,543,148	   89.49%	   3,295,467	   83.23%	   27,935	   0.71%	  
87	   4,311,858	   3,588,687	   83.23%	   3,356,769	   77.85%	   117,751	   2.73%	  
        




%	   Human/HPV	  mixed	  pairs	   %	  
Human:Human	  
mixed	  pairs	   %	  
CaSki	   3,222,204	   2,184,997	   67.81%	   315,043	   9.78%	   21,916	   0.68%	  
SiHa	   4,361,982	   104,428	   2.39%	   11,981	   0.27%	   338,634	   7.76%	  
13	   4,113,314	   616	   0.01%	   246	   0.01%	   328,743	   7.99%	  
105	   4,565,928	   755,624	   16.55%	   86,256	   1.89%	   287,300	   6.29%	  
101	   4,673,491	   271,627	   5.81%	   20,978	   0.45%	   316,375	   6.77%	  
106	   4,686,207	   57,373	   1.22%	   7,894	   0.17%	   420,761	   8.98%	  
34	   3,974,592	   1,374,755	   34.59%	   229,069	   5.76%	   168,675	   4.24%	  
108	   5,046,944	   694,729	   13.77%	   68,514	   1.36%	   255,947	   5.07%	  
88	   4,307,501	   278,471	   6.46%	   30,557	   0.71%	   297,450	   6.91%	  
95	   3,959,364	   24,868	   0.63%	   2,689	   0.07%	   323,933	   8.18%	  
87	   4,311,858	   106,870	   2.48%	   4,938	   0.11%	   201,561	   4.67%	  
        
Sample	  ID	   Total	   RNaseP	  pairs	   %	   RNaseP	  mixed	  pair	   %	  
  CaSki	   3,222,204	   438	   0.01%	   15	   0.00%	  
  SiHa	   4,361,982	   4,592	   0.11%	   260	   0.01%	  
  13	   4,113,314	   4,598	   0.11%	   294	   0.01%	  
  105	   4,565,928	   4,876	   0.11%	   342	   0.01%	  
  101	   4,673,491	   4,865	   0.10%	   295	   0.01%	  
  106	   4,686,207	   5,242	   0.11%	   353	   0.01%	  
  34	   3,974,592	   3,331	   0.08%	   225	   0.01%	  
  108	   5,046,944	   5,313	   0.11%	   282	   0.01%	  
  88	   4,307,501	   5,132	   0.12%	   278	   0.01%	  
  95	   3,959,364	   4,369	   0.11%	   310	   0.01%	  
  87	   4,311,858	   3,021	   0.07%	   142	   0.00%	  
  	  




Appendix	  II:	  Mapping	  Statistics	  for	  individual	  samples,	  excluding	  duplicate	  reads.	  
Human	  within	  chromosome	  pairs:	  Paired	  end	  reads	  mapping	  to	  human	  sequence	  at	  one	  or	  both	  
ends.	  Human	  Concordant	  Pairs:	  Concordant	  Human	  paired-­‐end	  reads,	  mapping	  within	  500bp.	  
Within	  HPV	  Pairs:	  Paired	  end	  reads	  both	  mapping	  to	  HPV	  sequence.	  HPV	  Concordant	  Pairs:	  
Concordant	  Viral	  paired-­‐end	  reads,	  mapping	  within	  500bp.	  Human:Human	  Mixed	  Pairs:	  Paired	  end	  
reads	  mapping	  to	  human	  sequence	  in	  excess	  of	  500bp	  from	  paired	  reads.	  RNaseP	  Pairs:	  Paired	  end	  
reads	  mapping	  to	  the	  341bp	  RNaseP	  gene	  sequence.	  RNaseP	  mixed	  Pair:	  Paired	  end	  reads	  mapping	  









Legend	  for	  Appendices	  III	  –	  XIII:	  For	  each	  of	  the	  individual	  appendices	  	  
Top	  figure:	  Human-­‐HPV	  Mixed	  Paired-­‐end	  Reads	  mapped	  to	  respective	  genome	  l(HPV	  and	  Human)	  
locations.	  	  
Blue	  read	  amplitude	  represents	  frequency	  of	  viral	  sequence	  read	  for	  specific	  viral	  genome	  location	  
(respective	  HPV	  open	  reading	  frame	  annotated	  in	  blue	  arrows,	  with	  exception	  of	  E4	  ORF	  which	  falls	  
within	  E2	  ORF).	  Proximal	  and	  distal	  HPV	  genome	  (no	  arrow)	  represents	  the	  HPV	  long	  control	  region.	  
Red	  localizing	  lines	  delineate	  location	  of	  corresponding	  paired	  read	  to	  chromosomal	  position	  (each	  
red	  annotated	  arrow	  reflects	  the	  respective	  chromosome).	  
For	  high	  frequency	  specific	  chromosomal	  integration	  sites	  the	  viral	  gene	  and	  human	  chromosome	  
are	  listed	  with	  chromosomal	  co-­‐ordinates	  and	  gene	  annotations	  where	  apparent	  (source:	  UCSC	  
genome	  browser	  &	  ensembl).	  
	  
Middle	  Dot	  Plot:	  Graphic	  representation	  of	  viral	  cleavage	  points	  (breakpoints)	  within	  chimaeric	  
reads	  distributed	  across	  the	  7904bp	  circular	  genome	  (x	  axis).	  Frequency	  of	  cleavage	  point	  read	  is	  
plotted	  on	  the	  y	  axis.	  	  
Chimaeric	  reads	  represent	  those	  reads	  for	  which	  both	  virus	  and	  human	  sequence	  are	  included	  in	  the	  
same	  single	  read,	  thus	  demonstrating	  the	  exact	  point	  of	  transition	  between	  the	  sequences	  of	  
differing	  origin	  (viral	  and	  human).	  
	  
Bottom	  Schematic:	  Representation	  of	  the	  HPV16	  genome	  highlighting	  the	  viral	  open	  reading	  frames	  
and	  long	  control	  region	  (LCR)	  with	  respective	  nucleotide	  sequence	  span.	  Figures	  in	  parenthesis	  
represents	  either	  start	  or	  end	  point	  for	  LCR	  which	  spans	  the	  0/7904	  circular	  start/end	  point	  for	  the	  








Appendix	  III:	  Viral	  &	  Host	  Sequencing	  Read	  Representations	  for	  the	  HPV16	  positive	  Cell	  Line	  CaSki	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Appendix	  V:	  Viral	  &	  Host	  Sequencing	  Read	  Representations	  for	  the	  HPV16	  positive	  OPSCC	  sample	  














Appendix	  VI:	  Viral	  &	  Host	  Sequencing	  Read	  Representations	  for	  the	  HPV16	  positive	  OPSCC	  sample	  
No.	  34	  (427T)	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Appendix	  VII:	  Viral	  &	  Host	  Sequencing	  Read	  Representations	  for	  the	  HPV16	  positive	  OPSCC	  sample	  
No.	  106	  (045-­‐09T)	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Appendix	  VIII:	  Viral	  &	  Host	  Sequencing	  Read	  Representations	  for	  the	  HPV16	  positive	  OPSCC	  sample	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Appendix	  IX:	  Viral	  &	  Host	  Sequencing	  Read	  Representations	  for	  the	  HPV16	  positive	  OPSCC	  samples	  















Appendix	  X:	  Viral	  &	  Host	  Sequencing	  Read	  Representations	  for	  the	  HPV16	  positive	  OPSCC	  sample	  
No.	  88	  (077-­‐08T)	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Appendix	  XI:	  Viral	  &	  Host	  Sequencing	  Read	  Representations	  for	  the	  HPV16	  positive	  OPSCC	  sample	  
No.	  108	  (239-­‐08T)	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Appendix	  XII:	  Viral	  &	  Host	  Sequencing	  Read	  Representations	  for	  the	  HPV16	  positive	  OPSCC	  sample	  
No.	  87	  (075-­‐08T)	  
	  
	   	  
	  	  
217	  
Appendix	  XIII:	  Viral	  &	  Host	  Sequencing	  Read	  Representations	  for	  the	  HPV16	  positive	  OPSCC	  sample	  
No.	  101	  (035-­‐09T)	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